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Guanine-rich nucleic acids can fold into distinctive four-stranded G-quadruplex 
structures which are found in telomeric DNA repeats as well as in sequences in 
the promoter and other regulatory regions of genes, especially those involved in 
cellular proliferation. Small molecules that can selectively bind and stabilize the 
G-quadruplex structure have become of significant interest to researchers, and 
are gaining momentum as a possible new class of anticancer agents. 
This project was based on a previously reported series of novel biaryl 
polyamides with significant selectively toward G-quadruplexes compared to 
duplex DNA, and with modest selectivity between different quadruplex types. 
Using a distamycin scaffold as a starting point, biaryl building blocks were 
introduced in place of pyrroles to switch preference from duplex to quadruplex 
DNA. This alteration in shape ensured that the molecules had low affinity for 
duplex DNA while increasing their interaction with a G-quadruplex structure 
since the ligands have similar 3D structures. The main aim of this project was to 
modify the structure of the previously reported biaryl polyamides (with the help 
of a molecular modelling based approach) through the incorporation of 
benzofused building blocks to improve their affinity for G-quadruplexes, while 
further reducing their affinity for duplex DNA, thereby enhancing their selectivity 
for quadruplex DNA. 
A small, focused benzofused-polyamide library (18 molecules) was initially 
synthesized and evaluated for the ability of members to stabilize G-quadruplex 
structures using a FRET-based DNA thermal denaturation assay and molecular 
dynamics (MD) simulations. However, these compounds failed to stabilize the 
F21T (human telomeric G-quadruplex), c-Kit quadruplexes and Bcl-2 
quadruplexes, and MD simulations suggested that the shape of the molecules 
required further modification to facilitate quadruplex interaction. A second library 
of molecules (43 in total) was then designed and synthesized using a molecular 
modelling-based approach. In this series, the shape of the polyamide fragment 
was changed, while retaining the original scaffold, by introducing benzofused 
moieties with 3,5-substitutions. Evaluation of these molecules in the same 
FRET assay showed a notable increase in stabilization of the F21T quadruplex 
for many library members. For example, compounds 4.93 and 4.71 stabilized 
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the quadruplex by 15°C and 17°C, respectively (at 1 µM concentration), while 
showing insignificant affinity for duplex DNA. Moreover a third set of benzofused 
polyamides (9 in total) has been synthesized by the addition of two consecutive 
benzofused moieties instead of three consecutive benzofused moieties for the 
ideal length of G-quadruplex DNA targeting ligand molecules. These molecules 
were also evaluated by the same FRET-based DNA thermal denaturation 
assay. The overall data showed that benzofused polyamides made of three 
consecutive benzofused moieties had a specific curvature which improved their 
G-quadruplex interacting capacities compared to those with two consecutive 
benzofused moieties. 
Cytotoxicity studies were undertaken on MDA-MB-231 and HeLa cell lines and 
some library members are active at the low micromolar level. Molecule 4.45 has 
emerged as a lead compound, possessing a cytotoxicity of 40nM in MDA-MB-
231. 
Given their low molecular weight (between 422-646 Daltons), reasonable water 
solubility and good cellular penetration properties compared to other known G-
quadruplex inhibitors which are mostly non-drug-like, molecules of this type 
have the potential to be developed into both reagents that can probe DNA 
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Chapter 1: Introduction 
 
1.1 Cancer 
Cancer is a term that applies to a group of multiple diseases. It is a malignant 
disease caused by alteration of normal cells due to genetic mutations. These 
genetic mutations may either be inherited or be originated by inaccurate DNA 
replication and chromosomal division or by various physiological, chemical and 
environmental factors. These permanent aberrations, either in a single DNA 
base or in a chromosomal fragment, ultimately lead to the divergent functions of 
a gene. Thus cells lose control of their proliferation, resulting in abnormal 
growth. This uncontrolled growth is likely to localise at the early stage of cancer. 
As cell division continues, the cellular mass is no longer fixed in its origin, but 
rather forms tumours which occupy neighbouring cellular spaces and share 
nutrients to make new blood vessels from pre-existing vessels through the 
process of angiogenesis. They invade nearby parts of the body 1 and also start 
to spread throughout the body through the lymphatic and cardiovascular 
pathways, and can eventually prove fatal (Figure-1.1). 
 
Figure 1.1: Diagram representing the growth and spread of cancer cells. 
Malignant cells spread away from their origin to the secondary site through the 
blood and lymph system. [taken from Schroeder A, Heller DA, Winslow MM, 
Dahlman and JE, Pratt GW. Nat. Rev. Cancer. 12(2012):39-50] 2. 
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Indeed, almost 90 percent of cancer-related deaths are due to the tumour 
spreading to secondary sites by a process called metastasis 3. Cancers are 
named mostly according to their origins including the types of cells and organs 
from where they start to get malignant phenotypes.  
 
Figure 1.2: The illustration of the classical hallmarks of cancer cells: 
autonomous cell proliferatin, escaping from apoptosis, angiogenesis, metastasis 
etc. In fact these are the major distinguishing characteristics of malignant cells 
from normal cells.  [taken from Dey I, Rath PC. BBRC. 327(2005):276-86]  4. 
 
 
Malignant cells usually have some distinguishing characteristics, familiar as the 
phenotypic hallmarks of cancers (Figure-1.2). These mainly include 
autonomous replication and proliferation, restriction to cytostatic and apoptotic 
signal, induction of neighbouring tissue invasion, metastasis and angiogenesis 
4. 
 
1.1.1 Treatment of Cancer 
 
There are many therapies including surgery, chemotherapy, radiation treatment, 
stem cell transplant and targeted therapy developed to fight cancer, but it is 
hard to get rid of completely. For example, surgery and chemotherapy are not 
capable of abolishing all of the cancerous cells and these are potentially harmful 
to normal cells as well. In addition, cancer cells can continue their proliferation if 
even a few of them remain in the area of origin and some of them may gain 
resistance to cytotoxic agents and thereby escape apoptosis 5. Thus in most 
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cases, therapies help to prolong the life expectancy of a cancer patient rather 
than (instead of) acting as a total cure. An effective medication can be 
rationalized by considering early accurate diagnosis and choosing an 
appropriate therapy. Indeed, current research places the emphasis on cell 
biology, genetics and biotechnology to understand the molecular mechanisms 
involved in tumorigenesis. However, it is necessary to take the advances in 
distinguishing the characteristics of cancer cells from normal cells and to know 
the genetic changes happening in cancer in order to develop a fruitful strategy 
for anticancer therapeutics. 
 
1.1.2 Cancer Chemotherapy 
 
Chemotherapy began to be used as a cancer therapy in the early stages of the 
20th century. The idea came from World War 2; the naval forces that were 
exposed to nitrogen mustard surprisingly developed reduced white blood cell 
counts. However, chemotherapy is one of the most preferable treatments to 
tackle any type of cancer. Recently a significant number of chemotherapeutic 
agents have been screened out based on their cytotoxic efficacy. They can be 
prescribed alone or be combined with other therapies like radiation, surgery, 
hormone or immune therapies to make them more effective than a single agent. 
They kill the cancer cells by either arresting cell division or through DNA/RNA 
damage so that cells can’t divide anymore and ultimately die. They are of 
different types due to their modes of action and target sites. For example, 
methotrexate and vinca alkaloids kill the cells belonging to a particular part of 
the cell cycle; on the other hand, platinum derivatives are non-specific and have 
a cytotoxic effect in both proliferating and resting phases. However, 
chemotherapy is limited in its action. It mainly targets the fast growing cells, 
thus chemotherapeutics don’t have enough of an effect on cancer cells of 
resting phase and restraint to play any positive role on tumour progression and 
metastasis. In addition, they may kill normal cells as well. It is better to adjust 
the chemotherapeutic dose to minimise this harmful effect on normal cells and 




A better understating of gene and protein expression patterns is supposed to 
help to identify the cancer-specific targets like enzymes, receptors or specific 
molecular targets expressed abnormally in cancer cells compared to normal 
cells.  
1.1.3 DNA as a Molecular Target in Cancer Therapeutics 
 
Mutated or damaged DNA is usually repaired by the normal cellular machinery. 
If a cell fails to repair a genetic abnormality, it results in cellular death through 
apoptosis or programmed cell death. In a malignant neoplasm, the damaged 
DNA remains unrepaired in the cancer cell, and the cell doesn’t die but instead 
proliferates further to generate new cells with the same faulty DNA as the first 
one. DNA and the processes concerning it have long been considered to be 
targets for cancer chemotherapeutics.  
 
Figure-1.3: (a) Represents the periodic road map for discovery and research of 
chemical drugs (i.e. DNA interacting agents) like alkylating agent,   targeting 
DNA molecules. 
 (b) Shows the various conformational modifications within DNA molecules due 
to the interaction of ligand molecules including crosslinking, intercalating and 
double strand breaking agents. 
 (c) Illustrates the different types of structural modifications of DNA in detail 
[taken from Hurley LH. Natural Reviews Cancer. 2 (2002):188-200] 7.  
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Alkylating agents including nitrogen mustards and triazines function in any 
phase of the cell cycle and are widely used against many cancers such as 
leukaemia, multiple myeloma, sarcoma and lymphoma. They directly damage 
DNA by alkylating guanine nucleotides within the DNA helix.  
They usually interact non-specifically and some of them can close down 
tumorigenesis by cross linking guanine bases between two complementary 
DNA strands. These DNA strands cannot be uncoiled and be separated due to 
the cross linkage. As a consequence, the DNA cannot undergo replication and 
cell stops further cell division. Because of their non-specificity, they are harmful 
to normal cells as well.  
Targeting a specific sequence of DNA or higher order DNA structures, like 
minor and major grooves or G-quadruplexes, with small-molecules can result in 
distortion or cleavage of the DNA and this can inhibit gene transcription, 
translation and/or other cellular processes specifically within tumour cells 8. 
More recently, the G-quadruplex secondary structure is attracting scientific 
interest as it represents a new and special architecture as a target for DNA 
interactive ligand molecules. These secondary structures are more frequently 
present in guanine-rich sequences, especially in the single-stranded 3’ 
overhang of telomeres and in promoter regions of various oncogenes like C-
myc, BCL-2, c-kit etc. Thus G-quadruplexes may be better targets against 
which to design drugs to control transcription in malignant neoplasms 7. 
 
1.1.4 DNA Structure 
 
Deoxyribonucleic acid (DNA), a passive library of genetic information, is a 
polymer comprised of nucleotides which are linked to one another by 
phosphodiester linkages (Figures 1.4 and 1.5). As the 2′ position of ribose 
sugar does not have an OH group, it is called deoxyribonucleic acid (DNA). Two 
complementary strands are paired together to make a double helical structure 
and this configuration is supported by hydrogen bonding between the purine 
and pyrimidine bases of both the anti-parallel chains. The ‘double helix model` 
was established by James Watson (b. 1928), Francis Crick (1916–2004), 
Maurice Wilkins (1916–2004), who were jointly awarded the Nobel Prize in 
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Physiology or Medicine in 1962. Together, they developed the idea that the 
fundamental unit of base-sugar-phosphate is an appropriate building block for a 
three dimensional helix 9. 
 
Figure 1.4: Diagram showing the double helical structure of DNA and the 
Watson-Crick base paring between purine and pyrimidine bases. It also 
illustrates the strand directions and the major and minor groove within the 




Figure 1.5: Diagram showing the X-ray diffraction studies of DNA done by 
Maurice Wilkins and Rosalind Franklin [taken from King’s College London 
Archive Project Blog, 15 October 2010] 
Francis Crick (left) and 




Detailed structural studies show that DNA has two grooves in its backbone, 
called major and minor grooves. These are due to the different arrangements of 
nucleotides in opposite directional complementary sequences. Nitrogen and 
oxygen atoms are pointed inward toward the helix in major grooves, whereas in 
minor grooves these atoms are pointed outward. These geometrical patterns 
make them different in size. Major grooves are larger (about 240° in angle) and 
wider compared to the minor grooves (about 120° in angle) (Figure 1.6). Thus 
major grooves can accommodate a pair of water molecules, unlike minor 
grooves. Major grooves are also an easy way for DNA binding proteins to bind 
duplex DNA.  
 
Figure 1.6: Major and minor grooves of DNA with sugar-phosphate backbone. 
The major groove is about two times wider than the minor groove present in the 
right handed duplex DNA [taken from UCLA Chemistry Illustrated Glossary of 
Organic Chemistry] 
 
DNA is a polymer of nucleotides consisting of a deoxyribose, a nitrogenous 
base and a phosphate group. The bases are of two types: purines and 
pyrimidines. Six-membered and five-membered nitrogenous rings are fused 
together to form a purine base. On the other hand, pyrimidines consist of a six-




Figure 1.7: Structures of the purine (i.e. adenine and guanine) and pyrimidine 
(i.e. cytosine, thymine and uracil) bases that constitute DNA and RNA. 
 
Figure 1.8: The phosphodiester bond formation between two consecutive 
nucleotides within a helical structure of DNA strand. Nucleotides are linked 
together through phosphodiester linkages. 
 
Figure 1.9: Diagram showing the hydrogen bonding between base pairs of 
complementary DNA strands. Adenine residue forms two hydrogen bonds with 




The two complementary strands within the double helical structure of DNA are 
associated with each other via hydrogen bonding between the nitrogenous 
bases. Hydrogen bonds can be formed in two ways: between amine and 
carbonyl groups (green in Figure 1.9) or between amine and imine groups (blue 
in Figure 1.9). Adenine forms two hydrogen bonds with thymine and cytosine 
forms three hydrogen bonds with guanine residues (Figure 1.9). The stability of 
the double helical structure is further enhanced by hydrogen bonds between the 
bases and water molecules around the helix. Moreover, the hydrophobic 
interactions and π-π stacking interactions among the bases play an important 
role in stabilising the double helix 11. 
 
1.1.5 Different Forms of DNA 
 
It is believed that DNA can be found in three conformations; A-form, B-form and 
Z-form DNA. The most common one is B-form DNA, the conformation proposed 
by Watson and Crick. A double helix composed of two anti-parallel and 
complementary right-handed strands which are wound around each other and 
remain together through hydrogen bonds between nucleotides of each strands. 
A-form DNA is similar to the most common form (B-form) of DNA, but short in 
size and, unlike B-form, its base pairs are not perpendicular to the DNA axis. 
The third form of DNA, Z-form, is totally different in terms of helical orientation. It 





Figure 1.10: (A) Intramolecular G-quadruplex, a secondary structure formed by 
by hoogsteen hydrogen bonding among the guanine residues, each of  which 
comes from one of the four  g-tracts of DNA strand.  
(B) t-loop formation, usually telomeric DNA associates with some telomeric 
associated protein collectively called sheterin and form T shaped loop to protect 
the telomeric end of a chromosome.  
 (C) I-motif, a secondary structure which is rich in cytosine residues can form i-
motif by hydrogen bonding among  the cytosine residues. 
 (D) Hairpin end formed by G-C pairing. Blue and green represent the G-rich 
and C-rich stretches of DNA respectively 
 [ Taken from Gilson E, Giraud-Panis M-J and  Pisano S, Frontiers in Oncology. 
3(2013)] 12. 
 
Besides, A-, B- and Z-form double helices, DNA can exist in various structures 
because of different orientations, helical pieces and number of residues per turn 
which ultimately can change the structure of DNA. Although canonical B-DNA is 
considered to be a most common form, detailed analysis shows it does not 
have straight, monotonous, uniform structures. The structural modifications of 
DNA are due to the presence of various types of sequences within a DNA 
sequence. Sometimes DNA may form triple helices, I-motifs or four strands may 
arrange together to form secondary structures (Figure 1.10).  
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Some of these structures are favourable and some are unfavourable in nature 
due to steric hindrance, but still special types of DNA are found to participate in 
different cellular processes. For example, sequences like inverted repeats, 
palindromic repeats, mirror repeats, direct repeats and homo purine-homo 
pyrimidine G-rich or A-T rich regions favour formation of unusual conformations 
13. 
 
1.1.6 Triplex DNA 
 
A triple DNA helix can form at some points of a canonical double helical DNA 
sequence through the accommodation of a third strand within its major groove. 
The three complementary helices are twisted together around a common axis to 









Figure 1.11: Formation of triplex DNA from two duplex DNA strands. [taken 
from Dey I, Rath PC. Biochem Biophys Res Comm. 327(2005):276-86.]  14. 
Triple helical DNA can also be formed from the interactions of two duplex DNA 
strands, where third strand may come from one of these two dsDNA strand. A 
dsDNA strand especially rich in guanine (G) and adenine (A) purines 







Figure 1.12: The mechanism of the Hoogsteen bonds and Watson-Crick base 
pairing between guanine, cytosine, adenine and thymine found in triple helix 
DNA.  
Although purine bases forming hydrogen bonds are involved in Watson-Crick 
base pairing, they still have two additional hydrogen-bonding sites in their major 
groove: N-7 and O-6 for guanine residues, N-7 and 6-N for adenine residues. 
Therefore, besides the Watson-Crick hydrogen bonds, they can also make 
Hoogsteen bonds with cytosine (C) and thymine (T) residues of the 
complementary sequence of a third strand (Figure 1.12). 
The cytosine residues of the third strand need to get protonated to recognize 
the complementary guanine residues of the duplex DNA. Thus the triplex DNA 
can be formed only at low pH. The triple helix is comparatively less stable than 
dsDNA; this is because of electrostatic repulsion between the negatively 
charged phosphate groups on the backbones of the three strands. Bivalent 
cations like Mg2+ can minimise this electrostatic repulsion and stabilise the 
triplex DNA. However, the formation of the triplex structure does not interfere 





DNA not only acts as a passive storage of genetic information, but is also 
reported to take part significantly in biological processes. Besides the Watson-
Crick duplex, DNA can transiently adopt secondary structures. DNA sequences 
especially rich in guanine residues can tetramerize to form a four-stranded 
architecture which can be stabilized by monovalent and bivalent cations like 
Na+, K+ or Mg2+. DNA may also make a special framework which is structurally 
and functionally different from that of DNA and of RNA (Figure 1.13). 
 
Figure 1.13: Diagram showing Hoogsteen hydrogen bonding among the 
guanine residues in a G-quadruplex quartet. A monovalent cation is 
incorporated with carbonyl (C-6) oxygen atoms of guanine bases within tetrads. 
 
These monovalent alkali metal cations effectively help to form and stabilize the 
quadruplex structure through coordination with the carbonyl (C-6) oxygen atoms 
of guanine bases within tetrads. In every quadruplex, a single alkali metal ion 








Figure 1.14: Topological view of (A) human telomeric G-quadruplex stabilized 
by a potassium cation (K+); 
(B) Telomeric G-quadruplex with anti-parallel strands in the presence of sodium 
(Na+);  
(C) The parallel G-quadruplex of c-Myc sequence (c-Myc);  
(D) G-quadruplex forming telomeric and c-Myc promoter oriented sequences 
labelled with chromophores FAM and TAM at both ends [taken from 
Schoonover M, Kerwin SM. Bioorganic & Medicinal Chemistry. 24(2012):6904-
18.] 15. 
 
The four guanine residues of a G-tetrad are arranged in a rotationally symmetric 
fashion to make a planar platform and thereby self-associate through 
Hoogsteen hydrogen bonding rather than Watson-Crick base-pairing (Figures 
1.13 and 1.14) 16. G-quartets stack together via π- π interactions 17. 
 
 
1.1.8 Sequence and Topology of Different G-Quadruplexes 
 
Guanine bases of a G-tetrad can orient together either in syn or anti glycosidic 
conformations. NMR and crystallographic studies of various G-quadruplexes 




Figure 1.15: (a) The various topologies of bimolecular and tetramolecular 
quadruplexes with different directions of the DNA stands and diferrent 
connecting loops types. (b) The multiple possible ways to form unimolecular 
quadruplexes, giving different topological conformations [taken from Burge S, 
Parkinson GN, Hazel P, Todd AK, Neidle S. Nucleic Acids Res .34( 2006):5402-
15.] 18. 
 
G-quadruplex complexes are found to be formed by either a single 
(unimolecular), two (bimolecular) or four (tetra molecular) different DNA strands 
19. These variations in possible combinations of DNA strands, strand directions, 
loop lengths and sequence contexts are also responsible for the topological 
diversity of different G-quadruplexes (Figure 1.15). Conformational dissimilarity 
due to particular folding patterns and loop types makes each particular type of 
G-quadruplex a unique drug-interacting cavity 19, 20. 
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Quadruplex structures can also be varied because of their stand 
polarities/directions and loop types. Loops do not always connect the strands 
aggregated together to make a quadruplex in the same way. 
Categorically, four types of loops are found to be present in G-quadruplex 
structures. The most common is the propeller type and the other three are 
lateral, diagonal and V-shaped type loops, respectively (Figure 1.16). 
 
 
Figure 1.16: (a) Lateral type connecting two adjacent and anti-parallel strands , 
(b) Diagonal type, , joins the opposite anti-parallel strands as lateral loop 
connect (c) Propeller type connecting two adjacent and parallel strands and (d) 
V-shaped type loops connect two adjacent g-tracts [ taken from Patel DJ, Phan 
AT, Kuryavyi V. Nucleic Acids Res. 35 (2007):7429-55] 21. 
 
Adjacent and parallel strands are linked together via a loop connecting the top 
G-tetrad to the bottom G-tetrad, forming a propeller type loop 22. On the other 
hand, lateral loop types connect between the two anti-parallel adjacent strands 
via linking the top G-tetrad of one strand to the top G-tetrad of another strand 23. 
Diagonal loops are a third type of antiparallel loop, joining the opposite anti-
parallel strands as lateral loop connect 24. V-shaped loops make a connection 
between two consecutive quartets via a guanine residue, but unlike the other 
guanine residues present in G-tracts, this residue has no further connection with 
other guanine residues immediately before or after it 25. 
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A G-quadruplex can be defined in a generalized form as a structure originating 
from the stacking of at least two G-tetrads. G-quadruplexes of four G-tracts 
(tetra molecular) with tetrad guanines adopting anti-glyosidic conformations are 
most commonly parallel-stranded. Oligonucleotide sequences forming a 
potential unimolecular G-quadruplex have already been formulated as shown 
below. 
GmXnGmXoGmXpGm 
Here ‘m’ indicates the number of guanine units in each G-tract, which in turn 
participate directly in Hoogsteen hydrogen bonding to connect with the guanine 
nucleotides of the three other G-tracts. ‘Xn’, ‘Xo’ and ‘Xp’ represent any 
combination of different nucleotide residues, forming a loop type 26. 
 
1.1.9 G-Quadruplex Sequence Occurrences and their Significance as 
Antitumour Targets 
 
G-quadruplex-forming sequences are reported to be present throughout the 
human genome, which includes exons, introns, and untranslated regions of 
genes, promoter sequences and gene deserts, amongst others. As many as 
5,713,900 possible potential quadruplex sequences have been reported by the 
Ensemble database (V20 NCBI assembly 34c) survey to be present in the 
human genome 27. According to bioinformatics and molecular sequence 
analysis reports, G-quadruplexes are found to be overexpressed in some 
particular regions of the genome, especially in the single-stranded overhang 
DNA of telomeres and in the nuclease hyper sensitive element (NHE) of 
promoter regions of several oncogenes 28. G-quadruplexes are also highly 
expressed within cancer-affected cells in regions of genomic damage, like 
translocation hot-spots 29, 30. 
These structures can also originate from the guanine-rich part of messenger 
RNA (mRNA), ribosomal DNA (rDNA) and thrombin-binding aptamer (TBA) 31. 
Recently, the existence of a G-quadruplex within the 5′ untranslated region 
(UTR) of RNA has also been reported 32. 
However, the enzyme telomerase appears to be highly expressed in tumours 
and plays a significant role in proliferation of cancer cells, controlling oncogene 
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transcription33, 34. A number of studies have reported that G-quadruplex 
formation on telomeres prevents telomere extension as they inhibit telomerase 
by displacing it from the telomere. Thus G-quadruplexes are gaining 
prominence as anti-cancer targets because of their genetic context and 
antineoplastic potential35-37. 
1.1.10 Telomere Structure and Function 
 
Telomeres are often likened to the protective plastic caps at both ends of a 
shoelace (Figure 1.17). They protect the ends of human chromosomes from 
deterioration or from fusion with neighbouring chromosomes.  
 
Figure 1.17: Diagrammatic representation of telomeric structure with a single-
stranded overhang at the end of a chromosome in the nucleus. [ taken from 
Wong LSM, van der Harst P, de Boer RA, Huzen J, van Gilst WH, van 
Veldhuisen DJ.Heart Fail Rev. 15(2010):479-86.] 38. 
If cell division were to take place without telomeres, a loss of DNA bases from 
the chromosomal ends would occur along with a potentially lethal loss of 
genetic information 39. 
Across different species, telomeres can reach a length of approximately 15,000 
base pairs and contain regions of highly conserved repetitive sequences. In 
humans, telomeres may extend to 15-20 kb in length at birth and have reduced 
to approximately 8-10 kb in adults. Because of the end replication problem, 
telomeres get shorter in size with each cell division. DNA synthesis goes in the 
59 
 
5′-3′ direction, as it requires the 3′-OH group from the template strand to add 
free nucleotides. The RNA primer used in starting the DNA replication provides 
a 3′-OH group and a complementary strand to run the lagging strand synthesis. 
Then, after as the RNA is removed shortly after DNA synthesis starts, the 5′ end 
of the lagging strand is placed inside of the utmost 3′ end of the complementary 
template strand and there is nothing for this piece to attach to. Thus the last 
section of the lagging strand cannot be synthesized, and after several cycles of 
replication, DNA molecules ultimately get shorter and smaller, causing the end 
replication problem. Thus the capacity of human cells to divide is limited and the 
number of cell divisions before the cells enter into senescence is called the Hay 
flick limit 40. 
The 3’ single stranded overhang DNA of telomeres has guanine-rich tandem 
repeats of d (TTAGGG) n sequences. The average length of this single-stranded 
overhang is 150 nucleotides and these stretches of DNA are prone to adopt a 
four-stranded G-quadruplex 21. This unimolecular secondary conformation is 
supported by monovalent cations and Hoogsteen hydrogen bonding between 
four guanine residues from each of the four G-tracts. The DNA strand is folded 
in such a way that four guanine residues of four tandem repeats (i.e. a G-tract) 
are close enough together in the same plane to make hydrogen bonds among 
themselves and form a G-tetrad. Two or more G-tetrads are then stacked 
together to form a G-quadruplex. This special secondary conformation then 
inhibits the enzyme telomerase. This enzyme complex helps to maintain the 
telomere length by synthesizing and adding telomeric DNA repeats and thereby 
protecting the DNA from becoming shortened during cell division. Telomerase 
inhibition through the G-quadruplex formation ultimately inhibits cellular growth 




Figure 1.18 : (A) Cytosine-cytosine base pairing and (B) i-motif formation 
through base pairing between c-rich tracts; N indicates any nucleotides [ taken 
from Gurung SP, Schwarz C, Hall JP, Cardin CJ, Brazier JA. Chem com. 
51(2015):5630-2] 41. 
 
Thus these G-quadruplexes formed within telomeres are potential therapeutic 
targets for anti-cancer drugs 42. Besides this 3’ single-stranded overhang, 
double-stranded telomeric DNA is found to be incorporated into several 
telomeric proteins. Telomeric DNA in association with these proteins favours 
formation of G-quadruplexes43. On the other hand, telomeric DNA has been 
shown to prefer duplex DNA over quadruplex and i- motif DNA in the absence 
of these proteins 44. 
Like the 3’ overhang, the telomeric duplex is also rich in (TTAGGG/CCCTAA)n 
repeats. Thus the complementary G-rich strand makes a secondary G-
quadruplex whereas the other complementary C-rich strand also makes a four 
stranded architecture which is supported and organised by the cytosine-
cytosine base pairings (Figure 1.18). 
A limited number of detailed structural reports on quadruplexes of topological 
diversity exist to date 45. Among those, crystallographic analyses of telomeric 
quadruplexes have been reported and a few oncogene promoter-oriented G-
quadruplexes have also been reported using NMR spectroscopy. 
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Crystallography of both intra- and intermolecular human telomeric quadruplexes 
(12 and 22 mer sequences shown in Figure 1.19) unveil a totally different 
folding conformation and topology type (Figure 1.20) 22.  
1) d (TAGGGTTAGGGT) 
2) d [AGGG(TTAGGG)3] 
Figure 1.19: 12 and 22 mer sequences of telomeric quadruplexes 46, 47. 
 
 
Figure 1.20: Crystallographic view of the two bimolecular G-quadruplex-
sequences d(G4T3G4). Alkali metal ions (green) are appeared to be 
incorporated with the oxygen atoms of guanine residues within tetrads. 
 a) Two visualisations of head-to-tail G-quadruplexes. b) Two visualisations of 
head-to-head G-quadruplexes.  [ taken from Burge S, Parkinson GN, Hazel P, 





1.1.11 Targeting G-Quadruplexes in Gene Promoters 
 
A structure-specific monoclonal antibody targeting G-quadruplexes has been 
engineered and the existing G-quadruples, either of DNA or RNA, have also 
been visualised 48,49. In 1990, G-quadruplexes were reported to be first seen at 
the ends of eukaryotic telomeres 50. Later, Hurley and co-workers revealed a 
potential G-quadruplex structure within the nuclease hypersensitive element 
III1 (NHEIII1) of the promoter of the c-myc oncogene, and they further showed 
that putative G-quadruplex formation induced by a sequence-targeting small 
ligand molecule caused the transcriptional repression of c-myc 51. Further 
studies have reported G-quadruplex-forming sequences are also in the 
promoter sequences of other oncogenes like c-kit 52, KRAS 53, bcl-2 54 and 
VEGF 55 . 
In general, it is now thought that nuclease hypersensitive element III1 (NHEIII1) 
in the promoter regions of most genes contain more guanine-rich quadruplex 
forming sequences relative to the rest of the genome, meaning G-quadruplex 
structures can be one of the regulatory factors affecting the expression of 
genes; they are linked to the processes of replication, transcription and 
recombination of DNA. In addition, these transiently-formed structures are more 
frequently expressed at sites of primary tumours relative to in normal tissues 56. 
Thus many G-quadruplex-containing gene promoters have been reported to 
date 57 and are reported to be highly connected with many diseases 48, 
including cancer 58, diabetes 59 and cardiovascular diseases 60. 
Table 1.1: The base sequences, topology and loop length of C-MYC, KIT1 and 
BCL-2 promoter-oriented G-quadruplexes 61 62. 
Gene Sequence Topology Loop PDB ID Ref 
MYC d[TGAG3TG2TGAG3TG4A2G2 Parallel 3’ P 2A5P 
63 
KIT1 d[AG3AG3CGCTG3AG2AG3] Parallel 2’ P 2O3M 
63 
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The discovery of G-quadruplex formation in oncogenic promoter sequences and 
their subsequent role in vital cellular processes, especially in transcription, may 




Figure 1.21: The topological conformations of G-quadruplexes belonging to the 
Myc, Kit and BCL-2 gene promoters and the Myc-TMPyP4 complex 64 through 
NMR studies [ taken from Balasubramanian S, Hurley LH, Neidle S. Nat. Rev. 
drug Disco.24(2011):261-75.] 20. 
The folding patterns of G-quadruplexes in gene promoter regions are not similar 
to those of telomeric G-quadruplexes (figure-1.21) 65. Promoter-oriented G-
quadruplexes are primarily influenced by the duplex nature of genomic DNA 63. 
On the other hand, the telomeric G-quadruplex is more frequently found to form 
on the 3’-end single-stranded overhang of a telomere. 
 
1.1.12 G-quadruplex Sequences Present in C-kit Promoter 
 
c-kit, a proto-oncogene encoding a transmembrane protein with tyrosine kinase 
activity, plays an important role as a cell surface receptor for cytokines to 
regulate cellular surveillance, proliferation and haematopoiesis 66. In response 
to Kit ligands like KITLG/SCF (stem cell growth factors), tyrosine kinase 
phosphorylates several regulatory proteins like PIK3R1 (phosphoinositide-3-
kinase, a regulatory subunit-1) and PLCG1 (phospholipase C, Gamma 1) 
amongst others, thereby ultimately activating the signalling pathway through the 
phosphorylating capacity of the c-kit gene product. This in turn involves the 
phosphorylation of transcription factors including STAT1 and STAT2 67. The 5’ 
flanking region of the human c-kit gene is rich in guanine and cytosine 
nucleotides 68. Putative G-quadruplex-forming G-rich tracts have already been 
recognized in the promoter region of the c-kit gene 62. One of these sequences, 
d(5’-GGG AGG GCG CTG GGA GGA GGG-3’), called c-kit-1, is reported to be 
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located 87bp ahead of transcriptional start site. The second quadruplex-forming 
sequence, d(5’-GGG CGG GCG CGA GGG AGG GG-3’) known as c-kit-2 has 
been identified in a site of core promoter activity 62, 69. G-quadruplex-forming 
sequences and their occurrence in the regulatory region of the c-kit gene make 
them target sites for gastro intestinal tumour therapy 70. 
The d (5’-AGGG AGG GCG CTG GGA GGA GGG-3’) DNA sequence of the c-
kit oncogene forms a four-stranded G-quadruplex architecture, as confirmed by 
the combined efforts of NMR and circular dichroism spectroscopy 52, 63. 
Guanine-rich tracts arrange together to have an intramolecular G-quadruplex 
structure in the presence of K+ ions, thereby giving a distinct topological 
structure with four loops including two propeller loops formed separately by 
nucleotide residues A5 and C9. Residues C11 and U12 together make another 
loop and a relatively long stem loop is formed of nucleotide residues A16-G17-
G18-A19-G20 (Figure 1.22). 
It has been reported that alkali metal ions like K+, Na+ and Li+ take part in 
stabilising G-quadruplexes 71-75. On the other hand, Mg2+ ions have been 
reported to destabilize human telomeric G-quadruplexes 76. Interestingly, 
promoter-based G-quadruplexes are stabilised by Mg2+ ions 77. In addition to K+ 




Figure 1.22: (a) A model presentation of two asymmetric and independent c-kit 
quadruplexes (blue coloured A and yellow coloured B). Violet and green 
coloured balls (indicated by arrows) symbolize K+ and Mg2+ ions, respectively. 
(b) The c-kit G-quadruplex topology with a non-G-tract guanine residue (G10)    
[ taken from Wei D, Parkinson GN, Reszka AP, Neidle S. Nucleic Acids Res. 40 
(2012):4691-700] 78. 
In addition to the G-tracts available for the formation of the G-quadruplex, an 
isolated non-G-tract guanine is thought to participate 79. Crystallographic 
analysis of c-kit-1 also reveals that the two independently formed asymmetric 
quadruplexes ( A and B) appear to be stacked upon each other and arranged in 
a head to head fashion, allowing the incorporation of water molecules into the 
structure 78. Therefore, this distinct conformational feature of c-kit oriented G-
quadruplexes makes them attractive as anticancer-specific therapeutic targets 






1.1.13 G-quadruplex Sequences Present in Bcl-2 Promoter 
 
Bcl-2 was first identified as an anti-apoptotic gene 80. As many as 25 Bcl-2 
genes have already been found to be present in human chromosomes. Bcl-2 
proto-oncogenes encode a family of proteins which control mitochondrial outer 
membrane permeability (MOMP) and can either be pro-apotopic (including Bax, 
BAD, Bak and Bok) or anti-apoptopic (including Bcl-2 proper and Bcl-w) 81. 
However, the proportional balance between these anti-functional proteins partly 
defines the cellular vulnerability towards entering apoptosis 82. Bcl-2 proto-
oncogenes were first discovered at the breakpoint of chromosome 14, linked to 
B-cell lymphoma-related bcl-2 gene translocation to chromosome 18 83. 
 
Bcl-2 proteins can trigger apoptosis by either inducing pro-apoptotic factors or 
repressing anti-apoptotic factors. They instigate the release of apoptogenic 
factors like cytochrome c into the cytosol which in turn facilitate the process of 
apoptosis through the activation of caspases 84. On the other hand, anti-
apoptotic Bcl-2 proteins may inhibit apoptosis possibly by inhibiting the pro-
apoptotic Bax, BAD,Bak, Bok etc85. However, the upregulated Bcl-2 gene plays 
an important role in the development of many of common cancers and has also 
been reported to have resistance to conventional cancer therapies. Bcl-2 
proteins are also found to coordinate signalling systems to inhibit cell 
proliferation and cell death86-88. 
 
Figure 1.23: Simplistic diagram of the folding pattern of G-tracts in Bcl-2 
quadruplexes. Red and blue coloured boxes indicate guanine residues with anti 
and syn configurations, respectively [ taken from Raghavan SC, Swanson PC, 
Wu X, Hsieh CL, Lieber MR. Nature. 428(2004):88-93.] 89. 
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Guanine-rich regions upstream of the Bcl-2 promoter can potentially form G-
quadruplexes and thereby play an important role in regulating Bcl-2 
transcription. Quadruplexes can also be formed within the G-rich stretches of 
chromosomal translocations83, 89 
A novel folding pattern gives the unimolecular G-quadruplexes of the Bcl-2 gene 
a unique conformation. An intramolecular quadruplex is built through the 
association of both parallel and antiparallel G-tracts to form two lateral and one 
propeller-type loops 54. Three nucleotides (C-G-C) in the non-G-tract region 
make a lateral loop. Another non-G-tract stretch of seven nucleotides (A-G-G-A-
A-T-T) forms a relatively bigger lateral loop. A single nucleotide C connects 
three consecutive G-tetrads and makes a propeller-type loop (Figure 1.23). 
These loops make a similar, but not identical, topology to that seen for the 22 
nucleotide-long telomeric quadruplex42, 90. This special topological feature 
emphasizes the significance of G-quadruplexes of the Bcl-2 gene as targets for 
small ligand molecules in the field of cancer therapeutics. 
 
1.1.14 G-quadruplex Sequences Present in STAT-3 Gene 
 
The Signal Transducer and Activator of Transcription 3 (STAT-3) gene encodes 
a family of proteins acting as transcriptional activators involved in intracellular 
signalling pathways, and thereby plays a substantial role in many cellular 
processes 91. 
It has already been reported that STAT-3 is constitutively active in various 
human cancers and mutated STAT-3 inhibits apoptosis and stimulates cell 
proliferation, angiogenesis, invasion and metastasis. Thus the suppression of 
STAT-3 activation through the stabilisation of G-quadruplexes at its downstream 
flanking region is believed to be a favourable target in the field of anticancer 
therapy 92. 
The STAT-3 G-quadruplex, of sequence d(5’-G3CTG3GATG3GAG3GG-3’), has 
a different type of topological conformation due to its sequence and folding 
pattern. Recently, STAT-3 G-quadruplex folding patterns have been studied 
using a combination of CD spectroscopy and molecular modelling. Loop 
isomers 3:2:2 and 3:3:1 have already been considered as potential G-
quadruplex conformations 93. 
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1.1.15 Therapeutic Significance of Promoter-Oriented G-quadruplex 
Sequences  
 
As anticancer targets, promoter G-quadruplexes has increased in therapeutic 
significance during the last decade. Small molecules capable of selectively 
targeting and interacting with to stabilise the G-quadruplex motif are receiving 
significant interest and gaining momentum as a possible new class of 
anticancer agents. In particular, a number of small ligand molecules have 
already been reported to inhibit transcription of some oncogenes by forming and 
stabilizing G-quadruplexes.  
 
Figure 1.24: c-myc gene operating as a central oncogenic switch for 
oncogenes and the tumour suppressor APC (adenomatous polyposis coli) 
[taken from Dang CV. Molecular and Cell Biology. January 19(1999):1-11.] 94. 
For example, transcriptional repression of the MYC proto-oncogene, which is 
overexpressed in up to 80% of solid tumours, has already been reported 95.The 
Myc gene is found to be mutated in many malignancies such as breast cancer, 
which makes Myc constitutively expressed. This ultimately upregulates the 
expression of numerous genes, such as the genes involving cell proliferation, 
and ultimately develops into cancer (Figures 1.24, 1.25). A number of 
publications provide evidence in support of the presence of parallel-stranded G-




Figure 1.25: Diagram showing c-MYC sensitization of a cell to a number of pro-
apoptotic stimuli. C-Myc may induce apoptosis in three possible ways via 
activating either BAX or p53 or FAS. Apoptosis can be blocked by antiapoptotic 
factor BCl-2 XL and BCL-2 proper via blocking the release of cytochrome c from 
the outer mitochondrial membrane [taken from Stella Pelengaris1 MKAtaGE. 
Nature Reviews Cancer October 2(2002):764-76 97].  
Cytochrome c is released from mitochondria into the cytosol in response to the 
induction of c-MYC; this may be due to the induction of BAX, a pro-apoptotic 
molecule 98-101 (a). Active BAX then alters membrane pores, causing 
mitochondrial-outer-membrane permeabilization (MOMP)101, 102. The 
apoptosome is formed by cytochrome attaching together with procaspase-9 and 
apoptotic protease-activating factor 1 (APAF1)103. This formation is then 
complexed with dATP and ultimately activates the downstream caspase 
pathways involving caspase-3, degrading cell components. C-MYC may induce 
apoptosis in an alternative p53/ARF pathway involving tumour suppressor 
protein p53 activation via ARF, leading to BAX (b) transcription104. An apoptotic 
signal may pass through the FAS ligand binding with prototype death receptor 
CD95. It is then further combined with an intracellular adaptor protein FADD 
(FAS-associated death domain) (c) and ultimately enters into the main caspase 
pathway via activation of caspase-8 (Figure 1.25). C-Myc-mediated apoptosis 
can be blocked by anti-apoptotic proteins such as BCL-2 or BCL-XL in a 
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pathway involving IGF-1 receptor (d). Binding of IGF-1 to its receptor leads to 
activation of RAS and AKT kinase105. Pro-apoptotic protein BAD is activated by 
phosphorylation and subsequently segregated and inactivated by cytosolic 14-
3-3 proteins106. BAX may be sequestered and cytochrome c release blocked by 
BCL2 and BCL-XL 107. 
 








Figure 1.26: Diagram illustrating the effect of promoter-oriented G-quadruplex 
targeting ligands on transcription. The stabilisation of promoter oriented G-
quadruplex with a ligand molecules blocks the transcription of a gene [ taken 
from Ma D-L, Ma VP-Y, Leung K-H, He H-Z, Chan DS-H, Zhong H-J: (2013):01-
24.] 28. 
G-quadruplex-stabilizing ligands can modulate transcription 108 and thereby play 
a major role in proliferation (Figure-1.26). An anthraquinone derivative (Figure 
1.27) was one of the very first small ligand molecules reported to interact with 
G-quadruplex structures in telomeres 109.  
 
 
Figure 1.27: Structures of G-quadruplex-targeting ligands; anthraquinone 
derivatives and fluorenone derivatives.  
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In fact it had been developed to target duplex and triplex DNA, but was 
observed to inhibit the enzyme telomerase (EC50=23 µM) via a mechanism 
involving the binding of G-quadruplex DNA 110. 
A series of structurally-similar molecules including fluorenones (Figure 1.27) 
and acridines111, 112 have been developed on the basis of the molecular motif of 
anthraquinones113. On the other hand, TMPyP4 was the first reported c-myc G-
quadruplex stabilizer that could inhibit c-Myc expression 114. Recently, a number 
of other c-myc G-quadruplex-interacting ligand molecules have been reported. 
For example, quindoline and berberine derivatives 115 and trisubstituted 
isoalloxazines 116, cationic porphyrins 114, BRACO-19, Piper, RHPS4 and 
Quarfloxin (figure 1.28) 117 all show notable interference with oncogenic 
transcription in vitro. Quarfloxin, designed by Cylene Pharmaceuticals, entered 
clinical phase-II trials having been reported to interact with G-quadruplexes in 
vivo 28. 
Trisubstituted acridine (AS1410, with a very similar structure to that of BRACO-
19) has been found to exert cytotoxic effects in two cancer cell lines including 
breast (MCF7) and lung (A549) at sub-cytotoxic concentrations118, 119. It has 





Figure 1.28: Structures of some classical G-quadruplex-interacting ligands with 




3, 6, 9-trisubstituted acridine is considered to be the most telomeric G-
quadruplex-interacting ligand amongst all other acridine derivatives reported 121. 
In fact, the molecular structure of BRACO-19 was designed carefully through 
computer modelling to target telomeric quadruplexes; it can fit in three grooves 
in addition to sitting/stacking on to the terminal G-tetrads of the target G-
quadruplex architecture121. Therefore, it is found to provide a significantly high 
degree of stabilisation. Although it has no a significant cytotoxic effect on cancer 
cells, it has been shown to have a great inhibitory impact on the enzyme 
telomerase 36 by displacing it from telomeres, which ultimately produces a 
number of biological responses including the onset of a senescence phenotype, 
telomere shortening, the induction of chromosomal end-to-end fusions 122, 
uncapping of telomeres and reduced expression of human telomerase reverse 
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transcriptase (hTERT) 123. BRACO-19 was found to be a highly active agent 
against various cancer cell lines in vivo. 
In fact, extensive studies of BRACO-19 both in vitro and in vivo helped to 
develop telomeric G-quadruplexes as valid targets for anti–cancer therapy. 
However, in vivo studies reported that BRACO-19 has rapid and significant anti-
tumour effects and it shows remarkable tumour regression in human uterus 
carcinoma UXF1138L xenograft models123. Although BRACO-19 has a number 
of anti-tumour activities, its entry into the cell membrane is a limitation. This 
restriction on membrane permeability gives it therapeutic value to be an anti-
cancer drug 124. Acridines have been structurally modified 125-128 further to get a 
new promising and drug-like lead compound, BSG-17, which has entered pre-




PIPER is one of the most potent perylene diimides, shown to bind with G-
quadruplex DNA through a π-π stacking interaction with the terminal G-tetrad 
as demonstrated by NMR studies129. Further experiments using single-stranded 
and duplex DNA showed that PIPER is complexed with duplex DNA, limiting its 
selectivity to G-quadruplexes. Later, PIPER was found to stabilize the 
secondary architecture of G-quadruplexes by preventing the unwinding of it 
through the inhibition of G-quadruplex-specific helicases Sgs1 and T-ag 130. 
This result led to further ligand development through a number of studies 
involving side chain optimisation, resulting in new analogues targeted to 
improve their telomerase inhibitory potentials131-133. The biological evaluation of 
these newly-synthesized analogues is not extensively aimed at scrutinising 
them to produce a drug-like molecule, which may be a major drawback in the 




Cationic porphyrins like TMPyP4 are commonly chosen to use as G-quadruplex 
ligands 134. The ligand TMPyP4 was first reported to interact with DNA 40 years 
ago; it has since been shown to be a G-quadruplex ligand 135, 136 with significant 
interaction; its four cationic side chains were reported to interact with each of 
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the four grooves of G-quadruplexes 136. Since then, the DNA-interacting 
capacity of this ligand has been widely assessed and it has been found to have 
a high level of affinity toward G-quadruplex DNA with poor selectivity 137-139. 
However, sometimes it might be peculiar to show extraordinary responses such 
as the unfolding of quadruplexes in both d(CGG) repeats 140 or antithrombin 
aptamer 141 and RNA sequences r(CGG) repeats 142. Interestingly, this ligand 
has interactions with the wide variety of quadruplexes and shows binding ability 
toward duplex DNA 143, RNA, triplex DNA 144 and DNA-RNA hybrids 145. Thus it 
is still extensively studied and analysed to investigate its interactive mode and 
capacities towards the different forms of DNA 146. Interestingly, crystallographic 
studies revealed that TMPyP4 did not stack to the G-tetrads, but rather 
intercalate into or stack to base pairs formed by the DNA loops 147. This finding 
was found to be consistent with the previous evidence of its poor selectivity 
towards quadruplexes with respect to duplex DNA 137, 138. However, TMPyP4 
and its analogues were found to exhibit their cytotoxic effects against a number 
of cancer cell lines with IC50 values of more than 50µM 
136, 148, 149. Moreover, 





Unlike chemically-synthesized BRACO-19 and TMPyP-4, telomestatin was first 
extracted from the bacterium Streptomyces anulatus 3533-sv4 150, 151. It has 
been reported to be the most potent telomerase inhibitor to date. It was 
identified as a G-quadruplex ligand based on its unique cyclic aromatic 
structure, resembling the G-quartet plane, which was established by molecular 
modelling studies 152. It is shown to interact with both intra- and intermolecular 
G-quadruplexes with about 70 times more affinity than for duplex DNA. 
Telomestatin has been proved to be a prolific anticancer agent in a number of 
cancer cell lines. It inhibits cellular growth through inhibition of telomerase, 
shortening the telomere, displacing telomerase associated proteins POT1 and 
TRF2 from telomerase and facilitating apoptosis, causing cell death 153, 154. 
However, it is challenging to synthesize this ligand chemically 155. A good 
number of structurally similar and related molecules have been studied in order 






A five-ring-containing polycyclic acridine, RHPS4 was first reported by Gowan’s 
group as a potent telomerase inhibitor and has been shown to interact with G-
quadruplexes by stacking at the end of the G-quadruplex in vitro 159. 
Subsequently, it was demonstrated to exhibit acute cellular cytotoxicity upon 
exposure of 21NT breast cancer and A431 vulval cancer cells with a significant 
reduction of telomerase activity at low concentrations. It has also been shown to 
reduce the cell growth in a number of melanoma cell lines by targeting the 
enzyme telomerase. However, further studies have suggested that the anti-
proliferating effect of RHPS4 was not due to the telomerase shortening but 
rather a dysfunction of telomerase with an alteration of telomeric capping 160. 
This, in turn, causes the interruption of the cell cycle, senescence, apoptosis 
and telomeric fusions. In vivo studies have showed that RHPS4-exposed MCF-7 
cells appear to be more sensitive to a combination therapy such as the 
combination of RHPS4 with taxol or doxorubicin 
161. This combinatory effect was 
thought to be caused by the enhanced telomerase dysfunction 162, 163. 
A large number of ligands targeting G-quadruplexes have already been 
reported to date. These molecules have been primarily designed through the 
rational drug design technique 164, 165. The common feature of all these G-
quadruplex interacting ligands is that they have extended planar functionalized 
polycyclic aromatic systems (Table 1.1). They can be categorized into two 
classes: putative groove binders 166 and end polycyclic aromatic chromophores. 
The second class is composed of cationic porphyrins (e.g. TMPyP4), 
anthraquinones or perylenes. 
Polycyclic ring systems within these ligand types are assumed to provide more 
π-π stacking interactions with the terminal quartet of G-quadruplexes. Many of 
them appear to have a positively charged cationic side chain so that they can 
interact with the phosphate backbone of G-quadruplexes. Thus most of the drug 
design process is based on targeting the π-π interactions 134 and introducing 
moieties to interact with the DNA backbone (for example, amidic tails) 121. One 
example of this is the design of the porphyrin TMPyP4. 
Although these ligands molecules can have a higher interactivity toward their 
target sequence G-quadruplex, they are mostly non-drug like and deviate from 
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the Lipinski Rule of Five concerning potential for oral bioavailability 167, 168. This 
is due to their planar surfaces, high molecular weights (∼600 or above), 
lipophilicity and (for some) their significant charge and poor water solubility 169.  
1.1.22 Quarfloxin 
 
To date, CX-3543 or itarnafloxin (generally known as quarfloxin) is the only G-
quadruplex ligand from the large number studied to have progressed to phase II 
clinical evaluation for therapeutic values against malignancies such as 
neuroendocrine tumours 170 171. This G-quadruplex-targeting ligand helps to 
move nucleolin from the nucleolus to the nucleoplasm through redistribution of 
it. This specifically breaks the nucleolin-G-quadruplex entity and thereby inhibits 
Pol I transcription to facilitate apoptosis 172, 173. 
 
Figure 1.29: The synthesis and clinical progression of quarfloxin. This is the 
only molecule developed by Hurley and coworkers, enter into the phase-II 
clinical trails. [ taken from Shankar Balasubramanian LHH, and Stephen Neidle. 




Figure 1.30: Diagram illustrating the proposed mechanism of action of 
quarfloxin upon the redistribution of transcription coactivator nucleolin into the 
nucleoplasm [taken from Shankar Balasubramanian LHH, and Stephen Neidle. 
Nature Rev Drug Disco. (2011): 261-75.] 58 
After penetrating the nucleus, quarfloxin dissociates nucleolin from the G-
quadruplex. Therefore, nucleolin gets redistributed within the nucleoplasm 
which in turn triggers the process of apoptosis and ultimately inhibits tumour 
growth (Figure 1.30) 28. 
1.1.23 Other G-quadruplex-Targeting Agents Reported 
 
Many other G-quadruplex-targeting potential ligands (Figure 1.31) have already 
been developed to date. These include triazine derivatives, shown to be potent 
inhibitors of telomerase with cytotoxic activity at sub-cytotoxic concentrations 
174, 175, diamidoanthraquinones such as GSU1051, found to show a different 
degree of selectivity and potency towards G-quadruplexes 109, 2,6-pyridine 
dicarboxylate derivatives such as 360A176, shown to bind telomeres in vivo 177, 
and the phenanthroline analogue EDL35 178 and isoalloxazines 35, shown to 
inhibit c-kit expression. Many of these ligand molecules are presently in different 




Figure 1.31: Structures of some G-quadruplex-interacting compounds. 
However, newly developed rational and drug-like molecules are being reported 
regularly with relevance to the G-quadruplex area of nucleic acid research. 
Recently published reviews on this issue provide important insights into G-
quadruplex ligands179, 180. 
SYUIQ-05, a quindoline derivative, is reported as a c-myc-oriented G-
quadruplex targeting ligand. Unlike other ligands, it has shown insignificant 
interaction with human telomeric G-quadruplexes. Therefore, it was found to 
inhibit cancer cell proliferation through selective binding with quadruplexes 
formed within the G-rich NHEIII1 (Nuclear hypersensitive element) of the 
promoter region of c-myc 181, 182. It has been reported to induce apoptosis and 
cancer cell senescence183-186. 
Tetrasubstituted naphthalene diimides have been reported to be highly active 
and selective ligands for G-quadruplexes, especially for human telomeric and c-
kit-2 G-quadruplexes 187. They induce G-rich sequences to form G-quadruplex 
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structures with parallel loops and have been shown to prevent hPOT1 and 
topoisomerase IIIα from binding telomeres 188. They also appear to inhibit 
telomerase in MCF7 cells 118. They are highly cytotoxic in a number of cancer 
cell lines with IC50 values of ~0.1 µM. 
Anthracene derivatives have been found to bind with telomeric quadruplexes, 
impairing telomere function, inhibiting cancer cell proliferation and promoting 
senescence 189. 
Both amidoanthraquinone and perylene derivatives have been reported to be 
telomeric G-quadruplex-binding ligands and thereby they inhibit telomerase with 
the inhibition of cancer cell proliferation190-192. 
Macrocyclic pyridyl polyoxazoles are reported to be selective ligands for G-
quadruplexes over duplex DNA 193, 194. 
Triethylene tetramine (TETA) has been reported to interrupt telomerase function 
by inhibiting human telomerase reverse transcriptase (hTERT) expression and 
promoting tumour cell senescence195, 196.  
Bisantrene, synthesized from an anthracene derivative through the substitution 
of two side chains (4, 5-dihydro-1H-imidazol-2-yl-hydrazonic groups) at the 1 
and 5 or 1 and 7 positions of the aromatic ring, has been reported to bind G-
quadruplexes on telomeres and inhibit telomerase 189, 197. 
A tetra-substituted naphthalene-diimine derivative (MM41) (Figure 1.32) has 
been reported as a strong ligand, targeting BCL-2, k-RAS1 and k-RAS1 gene 
promoter-oriented G-quadruplexes, as it shows significant ∆Tm values of 26.4 
°C, 22.5 °C and 19.8°C, respectively, from FRET experiments.  
 
 




This ligand molecule is found to have significant in vivo anti-tumour potential 
against the MIA PaCa-2 pancreatic cancer xenograft model 198. 
 
Distamycin A, a polyamide chemical compound, is being used as an anti-cancer 
drug 199. This drug prefers A-T rich minor grooves as this groove proves a 
narrow space to achieve tight contact and strong van der Waal’s interactions. 
However, distamycin alters the DNA conformation by changing structural 
dimensions within the particular part of the minor groove, in turn hampering the 
interaction of transcription factors, and ultimately altering genetic control 200. 
 
 
Figure 1.33: Structure of Distamycin A. 
 
Recent NMR studies show that distamycin A (Figure 1.33) also has binding 
affinity towards G-quadruplexes and stacks upon the terminal plane of G-
quadruplex conformations. They either interact as a dimer with two of the four 
grooves of the quadruplex or two molecules of distamycin A sit over each of the 
two G-tetrads planes 201. 
 
Stephen Neidle’s group reported that the pyrrole group’s (specially 2,5 bi-
substituted pyrrole group) inclusion within the distamycin A structure increases 
its affinity towards quadruplexes. They synthesized a number of polyamides by 
linking pyrrole rings based on the distamycin A molecules. Subsequently, they 
evaluated those molecules through the FRET melting assay. Few of these 
structurally modified molecules displayed a higher affinity for G-quadruplex DNA 
over duplex DNA than that of distamycin A 202. 
 
Recently, the Thurston/Rahman Group has reported a new set of G-quadruplex 
selective acyclic bi-aryl polyamides based on a distamycin motif (Figure 1.34) 
203. They replaced pyrroles by introducing biaryl building blocks to switch 
preference to quadruplex DNA from duplex DNA, using the distamycin scaffold 
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as a molecular backbone. G-quadruplex ligands of this novel class showed a 




Figure 1.34: A) Structures of the biaryl polyamides synthesized by the 
Thurston/Rahman Group 203. B) Crystal structure based on the molecular model 
of compound 4, which is shown to interact to the terminal G-tetrad (yellow) of a 
human intramolecular telomeric quadruplex–ligand complex, shows the 
distinguishing U shape of the biaryl polyamides [ taken from Rahman KM, 
Reszka AP, Gunaratnam M, Haider SM, Howard PW, Fox KR. Chem comm. 
27( 2009):4097-9.] 203. 
 
Those ligands with relatively large aromatic ring systems can be used as a 
rational scaffold to attempt to make molecules with improved affinity for 
quadruplex DNA while retaining selectivity. The design strategy is to change or 
introduce different functional groups and phenyl rings to target a particular type 




More recently, the Thurston/Rahman Group has identified 13 different drug-like 
chemical scaffolds by screening three different NCI chemical libraries (Figure 








Figure 1.35: Structures of the thirteen compounds of diverse chemical structure 
with selective telomeric G-quadruplex-binding activity discovered by the 
Thurston/Rahman Group. 
 
These compounds were screened from a total of 2307 structurally diverse 
molecules and evaluated through a FRET-based melting assay. These 
compounds showed notable binding affinity towards telomeric G-quadruplex 
sequences and it should prove possible to modify them to enhance their affinity 




Molecules, especially 1, 3-phenylene-bisbenzothiazole-urea (NSC 319990), a 
reported Chemokine Receptor 2 (CCR2) antagonist, are shown to be more 
selective stabilisers of telomeric G-quadruplex structures. It achieves 22.7°C 
stabilisation of the same at 1 µM concentration. Therefore, it could be a target 
scaffold to achieve structural modification with different benzofused building 
blocks for optimum activity 204. 
 
In fact, a good number of molecules interacting with DNA have already been 
reported, having benzofused rings in their structures. Some of them are 
discussed below. 
         
             
Figure 1.36: Structures of Hoechst 33342 and Hoechst 33358. 
Hoechst stains, particularly Hoechst 33258 and Hoechst 33342 (Figure 1.36), 
are blue fluorescent dyes used for staining DNA in emission or excitation 
spectra205, 206. These minor groove-targeting fluorescent compounds have two 
benzofused rings (benzimidazole rings) linked to one another. These flat 
molecules preferentially bind to AT base pairs and stabilise target DNA through 
hydrogen bonds, Van der Waals and electrostatic interactions 207. 
A lot of structural modification on Hoechst 33258 has already been done to tune 
its activity towards specific DNA sequences208, 209. Maji et al. (2013) reported 









They replaced the phenolic group and piperazine residue at both ends of 
Hoechst 33258 with p-pyben, m-pyben and o-pyben, respectively, to achieve 
positional isomers. The molecules they synthesized, named (2a), (2b) and (2c) 
(Figure 1.37), are found to show selectivity towards telomeric G-quadruplexes 
over duplex DNA 210. 
 
Novel indole derivatives, including bis-indole carboxamide and a derivative 
containing pyridine, (Figure 1.38) have been reported to interact with G-
quadruplex sequences.  
 
Figure 1.38: Structures of cationic bis-indole derivatives 1 and 2. 
These molecules appear to exhibit a high stabilization capsid against F21T, c-
kit-1, c-kit2 and c-myc quadruplex sequences 211.  
 
1.1.24 Biological Consequences of G-quadruplex-Targeting Ligands 
 
Ligands interacting with G-quadruplex DNA are shown to give biological 
responses in vivo; in some cases they are supported by in vitro observations as 
well. There are a number of biological effects including anti-proliferative 
activities at sub-cytotoxic concentrations in various cancer cell lines, inhibition of 
telomerase, induction of senescence and apoptosis, telomere shortening, 
chromosomal end-to-end fusion and DNA damage responses. Many cancer 
xenografts with various models have been found to show anti-tumour activity of 
individual ligands and in combination with other anticancer drugs. Initially, these 
activities shown by using different ligands were explained on the basis of 
telomerase inhibition, but now it is believed that the antitumor activity is not only 
due to the telomerase inhibition; the binding of the ligands to telomeres and the 
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subsequent telomere uncapping are also thought to be responsible for these 
biological effects. 
Recently, it has been evident that telomerase plays an independent role in 
maintaining telomere length during the process of tumorigenesis 212. In fact, 
telomerase at high expression levels is well connected with the development of 
cancer. Differences in both the telomeric lengths of cancer or normal cells and 
the levels of telomerase activity could both be particular indications for the 
selective toxicity effects of particular G-quadruplex ligand molecules in vivo. G-
quadruplex ligands are found to inhibit the expression of several oncogenes20, 
213. 
Human telomerase reverse transcriptase (hTERT) is highly expressed in cancer 
cells. It has been shown that oncogene c-myc-encoded transcription factors 
play a direct role in the upregulation of telomerase activity in cancer cells, as 
they stimulate expression of hTERT among others genes. The reduced 
telomerase activity due to G-quadruplex ligand binding could be correlated with 
reduced expression of oncogenes like c-myc 214. 
Biological evaluations are suggesting that G-quadruplex ligands are mainly 
dual-action molecules. The main mode of action is still thought to be the 
inhibition of telomerase activity. On the other hand, some other biological 
responses implicate an inhibitory role of G-quadruplex ligands in the 
transcription of particular genes. These different findings have attracted 
research into ligands molecules which can discriminate between various G-
quadruplex-forming sequences with different topologies within the human 
genome, with the aim of developing a more selective G-quadruplex ligand to act 
on a specific oncogene for the induction of selective biological responses. 
 
1.1.25 Design of New G-quadruplex Stabilizer 
 
Hurley and co-workers first reported the potential binding of cationic porphyrin 
TMPyP4 with telomeric G-quadruplexes in 1998 215. They proposed that 
TMPyP4 has an appropriate size and shape to stack with the G-tetrads in order 
to stabilise quadruplex DNA after obtaining the structural and conformational 
information of the telomeric G-quadruplex through UV and NMR spectroscopy 
86 
 
studies. They investigated the G-quadruplex stabilizing capacity of TMPyP4 
through several techniques and they also evaluated a large number of TMPyP4 
analogues and completed a SAR study to elucidate the mechanism of action 
and to identify the lead porphyrin TMPyP4. This lead molecule has been 
reported to be an effective inhibitor of human telomerase in HeLa cell extract. 
Accordingly, porphyrin TMPyP4 showed an IC50 of 6.5 ±1.4 µM 
215. 
Another promising method to design G-quadruplex stabilizing ligands is 
molecular docking. It is a computer-assisted drug design technique to visualise 
three dimensional features and evaluate newly-proposed drugs within their 
receptors. It informs about effective binding between ligand and receptor and at 
the same time helps to choose a rational molecule from a molecular library to fit 
with a specific topological conformation of diversified G-quadruplexes. The 
overall selection process involves several steps (figure 1.39) 28. 
 
Figure 1.39: Sequential drug design process using a molecular docking system 
28. 
This process has been successfully used to develop G-quadruplex-binding 
ligands. The following body of work contains a combined process whereby 
molecular docking and rational design have both been used to develop a library 






1.2 Biophysical Evaluation of G-quadruplex-Targeting Ligands 
 
There are many biophysical methods used to study the mode and the 
interaction capacity of ligands molecules towards G-quadruplex secondary 
structures. Experimental methods, especially different spectroscopic 
approaches, are widely used for biophysical evaluation of different chemically 
synthesized G-quadruplex ligand molecules. Some of these techniques are 
described below in short 216. 
 
1.2.1 Circular Dichroism Spectroscopy 
 
Circular Dichroism (CD) spectroscopy has long been used to study for G-
quadruplex structure types and their interactions with targeted ligand molecules. 
Its capacity to show structural signals based on the conformational differences 
of the target makes this method an efficient technique in the field of modern 
biochemistry. The conformational changes observed upon binding of specific 
ligands can be monitored by this method through the measurement of 
absorption differences between left-handed and right-handed polarized light. 
Zero CD intensity shows in the absence of regular structure. Initially, zero CD 
intensity shows as there no regular structure to monitor, but a specific 
conformation/structure produces both positive and negative signals in a 
spectrum. Therefore, it is widely used for the structural analysis of proteins and 
nucleic acids. Any changes including temperature, salt concentration and pH 
can significantly modify the DNA secondary structure and this modification 
exhibits particular signals in the absorption spectrum. It is also useful to know 
the binding mode and affinity of a ligand molecule 217-219. 
 
1.2.2 UV/Fluorescence Technique 
 
UV or fluorescence spectroscopy is a simple technique used to study the 
interaction of G-quadruplexes with their corresponding ligand molecules. It 
gives changes in the intensity and wavelength of the G-quadruplex 
absorption/emission signals upon the addition of the ligand molecules. Ligand 
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molecules in free form in solution show well-characterised absorption bands in 
the visible region. As the drug molecules soon complex with the secondary 
structure, it causes a maximum shift of this band. Therefore this method is an 
easy approach to determine the degree of ligand affinity toward G-quadruplex 
structure. However, these techniques can be used for both qualitative and 
quantitative analyses, like stoichiometry and binding constants of ligand 
molecules with DNA146, 220. 
DNA secondary structure stabilization by a specific ligand molecule can also be 
measured through thermal studies where UV absorbance of different 
temperatures is monitored at a certain wavelength. 
 
1.2.3 Isothermal Titration Calorimetry 
 
Isothermal Titration Calorimetry (ITC) is used for the direct measurement of 
thermodynamic characteristics such as binding affinity constant, enthalpy and 
stoichiometry of interaction between the G-quadruplex DNA and ligands. ITC 
can measure the heat either released or absorbed during DNA-ligand 
interactions. By measuring this heat, it is possible to characterise the total 
thermodynamic profile of a DNA-ligand interaction in a solution. The heat values 
represent the molar ratio between ligand and G-quadruplex and thereby provide 
a parameter to know the degree of interaction of ligand toward G-quadruplex. 
This technique has the capacity to allow direct comparison of a large number of 
ligand molecules like TMPyP4 and acridine in order to study their interaction 
capacity with G-quadruplex secondary structures221, 222. 
 
1.2.4 DNA Footprinting 
 
A method which is used for determining the selectivity and interacting capacity 
of a ligand binding with a target DNA sequence in vitro, DNA footprinting 
involves the target sequence containing radiolabelled DNA fragment being first 
incubated with the ligand. It is then allowed to be digested with the enzyme 
DNase I. DNase I is widely chosen as it can bind with the minor groove and 
break the phosphodiester bonds of the DNA template. This enzyme cuts the 
DNA in a random manner, but the sequence bound by ligand remains 
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protected. The resulting fragments are subjected to polyacrylamide gel 
electrophoresis (PAGE) for separating into different bands. The gel is then 
visualised by phosphor imager screen. The specific ligand-bound part of the 
target DNA can be identified by the absence of fragments corresponding to the 
cleavage of DNA in that region. This is also a simple method to investigate 
whether a ligand can selectively bind to a specific sequence of DNA 223. 
 
1.2.5 Equilibrium Dialysis 
 
It is a simple and convenient method to evaluate the interacting capacity and 
sequence selectivity of a G-quadruplex-targeting ligand molecule. This process 
involves two chambers separated by a selectively semi-permeable membrane 
which allows only ligand but not G-quadruplex to pass through. G-quadruplex 
DNA of known concentrations is placed in each of these two chambers. The 
ligand molecules can easily pass from their own chamber to the other chamber, 
while the G-quadruplex is retained in its chamber224, 225. Therefore, ligand 
molecules move freely between these two chambers and they are supposed to 
interact with the target G-quadruplex in the other chamber. 
The ultimate concentration of free ligand molecules becomes the same in both 
chambers at the equilibrium stage. If the ligand molecules bind with the G-
quadruplex, the ligand concentration will be higher in the G-quadruplex 
chamber. Thus the concentrations of ligands can be varied with their respective 
affinities towards their target G-quadruplex DNA. The concentrations of free and 
DNA-bound ligand are required to determine the equilibrium binding constant. 
One of the major advantages of this tool is to measure the low affinity of a 
ligand molecule which is not detectable by other methods available. 
 
1.2.6 Nuclear Magnetic Resonance 
 
Nuclear Magnetic Resonance has been used for studying the capacity of a 
ligand molecule to bind with a target G-quadruplex. It provides a distinguishing 
set of NMR signals in the proton spectrum upon the binding of the ligand with 
the G-quadruplex. It can also explain the conformational changes that occur 
due to G-quadruplex-ligand complex formation 226. 
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1.2.7 Mass Spectrometry 
 
Mass spectroscopy is a common tool used to determine the interacting 
characteristics between ligands and DNA molecules. The electrospray 
ionization technique can determine the mass of both the G-quadruplex and a G-
quadruplex–ligand complex as this approach allows minimum fragmentation of 
the biomolecules, which ultimately helps to reveal the stoichiometry of the G-
quadruplex-ligand complex 227-230. 
 
1.2.8 Voltammetric Methods 
 
The electrochemical voltammetric approach is also used to investigate the 
interacting capacity of a ligand toward its target G-quadruplex sequences. Data 
obtained from the voltammetric method helps to determine the binding constant 
(K) and binding site size of the target sequence. The binding site size suggests 
the binding area in terms of the number of base pairs covered by the ligand 
molecules. Electroactive species are excited by the application of voltage, which 
then increases the electric current. The intensity of the electric flow depends on 
the concentration of species under study. Ligands molecules with binding 
capacity for DNA reduce the current flow and also reduce the diffusion rate 231, 
232. 
 
1.2.9 Viscosimetry Titration 
 
Binding of a ligand to the target DNA changes the viscosity of the DNA solution. 
The relative specific viscosity coming from the change in the viscosity of the 
DNA solution upon addition of the ligand molecules can be used to study ligand 
binding affinity. A ligand which intercalates or electrostatically binds to a target 
DNA sequence causes conformational distortion in that DNA molecule, which 
ultimately increases DNA length. Therefore, the titration of duplex DNA with 
interacting ligands causes an increase of relative viscosity; it is because of the 
presence of more intercalating agents at the site of base pairs throughout of the 
target sequence. On the other hand, ligands with less intercalating activity 
cause no changes of DNA solution viscosity in aqueous state 233, 234. 
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1.2.10 Melting Experiment 
 
The melting experiment is based on the relative melting temperatures of both 
ligand-bound DNA and the unbound DNA molecules. It is a specific temperature 
at which fifty percent of DNA is denatured and takes a single stranded form. 
Generally ligands have a tendency to stabilize the DNA secondary structure. 
Thus DNA which is bound with a ligand molecule is found to melt at a higher 
temperature relative to the unbound DNA. Therefore, higher affinity of a ligand 
for the DNA results in a higher melting temperature of the ligand-bound DNA. 
The melting experiment can be monitored by a number of techniques like UV, 
CD or fluorescence spectroscopy 235. 
 
1.3 FRET-based DNA Melting Assay 
 
Fluorescence Resonance Energy Transfer (FRET) technology is extensively 
used to evaluate the interacting capacity of ligands towards specific secondary 
DNA structures like G-quadruplexes by measuring an increase in nucleic acid 
melting temperature (ΔTm) 236. The difference between the Tm of the ligand-
bound structure and the Tm of the unbound DNA is termed the ΔTm parameter 
237. One strand of an oligonucleotide is labelled with FAM (fluorescein) as a 
fluorescence donor and complementary strand (or other end of heparin) is 
labelled with TAMRA as an acceptor 238. The intensity of the FAM fluorescence 
upon excitation by heating is then measured as a function of temperature 239. 
1.3.1 Principle of FRET 
FRET is a fluorescence-based spectroscopic method with distance information 
based on structural changes of a molecular complex. It is based on the non-
radiative energy passing between molecules over long distances (10-80°A). The 
donor molecule absorbs photons and then transfers the energy gained to the 
acceptor molecule. The transfer of this energy needs to satisfy two factors: 
proximity and compatibility. The ‘Förster distance’ or R0 (also called the Förster 
radius, R representing the distance between the donor and acceptor 
chromophores) is defined as the characteristic distance between donor and 
acceptor chromophores within which the non-radiative energy transfer is 
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possible. It is usually within 10 - 80 0A. At the same time, the absorbance 
spectrum of the acceptor molecule needs to overlap with the emission spectrum 
of the donor molecule. This donor fluorophore can only then directly excite an 
acceptor fluorophore which ultimately emits energy at a new wavelength. Thus 
activation of the acceptor fluorophore can be detected by emitted energy at a 
new wavelength. Target DNA sequence and a ligand are associated together to 
make a stable complex with lower energy. The interacting affinities of different 
ligands toward target DNA sequence are assessed by the changes in their 
stabilisation through their corresponding melting temperatures. FRET results 
have been shown to correlate with results from UV melting profiles. Melting 
curves following the melting process of DNA-ligand complexes represent the 
corresponding melting temperatures (∆Tm) against various ligands of different 
concentrations. The changes in the melting temperatures due to the DNA bound 
ligands can be measured with respect a melting temperature of respective 
control DNA 240. 
A G-quadruplex-forming oligonucleotide (for example, human telomeric F21T 
sequence) can be labelled with the two fluorescent probes; one is a donor and 
the other an acceptor (Figure 1.40). 
 
 
Figure 1.40: Schematic diagram of the experimental determination of the 
stabilizing effect of a G-quadruplex-binding ligand using FRET Technology. 
  [taken from Renčiuk D, Zhou J, Beaurepaire L, Guédin A, Bourdoncle A, 






1.3.2 Advantages of the FRET Assay 
 
The FRET technique of DNA melting processes has a couple of advantages 
over other traditional techniques like CD or UV spectroscopy 241. FRET-based 
measurement is a relatively rapid and cheap process to implement, applicable 
to fluorescent derivatives of any molecular system and is an automatable 
process that requires a very small amount of DNA sample to monitor the 
melting process with high precision and accuracy. FRET-based assays with 
specificity for human DNA have been successfully adopted in a high-throughput 
format resulting in the rapid measurement of the quadruplex stabilisation 
potential of synthetic ligands. In contrast, both CD and UV spectroscopy require 
high concentrations of oligonucleotides, resulting in high costs and their 
measurements cannot easily be conducted in a high-throughput format. 
Moreover, the change in absorbance in the UV method is small in comparison 
with the large signal changes observed in the FRET fluorescence technique. 
FRET is also a more sensitive technique to determine the stability of a DNA by 
the means of melting temperature 242. 
 
1.4 Aim of the Current Study 
 
The diversity in shape and nature of G-quadruplex structures could be used to 
enhance selectivity to a particular type. In particular, analysis and exploitation of 
the different grooves and loops that are present in different types of G-
quadruplex DNA, like Telomeric, c-kit-1, c-kit-2, and Bcl-2 G-quadruplexes, has 
not yet been undertaken in a systemic manner from a drug design perspective. 
However, the overall goal of this project is to exploit the recent structural 
information available on human telomeric, bcl-2 and c-kit oncogenic DNA 
quadruplexes to achieve guidelines for the discovery of a novel set of 
quadruplex-specific small-molecule ligands. Based on the promising 
quadruplex-selectivity observed for the reported biaryl polyamides 203, the first 
objective was to synthesize libraries of novel ligands based on this template that 
could have potentially enhanced selectivity and binding affinity for quadruplex 
versus duplex DNA, and selectivity for quadruplexes of different types within the 
specific oncogene sequences. This should provide greater understanding of 
structure-activity relationships for molecules of this type. 
94 
 
The specific objectives are as follows: 
 Synthesise novel benzofused polyamide ligands by replacing the 5-
membered heterocycles and central biaryl ring with different benzofused 
groups using solution phase chemistry. 
 Evaluation of the new molecules using the FRET-based DNA thermal 
denaturation assay (including duplex competition) and also circular 
dichroism (CD) spectroscopy for determining their affinity and selectivity 
for a number of different G-quadruplex sequences including the c-Myc 
quadruplex. 
 Evaluation of the novel ligands for cytotoxicity against a panel of relevant 
tumour cell lines such as MDA-MB-231(Triple negative breast cancer cell 
line), HeLa (Cervical cancer cell line) etc. 
 A longer term objective of the project is to select a suitable candidate 
ligand for evaluation in a human tumour xenograft mouse model of a 
specific cancer type associated with the oncogenic quadruplex being 
targeted. Ligands with antitumor activity in this model may be selected 













Chapter 2: Results and Discussion 
 
2.1. Introduction 
A new set of G-quadruplex-selective acyclic biaryl polyamides based on a 
distamycin motif (Figure 2.1) 203 has already been reported by the 
Thurston/Rahman Group. They replaced pyrroles by introducing biaryl building 
blocks to switch preference to quadruplex DNA over duplex, using the 
distamycin scaffold as a molecular backbone. G-quadruplex ligands of this 
novel class showed a high degree of selectivity towards quadruplexes like HT4, 




Figure 2.1: Structure of Distamycin A. 
 
 
The Thurston/Rahman Group has also previously identified 13 different drug-
like chemical scaffolds by screening three different NCI chemical libraries. They 
screened those compounds out from a total of 2307 structurally different 
molecules and they evaluated them through the technique of FRET-based DNA 
melting assay. These compounds showed notable binding affinity towards 
telomeric G-quadruplex sequences. It is possible to modify their structures with 
the help of molecular modelling and bio-physical assay to enhance their affinity 




Figure 2.2: Structure of 1, 3-phenylene-bisbenzothiazole-urea (NSC 319990) 
with benzofused rings (red). 
Molecules, especially 1,3-phenylene-bisbenzothiazole-urea (NSC 319990) 
(Figure 2.2), a reported Chemokine Receptor 2 (CCR2) antagonist, are shown 
to be more selective stabilisers of telomeric G-quadruplex structure. It does 
22.7°C stabilisation of the same at 1 µM concentration. Therefore it could be 
target scaffold to get a structural modification with the different benzofused 
building blocks for optimum activities 204.  
 
In fact a good numbers of molecules interacting DNA have already been 




Figure 2.3: Molecular structures of Hoechst 33342 and Hoechst 33358. 
Benzofused rings are shown as red. 
 
Hoechst stains particularly Hoechst 33258 and Hoechst 33342 (Figure 2.3) are 
blue fluorescent dye, being used for staining DNA in emission or excitation 
spectra 205, 206. These minor groove targeting fluorescent compounds having 
two benzofused rings (benzimidazole rings) linked one after another. These flat 
faced molecules preferentially bind to the AT base pairs and stabilize the target 
DNA by forming hydrogen bonds, Vander Walls and electrostatic interactions207. 
A lot of structural modification on Hoechst 33258 has already been done to tune 
its activity towards specific DNA sequences interested208, 209. Maji et al. 2013 







Figure 2.4: Three isomers 2a (o-pyben), 2b (m-pyben) and 2c (p-pyben). 
Benzofused rings are shown as red. 
They replaced the phenolic group and piperazine residue at both ends of 
Hoechst 33258 with p-pyben, m-pyben and o-pyben respectively to have the 
positional isomers. The molecules they synthesized named (2a), (2b) and (2c) 
(Figure 2.4) are found to show the selectivity towards telomeric G-quadruplex 
over duplex DNA 210. 
 
In 2008 Dash and his group has also reported by the synthesis of novel indole 
derivatives including bis-indole carboxamide and a derivative containing 
pyridine to target G-quadruplex sequences (Figure 2.5).  
 
 
Figure 2.5: Cationic bis-indole derivatives 1 and 2 Benzofused rings are shown 
as red. 
 
They evaluated these ligands through FRET-based melting analysis. These 
molecules appear to exhibit high stabilization capacity against F21T, c-kit-1, c-
kit2 and c-myc quadruplex sequences 211.  
Therefore, a novel class of biaryl polyamides developed by the Rahman and 
Thurston group was taken as a template and benzofused building blocks of 
different types were chosen to make another new class of molecules which 
were assumed to be more potent and drug-like G-quadruplex ligands. 
 
2.1.1 Rational Design of Benzofused Polyamide Synthesis 
 
A number of different benzofused polyamides were synthesized based on biaryl 
polyamide as a structural motif. A benzofused building block was initially 
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coupled with a tertiary amine tail through an amide coupling reaction. Then two 
other consecutive benzofused carboxylic acids were coupled in a same way to 
synthesize a benzofused polyamide. Benzofused units were incorporated in 
place of the pyrrole and furan rings of biaryl polyamide motif (Figure 2.6).  
 
Figure 2.6: Benzofused building blocks incorporated in place of the pyrrole and 
furan rings of biaryl polyamide, 4 motifs. 
The idea is that the inclusion of more aromatic ring systems within biaryl 
polyamides is supposed to provide more π electrons to achieve improved π-π 
interaction between the G-quartet and polycyclic ring system of the ligand 
molecules (Figure 2.6). 
2.2 Rational Approaches and Strategies for Designing Different 
Libraries 
As many as 10 libraries of benzofused polyamides were designed and 
synthesized throughout the project period. FRET-based DNA melting assays 
and Molecular Modelling and Molecular Dynamics (MD) Studies on the 
molecules of a previous synthesized library provided the guidelines for 
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designing the structural motifs of the next libraries. These rational strategies 
helped to achieve better G-quadruplex interacting molecules. 
2.2.1 Design and Rationale of Library-1A Molecules 
 
At the beginning of this project, a set of benzofused polyamides (8 in total) were 
synthesized by adding three consecutive 5-nitro-benzofused-2-carboxylic acid 
units through the HOBt-DIC mediated amide coupling reaction with a tertiary 
amino tail via the N1,N1-dimethylpropane-1,3-diamine building block. This 
followed the 5′-2′ substitution reaction. A structural motif of these molecules is 
shown below (Figure 2.7). 
 
 
Figure 2.7: The basic chemical scaffold for 5’-2’ substituted benzofused 
polyamides; X= O or N or S. 
 
2.2.2 Design and Rationale of Library-1B Molecules 
 
As the molecules belonging to library-1A did not show any significant 
interaction towards any of the G-quadruplex sequences used in the FRET-
based analysis, a similar set of molecules (10 in total) were synthesized with 
structural modifications through the replacement of the tails and the functional 
groups at the third benzofused ring; these formed library-1B.  
 
 
Figure 2.8: The basic chemical scaffold for 5’-2’ substituted benzofused 
polyamides; X = O or N or S and R represents the tertiary amine tails including 
4-(pyrrolidin-1-yl) butan-1-amine and 2-(piperidin-1-yl) ethan-1-amine. 
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These modifications were done to investigate whether these molecules gave 
any improved interaction towards G-quadruplex DNA types. A structural motif of 
these molecules is shown below (Figure 2.8). 
2.2.3 Design and Rationale of Library-2 Molecules 
 
As the molecules belonging to both library-1A and 1B did not show a 
significant interaction with G-quadruplex DNA types, a set of new molecules (9 
molecules in total) were synthesized with the help of molecular modelling 
studies (Figure 2.21, 2.22 in sections 2.5). Here, a 5-nitro-benzofused-3 
carboxylic acid was included as a second building block instead of 5-nitro-
benzofused-2-carboxylic acid so that ligand molecules would have relatively 
more curvature in their structures compared to the library-1 ligand molecules. 
Commercially available 5-nitro-indole-3-carboxylic acid was introduced as the 
second building block through the 5′-3′ substitution instead of 5′-2′ substitution 
as used for synthesizing library-1A and 1-B molecules. The structural motif of 
this library is shown below (Figure 2.9). 
 
Figure 2.9: The basic chemical scaffold for library-2 molecules; X= O or N or 
S. 
2.2.4 Design and Rationale of Library-3A Molecules 
 
As the introduction of curvature within the library-2 molecules made the 
benzofused polyamides more potent towards the G-quadruplexes used, it 
encouraged the development of another library of molecules with enhanced 
curvature within the same scaffold. Therefore, two sets of molecules were 
synthesized by including two consecutive molecules of the 5-nitro-benzofused-
3- carboxylic acid unit in a benzofused polyamide structure in two different 
fashions. A first set of molecules was synthesized by coupling two consecutive 
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5-nitro-indole-3-carboxylic acids followed by termination with four different 
benzofused acids (Figure 2.10 (A)). A second set of molecules was then 
synthesized by starting with a 5-nitro-benzofused-2-carboxylic acid, which was 
then immediately coupled with 5-nitroindole-3-carboxylic acid and terminated 
with four different benzofused-3-carboxylic acids (Figure 2.10 (B)).  
 
Figure 2.10: The basic chemical scaffolds for library-3A molecules. (A) and (B) 
represent each set of molecules within this library. Here X = O, N, S. 
 
2.2.5 Design and Rationale of Library-3B Molecules 
 
This library was aimed at investigating the effect of an electron-withdrawing 
nitro-group at the terminal indole unit. Therefore the library-3A molecules were 
modified by keeping the nitro group of the terminal 5-nitro-indole-3-carboxylic 
acid unit without changing the shape of the molecules. The structural motif of 
library-3B is shown (Figure 2.11). 
 
Figure 2.11: Structural motif of library-3B molecules. Here X = O, S, N. 
As one (4.77) of the compounds (Figure 2.39) in this library showed a 
significantly higher interaction with G-quadruplex sequence types, that 
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benzofused polyamide (4.77) was taken as a lead ligand for further structural 
modifications through a structure-activity relationship (SAR) study. The 
structure-activity relationship (SAR) was done with various possible 
modifications of the shape, tail types and functional groups attached to the 
terminal building block as shown on the structural motif. 
It was found that the electron-withdrawing nitro group plays a positive role in 
enhancing the ligand-G-quadruplex interaction and at the same time it was 
apparently found that the indole is comparatively better than any other type of 
nitro-benzofused-acid building blocks used. The most curved molecule was 
found to be the most interactive towards G-quadruplex types as shown in the 
FRET-based DNA melting assay. 
 
2.2.6 Design and Rationale of Library-4A Molecules 
 
Molecular docking studies of molecules containing three consecutive 5’-3’ 
benzofused moieties (for example, 4.93) (Figure 2.39) suggested that the 
inclusion of a third 5’-3’-substituted benzofused moiety should enhance G-
quadruplex stabilisation to a small degree compared to two 5’-3’-substituted 
benzofused moieties (for example, 4.77) (Figure 2.39). 
A new library of molecules containing four different benzofused polyamides was 
synthesized to investigate the relevance of the electron-withdrawing NO2 group 
to the activity of the most active compound 4.93. The common structural motif 
of library-4A molecules is shown here (Figure 2.12). 
 




2.2.7 Design and Rationale of Library-4B Molecules 
 
Here, the most interactive lead ligand 4.93 was optimised through tertiary amine 
tail modifications. Therefore, a set of molecules was synthesized by structural 
modification of lead compound through the substitution of the N1, N1-
dimethylpropane-1,3-diamine tail with different tails including 3-(piperidin-1-
yl)propan-1-amine, 3-(pyrrolidin-1-yl)propan-1-amine, 3-(4-methylpiperazin-1-
yl)propan-1-amine and 3-morpholinopropan-1-amine tails, respectively. 
 
Figure 2.13: The chemical scaffold for 5′-3′ substituted benzofused polyamides 
for Library-4B. Here, R represents the tertiary amine tails including 3-
(pyrrolidin-1-yl) propan-1-amine, 3-(4-methylpiperazin-1-yl) propan-1-amine and 
3-(piperidin-1-yl) propan-1-amine and 3-morpholinopropan-1-amine. 
2.2.8 Design and Rationale of Library-4C Molecules 
 
 
Here, R1 = CN, Cl, –OCH3, -NH2, etc. and R2=–CH3, functional groups. 
Figure 2.14: The structural motif of Library-4C. 
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Here, the functional groups attached to the terminal benzofused unit of the lead 
compound 4.93 were optimised. Thus a set of molecules was made by 
structural modification of 4.93 through the substitution of nitro-groups with 
different functional groups (Figure 2.14). 
 
2.2.9 Design and Rationale of Library-4D Molecules 
 
Here a set of molecules were synthesized through the replacement of indole 
with indazole rings to investigate the preference between indole and indazole as 
a chemical scaffold for G-quadruplex ligands. The structural motif is given below 
(Figure 2.15). 
 
Figure 2.15: The structural motif of Library-4D molecules. 
 
2.2.10 Design and Rationale of Library-5 Molecules 
 
Two sets of molecules were made by using commercially available 5-nitro-
indole-3-carboxylic acid and 5-nitro-indazole-3-carboxylic acid building blocks 
targeting the shape of lead molecule 4.93 (Figure 2.71). This library was 
designed with an aim to check whether benzofused polyamides of three 
consecutive benzofused units were better interactive ligands over benzofused 
polyamides of two consecutive benzofused units. The structural motif of 
Library-5 is show below (Figure 2.16). 
 





2.3 Synthetic Scheme for Library-1A Molecules 
 
A set of 8 molecules (Figure 2.18) were synthesized by 5′-2′ substitution of 
benzofuran and benzothiophene building block types. A nitro-benzofused acid 
was initially coupled with a N1, N1-dimethylpropane-1,3-diamine tail to make an 
amide. Then two consecutive benzofused acids were coupled one after another 




Figure 2.17: Synthetic scheme of Library-1A molecules. Here X= O or N or S. 
Initially the acid (1.2 eq.) was dissolved in DMF (5 mL for 100 mg of starting 
material) in a round bottom flask fitted with a magnetic stirrer. Then DIC (1.75 
eq.) and HOBt (2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for the formation of the ester from the acid. 
The amine (1 eq.) was added to the mixture and the mixture allowed stirring 
until the reaction was complete, as indicated by TLC or LCMS. Finally the 
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reaction mixture was applied to a conditioned SCX-2 cartridge and the resultant 
product was purified by the ‘Catch and Release’ method (described in the 




Figure 2.18: Structures of benzofused polyamides of library-1A molecules. 
 
2.3.1 Characterisation of Library-1A Benzofused Polyamides through 
Various Spectroscopic Techniques 
 
The benzofused polyamides of this library were purified and fully characterized 
by different spectroscopic techniques including mass spectrometry, both 1H and 
13C NMR, and IR techniques (described in the ‘Experimental’ section of 
Chapter 4). Compounds were primarily identified by LCMS and confirmed using 
high resolution mass spectroscopy (HRMS) (Table 2.1). Finally the 





Table 2.1: HRMS data for library-1A molecules 
Number Compound code Theoretical mass 
Observed mass 
[M+H]+ 
1 4.5 580.1780 581.1851 
2 4.18 580.1780 581.1851 
3 4.11 596.1552 597.1625 
4 4.12 612.1324 613.1395 
5 4.15 596.1552 597.1625 
6 4.6 564.2121 565.2187 
7 4.24 575.2645 576.2714 
8 4.25 593.2097 594.2169 
 
2.3.2 Purity Analysis of Benzofused Polyamides Synthesized 
 
The purity of the benzofused polyamides of this library was checked by two 
different HPLC methods with two different retention times. Both methods were 
carried out on a Waters Alliance 1695 HPLC Pump with water and acetonitrile 
comprising the mobile phases. The Waters 996 PDA start wavelength was 210 
nm for the 10 minute method (Method A), with a start wavelength of 220 nm and 
end wavelength of 500 nm for the 5 minute method (Method B) (Table 2.2). 
 
Table 2.2: Purity data for library-1A observed by LCMS 
Number Compound code 
Purity 
Method A (10 min)% Method B (5 min)% 
1 4.5 100 100 
2 4.18 100 100 
3 4.11 100 100 
4 4.12 100 100 
5 4.15 100 100 
6 4.6 91 89.09 
7 4.24 100 100 

















Table 2.3: G-quadruplex and duplex DNA stabilization by ligands of library-1A in 
FRET melting experiments at concentrations of 5, 2 and 1 µM respectively (the 
data are means of three technical repeats) 
Compounds Quadruplex types 
∆Tm(°C) ±(s/d) 
5 µM 2 µM 1 µM 
 
4.5 
F21T 0.2±0.21 0.2±0.14 0.0±0.26 
C-kit-1 1.6±0.15 0.9±0.15 1.1±0.20 
C-kit-2 1.5±0.05 1.1±0.49 1.2±0.43 
BCL-2 1.6±0.60 1.5±0.15 1.3±0.15 




F21T 7.0±0.07 2.0±0.36 0.8±0.05 
C-kit-1 3.8±0.26 1.8±0.26 1.6±0.45 
C-kit-2 9.7±0.25 3.8±0.11 2.4±0.26 
BCL-2 5.7±0.1 0.9±0.30 0.6±0.35 




F21T 6.3±0.11 4.7±0.15 2.8±0.23 
C-kit-1 3.5±0.11 1.3±0.20 0.9±0.37 
C-kit-2 8.4±0.30 3.8±0.25 2.5±0.35 
BCL-2 0.8±0.17 0.9±0.16 0.7±0.32 




F21T 1.8±0.05 0.6±0.1 0.7±0.2 
C-kit-1 1.3±0.45 0.7±0.49 0.5±0.39 
C-kit-2 4.1±0.17 1.9±0.45 1.4±0.30 
BCL-2 1.5±0.25 1.2±0.20 1.2±0.25 
Duplex DNA 0.0±0.12 0.0±0.15 0.0±0.07 
 
 
Table 2.4: DNA Stabilization by ligands of library-1A in FRET at concentrations of 
5, 2 and 1 µM respectively (the data are means of three technical repeats) 
Compounds Quadruplex  ∆Tm(°C) ±(s/d) 
  5 µM 2 µM 1 µM 
4.15 
F21T 20.1±0.28 3.6±0.20 2.2±0.25 
C-kit-1 3.1±0.41 1.4±0.30 0.2±0.49 
C-kit-2 9.2±0.25 3.8±0.05 2.3±0.30 
BCL-2 17.5±0.26 1.8±0.37 0.2± 0.32 
Duplex DNA 0.0±0.11 0.0±0.06 0.0±0.07 
4.6 
F21T 20±0.32 4.0±0.12 2.0±0.35 
C-kit-1 1.5±0.25 1.3±0.20 1.1±0.17 
C-kit-2 5.0±0.30 2.5±0.11 1.8±0.25 
BCL-2 5.7±0.60 2.2±0.28 1.2±0.057 
Duplex DNA 0.0±0.10 0.0±0.21 0.0±0.16 
4.24 
F21T 0.8±0.20 0.4±0.31 0.3±0.12 
C-kit-1 1.3±0.40 1.0±0.65 0.7±`0.35 
C-kit-2 3.8±0.45 2.0±0.30 1.3±0.25 
BCL-2 1.2±0.05 0.5±0.25 0.3±0.17 
Duplex DNA 0.0±0.12 0.0±0.07 0.0±0.21 
4.25 
F21T 2.8±0.34 2.5±0.27 1.3±0.25 
C-kit-1 3.7±0.35 1.5±0.36 1.1±0.36 
C-kit-2 9.4±0.51 3.9±0.28 2.1±0.30 
BCL-2 13±0.32 2.7±0.26 1.5±0.25 
Duplex DNA 0.0±12 0.0±0.05 0.0±0.05 
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FRET data analysis (Table 2.3 and 2.4) showed that only 4.11, 4.15 and 4.6 
had moderate but significant interaction with telomeric F21T sequences and C-
kit-2 G-quadruplex sequences. These ligands provided 2.8°C, 2.2°C and 2.0°C 
stabilisation against telomeric F21T sequences and 2.5°C, 2.3°C and 1.8°C 
against C-kit-2 G-quadruplex sequences at 1 µM concentrations but they did not 
show notable interaction with C-kit-1 or Bcl-2 G-quadruplex sequences. 
In contrast, 4.5, 4.18, 4.12, 4.24 and 4.25 showed insignificant interaction 
against all the G-quadruplex sequences used except 4.18 and 4.25 against C-
kit-2 sequence as they provide stabilisations of 2.4°C and 2.1°C respectively.  
It was observed that some of the molecules, including 4.15 and 4.6, show 
significant interactions at higher concentrations (i.e. 5 µM) but suddenly lose 
their stabilisation capacities at lower concentrations (1, 2 µM). These molecules 
are assumed to form dimers at higher concentrations (5 µM) and that dimer may 
interact with the terminal quartet of G-quadruplex architectures. As soon as 
molecular density goes down at subsequent lower concentrations (1, 2 µM), the 
melting temperatures fall sharply (for example, ∆Tm=3.6°C and 2.2°C for 
4.15°C against F21T respectively). This means molecular density is not high 
enough for dimer formation at low concentrations. 
However, all of these ligands are specific toward G-quadruplex sequences as 
none of these molecules have shown any interaction with duplex DNA. 
2.3.3: Key Observations on Library-1A and Library-1B Molecules 
 
A number of conclusions can be drawn from the FRET-based DNA thermal 
denaturation assays conducted on the library-1A molecules. 
 These compounds showed insignificant interaction with the F21T 
(human telomeric G-quadruplex), C-kit-1, C-kit-2 and Bcl-2 G-
quadruplexes. 
 The inclusion of either a benzofuran or benzothiophene building block in 
the structure of these molecules does not make any notable difference. 
 Linear molecules, especially 4.15 and 4.6, are assumed to form dimers 
at higher concentrations (5 µM) and these dimers may interact with the 




2.4 Synthetic Scheme of Library-1B Molecules 
As a whole, the benzofused polyamides of library 1-A were not capable of 
achieving significant interaction with the G-quadruplex DNA types used. At the 
same time, the alteration of building block types at their respective positions 
didn’t result in impressive ∆Tm values. This means the activity of these ligands 
was not depend on either the benzofuran or benzothiophene building block 
types. 
 
Figure 2.20: Synthetic scheme of Library-1B molecules. Here X = O or N or S 
and R represents the tertiary amine tails including 4-(pyrrolidin-1-yl) butan-1-
amine and 2-(piperidin-1-yl) ethan-1-amine. 
Therefore, further structural modifications using different tail types were done to 
design library-1B (Figure 2.20) in order to investigate whether different tail 
types may have any additional effect on the ligand-quadruplex DNA interaction. 
A nitro-benzofused acid was initially coupled with tail types 4-(pyrrolidin-1-yl) 
butan-1-amine and 2-(piperidin-1-yl) ethan-1-amine, respectively. Then two 
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consecutive benzofused acids were coupled further through amide coupling 
reactions to get benzofused polyamides. This library was comprised of 9 
molecules in total (Figure 2.19). 
Initially, the acid (1.2 eq.) was dissolved in DMF (5 mL for 100 mg of starting 
material) in a round bottom flask fitted with a magnetic stirrer. Then DIC (1.75 
eq.) and HOBt (2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for the formation of the ester from the acid. 
The amine (1 eq.) was added to the mixture and the mixture allowed to stir until 
the reaction was complete, as indicated by TLC or LCMS. Finally the reaction 
mixture was applied to a conditioned SCX-2 cartridge and the resultant product 
was purified by the ‘Catch and Release’ method (described in the section 
‘Method and Materials’ of Chapter 3). 
 
Figure 2.21: Structures of the library-1B molecules. 
2.4.1 Characterisation of Benzofused Polyamides through Various 
Spectroscopic Techniques 
The benzofused polyamides of library-1B were purified and fully characterized 
by different spectroscopic techniques including mass spectrometry, both 1H and 
13C NMR, and IR techniques (described in the Experimental section of Chapter 
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4). Compounds were primarily identified by LCMS and confirmed using high 
resolution mass spectroscopy (HRMS) (Table 2.5 and 2.6). Finally these well 
characterised compounds were evaluated by FRET based DNA melting assay. 
Table 2.5: HRMS data for library-1B molecules 
Number Compound code Theoretical mass 
Observed mass 
[M+H]+ 
1 4.37 620.2093 621.2155 
2 4.40 636.1865 637.1934 
3 4.36 604.2322 605.2401 
4 4.31 606.1937 607.2010 
5 4.30 590.2165 591.2244 
6 4.42 618.2478 619.2544 
7 4.43 638.1932 639.2006 
8 4.45 633.2410 634.2473 
9 4.41 617.2638 618.2708 
10 4.44 604.2434 605.2511 
 
2.4.2 Purity Analysis of Benzofused Polyamides Synthesized 
The purity of the benzofused polyamides of this library was checked by two 
different HPLC methods with two different retention times. Both methods were 
carried out on a Waters Alliance 1695 HPLC Pump with water and acetonitrile 
comprising the mobile phases. The Waters 996 PDA start wavelength was 210 
nm for the 10 minute method (Method A), with a start wavelength of 220 nm and 
end wavelength of 500 nm for the 5 minute method (Method B) (Tables 2.5 and 
2.6). 




Method A(10 min)% Method B(5 min)% 
1 4.37 91 89.09 
2 4.40 100 100 
3 4.36 100 100 
4 4.31 94 100 
5 4.30 100 100 
6 4.42 100 100 
7 4.43 100 100 
8 4.45 100 100 
9 4.41 100 94.37 












Table 2.7: G-quadruplex and duplex DNA stabilization by ligands of library-1B 
in FRET melting experiments at concentrations of 5, 2 and 1 µM respectively 
(the data are means of three technical repeats) 
Compounds Quadruplex types 
∆Tm(°C) ±(s/d) 
5 µM 2 µM 1 µM 
4.37 
F21T 18.1±0.21 1.8±0.31 1.1±0.23 
C-kit-1 2.4±0.15 1.5±0.35 1.2±0.23 
C-kit-2 4.7±0.20 2.8±0.11 1.9±0.40 
BCL-2 5.1±0.36 2.5±0.20 2.1±0.20 
Duplex DNA 0.0±0.20 0.0±0.11 0.0±0.07 
4.40 
F21T 4.1±0.3 2.5±0.13 1.9±0.7 
C-kit-1 1.8±0.26 0.6±0.07 0.5±0.21 
C-kit-2 5.4±0.20 2.8±0.26 2.1±0.17 
BCL-2 2.8±0.40 1.3±0.25 1.4±0.45 
Duplex DNA 0.0±0.07 0.0±0.2 0.0±0.04 
4.36 
F21T 9.3±0.23 2.8±0.13 1.8±0.16 
C-kit-1 3.4±0.15 2.2±0.15 1.5±0.3 
C-kit-2 5.7±0.1 2.8±0.11 2.2±0.15 
BCL-2 4.7±0.34 2.9±0.11 2.7±0.41 
Duplex DNA 0.0±0.06 0.0±0.21 0.0±0.25 
4.31 
F21T 0.5±0.32 0.7±0.12 0.6±0.24 
C-kit-1 0.8±0.15 0.9±0.20 0.8±0.32 
C-kit-2 2.0±0.47 1.1±0.17 0.8±0.05 
BCL-2 1.9±0.20 1.5±0.30 1.5±0.05 














Table 2.8: G-quadruplex and duplex DNA stabilization by ligands in FRET 
melting experiments at concentrations of 5, 2 and 1 µM respectively               





5 µM 2 µM 1 µM 
4.30 
F21T 1.2±0.20 0.5±0.27 0.3±0.31 
C-kit-1 0.9±0.20 1.0±0.15 0.4±0.10 
C-kit-2 2.1±0.20 1.2±0.36 0.9±0.17 
BCL-2 1.7±0.20  0.5±0.30 0.6±0.15 
Duplex DNA 0.0±0.15 0.0±0.34 0.0±0.06 
4.42 
F21T 4.6±0.20 0.9±0.05 0.4±0.05 
C-kit-1 2.9±0.10 1.1±0.32 0.3±0.26 
C-kit-2 6.1±0.11 2.0±0.30 0.9±0.45 
BCL-2 3.9±0.10 1.3±0.14 0.3±0.14 
Duplex DNA 0.0±0.06 0.0±0.20 0.0±0.21 
4.43 
 
F21T 5.1±0.11 2.3±0.41 1.0±0.12 
C-kit-1 1.1±0.20 0.6±0.10 0.7±0.20 
C-kit-2 4.3±0.35 1.9±0.20 1.4±0.20 
BCL-2 2.9±0.23 1.7±0.32 1.4±0.05 
Duplex DNA 0.0±0.31 0.0±0.24 0.0±0.07 
4.45 
F21T 4.1±0.21 1.9±0.23 0.6±0.11 
C-kit-1 3.9±0.25 1.2±0.15 1.3±0.15 
C-kit-2 7.3±0.40 3.7±0.15 2.7±0.21 
BCL-2 6.8±0.14 1.6±0.10 1.5±0.26 
Duplex DNA 0.0±0.06 0.0±0.12 0.0±0.16 
4.41 
F21T 3.1±0.11 2.5±0.32 0.3±0.21 
C-kit-1 2.5±0.34 1.3±0.15 1.0±0.20 
C-kit-2 3.8±0.35 1.8±0.30 1.5±0.20 
BCL-2 3.5±0.32 1.9±0.45 1.6±0.47 
Duplex DNA 0.0±0.32 0.0±0.25 0.0±0.10 
4.44 
F21T 12.1±0.31 3.7±0.18 2.3±0.12 
C-kit-1 3.7±0.32 1.8±0.14 1.5±0.15 
C-kit-2 6.1±0.30 2.9±0.32 2.2±0.40 
BCL-2 7.8±0.20 3.7±0.31 2.9±0.21 
Duplex DNA 0.0±0.31 0.0±0.13 0.0±0.12 
 
Molecules (except 4.44) mentioned in this section (Table 2.7 and 2.8) did not 
show any significant interaction with G-quadruplex sequences. Thus tail 
replacement does not make a notable improvement of the interacting capacity 
of ligand molecules. However, although the ∆Tm values were not significant, it 
is notable that the ligands (4.37, 4.40 and 4.36) possessing 4-(pyrrolidin-1-yl) 
butan-1-amine tail showed better interacting ability than those molecules (4.31 
and 4.30) possessing 2-(piperidin-1-yl) ethan-1-amine tails. 4.37 provided 
1.1°C, 1.2°C, 1.9°C and 2.1°C  stabilisation; 4.40 provided stabilisations of 
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1.9°C, 0.5°C, 2.1°C and 1°C; 4.36 provided 1.8°C, 1.5°C, 2.2°C and 2.7°C 
stabilisation; 4.31 provided 0.6°C, 0.8°C, 0.8°C and 1.5°C stabilisation; 4.30 
provided 0.3°C, 0.4°C, 0.9°C and 0.6°C stabilisation at 1 µM concentration 
against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences respectively. 
This stabilisation indicates the superiority of the 4-(pyrrolidin-1-yl) butan-1-
amine tail over the 2-(piperidin-1-yl) ethan-1-amine tails. On other hand, 4.37 
and 4.40 are nearly identical in their interactions toward G-quadruplexes. This 
further indicates that the activity of these molecules does not depend on either 
the benzothiophene or benzofuran building blocks types. 
Two similar molecules attached with the preferred 4-(pyrrolidin-1-yl) butan-1-
amine tail were made to get an idea of whether any kind of substitution in these 
structures may have an extra effect. 4.42 and 4.43 were synthesized in the form 
of 4.36 with the exception of a substitution at the terminal building block. 4.42 
possessed the substitution of an electron-pushing methyl (-CH3) group and 4.43 
possessed an electron-pulling chloride (Cl-) group. 
Melting temperatures of these two molecules were not more impressive than 
those of 4.36. This means these substitutions may not have a positive effect on 
ligand activity. But it is assumed that the electron-pulling group (chloride group) 
may have an enhancing effect on G-quadruplex interactivity of the benzofused-
polyamide structure; 4.43 showed stabilisation of 1.0°C, 0.7°C, 1.4°C and 1.4°C 
at 1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex 
sequences respectively, which is insignificantly better than 4.42, which itself 
provided ∆Tm values of a 0.4°C, 0.3°C, 0.9°C and 0.3°C at 1 µM concentration 
against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences. This 
difference of melting temperatures between 4.43 and 4.42 provides a 
preliminary idea that electron-pushing groups like methyl (CH3-) group may 
reduce the interacting capacity of a ligand, whereas electron-pulling group like 
chloride (Cl-) enhance the interacting capacity of ligands towards G-quadruplex 
DNA. These ideas helped to guide further ligand synthesis. 4.44 is slightly more 
interactive than any other molecules of this library, as it provided 2.3°C,1.5°C, 
2.2°C C and 2.9°C stabilisation at 1 µM concentration against F21T, C-kit-1, C-
kit-2 and Bcl-2 G-quadruplex sequences, which is insignificantly better than any 
other members of this library. Therefore, it was assumed that the inclusion of 
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nitrogen-contacting building blocks (i.e. Imidazole) may allow the formation of 
hydrogen bonds with the guanine residues of quadruplex DNA and thereby 
enhance ligand interacting capacity with G-quadruplex structures to a certain 
extent. 
It was observed that some of the molecules, including 4.15, 4.6 and 4.37, were 
found to show significant interaction at higher concentrations (5 µM) but 
suddenly lose their stabilisation capacities at lower concentrations. These 
unexpected higher melting temperatures (for example, 18.1°C for 4.37) were 
assumed to be contributed by the cooperative binding of these molecules at 
high concentrations (5 µM). A dimer of 4.37 may stack together over the 
terminal quartet of a G-quadruplex. As soon as molecular density goes down at 
lower concentrations (1, 2 µM), the melting temperatures fall sharply 
(∆Tm=1.8°C and 1.1°C, respectively). This means the molecular density is not 
great enough to make a dimer at low concentrations of 4.37. 
 
2.4.3: Key Observations on Library-1A and Library-1B Molecules 
 
 These compounds showed insignificant interaction with the F21T, C-kit-
1, C-kit-2 and Bcl-2 G-quadruplexes. 
 The inclusion of either a benzofuran or benzothiophene building block in 
the structure of these molecules does not make any notable difference. 
 N1, N1-dimethyl propane-1, 3-diamine and 4-(pyrrolidin-1-yl) butan-1-
amine are comparatively better than 2-(piperidin-1-yl) ethan-1-amine as 
tails in benzofused-polyamides. 
 Inclusion of N-containing benzofused rings may increase the stabilising 
capacity of benzofused polyamides. 
 Electron-pulling groups like chloride group (Cl-) attached to a 
benzofused ring is better than electron-pushing groups like methyl 







2.5 Molecular Modelling of Benzofused Polyamides of Library-
1A and 1-B as G-quadruplex Stabilising Agents 
 
Molecular modelling studies were undertaken in an effort to rationalise the poor 
FRET binding results obtained for the Library 1 molecules.  
Molecular docking experiments were undertaken on the human telomeric 
quadruplex F21T (PDB ID 3CDM). It was immediately evident from visual 
analysis that 5’-2’ substituted benzofused moieties do not have the appropriate 
curvature to stack on the quadruplex interface. 
 
Figure 2.23: Molecular model of the G-quadruplex-interactive biaryl polyamide 
(left panel) showing the curvature of the molecule, which assists the 
stabilisation of DNA. Library-1 molecules (e.g., 4.5, black sticks, right panel) do 










Traditional quadruplex inhibitors such as quarfloxacin and the small molecule 
biaryl polyamides are composed of fused rings and possess a specific curvature 
which enables them to stack on the quadruplex interface (Figure 2.21). 
Library-1 molecules, on the other hand, are linear in structure. For example, 
molecular models of 4.5 (containing benzothiophene and benzofuran building 
blocks) show that the molecule does not stack effectively on the quadruplex 
interface, thereby producing few non-covalent interactions (Figure 2.21). 
FRET binding results also suggest that the introduction of nitrogen-containing 
benzofused groups (i.e., indole and benzimidazole) does not enhance binding 
to the quadruplex interface. Although indole, and particularly benzimidazole, 
contain nitrogen groups capable of forming H-bonding interactions, and 
therefore interacting with amine groups of guanines in the quadruplex, FRET 
binding results suggest that the presence of these moieties does not alter the 
binding capability of the molecule. This is reflected in docking results where 
nitrogen-containing molecules possess similar binding energies to sulphur and 
oxygen-containing compounds. For example 4.15 containing both 
benzothiophene and benzofuran, and 4.6 containing benzimidazole and 
benzofuran groups both have similar GBSA binding energies (i.e., -
66.29kcal/mol and -69.25kcal/mol respectively), thereby suggesting that the 
introduction of nitrogen does not affect binding to the DNA. This is reflected in 
visual analysis of the docked models where the nitrogens of the indole and 
benzimidazole moieties do not form H-bonds with the quadruplex structure. H-
bonds are absent, presumably, due to the lone pairs of the nitrogens not being 
in the appropriate orientation to interact with quadruplex DNA. Furthermore, the 
replacement of the amidic tail of the molecule with a variety of amine tails has 
little effect on the binding of the series of molecules to DNA, and this is reflected 
in GBSA binding calculations. For example, binding calculations are similar to 
other members of Library-1, where GBSA scores are in the region of -
60kcal/mol (e.g., in the case of 4.30 and 4.43, binding energies are -
59.83kcal/mol and -68.54kcal/mol respectively).    
It is evident from modelling analysis that shape-based factors are critical in 
affecting interactivity of benzofused polyamides with G-quadruplex DNA. When 
compared with the highly interactive biaryl polyamide produced by Rahman et al 
(Figure 2.21, left panel), there is a distinct difference in curvature of both sets of 
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molecules. In order to enhance quadruplex binding, it is recommended that the 
5’-2’ substituted central benzofused moiety is replaced with a 5’-3’ substituted 
benzofused moiety. Such a substitution is likely to enhance curvature of the 
molecule and increase binding with the quadruplex structure through efficient 
stacking on the G-tetrad (Figure 2.22). 
 
Figure 2.24: Schematic of Library-1A and 1B molecules (top) and proposed 












2.6 Synthetic Scheme for Library-2 Molecules. 
As the molecules belonging to library-1A and library-1B did not show 
significant interaction with G-quadruplex DNA types, a set of new molecules (9 
molecules in total) were synthesized (Figure 2.24) with the help of molecular 
modelling studies (Figure 2.21). Here, a 5-nitro-benzofused-3-carboxylic acid 
was included as a second building block instead of 5-nitro-benzofused-2-
carboxylic acid so that ligand molecules would have relatively more curvature in 
their structures compared to library-1A and 1B ligand molecules. Commercially 
available 5-nitro-indole-3-carboxylic acid was introduced at the middle of the 
benzofused polyamide (Figure 2.23). 
 
Figure 2.25: Synthetic Scheme of Library-2 molecules. Here X = O or N or S. 
5-nitro-benzofused-3-carboxylic acid was used as a second building block, as 
shown as green.  
Initially the acid (1.2 eq.) was dissolved in DMF (5 mL for 100 mg of starting 
material) in a round bottom flask fitted with a magnetic stirrer. Then DIC (1.75 
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eq.) and HOBt (2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for formation of the ester from the acid. The 
amine (1 eq.) was added to the mixture and the mixture allowed for stirring until 
the reaction was complete, as indicated by TLC or LCMS. Finally the reaction 
mixture was applied to a conditioned SCX-2 cartridge and the resultant product 
was purified by the ‘Catch and Release’ method (described in the section 
‘Method and Materials’ of Chapter 3).  
 
 





2.6.1 Characterisation of Benzofused Polyamides through Various 
Spectroscopic Techniques 
 
Molecules of library-2 were purified and fully characterized by different 
spectroscopic techniques including mass spectrometry, both 1H and 13C NMR, 
and IR techniques (described in the Experimental section of Chapter 4). 
Compounds were primarily identified by LCMS and confirmed using high 
resolution mass spectroscopy (HRMS) (Table 2.9). 
Table 2.9: HRMS data for library-2 molecules 
Number Compound code Theoretical mass 
Observed mass 
[M+H]+ 
1 4.48 579.1940 580.2000 
2 4.49 595.1712 596.1771 
3 4.53 592.2257 593.2314 
4 4.54 579.2053 580.2113 
5 4.52 563.2169 564.2230 
6 4.55 579.1940 580.2003 
7 4.57 576.2485 577.2544 
8 4.56 563.2281 564.2340 
9 4.61 562.2329 563.2387 
 
 
2.6.2 Purity Analysis of Benzofused Polyamides Synthesized 
 
The purity of the benzofused polyamides of this library was checked by two 
different HPLC methods with two different retention times. Both methods were 
carried out on a Waters Alliance 1695 HPLC Pump with water and acetonitrile 
comprising the mobile phases. The Waters 996 PDA start wavelength was 210 
nm for the 10 minute method (Method A), with a start wavelength of 220 nm and 
end wavelength of 500 nm for the 5 minute method (Method B) (Table 2.10). 
Table 2.10: Purity data for library-2 molecules as observed by HPLC 
Number Compound code 
Purity 
Method A (10 min)% Method B (5 min)% 
1 4.48 100 100 
2 4.49 100 100 
3 4.53 100 100 
4 4.54 100 100 
5 4.52 100 100 
6 4.55 91 89.09 
7 4.57 100 100 
8 4.56 100 100 












Table 2.11: G-quadruplex and duplex DNA stabilization by ligands in FRET 
melting experiments at concentrations of 5, 2 and 1 µM respectively              






5 µM 2 µM 1 µM 
4.48 
F21T 14.3±0.23 6.6±0.20 3.0±0.21 
C-kit-1 19.2±0.15 13.1±0.17 9.6±0.05 
C-kit-2 16.2±0.28 9.2±0.23 6.9±0.05 
BCL-2 13.9±0.20 9.1±0.28 8.4±0.10 
Duplex DNA 0.0±0.15 0.0±0.05 0.0±0.21 
4.49 
F21T 14.6±0.20 7.5±0.14 3.4±0.34 
C-kit-1 13.1±0.25 10.4±0.36 9.9±0.21 
C-kit-2 17.2±0.23 11.7±0.05 11.0±0.20 
BCL-2 12.3±0.15 5.6±0.20 5.3±0.20 
Duplex DNA 0.0±0.23 0.0±0.21 0.0±0.35 
4.53 
F21T 13.8±0.07 8.3±0.23 4.3±0.11 
C-kit-1 14.6±0.17 11.4±0.37 8.2±0.45 
C-kit-2 16.4±0.25 10.3±0.20 9.5±0.15 
BCL-2 13.6±0.45 7.0±0.20 4.6±0.34 
Duplex DNA 0.0±0.10 0.0±0.21 0.0±0.26 
4.54 
F21T 17.0±21 10.4±017 5.5±0.13 
C-kit-1 20.8±0.20 15.1±0.10 12.0±0.40 
C-kit-2 19.6±0.15 12.2±0.30 8.9±0.37 
BCL-2 18.9±0.36 12.0±0.20 9.3±0.23 
Duplex DNA 0.0±0.24 0.0±0.20 0.0±0.25 
 
Here, 4.48 provided 3.0°C, 9.6°C, 6.9°C and 8.4°C stabilisation, 4.49 provided 
3.4°C, 9.9°C, 11.0 °C and 5.3°C stabilisation, 4.53 provided 4.3°C, 8.2°C, 9.5°C 
and 4.6°C stabilisation and 4.54 provided 5.5°C, 12.0°C, 8.9°C and 9.3°C 
stabilisation at 1 µM concentrations against F21T, C-kit-1, C-kit-2 and Bcl-2 G-
quadruplex sequences respectively. 
FRET data analysis showed that, as a whole, the introduction of curvature 
within the library-1A and 1B molecules significantly improved ligand 
interactivity with all G-quadruplex sequences used. 4.54 was found to be the 
most active member of this library, possibly due to the extra nitrogen atom of its 
terminal imidazole ring. This additional electronegative nitrogen may form a 
hydrogen bond with an amine, carbonyl or imine group of the G-quadruplex 
DNA or it may provide an electronic interaction within the ligand molecule which 
may reinforce the π-π stacking interaction. 
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Table 2.12: G-quadruplex and duplex DNA stabilization by ligands in FRET 
melting experiments at concentrations of 5, 2 and 1 µM respectively              






5 µM 2 µM 1 µM 
4.52 
F21T 6.22±0.41 3.5±0.24 2.4±0.37 
C-kit-1 13.1±0.23 8.5±0.25 7.8±0.15 
C-kit-2 18.0±0.15 10.3±0.40 8.1±0.36 
BCL-2 14.8±0.40 8.3±0.35 5.6±0.36 
Duplex DNA 0.0±0.17 0.0±0.14 0.0±0.22 
4.55 
F21T 12.2±0.11 7.1±0.14 5.0±0.32 
C-kit-1 15.6±0.26 11.1±0.1 10.7±0.10 
C-kit-2 15.8±0.30 9.7±0.30 6.7±0.28 
BCL-2 11.9±0.15 5.7±0.26 3.2±0.26 
Duplex DNA 0.0±0.12 0.0±0.23 0.0±0.31 
4.57 
F21T 10.6±0.10 5.0±0.07 3.9±0.21 
C-kit-1 11.8±0.15 7.8±0.05 3.3±0.26 
C-kit-2 18.2±0.37 8.8±0.25 8.1±0.37 
BCL-2 9.3±0.20 5.7±0.46 3.6±0.23 
Duplex DNA 0.0±0.14 0.0±0.12 0.0±0.17 
4.56 
F21T 17.2±0.23 10.7±0.41 6.6±0.12 
C-kit-1 12.5±0.17 9.8±0.25 8.7±0.15 
C-kit-2 20.6±0.15 14.1±0.15 10.6±0.05 
BCL-2 14.9±0.17 8.3±0.32 6.4±0.37 
Duplex DNA 0.0±0.32 0.0±0.21 0.0±0.27 
4.61 
F21T 18.0±0.20 7.4±0.13 5.2±0.34 
C-kit-1 14.4±0.10 8.8±0.10 7.4±0.32 
C-kit-2 18.1±0.45 11.4±0.20 7.7±0.30 
BCL-2 13.9±0.15 7.6±0.17 4.7±0.30 
Duplex DNA 0.0±0.14 0.0±0.21 0.0±0.15 
 
Here, introduction of curvature improved the interacting capacity of ligand 
molecules in an apparently similar pattern to the first set (Table 2.11). Although 
these molecules were composed differently, as they start with a 
benzothiophene and end with the same benzothiophene building block instead 
of a benzofuran as in the previous set, they were nearly identical in their 
stabilisation capacities. This further indicated that the effect of these two 
different benzofused ring types (benzothiophene and benzofuran) were very 
similar. In more detail, it was found that molecules of this type interacted 
equivalently with F21T (human telomeric quadruplex) and Bcl-2 G-
quadruplexes. They were more active toward C-kit-1 and relatively better 
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toward C-kit-2 G-quadruplexes. 4.56 is likely to be the most interactive library 
member, again possibly due to the imidazole ring as previously discussed. 
It is interesting to note that although 4.61 was equivalent to 4.52, it provided 
relatively higher melting temperatures of 5.2°C, 7.4°C, 7.7°C and 4.7°C 
stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-
quadruplex sequences respectively. This indicated the preference of indole 
building blocks over either benzofuran or benzothiophene building blocks with 
regard to G-quadruplex interacting capacities. 
Two equivalent molecules from each of the libraries (for example, 4.15 and 4.18 
of library-1 can be compared directly with 4.49 and 4.52 of library-2) were 
taken and their FRET data subsequently analysed to evaluate the introduction 
of curvature. 
 
Figure 2.28: Structures of 4.15 and 4.49 from library-1 and library-2 
respectively. 
 
Table 2.13: Comparative FRET data analysis between 4.15 and 4.49            




4.15 4.49 4.15 4.49 4.15 4.49 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 20.1±0.28 14.6±0.20 3.6±0.2 7.5±0.14 2.2±0.25 3.4±0.34 
C-kit-1 3.1±0.41 13.1±0.25 1.4±0.30 10.4±0.36 0.2±0.49 9.9±0.21 
C-kit-2 9.2±0.25 17.2±0.23 3.8±0.05 11.7±0.05 2.3±0.30 11.0±0.20 
BCL-2 17.5±0.26 12.3±0.15 1.8±0.37 5.6±0.20 0.2± 0.32 5.3±0.20 
Duplex DNA 0.0±0.11 0.0±0.23 0.0±0.06 0.0±0.21 0.0±0.07 0.0±0.35 
 
Here, 4.49 provided 3.4°C, 9.9°C, 11.0°C and 5.3°C stabilisation at 1 µM 
concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, 
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respectively. In contrast, 4.15 provided 2.2°C, 0.2°C, 2.3°C and 0.2°C 
stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-
quadruplex sequences, respectively. This difference in ∆Tm values implicates 
the enhanced curvature in the improved interactivity of the ligands with the G-
quadruplex sequences. Both of these molecules showed a similar degree of G-
quadruplex stabilisation from higher to lower concentrations for all of the G-
quadruplex sequences used. However, 4.15 showed a higher degree of 
stabilisation (∆Tm=20.1°C) at 5 µM for human telomeric G-quadruplex. This 
was higher even than 4.49 (∆Tm=14.6°C). These unexpected higher melting 
temperatures were assumed to be contributed by cooperative binding of 4.15 at 
high concentration. A dimer of 4.15 may stack together over the terminal quartet 
of G-quadruplexes. As soon as molecular density decreases at subsequent 
lower concentrations (1, 2 µM), the melting temperatures fall sharply (∆Tm=3.6 
°C and 2.2 °C, respectively). This means the molecular density is not sufficient 
to make a dimer at low concentrations of 4.15. 
 
Figure 2.29: Structures of 4.18 and 4.52 
 
Table 2.14: Comparative FRET data analysis between 4.18 and 4.52           




4.18 4.52 4.18 4.52 4.18 4.52 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 7.0±0.07 6.22±0.41 2.0±0.36 3.5±0.24 0.8±0.05 2.4±0.37 
C-kit-1 3.8±0.26 13.1±0.23 1.8±0.26 8.5±0.25 1.6±0.45 7.8±0.15 
C-kit-2 9.7±0.25 18.0±0.15 3.8±0.11 10.3±0.40 2.4±0.26 8.1±0.36 
BCL-2 5.7±0.1 14.8±0.40 0.9±0.30 8.3±0.35 0.6±0.35 5.6±0.36 
Duplex DNA 1.2±0.11 0.0±0.17 0.0±0.06 0.0±0.14 0.0±0.11 0.0±0.22 
 
Here, 4.18 and 4.52 followed the same pattern of stabilising capacities as for 
4.15 and 4.49. 4.52 gave 2.4°C, 7.8°C, 8.1°C and 5.6°C stabilisation at 1 µM 
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concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, 
respectively. In contrast, 4.18 provided 0.8°C, 1.6°C, 2.4°C and 0.6°C 
stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-
quadruplex sequences, respectively. Therefore, it was further evident that the 
introduction of curvature made the aryl-polyamides more potent towards G-
quadruplexes used. However, 4.49 and 4.52 were more active towards C-kit-2 
compared to the other sequences. The pattern of activation against F21T and 
BCL-2 quadruplex sequences was nearly equivalent. 
2.6.3 Key Observations Based on the Overall FRET Data Analysis of 
Library-2 Molecules 
 
 Introduction of curvature in the benzofused polyamide structural motif 
through the 5′-3′ substitution enhanced the stabilising capacity of the 


















2.7 Molecular Modelling of Library-2 Molecules 
It is evident from biophysical studies that the introduction of a 5’-3’ substituted 
moiety instead of a 5’-2’-substituted moiety has a considerable effect on the 
binding of triaryl benzofused molecules to quadruplex DNA. For example, in the 
case of 4.18 and 4.52 (Figure: 2.24), stabilisation is enhanced by 6-7 °C in the 
case of c-kit-1 and c-kit2, and an increase in 2-3°C in other quadruplexes such 
as F21T.  
 
Figure 2.30: Molecular model of 4.18 (left panel) and 4.52 (right panel) bound 
to the telomeric F21T G-quadruplex illustrating the difference in accommodation 
of a Library 1 molecule (4.18) and Library 2 molecule (4.52). In the case of 
4.52 (black sticks), three benzofused molecules are capable of orienting directly 
over guanine bases (blue nucleotide objects), thereby enhancing stabilisation. 
In the case of 4.18, only two benzofused moieties are capable of inducing G-
quadruplex stabilisation. 
Molecular modelling studies suggest that this increase in binding affinity occurs 
due to increased stacking on the quadruplex interface. This is particularly 
evident in docking studies of the human telomeric quadruplex (PDB ID 3CDM), 
where 4.52 stacks effectively on the quadruplex interfaces and enhances 
interaction through pi-pi interactions, whereby 4.18 does not (Figure 2.27). This 
is supported by GBSA calculations which suggest that 4.18 has an affinity of -
67.11kcal/mol, whereas 4.52 has a considerably enhanced binding affinity of -
75.35kcal/mol. Interestingly, a significant selective enhancement of stabilisation 
of both c-kit-1 and c-kit2 was observed over other quadruplexes. Although 
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crystal or NMR structures of the c-kit-1 and c-kit2 sequences used in the 
biophysical study were not available, and therefore relevant docking studies 
could not be undertaken, it is likely that differences in the topologies of c-kit-1 
and c-kit2 allowed greater accommodation of Library-2 molecules over 
Library-1. 
Preliminary docking studies also suggested that the introduction of further 5’-3’-
substituted benzofused moieties to the polyamide core instead of 5’-2’-
benzofused moieties should enhance binding further (Fig. 2.28), and this was 
explored in Library 3A.   
 
Figure 2.31: Schematic of Library-2 molecules (top) and proposed modification 














2.8 Synthetic Scheme for First Set of Library-3A Molecules 
As evaluated by the DNA modelling studies (Figure 2.27 and Figure 2.28), it 
was suggested to introduce further curvature within the library-2 ligand 
molecules. Thus a set of new molecules (7 in total) were synthesized (Figure 
2.31) by replacing the 1st building block of the library-2 molecules (5-nitro 
benzofused-2-carboxylic acid) with 5-nitro benzofused-3-carboxylic acid). Thus 
the final benzofused polyamides were hoped to have more curvature compared 
to those of library-2. Two sets of molecules were synthesized by including two 
molecules of 5-nitro-benzofused-3- carboxylic acids in benzofused polyamide 
structures in two different fashions. The first set of molecules was made by the 
coupling of two consecutive 5-nitro-indole-3-carboxylic acids followed by 
termination with four different benzofused acids (Figure 2.29). The second set 
of molecules was made by starting with a 5-nitro-benzofuran-2-carboxylic acid 
which was immediately coupled with 5-nitroindole-3-carboxylic acid and 
terminated with different benzofused-3 carboxylic acids (Figure 2.30). 
 
Figure 2.32: The synthetic reaction scheme for the first set of library-3A 
molecules. Here, X = O or N or S. 
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Initially, the acid (1.2 eq.) was dissolved in DMF (5 mL for 100 mg of starting 
material) in a round bottom flask fitted with a magnetic stirrer. Then DIC (1.75 
eq.) and HOBt (2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for formation of the ester from the acid. The 
amine (1 eq.) was added to the mixture and the mixture allowed stirring until the 
reaction was complete, as indicated by TLC or LCMS. Finally the reaction 
mixture was applied to a conditioned SCX-2 cartridge and the resultant product 
was purified by the ‘Catch and Release’ method (described in the section 
‘Methods and Materials’ of Chapter 3). 
 
2.8.1 Synthetic Scheme for Second Set of Library-3A Molecules 
 
 
Figure 2.33: The synthetic reaction scheme for the second set of library-3A 
molecules. Here X = O or N or S. 
Initially the acid (1.2 eq.) was dissolved in DMF (5 mL for 100 mg of starting 
material) in a round bottom flask fitted with a magnetic stirrer. Then DIC (1.75 
eq.) and HOBt (2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for formation of the ester from the acid. The 
amine (1 eq.) was added to the mixture and the mixture allowed stirring until the 
reaction was complete, as indicated by TLC or LCMS. Finally the reaction 
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mixture was applied to a conditioned SCX-2 cartridge and the resultant product 
was purified by the ‘Catch and Release’ method (described in the section 
‘Methods and Materials’ of Chapter 3). 
 
 
Figure 2.34: Structures of the library-3A molecules. 
 
2.8.2 Characterisation of Library-3A Molecules through Various 
Spectroscopic Techniques 
 
The benzofused polyamides of library-3A were purified and fully characterized 
by different spectroscopic techniques including mass spectrometry, both 1H and 
13C NMR, and IR techniques (described in the ‘Experimental’ section of 
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Chapter 4). Compounds were primarily identified by LCMS and confirmed using 
high resolution mass spectroscopy (HRMS) (Tables 2.15 and 2.16). 
 
Table 2.15: HRMS data for library-3A molecules 
Number Compound code Theoretical mass 
Observed mass 
[M+H]+ 
1 4.70 562.2329 563.2388 
2 4.71 578.2100 579.1430 
3 4.72 575.2645 576.2703 
4 4.73 562.2441 563.2502 
5 4.74 563.2169 564.2228 
6 4.75 579.1940 580.2000 
7 4.76 563.2281 564.2344 
 
2.8.3 Purity Analysis of Benzofused Polyamides Synthesized 
 
The purity of the benzofused polyamides of this library was checked by two 
different HPLC methods with two different retention times. Both methods were 
carried out on a Waters Alliance 1695 HPLC Pump with water and acetonitrile 
comprising the mobile phases. The Waters 996 PDA start wavelength was 210 
nm for the 10 minute method (Method A), with a start wavelength of 220 nm and 
end wavelength of 500 nm for the 5 minute method (Method B) (Table 2.15 and 
2.16). 
Table 2.16: Purity data for library-3A as observed by HPLC 
Number Compound code 
Purity 
Method A(10 min)% Method B(5 min)% 
1 4.70 100 100 
2 4.71 100 100 
3 4.72 93 94 
4 4.73 100 100 
5 4.74 100 100 
6 4.75 91 89.09 















Table 2.17: G-quadruplex and duplex DNA stabilization by ligands of library-3A 
in FRET melting experiments at concentrations of 5, 2 and 1 µM respectively 
(the data are means of three technical repeats) 
Compounds Quadruplex 
∆Tm(°C) ±(s/d) 
5 µM 2 µM 1 µM 
4.70 
F21T 13.6±0.37 8.6±0.23 4.89±0.11 
C-kit-1 14.2±0.28 10.7±0.28 9.2±0.34 
C-kit-2 18.3±0.15 11.4±0.11 8.6±0.26 
BCL-2 15.7±0.23 10.4±0.20 7.4±0.20 
Duplex DNA 0.0±0.11 0.0±0.23 0.0±0.25 
4.71 
F21T 17.7±0.2 9.3±0.07 7.2±0.14 
C-kit-1 23.0±0.35 18.3±0.05 15.1±0.17 
C-kit-2 17.7±0.26 11.8±0.15 8.3±0.32 
BCL-2 15.5±0.26 8.9±0.23 5.9±0.14 
Duplex DNA 0.0±0.11 0.0±0.37 0.0±0.11 
4.72 
F21T 9.4±0.17 4.2±20 2.6±0.14 
C-kit-1 12.3±0.17 8.4±0.15 6.8±0.32 
C-kit-2 12.8±0.37 7.2±0.17 5.8±0.30 
BCL-2 10.2±0.11 5.3±0.32 4.2±0.20 
Duplex DNA 0.0±0.23 0.0±0.12 0.0±0.31 
4.73 
F21T 11.5±0.21 7.6±0.34 6.0±0.23 
C-kit-1 15.0±0.0 11.7±0.20 9.7±0.25 
C-kit-2 17.6±0.23 11.4±0.05 8.8±0.11 
BCL-2 15.8±0.05 10.4±0.25 7.8±0.36 
Duplex DNA 0.0±0.32 0.0±0.26 0.0±0.34 
 
All the molecules belonging to this library showed significant interaction with the 
different G-quadruplex sequences used. 4.70 provided 4.89°C, 9.2°C, 8.6°C 
and 7.4°C stabilisation, 4.71 provided a 7.2°C, 15.1°C, 8.3°C and 5.9°C 
stabilisation, 4.72 provided 2.6 °C, 6.8 °C, 5.8 °C and 4.2 °C stabilisation and 
4.73 provided 6.0°C, 9.7°C, 8.8°C and 7.8°C stabilisation at 1 µM 
concentrations against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex 
sequences, respectively. It is notable that 4.71 showed a significantly higher 
degree of stabilisation against the C-kit-1 quadruplex sequence. Thus 4.71 is 






Table 2.18: G-quadruplex and duplex DNA stabilization by ligands of library-3A 
in FRET melting experiments at concentrations of 5, 2 and 1 µM respectively    





5 µM 2 µM 1 µM 
4.74 
F21T 16.2±0.12 10.2±0.20 5.2±0.23 
C-kit-1 17.0±0.05 13.9±0.35 11.4±0.26 
C-kit-2 22.2±0.28 15.7±0.40 12.5±0.35 
BCL-2 17.1±0.15 11.7±0.28 10.0±0.15 
Duplex DNA 0.0±0.12 0.0±0.07 0.0±0.11 
4.75 
F21T 17.7±0.13 10.6±0.12 7.8±0.31 
C-kit-1 17.8±0.36 15.4±0.25 12.8±0.11 
C-kit-2 24.4±0.05 18.4±0.30 14.6±0.10 
BCL-2 18.7±0.10 13.5±0.25 10.0±0.20 
Duplex DNA 0.0±0.41 0.0±0.14 0.0±0.07 
4.76 
F21T 21.3±0.33 15.2±0.41 12.0±0.11 
C-kit-1 22.4±0.11 18.2±0.11 15.6±0.50 
C-kit-2 22.0±0.11 17.5±0.05 13.6±0.25 
BCL-2 19.3±0.11 13.6±0.15 9.9±0.10 
Duplex DNA 0.0±0.1 0.0±0.23 0.0±0.11 
 
The second set of molecules showed similar interactions to the first set. Here, 
4.74 provided 5.2°C, 11.4°C, 12.5°C and 10.0°C stabilisation, 4.75 provided 
7.8°C, 12.8 °C, 14.6°C and 10.0°C stabilisation and 4.76 provided 12.0°C, 
15.6°C, 13.6°C and 9.9°C stabilisation at 1 µM concentrations against F21T, C-
kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively. 4.76 was 
relatively more active towards G-quadruplex sequences. This is possibly due to 
the extra nitrogen atom of the terminal benzimidazole building block. However, 
when compared to the molecules from both libraries (library-2 and library-3) 
with equivalent melting temperatures, it would be more convenient to 
investigate the effect of the introduction of additional curvature within the ligand 
molecules.  
FRET data comparison between library-2 and library-3A clearly identified a 
distinguishing feature. Two equivalent molecules (4.52 and 4.49 from library-2 
compared with 4.70 and 4.71 from library-3A) were taken from both libraries to 
compare directly for the effects of curvature. 4.70 started with an indole building 
block instead of benzofuran as in 4.52. In contrast, 4.71 started with an indole 




Figure 2.36: Structures of 4.52 and 4.70. 
 
Table 2.19: Direct comparison between the equivalent molecules of library-2 




4.52 4.70 4.52 4.70 4.52 4.70 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 6.22±0.41 13.6±0.37 3.5±0.24 8.6±0.23 2.4±0.37 4.89±0.11 
C-kit-1 13.1±0.23 14.2±0.28 8.5±0.25 10.7±0.28 7.8±0.15 9.2±0.34 
C-kit-2 18.0±0.15 18.3±0.15 10.3±0.40 11.4±0.11 8.1±0.36 8.6±0.26 
BCL-2 14.8±0.40 15.7±0.23 8.3±0.35 10.4±0.20 5.6±0.36 7.4±0.20 
Duplex DNA 0.0±0.17 0.0±0.11 0.0±0.14 0.0±0.23 0.0±0.22 0.0±0.25 
 
FRET data analysis of the benzofused polyamides of library-2 and library-3A 
showed a clear difference in melting temperatures (∆Tm). The introduction of a 
second 5′-3′-benzofused moiety moderately improved the interacting capacity of 
the polyamides. This could be explained by the comparison of ∆Tm values of 
two equivalent molecules (i.e. 4.70 from library-3A and 4.52 from library-2). 
4.70 showed comparatively more stabilising capacity than 4.52; 4.52 provided 
2.4°C, 7.8°C, 8.1°C and 5.6°C stabilisation, whereas 4.70 provided 4.9°C, 
9.2°C, 8.6°C and 7.4°C stabilisation at 1 µM concentrations against F21T, C-kit-
1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively. This suggested that 
the introduction of more curvature made the ligands more potent. In addition, 
4.52 and 4.70 both showed a nearly identical pattern of stabilisation towards the 




Figure 2.37: Structures of equivalent molecules 4.49 and 4.71. 
Table 2.20: Direct comparison between the equivalent molecules of library-2 




4.49 4.71 4.49 4.71 4.49 4.71 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 14.6±0.20 17.7±0.2 7.5±0.14 9.3±0.07 3.4±0.34 7.2±0.14 
C-kit-1 13.1±0.25 23.0±0.35 10.4±0.36 18.3±0.05 9.9±0.21 15.1±0.17 
C-kit-2 17.2±0.23 17.7±0.26 11.7±0.05 11.8±0.15 11.0±0.20 8.3±0.32 
BCL-2 12.3±0.15 15.5±0.26 5.6±0.20 8.9±0.23 5.3±0.20 5.9±0.14 
Duplex DNA 0.0±0.23 0.0±0.11 0.0±0.21 0.0±0.37 0.0±0.35 0.0±0.11 
 
4.49 and 4.71 also showed the same pattern of stabilisation as 4.52 and 4.70. 
4.71 was found to show comparatively more stabilisation capacity than 4.49; 
4.49 provided 3.4°C, 9.9°C, 11.0°C and 5.3°C stabilisation at 1 µM 
concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, 
respectively, whereas 4.71 provided 7.2°C, 15.1°C, 8.3°C and 5.9°C 
stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-
quadruplex sequences, respectively. 
These obseravations are suggesting an idea that the introduction of more 
curvature within the benzofused polyamides results in a greater stabilisation 
capacity of the ligand molecules. In addition, 4.52 and 4.70 followed a similar 
pattern of stabilizing capacities toward the different G-quadruplex sequence 
types tested. 
These molecules of library-3A were supposed to interact differently as they 
include four different benzofused ring types; however, all of them are following a 
nearly similar pattern of activities. This infers that first and second consecutive 





Figure 2.38: Structures of 4.61 and 4.70. 
 
Table 2.21: Direct comparison between first and second degree curvature of 
molecules starting with two consecutive indole rings (the data are means of 




4.61 4.70 4.61 4.70 4.61 4.70 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 18.0±0.20 13.6±0.37 7.4±0.13 8.6±0.23 5.2±0.34 4.89±0.11 
C-kit-1 14.4±0.10 14.2±0.28 8.8±0.10 10.7±0.28 7.4±0.32 9.2±0.34 
C-kit-2 18.1±0.45 18.3±0.15 11.4±0.20 11.4±0.11 7.7±0.30 8.6±0.26 
BCL-2 13.9±0.15 15.7±0.23 7.6±0.17 10.4±0.20 4.7±0.30 7.4±0.20 
Duplex DNA 0.0±0.14 0.0±0.11 0.0±0.21 0.0±0.23 0.0±0.15 0.0±0.25 
 
Here, it was found that 4.70 interacts with G-quadruplex sequences more 
strongly than 4.61; 4.61 provided 5.2°C, 7.4°C, 7.7°C and 4.7°C stabilisation at 
1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex 
sequences, respectively, whereas 4.70 provided 4.89°C, 9.2°C, 8.6°C and 
7.4°C stabilisation at 1 µM concentration against the same G-quadruplex 
sequences. This result indicated that 4.61 may be the best ligand out of the 
library in providing G-quadruplex stabilisation, and supports the notion that the 
curvature of the ligand molecules contributes towards an enhanced stabilisation 
of G-quadruplex. 
2.8.4 Key Observations from the Overall Library-3A FRET Melting Data 
Analysis 
 
 Introduction of curvature strongly correlates with increases in the 
stabilisation capacity of ligand molecules. 
 A second degree of curvature is better than a first degree of curvature. 
 Indole, rather than the benzothiophene or benzofuran building blocks, 
appears to be the best scaffold for making more potent ligands. 
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2.9 Molecular Modelling Study of Library-3A Molecules 
Molecular docking studies of the molecules synthesised in Library-3A support 
predictions made during analysis of Library-2 molecules. In general, the 
introduction of a second 5’-3’-benzofused moiety enhanced stabilisation of each 
quadruplex structure. This likely occurs due to an enhanced shape-fit of the 
molecule with DNA. For example, in the case of 4.61 and 4.70 (Figure: 2:24 
and 2.31, Table: 2.12 and 2.17) (which have identical benzofused content and 
only differ by benzofused substitution pattern), G-quadruplex stabilisation was 
increased by up to 2.7°C at 1 μM concentration in the case of BCL-2. Although 
this increase is not as substantial as the increase observed between Libraries 
1 and 2, the increase is nonetheless significant. This difference is reflected in 
binding energies calculated for 4.61 and 4.70 (-74.54kcal/mol and -76.5 
kcal/mol, which suggest that 4.70 should enhance G-quadruplex stabilisation to 
a greater extent than 4.61 (Figure 2.35). 
 
Figure 2.39: Molecular model of 4.61 (left panel) and 4.70 (right panel) bound 
to the telomeric F21T G-quadruplex illustrating the difference in accommodation 
of a Library 2 molecule (4.61) and Library 3 molecule (4.70). In the case of 
4.61 (black sticks), two benzofused molecules are capable of orienting directly 
over guanine bases (blue nucleotide objects), thereby enhancing stabilisation. 
In the case of 4.70, two benzofused moieties are capable of interacting with the 
G-quadruplex, but appear to stack directly over the G tetrad. The amidic tail of 






2.10 Synthesis of Library-3B Molecules by the Structural 
Modification of Library-3A Molecules 
Initially, 4 molecules (Figure 2.37) were synthesized and evaluated to 
investigate the effect of an electron-withdrawing nitro group on the terminal 
indole unit of library-3A molecules. Then 5 more molecules (Figure 2.37) were 
synthesized further for a structure activity relationship (SAR) of 4.77 through 
modification of the shape of 4.77. Here, 5-nitro-benzofused-2-carboxylic acid 
was chosen to be a capping acid instead of benzofused-3-carboxylic acid in 
order to observe the effect of a nitro group on the G-quadruplex interactive 
capacities of the ligand molecules. 
 
Figure 2.40: Synthetic scheme of library-3B molecules. Here X = O or N or S. 
Two consecutive 5-nitro-indole-3 carboxylic acids were coupled one after 
another and then this intermediate was capped with four different 5-nitro-
benzofused-2-carboxylic acids to get final ligands with the same shape as the 
library-3A molecules (Figure 2.36). In addition to this, 4.80, an equivalent 
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molecule of 4.77, was synthesized to investigate the relative effects of indole 
and indazole as terminal capping acids. 
 
Figure 2.41: Structures of library-3B molecules. 
Initially the acid (1.2 eq.) was dissolved in DMF (5 mL for 100 mg of starting 
material) in a round bottom flask fitted with a magnetic stirrer. Then DIC (1.75 
eq.) and HOBt (2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for formation of the ester from the acid. The 
amine (1 eq.) was added to the mixture and the mixture allowed to stir until the 
reaction was complete, as indicated by TLC or LCMS. Finally the reaction 
mixture was applied to a conditioned SCX-2 cartridge and the resultant product 
was purified by the ‘Catch and Release’ method (described in the section 
‘Methods and Materials’ of Chapter 3). 
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2.10.1 Characterisation of Benzofused Polyamides through Various 
Spectroscopic Techniques 
 
The benzofused polyamides of library-3B were purified and fully characterized 
by different spectroscopic techniques including mass spectrometry, both 1H and 
13C NMR, and IR techniques (described in the ‘Experimental’ section of 
Chapter 4). Compounds were primarily identified by LCMS and confirmed using 
high resolution mass spectroscopy (HRMS) (Table 2.22 and 2.23). 








1 4.79 607.2179 608.2244 
2 4.78 623.1951 624.2017 
3 4.77 606.2339 607.2396 
4 4.80 607.2292 608.2362 
5 4.23 606.2339 607.2405 
6 4.66 606.2339 607.2398 
7 4.60 606.2339 607.2400 
8 4.67 606.2339 607.2399 
9 4.93 606.2339 607.2402 
 
2.10.2 Purity Analysis of Benzofused Polyamides Synthesized 
 
The purity of the benzofused polyamides of this library was checked by two 
different HPLC methods with two different retention times. The Waters 996 PDA 
start wavelength was 210 nm for the 10 minute method (Method A), with a start 
wavelength of 220 nm and end wavelength of 500 nm for the 5 minute method 
(Method B) (Table 2.22 and 2.23). 
Table 2.23: Purity data for library-3B molecules as observed by HPLC 
Number Compound code 
Purity 
Method A (10 min)% Method B (5 min)% 
1 4.79 100 100 
2 4.78 100 100 
3 4.77 100 100 
4 4.80 100 100 
5 4.23 100 100 
6 4.66 100 100 
7 4.60 100 100 
8 4.67 100 100 











Table 2.24: G-quadruplex and duplex DNA stabilization by ligands in FRET 
melting experiments at concentrations of 5, 2 and 1 µM respectively              





5 µM 2 µM 1 µM 
4.79 
F21T 15.8±0.23 9.9±0.21 6.0±0.20 
C-kit-1 19.5±0.35 12.8±0.34 9.2±0.20 
C-kit-2 19.3±0.20 14.8±0.36 11.2±0.40 
BCL-2 22.9±0.07 11.4±0.35 7.7±0.24 
Duplex DNA 0.0±0.32 0.0±0.21 0.0±0.43 
4.78 
F21T 18.8±0.12 11.6±0.23 8.8±0.07 
C-kit-1 21.6±0.07 14.8±0.28 11.7±0.35 
C-kit-2 27.0±0.32 15.8±0.15 13.0±0.32 
BCL-2 23.9±0.05 14.7±0.10 10.5±0.15 
Duplex DNA 1.0±0.23 0.0±0.12 0.0±0.07 
4.77 
F21T 21.7±0.26 15.6±0.07 12.2±0.23 
C-kit-1 24.5±0.40 16.7±0.26 14.4±0.35 
C-kit-2 27.8±0.36 17.9±0.21 14.7±0.26 
BCL-2 30.8±0.21 15.7±0.28 12.1±0.25 
Duplex DNA 1.0±0.12 0.0±0.1 0.0±0.23 
4.80 
F21T 12.7±0.24 8.4±0.16 4.8±0.21 
C-kit-1 16.2±0.20 11.6±0.32 7.6±0.15 
C-kit-2 22.1±0.20 15.0±0.34 10.2±0.26 
BCL-2 18.6±0.41 10.7±0.40 7.7±0.11 
Duplex DNA 0.0±0.23 0.0±0.31 0.0±0.12 
 
From this FRET data analysis, it is very clear that the introduction of a nitro 
group enhances the interactive capacities of ligand molecules. This could be 
explained in a number of possible ways, including hydrogen bond formation 
between the nitro group and amino, imine or carbonyl groups from guanine 
residues of the G-quartet, the nitro group potentially recruiting potassium ions 
which could help to stack the quartet together, or the nitro group providing 
additional electronic interactions. 
However, it is more convenient to evaluate the effect of the nitro group’s 





Figure 2.43: Structures of 4.70 and 4.79. 
 
Table 2.25: Comparative G-quadruplex and duplex DNA stabilization between 
ligands 4.70 and 4.79 in FRET melting experiments at concentrations of 5, 2 




4.70 4.79 4.70 4.79 4.70 4.79 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 13.6±0.37 15.8±0.23 8.6±0.23 9.9±0.21 4.89±0.11 6.0±0.20 
C-kit-1 14.2±0.28 19.5±0.35 10.7±0.28 12.8±0.34 9.2±0.34 9.2±0.20 
C-kit-2 18.3±0.15 19.3±0.20 11.4±0.11 14.8±0.36 8.6±0.26 11.2±0.40 
BCL-2 15.7±0.23 22.9±0.07 10.4±0.20 11.4±0.35 7.4±0.20 7.7±0.24 
Duplex DNA 0.0±0.11 0.0±0.32 0.0±0.23 0.0±0.21 0.0±0.25 0.0±0.43 
 
Here, 4.79 is shown to have a better interacting capacity compared to the 
equivalent ligand 4.70, since 4.70 provided 4.89°C, 9.2°C, 8.6°C and 7.4°C 
stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-
quadruplex sequences, respectively, whilst 4.79 provided 6.0°C, 9.2°C, 11.2°C 
and 7.7°C stabilisation at 1 µM concentration against the same G-quadruplex 
sequences, respectively. Thus the molecules terminating with benzofuran did 
not show a significant difference in their melting temperatures even though they 
have an electron-withdrawing nitro group in their structures. 
 




Table 2.26: Comparative FRET data analysis between 4.71 and 4.78 (the data 




4.71 4.78 4.71 4.78 4.71 4.78 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 17.7±0.2 18.8±0.12 9.3±0.07 11.6±0.23 7.2±0.14 8.8±0.07 
C-kit-1 23.0±0.35 21.6±0.07 18.3±0.05 14.8±0.28 15.1±0.17 11.7±0.35 
C-kit-2 17.7±0.26 27.0±0.32 11.8±0.15 15.8±0.15 8.3±0.32 13.0±0.32 
BCL-2 15.5±0.26 23.9±0.05 8.9±0.23 14.7±0.10 5.9±0.14 10.5±0.15 
Duplex DNA 0.0±0.11 1.0±0.23 0.0±0.37 0.0±0.12 0.0±0.11 0.0±0.07 
 
Here, 4.71 provided 7.2°C, 15.1°C, 8.3°C and 5.9°C stabilisation at 1 µM 
concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, 
respectively, and 4.78 provided 8.8°C, 11.7°C, 13.0°C and 10.5°C stabilisation 
at 1 µM concentration against the same G-quadruplex sequences. Both of them 
were found to be equally interactive towards G-quadruplex sequences. 
Moreover, 4.71 had a tendency to be a partially specific toward C-kit-1 and c-kit-
2. On the other hand, 4.78 tended to show a partial specificity toward-kit-2 
rather than C-kit-1. However, like 4.70 and 4.79, the molecules terminating with 
nitro group-containing thiophenes did not possess significantly improved melting 
temperatures. 
 
Figure 2.45: Structures of 4.72 and 4.77. 
Table 2.27: Comparative FRET data analysis between 4.72 and 4.77 molecules 




4.72 4.77 4.72 4.77 4.72 4.77 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 9.4±0.17 21.7±0.26 4.2±20 15.6±0.07 2.6±0.14 12.2±0.23 
C-kit-1 12.3±0.17 24.5±0.40 8.4±0.15 16.7±0.26 6.8±0.32 14.4±0.35 
C-kit-2 12.8±0.37 27.8±0.36 7.2±0.17 17.9±0.21 5.8±0.30 14.7±0.26 
BCL-2 10.2±0.11 30.8±0.21 5.3±0.32 15.7±0.28 4.2±0.20 12.1±0.25 
Duplex DNA 0.0±0.23 1.0±0.12 0.0±0.12 0.0±0.1 0.0±0.31 0.0±0.23 
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Here, 4.77 provided relatively higher melting temperatures of 12.2°C, 14.4°C, 
14.7°C and 12.2°C stabilisation at 1 µM concentration against F21T, C-kit-1, C-
kit-2 and Bcl-2 G-quadruplex sequences, respectively. On the other hand, an 
equivalent molecule 4.72 lacking the nitro group provided 2.6°C, 6.8°C, 5.8°C 
and 4.2°C stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and 
Bcl-2 G-quadruplex sequences, respectively. Here, unlike with the benzofuran 
or benzothiophene, the molecules with nitro-indole groups had significantly 
higher melting temperatures compared to the equivalent ligands without the 
nitro group. Therefore, it is evident that the electron-withdrawing nitro group 
plays a positive role in improving the G-quadruplex interacting capacity of these 
ligands. 
 
Figure 2.46: Structures of 4.73 and 4.80. 
Table 2.28: Comparative FRET data analysis between 4.73 and 4.80           




4.73 4.80 4.73 4.80 4.73 4.80 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 11.5±0.21 12.7±0.24 7.6±0.34 8.4±0.16 4.8±0.21 6.0±0.23 
C-kit-1 15.0±0.0 16.2±0.20 11.7±0.20 11.6±0.32 7.6±0.15 9.7±0.25 
C-kit-2 17.6±0.23 22.1±0.20 11.4±0.05 15.0±0.34 10.2±0.26 8.8±0.11 
BCL-2 15.8±0.05 18.6±0.41 10.4±0.25 10.7±0.40 7.7±0.11 7.8±0.36 
Duplex DNA 0.0±0.32 0.0±0.23 0.0±0.26 0.0±0.31 0.0±0.12 0.0±0.34 
 
The overall data analysis showed that 4.77 was better than any other members 
of this library. Therefore 4.77 was taken to be a lead benzofused polyamide for 
a subsequent structure activity relationship (SAR) study.  
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It was possible to find a preferred building block by comparing the two 
equivalent molecules 4.80 and 4.77 (both of them are structurally equivalent 
with the exception of their terminal building block types). 
 
Figure 2.47: Structures of equivalent molecules 4.80 and 4.77. 
 
 
Table 2.29: Comparative FRET data analysis between 4.80 and 4.77 (the data 




4.80 4.77 4.80 4.77 4.80 4.77 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 12.7±0.24 21.7±0.26 8.4±0.16 15.6±0.07 6.0±0.23 12.2±0.23 
C-kit-1 16.2±0.20 24.5±0.40 11.6±0.32 16.7±0.26 9.7±0.25 14.4±0.35 
C-kit-2 22.1±0.20 27.8±0.36 15.0±0.34 17.9±0.21 8.8±0.11 14.7±0.26 
BCL-2 18.6±0.41 30.8±0.21 10.7±0.40 15.7±0.28 7.8±0.36 12.1±0.25 
Duplex DNA 0.0±0.23 1.0±0.12 0.0±0.31 0.0±0.1 0.0±0.34 0.0±0.23 
  
4.77 provided relatively high melting temperature of 12.2°C, 14.4°C, 14.7°C and 
12.2°C stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and 
Bcl-2 G-quadruplex sequences, respectively, whilst an equivalent 4.80 provided 
relatively low ∆Tm values of 6.0°C, 9.2°C, 11.2°C and 7.7°C stabilisation at 1 
µM concentration against the same G-quadruplex sequences, respectively. It 
was very clear from the overall data analysis that for the molecules belonging to 
library-3B, 4.77 is a more highly G-quadruplex-interactive molecule than 4.80, 
even though 4.80 possessed a terminal nitro-benzimidazole group instead of 
the nitro-indole seen in 4.77. This indicated that indole was a better group 
compared to any of the other building blocks used. At the same time, 4.77 could 
be rationally considered to be a lead ligand for all of G-quadruplex sequences 
used, for further optimisation in order to get a more potent ligand.  
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2.10.3 Structure Activity Relationship of Lead Ligand 4.77 
 
4.77 showed significantly interaction with G-quadruplex sequences; therefore 
this was taken as a lead ligand for further structural modifications. A structural 
activity relationship (SAR) was done including modifications of the shape 
(Figure 2.37, Table 2.30), tail types (Figure 2.55, Table 2.42) and functional 
groups (Figure 2.57, Table 2.45) attached to the terminal indole group. 
 
 
Table 2.30: G-quadruplex and duplex DNA stabilization by ligands (4.23, 4.66, 
4.60, 4.67, 4.77 and 4.93) in FRET melting experiments (the data are means of 






5 µM 2 µM 1 µM 
4.23 
F21T 0.5±0.13 0.4±0.34 0.3±0.17 
C-kit-1 0.8±0.2 0.1±0.35 0.4±0.23 
C-kit-2 1.9±0.20 0.7±0.15 0.03±0.23 
BCL-2 0.8±0.36 0.3±0.20 0.5±0.34 
Duplex DNA 0.0±0.15 0.0±0.11 0.0±0.14 
4.66 
F21T 0.6±0.11 0.3±0.32 0.3±0.37 
C-kit-1 10.5±0.25 0.8±0.26 0.3±0.20 
C-kit-2 6.1±0.30 1.3±0.20 1.0±0.30 
BCL-2 5.1±0.25 1.8±0.12 1.3±0.15 
Duplex DNA 1.0±0.34 0.0±0.21 0.0±0.07 
4.60 
F21T 18.2±0.05 7.4±0.07 5.7±0.21 
C-kit-1 18.6±0.15 14.3±0.05 11.5±0.25 
C-kit-2 21.7±0.15 14.0±0.26 10.9±0.20 
BCL-2 17.8±0.15 9.4±5.34 6.6±0.11 
Duplex DNA 0.0±0.27 0.0±0.11 0.0±0.31 
4.67 
F21T 5.6±0.21 2.5±0.41 1.5±0.15 
C-kit-1 10.2±0.20 5.3±0.36 3.1±0.23 
C-kit-2 11.0±0.11 5.7±0.20 4.1±0.35 
BCL-2 17.3±0.36 4.1±0.36 2.2±0.26 
Duplex DNA 1.0±0.10 1.0±0.10 0.0±0.360.05 
4.93 
F21T 21.0±0.17 15.9±0.28 12.6±0.26 
C-kit-1 27.7±0.30 22.1±0.35 17.6±0.28 
C-kit-2 21.3±0.23 14.8±0.20 11.4±0.32 
BCL-2 25.4±0.30 17.8±0.14 13.5±0.20 
Duplex DNA 0.0±0.05 0.0±0.05 0.0±0.05 
 
Here, 4.23 did not show any interaction with the G-quadruplex types used, as 
seen before for similar molecules belonging to library-1. This 5’-2’ substituted 
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molecule was structurally the same as the molecules of library-1. Its FRET data 
further verified that of the library-1 molecules and indicated that 5’-2’ 
substituted ligands do not have sufficient curvature in their structures to fit into 
G-quartets. However, 4.66, a molecule with a first degree of curvature, showed 
very minor interaction with G-quadruplexes, similar to that of 4.23. This 
indicated that the introduction of curvature at the beginning of a ligand through 
5’-3’ substitution started to change the shape correctly so that the molecule 
could fit into the G-quartet. Whereas 4.60 provided 5.7°C, 11.5°C, 10.9°C and 
6.6 °C stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-
2 G-quadruplex sequences, respectively, 4.67 showed 1.5°C, 3.1°C, 4.1°C and 
2.2°C stabilisation at 1 µM concentration against the same G-quadruplex 
sequences. It had better interaction with G-quadruplexes than 4.66, meaning 
that the 5’-3’ substitution at the terminal gave molecules comparatively better 
shapes with which to interact than for the same substitution at the beginning of 
the ligand. However, the sudden change in the melting temperatures for 4.60, 
4.23, 4.66 and 4.67 suggested that a 5’-3’ substitution in the middle of a ligand 
can help to give a molecule a better shape with which to fit onto the G-
quadruplex. 4.77, a molecule of second degree curvature, showed a more 
significant interaction with all types of G-quadruplex sequences used as it 
provided 12.2°C, 14.4°C, 14.7°C and 6.0°C stabilisation at 1 µM concentration 
against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively. 
These high interactions were assumed to be due to the introduction of more 
curvature within the structure of this molecule. Finally, the most curved 
molecule, 4.93, a molecule of the third degree of curvature, was made to 
complete all possible shapes based on structural modifications of 4.77. 4.93 
provided ∆Tm of 12.6°C, 17.6°C, 11.4°C and 13.5°C stabilisation at 1 µM 
concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, 
respectively. It was obvious that 4.93 was a better interactive ligand than 4.77, 






2.10.4 Key Observations made from the Comparative FRET Data Analysis 
of Library-3B Molecules 
 
 Electron-withdrawing groups (such as the NO2 group) enhance the 
interacting capacity of benzofused polyamides towards G-quadruplex 
DNA. 
 Indole is comparatively better than any other types of nitro-benzofused-
acid building blocks for the enhancement of G-quadruplex interactivity. 
 Compound 4.93 was taken as a new lead for further structure activity 
relationship studies. 
2.11 Shape-Based Assessment of 4.93 Analogues 
Four directly equivalent analogues of 4.77 were assessed using molecular 
docking studies in order to establish a rationale behind the enhanced 
stabilisation of libraries 2, 3 and 4 relative to library 1. The four chosen 
molecules contain the same skeleton (i.e., three indole rings and tail), and differ 
only by shape. 4.23 (containing three 5’-2’ substituted indoles) has a GBSA 
score of -66.48 kcal/mol, which is the lowest calculated binding affinity. Visual 
analysis of the docked complex suggests that the molecule is not positioned 
appropriately on the G-quadruplex for interaction, relative to the highly 
interactive biaryl polyamide (Figure 2.43 left and right panel), thereby providing 
a rationale behind its poor quadruplex stabilisation and FRET binding results. 
 
 
Figure 2.48: Left Panel 4.23 (black) docked on the G-quadruplex interface of 
the Human telomeric quadruplex (PDB ID: 3CDM). The molecule is too straight 
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in nature to bind to the full tetrad. Right Panel shows molecular model of G-
quadruplex-interacting U-shaped biaryl polyamide (blue) based on distamycin A 
motif docked on the Human telomeric quadruplex (yellow). 
Energy calculations also suggest that 4.60, 4.77 and 4.93 (Library- 2, 3 and 4 
respectively) have enhanced binding over 4.23. In particular, 4.93 has the 
greatest calculated binding affinity (-77.20kcal/mol), and this molecule 
possesses three 5’-3’ substituted indole groups. Our hypothesis suggests that 
increasing curvature (i.e., introducing a greater number of 5’-3’ substituted 
benzofused building blocks) should increase DNA binding, and this is reflected 
in the enhanced ΔTm of 17°C at 1 μM observed for 4.93. 4.77 has a similarly 
high ΔTm (i.e., 16 °C at 1 μM), and has a GBSA score which is greater than -70 
kcal/mol. 4.60, which has one 5’-3’ substituted indole group, has a GBSA score 
of -76.81 kcal/mol and ΔTm of 10°C. Visual analysis of the docked molecules 
shows reasons behind their enhanced stabilisation, relative to 4.23. For 
instance, in the case of 4.60, the introduction of a 5’-3’ substitution to the central 
indole (Figure 2.44), orients the ligand over the central G-tetrad, thereby 
inducing stabilisation of the quadruplex. A similar observation can be made with 
4.77 and 4.93 (Figure 2.45 and Figure 2.46), whereby the introduction of 
greater curvature allows the molecules to capture a greater area of the 
quadruplex. 
 
Figure 2.49: 4.60 (black) docked on the G-quadruplex interface of the Human 
telomeric quadruplex (PDB ID: 3CDM). The molecule has a curved shape, and 




Figure 2.50: 4.77 (black) docked on the G-quadruplex interface of the Human 
telomeric quadruplex (PDB ID: 3CDM). The molecule has a more enhanced 
curvature than 4.23 and 4.60 and is therefore capable of stabilising the G-
quadruplex structure to a greater extent. 
 
Figure 2.51: Molecular model of 4.93 (black sticks) binding to the G-quadruplex 
interface. It can be seen that the three benzofused components of the molecule 
stack directly over the G-tetrad, thereby stabilising the quadruplex. The 
presence of 5’-3’-substituted to benzofused building blocks help to create a 
sufficient shape of molecule to maximise interaction. 
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Table 2.31: Molecule names, structures, GBSA scores (kcal/mol) and FRET 
melting temperatures for 4.23, 4.60, 4.77 and 4.93. 
 
It is evident from molecular docking results that a clear shape-based rationale 
for enhanced DNA stabilisation can be established. The introduction of a 5’-3’-
substituted indole as the second of three amide-linked benzofused building 
blocks (instead of a 5’-2’-substituted indole) can dramatically enhance binding 
of the triaryl scaffold to the quadruplex. Introduction of further 5’-3’-substituted 
benzofused moieties (for example, in the case of 4.77 and 4.93) can further 
enhance stabilisation, and this occurs due to the presence of aryl structures in 





































































2.12 Synthetic Scheme for Library-4A Molecules 
The molecular docking studies of molecules containing three consecutive 5’-3’ 
benzofused moieties (for example, 4.93) suggested that the inclusion of a third 
5’-3’-substituted benzofused moiety should enhance G-quadruplex stabilisation 
to a small degree compared to two 5’-3’-substituted benzofused moieties (for 
example, 4.77). 
 
Figure 2.52: Synthetic scheme of library-4A molecules. Here X = O, N, S. 
A new library of molecules containing four different benzofused polyamides was 
synthesized to investigate the relevance of the electron-withdrawing NO2 group 
to the activity of the most active compound 4.93. The synthesised molecules 
were capped with a benzofused building block containing a carboxylic acid in 
the 3’ position only, instead of a 5-nitro-3-carboxylic acid benzofused building 
block as found in 4.93, to assess this factor. At the same time, the equivalent 
molecules from library-3A and library-4A were directly compared to investigate 
the effect of structural curvature within their structures to provide the interactive 
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capacity towards G-quadruplexes. This would provide a guideline for finding the 
right degree of curvature to fit into G-quadruplex architecture. 
Initially, the acid (1.2 eq.) was dissolved in DMF (5 mL for 100 mg of starting 
material) in a round bottom flask fitted with a magnetic stirrer. Then DIC (1.75 
eq.) and HOBt (2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for formation of the ester from the acid. The 
amine (1 eq.) was added to the mixture and the mixture allowed for stirring until 
the reaction was complete, as indicated by TLC or LCMS. Finally the reaction 
mixture was applied to a conditioned SCX-2 cartridge and the resultant product 
was purified by the ‘Catch and Release’ method (described in the section 
‘Methods and Materials’ of Chapter 3). 
 
 









2.12.1 Characterisation of Benzofused Polyamides through Various 
Spectroscopic Techniques 
 
Benzofused polyamides of this library were purified and fully characterized by 
different spectroscopic techniques including mass spectrometry, both 1H and 
13C NMR, and IR techniques (described in the Experimental section of Chapter 
4). Compounds were primarily identified by LCMS and confirmed using high 
resolution mass spectroscopy (HRMS) (Table 2.32 and 2.33). 
Table 2.32: HRMS data for library-4A molecules 
Number Compound code Theoretical mass 
Observed mass 
[M+H]+ 
1 4.90 562.2329 563.2388 
2 4.89 578.2100 578.2100 
3 4.91 575.2645 576.2703 
4 4.92 562.2441 563.2498 
 
2.12.2 Purity Analysis of Benzofused Polyamides Synthesized 
 
The purity of the benzofused polyamides of this library was checked by two 
different HPLC methods with two different retention times. Both methods were 
carried out on a Waters Alliance 1695 HPLC Pump with water and acetonitrile 
comprising the mobile phases. The Waters 996 PDA start wavelength was 210 
nm for the 10 minute method (Method A), with a start wavelength of 220 nm and 
end wavelength of 500 nm for the 5 minute method (Method B) (Table 2.32 and 
2.33). 
Table 2.33: Purity data for library-4A molecules as observed by HPLC 
Number Compound code 
Purity 
Method A (10 min)% Method B (5 min)% 
1 4.90 100 95 
2 4.89 100 95 
3 4.91 100 88 
















Table 2.34: G-quadruplex and duplex DNA stabilization by library-4A 
molecules in FRET melting experiments at concentrations of 5, 2 and 1 µM 





5 µM 2 µM 1 µM 
4.90 
F21T 8.8±0.07 5.2±0.20 3.2±0.12 
C-kit-1 13.1±0.20 8.7±0.2 4.9±0.25 
C-kit-2 14.8±0.05 7.8±0.23 6.2±0.28 
BCL-2 13.4±0.36 7.4±0.15 4.2±0.11 
Duplex DNA 0.0±0.12 0.0±0.15 0.0±0.08 
4.89 
F21T 8.6±0.10 5.1±0.05 3.5±0.20 
C-kit-1 12.0±0.20 7.7±0.20 5.9±0.20 
C-kit-2 13.2±0.20 7.7±0.25 5.3±0.15 
BCL-2 11.2±0.2 6.0±0.35 3.6±0.21 
Duplex DNA 0.0±0.12 0.0±0.15 0.0±0.18 
4.91 
F21T 10.9±0.13 6.7±0.22 2.9±0.14 
C-kit-1 15.2±0.30 9.9±0.17 8.2±0.25 
C-kit-2 17.2±0.15 11.6±0.05 8.9±0.10 
BCL-2 16.3±0.20 10.4±0.23 7.5±0.14 
Duplex DNA 0.0±0.17 0.0±0.32 0.0±0.31 
4.92 
F21T 17.2±0.21 10.7±0.21 9.3±0.05 
C-kit-1 20.4±0.20 17.1±0.11 15.7±0.17 
C-kit-2 22.1±0.15 15.9±0.26 13.4±0.36 
BCL-2 22.4±0.10 13.4±0.11 10.3±0.30 
Duplex DNA 0.0±0.29 0.0±0.34 0.0±0.16 
 
Here, all of the molecules except 4.92 were found to be moderately interactive 
towards the different G-quadruplex sequence types. 4.92 provided 9.3°C, 15.7 
°C, 13.4°C and 10.3°C stabilisation at 1 µM concentration against F21T, C-kit-1, 
C-kit-2 and Bcl-2 G-quadruplex sequences, respectively. This significant activity 
of 4.92 was due to the effect of the additional nitrogen atom of the terminal 
indazole building block as previously discussed. 
The effect of an electron-withdrawing nitro group on the interaction capacity of 
benzofused polyamides towards G-quadruplex DNA can be shown by the direct 
comparison of the equivalent molecules 4.93 from library-3B and 4.91 from 




Figure 2.55: Structures of 4.91 and 4.93. 
Table 2.35: Direct comparison between molecules 4.91 and 4.93 of library-4A 




4.91 4.93 4.91 4.93 4.91 4.93 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 10.9±0.13 21.0±0.17 6.7±0.22 15.9±0.28 2.9±0.14 12.6±0.26 
C-kit-1 15.2±0.30 27.7±0.30 9.9±0.17 22.1±0.35 8.2±0.25 17.6±0.28 
C-kit-2 17.2±0.15 21.3±0.23 11.6±0.05 14.8±0.20 8.9±0.10 11.4±0.32 
BCL-2 16.3±0.20 25.4±0.30 10.4±0.23 17.8±0.14 7.5±0.14 13.5±0.20 
Duplex DNA 0.0±0.17 0.0±0.05 0.0±0.32 0.0±0.05 0.0±0.31 0.0±0.05 
 
4.91 provided 2.9°C, 8.2°C, 8.9°C and 7.5°C stabilisation at 1 µM concentration 
against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively, 
whereas 4.93, a nitro group-containing benzofused polyamide, provided 12.6°C, 
17.6°C, 11.4°C and 13.5°C stabilisation at 1 µM concentration against F21T, C-
kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively. Thus it was 
obvious that 4.93 was more interactive towards all types of G-quadruplex 
sequences used than 4.91.  
Two other molecules (4.90 and 4.89) were not as interactive as 4.93 towards G-
quadruplex DNA, although they have the same degree of curvature in their 
structure. This observation also supports the positive impact of an electron-
withdrawing nitro group at the terminal benzofused unit on interaction ability 
with G-quadruplex DNA. 
It was important to compare the equivalent molecules from library-3A and 
library-4A to investigate the effect of structural curvature on their G-quadruplex 
interactive capacities - it would provide guidelines for finding the right degree of 
curvature to fit into G-quadruplex architecture. 4.70, a member of library-3A 
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(with a second degree of curvature) was equivalent to 4.90 (with a third degree 
of curvature), a member of library-4A, and the two are directly comparable. 
 
Figure 2.56: Structures of 4.70 and 4.90. 
  
Table 2.36: Direct comparison between molecules 4.70 and 4.90 of library-3A 




4.70 4.90 4.70 4.90 4.70 4.90 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 13.6±0.37 8.8±0.07 8.6±0.23 5.2±0.20 4.89±0.11 3.2±0.12 
C-kit-1 14.2±0.28 13.1±0.20 10.7±0.28 8.7±0.2 9.2±0.34 4.9±0.25 
C-kit-2 18.3±0.15 14.8±0.05 11.4±0.11 7.8±0.23 8.6±0.26 6.2±0.28 
BCL-2 15.7±0.23 13.4±0.36 10.4±0.20 7.4±0.15 7.4±0.20 4.2±0.11 
Duplex DNA 0.0±0.11 0.0±0.12 0.0±0.23 0.0±0.15 0.0±0.25 0.0±0.08 
 
Here, 4.90 provided 3.2°C, 4.9°C, 6.2°C and 4.2°C stabilisation and 4.70 
provided 4.89°C, 9.2°C, 8.6°C and 7.4°C stabilisation at 1 µM concentration 
against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively. 
This result suggested that these two molecules were approximately equivalent 
to each other with regards to interaction with G-quadruplex DNA. 
Similarly, molecules 4.71 and 4.89 from library-3A and library-4A, 
respectively, are also directly comparable. 
 
Figure 2.57: Structures of equivalent molecules 4.71 and 4.89. 
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Table 2.37: Direct comparison between 4.71 and 4.89 of library-3 and library-




4.71 4.89 4.71 4.89 4.71 4.89 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 17.7±0.2 8.6±0.10 9.3±0.07 5.1±0.05 7.2±0.14 3.5±0.20 
C-kit-1 23.0±0.35 12.0±0.20 18.3±0.05 7.7±0.20 15.1±0.17 5.9±0.20 
C-kit-2 17.7±0.26 13.2±0.20 11.8±0.15 7.7±0.25 8.3±0.32 5.3±0.15 
BCL-2 15.5±0.26 11.2±0.2 8.9±0.23 6.0±0.35 5.9±0.14 3.6±0.21 
Duplex DNA 0.0±0.11 0.0±0.12 0.0±0.37 0.0±0.15 0.0±0.11 0.0±0.18 
 
Here, 4.89 provided 3.5°C, 5.9°C, 5.3°C and 3.6°C stabilisation and 4.71 
provided 7.2°C, 15.1°C, 8.3°C and 5.9°C stabilisation at 1 µM concentration 
against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively.  




Figure 2.58: Structures of 4.72 and 4.91. 
Table 2.38: Direct comparison between equivalent molecules 4.72 and 4.91 of 





4.72 4.91 4.72 4.91 4.72 4.91 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 9.4±0.17 10.9±0.13 4.2±20 6.7±0.22 2.6±0.14 2.9±0.14 
C-kit-1 12.3±0.17 15.2±0.30 8.4±0.15 9.9±0.17 6.8±0.32 8.2±0.25 
C-kit-2 12.8±0.37 17.2±0.15 7.2±0.17 11.6±0.05 5.8±0.30 8.9±0.10 
BCL-2 10.2±0.11 16.3±0.20 5.3±0.32 10.4±0.23 4.2±0.20 7.5±0.14 




4.91 provided 2.9°C, 8.2°C, 8.9°C and 7.5°C stabilisation whilst 4.72 provided 
2.6°C, 6.8°C, 5.8°C and 4.2°C stabilisation at 1 µM concentration against F21T, 
C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively. 4.91 (relatively 
more curved) was found to be more G-quadruplex interactive than the 
equivalent molecule 4.72 (relatively less curved). This observation suggested 
that the inclusion of a third 5’-3’-substituted benzofused moiety should enhance 
G-quadruplex stabilisation to a small degree compared to two 5’-3’-substituted 
benzofused moieties (Figure 2.39). 
 
Figure 2.59: Structures of the equivalent molecules 4.73 and 4.92. 
 
Table 2.39: Direct comparison between equivalent molecules 4.73 and 4.92 of 





4.73 4.92 4.73 4.92 4.73 4.92 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 11.5±0.21 17.2±0.21 7.6±0.34 10.7±0.21 6.0±0.23 9.3±0.05 
C-kit-1 15.0±0.0 20.4±0.20 11.7±0.20 17.1±0.11 9.7±0.25 15.7±0.17 
C-kit-2 17.6±0.23 22.1±0.15 11.4±0.05 15.9±0.26 8.8±0.11 13.4±0.36 
BCL-2 15.8±0.05 22.4±0.10 10.4±0.25 13.4±0.11 7.8±0.36 10.3±0.30 
Duplex DNA 0.0±0.32 0.0±0.29 0.0±0.26 0.0±0.34 0.0±0.34 0.0±0.16 
 
4.92, with a third degree of curvature, provided 9.3°C, 15.7°C, 13.4°C and 
10.3°C stabilisation and the equivalent 4.73, a molecule with a second degree 
of curvature, provided a 6.0°C, 9.7°C, 8.8°C and 7.8°C stabilisation at 1 µM 
concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, 
respectively. It is evident that 4.92 had more significant interactions due to 
having an extra electronegative nitrogen atom in the terminal indazole ring. 
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2.12.3 Key Observations from Library-4A 
 
 Results from library 4A suggest that an electron-withdrawing nitro group 
at the terminal benzofused building block enhances G-quadruplex 
stabilisation considerably. 
 The molecules made of three consecutive indole units with a third degree 
of curvature are assumed to fit nicely within the G-quadruplex to provide 
more interaction than the molecules of the same unit with a second 





















2.13 Synthetic Scheme for Library-4B Molecules 
 
Figure 2.60: Synthetic scheme of library-4B molecules. 
A set of molecules (4 in total) was next synthesized for the structure activity 
relationship of 4.93 through the modification of the tertiary amine tails initially 
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attached through an amide coupling reaction. These structural modifications of 
4.93 were done by the substitution of the N1, N1-dimethylpropane-1,3-diamine 
tail with different tails including 3-(piperidin-1-yl)propan-1-amine, 3-(pyrrolidin-1-
yl)propan-1-amine, 3-morpholinopropan-1-amine and 3-(4-methylpiperazin-1-
yl)propan-1-amine 
Initially the acid (1.2 eq.) was dissolved in DMF (5 mL for 100 mg of starting 
material) in a round bottom flask fitted with a magnetic stirrer. Then DIC (1.75 
eq.) and HOBt (2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for formation of the ester from the acid. The 
amine (1 eq.) was added to the mixture and the mixture allowed to stir until the 
reaction was complete, as indicated by TLC or LCMS. Finally the reaction 
mixture was applied to a conditioned SCX-2 cartridge and the resultant product 
was purified by the ‘Catch and Release’ method (described in the section 
‘Methods and Materials’ of Chapter 3). 
Four molecules with the highest curvature were synthesized to investigate the 
effect of tertiary tail types on interaction with G-quadruplex DNA. Here, ligands 
were synthesized by using different tails. 
 
 




2.13.1 Characterisation of Benzofused Polyamides through Various 
Spectroscopic Techniques 
 
Benzofused polyamides of library-4B were purified and fully characterized by 
different spectroscopic techniques including mass spectrometry, both 1H and 
13C NMR, and IR techniques (described in the Experimental section of Chapter 
4). Compounds were primarily identified by LCMS and confirmed using high 
resolution mass spectroscopy (HRMS) (Table 2.40 and 2.41). 
Table 2.40: HRMS data for library-4B molecules 





1 4.98 646.2652 647.2709 
2 4.104 632.2496 633.2557 
3 4.109 648.2445 649.2513 
4 4.115 661.2761 662.2820 
 
2.13.2 Purity Analysis of Benzofused Polyamides Synthesized 
 
 
The purity of the benzofused polyamides of this library was checked by two 
different HPLC methods with two different retention times. Both methods were 
carried out on a Waters Alliance 1695 HPLC Pump with water and acetonitrile 
comprising the mobile phases. The Waters 996 PDA start wavelength was 210 
nm for the 10 minute method (Method A), with a start wavelength of 220 nm and 
end wavelength of 500 nm for the 5 minute method (Method B) (Table 2.41 and 
2.42). 





Method A (10 min)% Method B (5 min)% 
1 4.98 100 100 
2 4.104 100 100 
3 4.109 100 92 













Table 2.42: G-quadruplex and duplex DNA stabilization by library-4B ligands in 
FRET melting experiments at concentrations of 5, 2 and 1 µM respectively (the 





5 µM 2 µM 1 µM 
4.98 
F21T 18.0±0.11 10.0±0.31 5.0±0.43 
C-kit-1 23.8±0.23 18.7±0.24 15.5±0.32 
C-kit-2 20.5±0.15 13.9±0.17 11.3±0.21 
BCL-2 22.1±0.24 13.0±0.15 9.6±0.22 
Duplex DNA 0.0±0.20 0.0±0.26 0.0±0.23 
4.104 
F21T 16.3±0.11 9.6±0.20 4.8±0.15 
C-kit-1 21.3±0.30 14.5±0.21 12.2±0.26 
C-kit-2 20.4±017 14.2±0.12 11.1±0.27 
BCL-2 17.9±0.42 11.6±0.05 7.8±0.20 
Duplex DNA 0.0±0.12 0.0±0.11 0.0±0.13 
4.109 
F21T 11.6±0.14 7.0±0.15 5.3±0.06 
C-kit-1 14.9±0.17 10.4±0.27 9.1±0.07 
C-kit-2 10.3±0.19 6.7±0.11 4.7±0.22 
BCL-2 11.6±0.11 7.0±0.42 5.6±0.21 
Duplex DNA 0.0±0.32 0.0±0.27 0.0±0.34 
4.115 
F21T 18.2±0.13 10.7±0.21 6.9±0.15 
C-kit-1 22.1±0.06 16.9±0.16 13.9±0.23 
C-kit-2 21.1±0.07 12.6±0.06 11.6±0.27 
BCL-2 20.9±0.20 13.2±0.37 10.8±0.08 
Duplex DNA 0.0±0.25 0.0±0.17 0.0±0.05 
 
4.98 provided 5.9°C, 15.5°C, 11.3°C and 9.6°C stabilisation; 4.104 provided 
4.8°C, 12.2°C, 11.1°C, 7.8°C stabilisation; 4.99 provided 5.3 °C, 9.1 °C, 4.7°C 
5.6°C stabilisation; and 4.115 provided 6.9°C,13.9°C,11.6°C, 10.8°C 
stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-
quadruplex sequences, respectively. None of them showed better interaction 
with F21T, C-kit-1 and C-kit-2 than 4.93 (12.6°C, 17.6°C and 11.4°C 
stabilisation at 1 µM concentration, respectively). 4.93 was most active towards 
F21T compared to the other G-quadruplex sequences, while the rest of the 
ligand molecules showed only moderate activity towards  the F21T G-
quadruplex. 4.98, 4.104 and 4.115 were equivalent in their interactions with C-
kit-1, C-kit-2 and Bcl-2 sequences and 4.115 showed better interactivity towards 
Bcl-2 G-quadruplexes than the rest of the molecules. 4.109 showed 
comparatively less interactivity towards all of the sequences used. The overall 
data analysis concluded that the N1, N1-dimethylpropane-1, 3-diamine tail 
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provides a better interactive entity within the ligand molecules than any other 
tails types used. It is noticeable that the tail 3-morpholinopropan-1-amine is not 
sufficient to provide interactive capacity for ligand molecules, since 4.109 is not 
as interactive as the other ligands. This may be due to the less electronegative 
oxygen atom in place of more electronegative nitrogen atom as in the other 
ligands, or it may be due to the presence of an electron-withdrawing oxygen 
atom within the cyclic system of this tail; this oxygen atom may attract the 
electron cloud and increase the electronegativity on the nitrogen atom which 
could ultimately hamper the electrostatic balance. 
2.13.3 Key Observations from Library-4B 
 
 The tertiary amine tail n N1, N1-dimethylpropane-1,3-diamine is 
comparatively better than other tails, including 3-(piperidin-1-yl)propan-1-
amine, 3-(pyrrolidin-1-yl)propan-1-amine, 3-morpholinopropan-1-amine 
and 3-(4-methylpiperazin-1-yl)propan-1-amine, at providing the 


















2.14 Synthetic Scheme for Library-4C Molecules. 
Here, a set of four molecules (Figure 2.57) were made by the structural 
modification of 4.93 through the substitution of the nitro group with different 
functional groups for the optimisation of the interacting capacity of the lead 
ligand 4.93.  
 
Figure 2.63: Synthetic scheme of library-4C molecules. Here, R1 = CN, Cl, –
OCH3, -NH2 etc. and R2 = –CH3, functional groups. 
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Initially the acid (1.2 eq.) was dissolved in DMF (5 mL for 100 mg of starting 
material) in a round bottom flask fitted with a magnetic stirrer. Then DIC (1.75 
eq.) and HOBt (2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for formation of the ester from the acid. The 
amine (1 eq.) was added to the mixture and the mixture allowed to stir until the 
reaction was complete, as indicated by TLC or LCMS. Finally the reaction 
mixture was applied to a conditioned SCX-2 cartridge and the resultant product 
was purified by the ‘Catch and Release’ method (described in the section 
‘Methods and Materials’ of Chapter 3). 
 
Figure 2.64: Structure of library-4C molecules. 
 
2.14.1 Characterisation of Benzofused Polyamides through Various 
Spectroscopic Techniques 
 
The benzofused polyamides were purified and fully characterized by different 
spectroscopic techniques including mass spectrometry, both 1H and 13C NMR, 
and IR techniques (described in the Experimental section of Chapter 4). 
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Compounds were primarily identified by LCMS and confirmed using high 
resolution mass spectroscopy (HRMS) (Table 2.43 and 2.44). 
Table 2.43: HRMS data for library-4C molecules 





1 4.99 615.2958 616.3023 
2 4.110 576.2597 577.2668 
3 4.116 591.2594 592.2662 
4 4.117 595.2092 596.2165 
5 4.87 586.2441 587.2508 
 
2.14.2 Purity Analysis of Benzofused Polyamides Synthesized 
 
The purity of the benzofused polyamides of this library was checked by two 
different HPLC methods with two different retention times. Both methods were 
carried out on a Waters Alliance 1695 HPLC Pump with water and acetonitrile 
comprising the mobile phases. The Waters 996 PDA start wavelength was 210 
nm for the 10 minute method (Method A), with a start wavelength of 220 nm and 
end wavelength of 500 nm for the 5 minute method (Method B) (Table 2.43 and 
2.44). 
Table 2.44: Purity data for library-4C molecules as observed by HPLC 
Number Compound code 
Purity 
Method A (10 min)% Method B (5 min)% 
1 4.99 100 94.2 
2 4.110 100 100 
3 4.116 88 93 
4 4.117 91 100 
















Table 2.45: G-quadruplex and duplex DNA stabilization by ligands in FRET 
melting experiments at concentrations of 5, 2 and 1 µM respectively (the data 





5 µM 2 µM 1 µM 
4.110 
F21T 7.0±0.21 3.6±0.14 2.1±0.10 
C-kit-1 12.3±0.07 7.8±0.20 5.2±0.17 
C-kit-2 13.3±0.20 8.2±0.17 6.1±0.20 
BCL-2 13.3±0.31 8.2±0.32 5.8±0.32 
Duplex DNA 0.0±0.35 0.0±0.21 0.0±0.41 
4.116 
F21T 14.2±0.41 9.2±0.31 6.8±0.12 
C-kit-1 18.5±0.12 13.5±0.06 10.4±0.27 
C-kit-2 21.1±0.32 16.4±0.29 12.8±0.25 
BCL-2 21.4±0.15 15.6±0.34 12.0±0.05 
Duplex DNA 1.0±0.14 0.0±0.21 0.0±0.31 
4.117 
F21T 12.1±0.15 4.5±0.15 2.9±0.22 
C-kit-1 15.8±0.20 7.2±0.26 4.4±0.12 
C-kit-2 17.8±0.14 10.6±0.12 7.6±0.32 
BCL-2 16.8±0.17 9.5±0.16 5.1±0.41 
Duplex DNA 0.0±0.32 0.0±0.07 0.0±0.36 
4.87 
F21T 16.0±0.37 10.0±0.12 6.4±0.27 
C-kit-1 18.0±0.24 9.8±0.17 2.9±0.10 
C-kit-2 22.2±0.25 15.1±0.14 11.6±0.17 
BCL-2 20.8±0.11 11.9±0.15 8.1±0.20 
Duplex DNA 0.0±0.00 0.0±0.10 0.0±0.05 
 
No compound in this group was as good as 4.93 at interacting with the F21T 
and C-kit-1 G-quadruplex sequences. 4.110 showed moderate interaction with 
all types of G-quadruplex used, providing 2.1°C, 5.2°C, 6.1°C and 5.8°C 
stabilisation against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, 
respectively. 4.117 only slightly improved the stabilisation with respect to 4.110. 
On the other hand, 4.116 and 4.87 provided comparatively better stabilisation 
than that of 4.110 or 4.117; 4.116 provided 10.4°C, 12.8°C and 12.0°C 
stabilisation at 1 µM concentration against C-kit-1, C-kit-2 and Bcl-2 G-
quadruplex sequences respectively, but did not show any significant 
stabilisation against the F21T G-quadruplex. In contrast, 4.87 provided 11.6°C 
and 8.1°C stabilisation at 1 µM concentration against C-kit-2 and Bcl-2 G-
quadruplex sequences, respectively, and provided 6.4°C and 2.9°C stabilisation 
at 1 µM concentration against F21T and C-kit-1 G-quadruplex sequences 
respectively. Thus 4.87 is assumed to be more specific to the C-kit-2 sequence. 
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From the overall data analysis, it is concluded that electron-withdrawing nitro 
groups can enhance the interaction between ligands and G-quadruplexes. 
 
Figure 2.66: Craig plot representing σ constants versus π values of aromatic 
substituent groups 
(http://medchem4410.up.n.seesaa.net/medchem4410/image/110926.jpg?d=a1) 
At the same time the comparative FRET data analysis of the different 
benzofused polyamides in this group suggested that electron-withdrawing 
groups like chloride groups (-Cl) for 4.117 and cyanide groups (-CN) for 4.87 
appeared to enhance the interacting capacity whereas electron-donating groups 
like methyl groups (-CH3) for 4.99, methoxy groups (-O-CH3) for 4.116 and 
amino groups (-NH2) for 4.110 appeared to reduce the interacting capacity of 
benzofused polyamides (Table 2.45 and Table 2.46). Moreover, it is interesting 
to note that the comparatively more electron-withdrawing cyanide group (-CN) 
group-containing 4.87 provided more stabilisation than the less electron-
withdrawing chloride group-containing 4.117 (Figure 2.58). Similarly, electron-
donating groups like methyl and methoxy appeared to reduce the interacting 
capacity of benzofused polyamides in proportion to their electron donating 





2.14.3 Introduction of Electron-Donating Group 
 
Interestingly, the molecule 4.99 was made in the form of 4.98 to further verify 
the nitro group effect previously detailed. Here, the effect of nitro group was 
observed by using a 3-(piperidin-1-yl) propan-1-amine tail instead of a N1, N1-
dimethylpropane-1,3-diamine tail with which this effect had already been 
observed. 
 
Figure 2.67: Structure of 4.99. 
Table 2.67: G-quadruplex and duplex DNA stabilization by ligand 4.99 in FRET 
melting experiments at concentrations of 5, 2 and 1 µM respectively (the data 





5 µM 2 µM 1 µM 
4.99 
F21T 7.2±0.11 3.9±0.17 1.3±0.21 
C-kit-1 11.5±0.17 7.9±0.11 1.0±0.16 
C-kit-2 14.0±0.18 8.9±0.35 6.5±0.25 
BCL-2 11.6±0.07 6.0±0.21 4.4±0.31 
Duplex DNA 0.0±0.23 0.0±0.05 0.0±0.06 
 
4.99 provided 1.3 °C, 1.0 °C, 6.5 °C and 4.4 °C stabilisation at 1 µM 
concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, 
respectively. These values clearly distinguish the effect of nitro groups, as 4.98 
provided 5.9 °C, 15.5 °C, 11.3 °C and 9.6 °C stabilisation at 1 µM concentration 
against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively. 
Thus this further indicated that unlike electron-withdrawing groups, electron-
donating groups like methyl (-CH3) groups play a negative role in the interaction 







2.15 Synthetic sScheme for Library-4D Molecules. 
A set of molecules (Figure 2.59) was synthesized through the replacement of 
indole with indazole rings by mirroring the structures of 4.77 and 4.93 in order to 
verify the relative abilities of indole or indazole in providing interaction capacity 
for the ligand towards G-quadruplex DNA. 
Figure 2.68: Synthetic scheme of library-4D molecules. 
Initially the acid (1.2 eq.) was dissolved in DMF (5 mL for 100 mg of starting 
material) in a round bottom flask fitted with a magnetic stirrer. Then DIC (1.75 
eq.) and HOBt (2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for formation of the ester from the acid. The 
amine (1 eq.) was added to the mixture and the mixture allowed stirring until the 
reaction was complete, as indicated by TLC or LCMS. Finally the reaction 
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mixture was applied to a conditioned SCX-2 cartridge and the resultant product 
was purified by the ‘Catch and Release’ method (described in the section 
‘Methods and Materials’ of Chapter 3). 
 
 
Figure 2.69: Structure of library-4D molecules. 
 
2.15.1 Characterisation of Benzofused Polyamides through Various 
Spectroscopic Techniques 
 
These benzofused polyamides were purified and fully characterized by different 
spectroscopic techniques including mass spectrometry, both 1H and 13C NMR, 
and IR techniques (described in the Experimental section of Chapter 4). 
Compounds were primarily identified by LCMS and confirmed using high 




Table 2.47: HRMS data for library-4D molecules 





1 4.85 609.2197 610.2264 
2 4.86 609.2197 610.2258 
3 4.119 608.2244 609.2318 
4 4.88 608.2244 609.2317 
5 4.118 607.2292 608.2354 
 
2.15.2 Purity Analysis of Benzofused Polyamides Synthesized 
 
The purity of the benzofused polyamides of this library was checked by two 
different HPLC methods with two different retention times. Both methods were 
carried out on a Waters Alliance 1695 HPLC Pump with water and acetonitrile 
comprising the mobile phases. The Waters 996 PDA start wavelength was 210 
nm for the 10 minute method (Method A), with a start wavelength of 220 nm and 
end wavelength of 500 nm for the 5 minute method (Method B) (Table 2.48). 
Table 2.48: Purity data for library-4D molecules as observed by HPLC 
Number Compound code 
Purity 
Method A(10 min)% Method B(5 min)% 
1 4.85 100 100 
2 4.86 100 100 
3 4.119 100 92 
4 4.88 91 100 










Figure 2.70: Example of an adapted LCMS profile of Library-4D compound 
4.88 
Two molecules of benzofused polyamides were synthesized by the coupling of 
three consecutive, commercially available 5-nitro-indazole-3-carboxylic acid 
equivalents to produce molecules including 4.93 and 4.77 in order to investigate 




Figure 2.71: Structure of equivalent molecules 4.85 and 4.86. 
Table 2.49: G-quadruplex and duplex DNA stabilization by ligands 4.85 and 
4.86 in FRET melting experiments at concentrations of 5, 2 and 1 µM 





5 µM 2 µM 1 µM 
4.85 
F21T 11.0±0.21 4.3±0.15 1.4±0.32 
C-kit-1 11.8±0.31 8.0±0.20 4.4±0.42 
C-kit-2 17.9±0.11 10.7±0.25 8.2±0.26 
BCL-2 20.8±0.31 7.8±0.33 4.7±0.12 
Duplex DNA 0.0±0.16 0.0±0.31 0.0±0.20 
4.86 
F21T 14.8±0.30 10.5±0.11 8.0±0.06 
C-kit-1 16.9±0.12 13.1±0.36 9.9±0.32 
C-kit-2 21.7±0.04 16.6±0.7 13.1±0.21 
BCL-2 19.9±0.14 13.5±0.20 8.5±0.20 
Duplex DNA 0.0±0.12 0.0±0.17 0.0±0.06 
 
4.85 (structurally equivalent to 4.93) provided 1.4°C, 4.4°C, 8.2 °C and 4.7°C 
stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-
quadruplex sequences, respectively. These ∆Tm values were significantly less 
than those of 4.93, which indicated that benzofused polyamides made of three 
consecutive indole units (4.93) were preferable over benzofused polyamides 
made of three consecutive indazole units (4.85). However, 4.85 seemed to be 
specific to the C-kit-2 G-quadruplex sequence. 4.86 (structurally equivalent to 
4.77) provided 8.0°C, 9.9°C, 13.1°C and 8.5°C stabilisation at 1 µM 
concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences 
respectively, thus 4.86 showed significantly more stabilising capacity than 4.85. 
This difference in melting temperature is possibly due to the formation of 
intramolecular hydrogen bonds between proximal amine and imine groups of 
the indazoles in the middle and terminal positions of 4.85. In contrast, in 4.86 
the terminal building block is 5’-2’ substituted rather than 5’-3’ substitution as in 
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4.85, making the amine and imine groups of 4.86 too far from each other, so 
that these groups can only form hydrogen bonds with the guanine residues of 
the G-quadruplex sequences rather making an intramolecular hydrogen bond 
as in 4.85. 
 
Figure 2.72: Structures of equivalent molecules 4.85 and 4.93. 
 
Table 2.50: Comparative stabilising abilities of the equivalent molecules 4.85 




4.85 4.93 4.85 4.93 4.85 4.93 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 11.0±0.21 21.0±0.17 4.3±0.15 15.9±0.28 1.4±0.32 12.6±0.26 
C-kit-1 11.8±0.31 27.7±0.30 8.0±0.20 22.1±0.35 4.4±0.42 17.6±0.28 
C-kit-2 17.9±0.11 21.3±0.23 10.7±0.25 14.8±0.20 8.2±0.26 11.4±0.32 
BCL-2 20.8±0.31 25.4±0.30 7.8±0.33 17.8±0.14 4.7±0.12 13.5±0.20 
Duplex DNA 0.0±0.16 0.0±0.05 0.0±0.31 0.0±0.05 0.0±0.20 0.0±0.05 
 
Here, 4.85 (structurally equivalent to 4.93) provided 1.4°C, 4.4°C, 8.2 °C and 
4.7°C stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-
2 G-quadruplex sequences, respectively. On the other hand, 4.93 provided 
12.6°C, 17.6°C, 11.4°C and 13.5°C stabilisation at 1 µM concentration against 
F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively. 
From this DNA melting assay comparison, it is evident that 4.93 had far greater 
stabilisation capacity than 4.85 for all the G-quadruplex sequences used, 
reflecting the greater applicability of indole. Even though 4.86 showed a 





Figure 2.73: Structures of equivalent molecules 4.86 and 4.77. 
Table 2.51: Comparative stabilising abilities between equivalent molecules 4.86 




4.86 4.77 4.86 4.77 4.86 4.77 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 14.8±0.30 21.7±0.26 10.5±0.11 15.6±0.07 8.0±0.06 12.2±0.23 
C-kit-1 16.9±0.12 24.5±0.40 13.1±0.36 16.7±0.26 9.9±0.32 14.4±0.35 
C-kit-2 21.7±0.04 27.8±0.36 16.6±0.7 17.9±0.21 13.1±0.21 14.7±0.26 
BCL-2 19.9±0.14 30.8±0.21 13.5±0.20 15.7±0.28 8.5±0.20 12.1±0.25 
Duplex DNA 0.0±0.12 1.0±0.12 0.0±0.17 0.0±0.1 0.0±0.06 0.0±0.23 
 
Here, 4.86 (structurally equivalent to 4.77) provided 8.0°C, 9.9°C, 13.1°C and 
8.5°C stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-
2 G-quadruplex sequences, respectively. On the other hand, 4.77 provided 
12.2°C, 14.4°C, 14.7°C and 12.1°C stabilisation at 1 µM concentration against 
F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively. 
From this DNA melting assay comparison, it is evident that 4.77 had a greater 
stabilisation capacity than 4.86 for all the G-quadruplex sequences used, further 
reflecting the superiority of the indole building block in this application. 
 
2.15.3 Structural Modifications of 4.85 and 4.86 
 
Although the benzofused polyamides made of three consecutive indazole 
carboxylic acids did not have show interactions towards the G-quadruplex 
DNAs than 4.93 and 4.77, they showed significant improved melting 
temperatures. Therefore there is a possibility that structural modifications of 
4.85 and 4.86, specifically capping with 5-nitro-indole-3-carboxylic acid and 5-




Figure 2.74: Structures of 4.119 and 4.88. 
 
Table 2.52: Comparative G-quadruplex and duplex DNA stabilization between 





5 µM 2 µM 1 µM 
4.119 
F21T 17.8±0.17 14.8±0.26 13.0±0.35 
C-kit-1 18.2±0.13 14.2±0.23 11.1±0.21 
C-kit-2 20.4±0.23 17.8±0.24 16.4±0.32 
BCL-2 18.1±0.26 14.1±0.05 10.8±0.13 
Duplex DNA 0.0±0.1 0.0±0.05 0.0±0.11 
4.88 
F21T 12.1±0.2 8.1±0.20 6.1±0.11 
C-kit-1 10.8±0.27 6.1±0.36 2.6±0.23 
C-kit-2 18.9±0.15 14.6±0.20 12.8±0.18 
BCL-2 15.3±0.23 8.8±0.20 7.1±0.34 
Duplex DNA 0.0±0.11 0.0±0.10 0.0±0.20 
 
Here, 4.119 (structurally equivalent to 4.85 and 4.93) provided 13.0°C, 11.1°C 
16.4°C and 10.8°C stabilisation at 1 µM concentration against F21T, C-kit-1, C-
kit-2 and Bcl-2 G-quadruplex sequences, respectively. 4.88 (structurally 
equivalent to 4.86 and 4.77) provided 6.1°C, 2.6°C, 12.8°C and 7.1°C 
stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-
quadruplex sequences, respectively. It is notable that 4.88 was more specific 
towards the C-kit-2 sequence. Therefore, it is evident that indole in place of 
indazole improved the stabilisation capacity of the ligands and the third degree 
of curvature is preferable for fitting into the terminal quartet of the G-quadruplex 
sequence types. The higher activity of 4.119 was assumed to be because the 
distance between the nitrogen atoms of indazole and the terminal indole unit is 
far enough to avoid the intramolecular hydrogen bonding as assumed for 4.85. 
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The comparative melting data analysis indicates the preference of the indole 
over indazole building block at the terminal point of the ligands. 
 
Figure 2.75: Structures of semi-equivalent molecules 4.85 and 4.119. 
Table 2.53: FRET data comparison between 4.85 and 4.119 (the data are 




4.85 4.119 4.85 4.119 4.85 4.119 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 11.0±0.21 17.8±0.17 4.3±0.15 14.8±0.26 1.4±0.32 13.0±0.35 
C-kit-1 11.8±0.31 18.2±0.13 8.0±0.20 14.2±0.23 4.4±0.42 11.1±0.21 
C-kit-2 17.9±0.11 20.4±0.23 10.7±0.25 17.8±0.24 8.2±0.26 16.4±0.32 
BCL-2 20.8±0.31 18.1±0.26 7.8±0.33 14.1±0.05 4.7±0.12 10.8±0.13 
Duplex DNA 0.0±0.16 0.0±0.1 0.0±0.31 0.0±0.05 0.0±0.20 13.0±0.35 
 
Here, 4.85 (structurally equivalent to 4.119, only with exception of the terminal 
building block) provided 1.4°C, 4.4°C, 8.2°C and 4.7°C stabilisation at 1 µM 
concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, 
respectively. In contrast, 4.119 provided 13.0°C, 11.1°C, 16.4°C and 10.8°C 
stabilisation at 1 µM concentration against the same G-quadruplex sequences, 
respectively. Therefore, it is further evident that the indole, especially at the 
terminal position, is better than the benzimidazole building block at providing 
significant G-quadruplex stabilisation capacity. 
 




Table 2.54: FRET data comparison between equivalent molecules 4.86 and 4.88 




4.86 4.88 4.86 4.88 4.86 4.88 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 14.8±0.30 12.1±0.2 10.5±0.11 8.1±0.20 8.0±0.06 6.1±0.11 
C-kit-1 16.9±0.12 10.8±0.27 13.1±0.36 6.1±0.36 9.9±0.32 2.6±0.23 




BCL-2 19.9±0.14 15.3±0.23 13.5±0.20 8.8±0.20 8.5±0.20 7.1±0.34 
Duplex DNA 0.0±0.12 0.0±0.11 0.0±0.17 0.0±0.10 0.0±0.06 0.0±0.20 
 
Here, 4.86 (structurally equivalent to 4.88, only with the exception of the 
terminal building block) provided 8.0°C, 9.9°C, 13.1°C and 8.5°C stabilisation at 
1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex 
sequences, respectively. By comparison, 4.88 provided 6.1°C, 2.6°C 12.8°C 
and 7.1°C stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and 
Bcl-2 G-quadruplex sequences, respectively. Both of them showed equivalent 
∆Tms against the sequences used, but it is notable that 4.119 showed better 
interaction than 4.88, since 4.119 provided 13.0°C, 11.1°C, 16.4°C and 10.8°C 
stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-
quadruplex sequences, respectively. Therefore, it is evident that third degree 
curved molecules of this type show more interactive capacity than their second 
degree curved equivalents. 
Since a terminal indole in place of an indazole makes a ligand more potent, a 
molecule (4.118 in the form of 4.119) was made by replacing indazole with 
another indole in the middle. 
 




Table 2.55: G-quadruplex and duplex DNA stabilization by ligand 4.118 in 
FRET melting experiments at concentrations of 5, 2 and 1 µM respectively    





5 µM 2 µM 1 µM 
4.118 
F21T 15.1±0.21 12.2±0.11 10.2±0.16 
C-kit-1 18.6±0.07 14.8±0.12 10.7±0.27 
C-kit-2 19.3±0.35 16.1±0.38 13.9±0.23 
BCL-2 26.4±0.31 15.9±0.06 12.2±0.27 
Duplex DNA 0.0±0.17 0.0±0.20 0.0±0.20 
 
Here, 4.118 (structurally equivalent to 4.119 and 4.93) provided 10.2°C, 10.7°C, 
13.9°C and 12.2°C stabilisation at 1 µM concentration against F21T, C-kit-1, C-
kit-2 and Bcl-2 G-quadruplex sequences, respectively. By comparison, 4.119 
provided 13.0°C, 11.1°C 16.4°C and 10.8°C stabilisation at 1 µM concentration 
against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively. 
Although 4.118 showed comparatively better activity towards Bcl-2 G-
quadruplex, 4.119 showed stabilising capacity for the other G-quadruplex types 
used. This indicated that the molecules made of consecutive indole building 
blocks were more potent with regard G-quadruplex interaction. These two 
molecules were equivalent in their G-quadruplex stabilising capacities. Finally, 










Table 2.56: Comparative FRET data analysis between ligands 4.119, 4.118 and 





5 µM 2 µM 1 µM 






















0.0±0.05 0.0±0.05 0.0±0.20 0.0 0.0±0.11 0.0±0.20 0.0 
 
Here, 4.93 is a better ligand for providing stabilisation towards all of the G-
quadruplex sequences; the only exception is for c-kit-2. 4.93 provided 12.6 °C, 
17.6°C and 13.5°C stabilisation at 1 µM concentration against F21T, C-kit-1 and 
Bcl-2 G-quadruplex sequences, respectively; 4.118 and 4.119 showed greater 
melting temperatures (∆Tm=13.9 °C) and (∆Tm=12.2 °C) against the C-kit-2 
sequence. 4.119 had a greater stabilising capacity towards C-kit-2 than 4.118 
and 4.93; therefore it is evident that 4.93 is the ultimate lead ligand against 
F21T, C-kit-1 and Bcl-2 G-quadruplex sequences respectively. 4.93 is most 
active towards F21T compared to the other G-quadruplex sequences. In fact 
the ligands 4.119, 4.118 and 4.93 are interact equivalently and significantly with 
G-quadruplex DNA types. Thus these molecules can be used as structural 
scaffolds for further modification to achieve better G-quadruplex-targeting, drug-
like ligands. Although indazole at certain positions of the benzofused polyamide 
structure improves the ligand’s G-quadruplex interactivity, evidence from a 
variety of experiments previously discussed has established indole as a better 
benzofused unit which has a positive impact on the interaction of benzofused 








2.16 Synthetic Scheme for Library-5 Molecules 
Library-5 was comprised of 9 compounds (Figure 2.70). Two sets of molecules 
were made by using commercially available 5-nitro-indole-3-carboxylic acid and 
5-nitro-indazole-3-carboxylic acid building blocks by following the structural 
motif of lead molecule 4.93. These molecules were synthesized with the aim to 
check whether benzofused polyamides with three consecutive building blocks 
are better G-quadruplex-interactive ligands than benzofused polyamides with 
two consecutive building blocks. 
 
Figure 2.79: Synthetic scheme of library-5 molecules. 
Initially the acid (1.2 eq.) was dissolved in DMF (5 mL for 100 mg of starting 
material) in a round bottom flask fitted with a magnetic stirrer. Then DIC (1.75 
eq.) and HOBt (2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for formation of the ester from the acid. The 
amine (1 eq.) was added to the mixture and the mixture allowed to stir until the 
reaction was complete, as indicated by TLC or LCMS. Finally the reaction 
mixture was applied to a conditioned SCX-2 cartridge and the resultant product 
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was purified by the ‘Catch and Release’ method (described in the section 
‘Methods and Materials’ of Chapter 3). 
 
 
Figure 2.80: Structures of library-5 molecules. 
2.16.1 Characterisation of Benzofused Polyamides through Various 
Spectroscopic Techniques 
 
Library-5 is comprised of 9 compounds. These benzofused polyamides were 
purified and fully characterized by different spectroscopic techniques including 
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mass spectroscopy, both 1H and 13C NMR, and IR techniques (see 
Experimental section in Chapter 4). Compounds were primarily identified by 
LCMS and confirmed using high resolution mass spectroscopy (HRMS) (Table 
2.57 and 2.58). 
Table 2.57: HRMS data for library-5 molecules 
Number Compound code Theoretical mass 
Observed mass 
[M+H]+ 
1 4.21 448.1859 449.1924 
2 4.64 448.1859 449.1925 
3 4.68 448.1859 449.1926 
4 4.120 403.2008 404.2072 
5 4.122 450.1764 451.1835 
6 4.83 450.1764 451.1826 
7 4.121 405.1913 406.1980 
8 4.84 420.2022 421.2095 
9 4.69 418.2117 419.2182 
 
2.16.2 Purity Analysis of Benzofused Polyamides Synthesized 
 
The purity of the benzofused polyamides of library-5 was checked by two 
different HPLC methods with two different retention times. Both methods were 
carried out on a Waters Alliance 1695 HPLC Pump with water and acetonitrile 
comprising the mobile phases. The Waters 996 PDA start wavelength was 210 
nm for the 10 minute method (Method A), with a start wavelength of 220 nm and 
end wavelength of 500 nm for the 5 minute method (Method B) (Tables 2.3 and 
2.4). 
Table 2.58: Purity data for library-5 molecules as observed by HPLC 
Number Compound code 
Purity 
Method A (10 min)% Method B (5 min)% 
1 4.21 100 100 
2 4.64 100 100 
3 4.68 100 92 
4 4.120 100 100 
5 4.122 100 100 
6 4.83 100 100 
7 4.121 100 100 
8 4.84 92 87 














Table 2.59: G-quadruplex and duplex DNA stabilization by ligands in FRET 
melting experiments at concentrations of 5, 2 and 1 µM respectively (the data 





5 µM 2 µM 1 µM 
4.21 
F21T 3.4±0.11 1.3±0.27 0.5±0.30 
C-kit-1 6.2±0.27 3.1±0.29 1.5±0.07 
C-kit-2 10.8±0.32 5.7±0.21 3.4±0.22 
BCL-2 7.7±0.30 3.9±0.21 2.8±0.15 
Duplex DNA 0.0±0.26 0.0±0.15 0.0±0.18 
4.64 
F21T 4.8±0.25 2.5±0.28 1.2±0.11 
C-kit-1 8.7±0.13 5.9±0.23 3.7±0.26 
C-kit-2 14.2±0.11 9.4±0.14 7.0±0.16 
BCL-2 9.7±0.28 6.1±0.31 3.6±0.05 
Duplex DNA 0.0±0.6 0.0±0.17 0.0±0.27 
4.68 
F21T 10.0±0.13 6.5±0.35 3.9±0.18 
C-kit-1 13.3±0.38 10.2±0.42 7.3±0.45 
C-kit-2 15.7±0.11 12.2±0.17 9.1±0.41 
BCL-2 12.8±0.15 8.8±0.20 5.9±0.12 
Duplex DNA 0.0±0.23 0.0±0.18 0.0±0.28 
4.120 
F21T 2.3±0.31 0.9±0.25 0.4±0.17 
C-kit-1 4.9±0.33 2.8±0.15 1.6±0.06 
C-kit-2 7.7±0.12 5.4±0.27 3.7±.010 
BCL-2 3.9±0.16 1.8±0.20 1.3±0.11 
Duplex DNA 0.0±0.11 0.0±0.10 0.0±0.27 
 
Here, 4.21, a 5’-2’ substituted benzofused polyamide of two consecutive 5-nitro 
indole-2-carboxylic acids, provided 0.5°C, 1.5°C 3.4°C and 2.8°C stabilisation at 
1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex 
sequences, respectively. 4.64 (a first degree curved molecule), a 5’-3’ and 5’-2’ 
substituted benzofused polyamide of two consecutive 5-nitro indole-3-carboxylic 
acids and 5-nitro indole-2-carboxylic acid, showed a marginally better G-
quadruplex sequence interacting capacity with 1.2°C, 3.7°C, 7.0°C and 3.6°C 
stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-
quadruplex sequences, respectively. This difference in melting temperatures 
suggests that the introduction of curvature by the 5′-3′ substitution makes a 
ligand more potent towards the G-quadruplex sequences used in this study. 
This is further justified by FRET data of second degree curved molecule 4.68, 
made through the 5’-3’ substitution of consecutive 5-nitro-indole-3-carboxylic 
acids, which showed 3.9°C, 7.3°C, 9.1°C and 5.9°C stabilisation at 1 µM 
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concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, 
respectively.  
It is necessary to investigate the effect of nitro group of a ligand molecule. 
Therefore, 4.120 was made by following the shape of 4.68, capped with indole-
3-carboxylic acid instead of 5-nitro-indole-3-carboxylic acid. The melting 
temperatures against the different G-quadruplex types suddenly decreased as it 
provided stabilisation of 0.4°C, 1.6°C, 3.7°C and 1.3°C at 1 µM concentration 
against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively. 
This means the nitro group must play a positive role in increasing the stabilising 
capacity of these ligands. 
A molecule in the form of 4.68 with an electron-donating amino group rather an 
electron-withdrawing nitro group would be expected to enhance the interaction 
capacity of ligand molecules. 
A molecule was made by reducing the nitro group of 4.68 and was assessed by 
FRET melting assay to investigate further the effects of the nitro group. 
 
Figure 2.82: Structure of 4.69. 
Table 2.60: G-quadruplex and duplex DNA stabilization by ligand 4.69 in FRET 
melting experiments at concentrations of 5, 2 and 1 µM respectively (the data 





5 µM 2 µM 1 µM 
4.69 
F21T 3.0±0.41 1.7±0.22 1.0±0.18 
C-kit-1 4.8±0.13 2.9±0.33 0.7±0.16 
C-kit-2 7.7±0.15 5.1±0.42 3.6±0.07 
BCL-2 6.5±0.23 3.6±0.13 1.9±0.21 
Duplex DNA 0.0±0.15 0.0±0.15 0.0±0.11 
 
It is evident that the reduced form of the nitro group reduces the stabilisation 
capacity of 4.68 as the melting temperatures were decreased to 1.0°C, 0.7°C, 
3.6°C and 1.9°C stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-
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2 and Bcl-2 G-quadruplex sequences respectively. However, it would be easier 
to visualise the effect of the nitro group by the direct comparison of the 
stabilisation capacities of both 4.68 and 4.69 in a same table. 
Table 2.61: Comparison of G-quadruplex and duplex DNA stabilization of 
ligands 4.69 and 4.68 in FRET melting experiments at concentrations of 5, 2 
and 1 µM, respectively (the data are means of three technical repeats) 
Quadruplex type 
∆Tm(°C) ±(s/d) 
4.69 4.68 4.69 4.68 4.69 4.68 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 3.0±0.41 10.0±0.13 1.7±0.22 6.5±0.35 1.0±0.18 3.9±0.18 
C-kit-1 4.8±0.13 13.3±0.38 2.9±0.33 10.2±0.42 0.7±0.16 7.3±0.45 
C-kit-2 7.7±0.15 15.7±0.11 5.1±0.42 12.2±0.17 3.6±0.07 9.1±0.41 
BCL-2 6.5±0.23 12.8±0.15 3.6±0.13 8.8±0.20 1.9±0.21 5.9±0.12 
Duplex DNA 0.0±0.15 0.0±0.23 0.0±0.15 0.0±0.18 0.0±0.11 0.0±0.28 
 
As shown above, 4.68, a 5’-3’ substituted benzofused polyamide with a terminal 
nitro group, provided 3.9°C, 7.3°C, 9.1°C and 5.9°C stabilisation at 1 µM 
concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences 
respectively, far better than 4.69, a 5’-3’ substituted benzofused polyamide with 
the terminal amino group, which showed stabilisation of 1°C, 0.7°C, 3.6°C and 
1.9°C at 1 µM concentration against the same G-quadruplex sequences 
respectively. 
 
The overall FRET data analysis of this library of molecules suggests the 
following conclusions- 
 Most curved molecules potentially have a greater stabilisation capacity to 
interact with G-quadruplex sequences. This result resembles the findings 
as found for the structure activity relationship of 4.93. 
 Electron-withdrawing groups (for example, nitro groups) play a positive 







Table 2.62: G-quadruplex and duplex DNA stabilization by ligands in FRET 
melting experiments at concentrations of 5, 2 and 1 µM respectively (the data 





5 µM 2 µM 1 µM 
4.122 
F21T 7.3±0.25 3.9±0.15 1.8±0.25 
C-kit-1 8.5±0.20 6.6±0.24 3.9±0.14 
C-kit-2 16.4±0.11 11.8±0.10 8.1±0.23 
BCL-2 13.8±0.31 8.4±0.37 5.1±0.12 
Duplex DNA 0.0±0.1 0.0±0.05 0.0±0.2 
4.83 
F21T 17.1±0.17 13.3±0.05 10.6±0.15 
C-kit-1 17.4±0.05 13.2±0.21 11.8±0.07 
C-kit-2 23.5±0.11 18.7±0.17 15.8±0.17 
BCL-2 21.1±0.20 16.2±0.23 12.8±0.15 
Duplex DNA 0.0±0.05 0.0±0.07 0.0±0.05 
4.121 
F21T 10.6±0.20 7.2±0.25 5.1±0.25 
C-kit-1 13.0±0.23 9.5±0.14 7.1±0.33 
C-kit-2 15.0±0.34 11.7±0.18 9.3±0.16 
BCL-2 12.5±0.16 9.4±0.35 6.5±0.37 
Duplex DNA 0.0±0.10 0.0±0.10 0.0±0.46 
4.84 
F21T 8.7±0.20 4.8±0.10 2.6±0.18 
C-kit-1 13.0±0.32 9.0±0.15 6.6±0.15 
C-kit-2 15.3±0.23 9.7±0.34 7.9±0.27 
BCL-2 12.6±0.14 6.9±0.16 2.9±0.26 
Duplex DNA 0.0±0.11 0.0±0.10 0.0±0.05 
4.69 
F21T 3.0±0.05 1.7±0.11 1.0±0.2 
C-kit-1 4.8±0.14 2.9±0.17 0.7±0.15 
C-kit-2 7.7±0.20 5.1±0.41 3.6±0.45 
BCL-2 6.5±0.16 3.6±0.18 1.9±0.13 
Duplex DNA 0.0±0.05 0.0±0.05 0.0±0.20 
 
As the indole derivatives did before, the above table illustrates the strong 
correlation between the interactive ability of ligands and both their shape and 
the presence electron-withdrawing groups in their structures. 
4.122, a 5’-3’ and 5’-2’ substituted benzofused polyamide formed of 5-nitro 
indazole-3-carboxylic acid and 5-nitro indazole-2-carboxylic acid, showed G-
quadruplex sequence interacting capabilities of 1.8 °C, 3.9 °C, 8.1 °C and 5.1 
°C at 1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex 
sequences, respectively, whereas the most curved molecule 4.83, a 5’-3’ and 
5’-3’ substituted benzofused polyamide of two consecutive indazole-3-
carboxylic acids, showed G-quadruplex sequence stabilisation of 10.6°C, 
11.8°C, 15.8°C and 12.8°C at 1 µM concentration against the same G-
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quadruplex sequences. The significant difference in the melting temperatures of 
each suggests again that the most curved ligands have better shapes with 
which to fit into G-quadruplex sequences. 
Now it is necessary to investigate the effect of the nitro group of the ligand 
molecules. Therefore, 4.121 was made by following the shape of 4.83, but 
capped with indazole-3-carboxylic acid instead of 5-nitro-indole-3-carboxylic 
acid. Melting temperatures against the different G-quadruplex types suddenly 
decreased as it provided stabilisation of 5.1°C, 7.1°C, 9.3°C and 6.5°C at 1 µM 
concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, 
respectively. This means the nitro group must play a positive role in increasing 
the stabilising capacity of these ligands. 
Making of a molecule in the form of 4.83 with an electron-donating amino group 
rather than an electron-withdrawing nitro group helped to investigate the effect 
of the nitro group. 
 
Figure 2.83: Structure of 4.84. 
Here, it was evident that the reduced form of the nitro group clearly reduced the 
stabilisation capacity of 4.83 as the melting temperatures decreased. However, 
it is easier to visualise the effect of the nitro group by directly comparing the 
stabilisation capacities of both 4.83 and 4.84 in one table. 
Table 2.63: Comparative FRET data analysis between the equivalent 




4.84 4.83 4.84 4.83 4.84 4.83 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 8.7±0.20 17.1±0.17 4.8±0.10 13.3±0.05 2.6±0.18 10.6±0.15 
C-kit-1 13.0±0.32 17.4±0.05 9.0±0.15 13.2±0.21 6.6±0.15 11.8±0.07 
C-kit-2 15.3±0.23 23.5±0.11 9.7±0.34 18.7±0.17 7.9±0.27 15.8±0.17 
BCL-2 12.6±0.14 21.1±0.20 6.9±0.16 16.2±0.23 2.9±0.26 12.8±0.15 




Here, 4.83, a 5’-3’ and 5’-3’ substituted benzofused polyamide of two 
consecutive 5-nitro indazole-3-carboxylic acids, showed G-quadruplex 
sequence stabilisation of 10.6°C, 11.8°C, 15.8°C and 12.8°C stabilisation at 1 
µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex 
sequences, respectively, which are far better than those of 4.84, a 5’-3’ 
substituted benzofused polyamide with the terminal amino group, which showed 
stabilisation of 2.6°C, 6.6°C, 7.9°C and 2.9°C at 1 µM concentration against the 
same G-quadruplex sequences. 
2.16.3 Comparative Study between Benzofused Polyamides of Two and 
Three Consecutive 5-Nitro-indazole-3-carboxylic acids respectively 
 
The pair of equivalent molecules 4.68 and 4.93 are directly comparable to each 
other. 
 
Figure 2.84: Structures of 4.68 and 4.93. 
Table 2.64: Comparative G-quadruplex and duplex DNA stabilization between 
ligands 4.68 and 4.93 in FRET melting experiments at concentrations of 5, 2 




4.68 4.93 4.68 4.93 4.68 4.93 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
















Duplex DNA 0.0±0.23 0.0±0.05 0.0±0.18 0.0±0.05 0.0±0.28 0.0±0.05 
 
Here, the most potent tri- and bi-aryl benzofused polyamides were taken to 
compare their melting temperatures against the G-quadruplex sequences used. 
It is evident that 4.93 (which provided ∆Tms of 12.6°C, 17.6°C, 11.4°C and 
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13.5°C stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and 
Bcl-2 G-quadruplex sequences, respectively) showed a significantly higher 
degree of stabilisation than 4.68 (which showed 3.9°C, 7.3 °C, 9.1°C and 5.9°C 
stabilisation at 1 µM concentration against the same G-quadruplex sequences). 
Another pair of equivalent molecules, 4.83 and 4.119, are directly comparable 
to each other. 
 
Figure 2.85: Structures of 4.83 and 4.119. 
 
Table 2.65: Comparative G-quadruplex and duplex DNA stabilization between 
ligands 4.83 and 4.119 in FRET melting experiments at concentrations of 5, 2 




4.83 4.119 4.83 4.119 4.83 4.119 
5 µM 5 µM 2 µM 2 µM 1 µM 1 µM 
F21T 17.1±0.17 17.8±0.17 13.3±0.05 14.8±0.26 10.6±0.15 13.0±0.35 
C-kit-1 17.4±0.05 18.2±0.13 13.2±0.21 14.2±0.23 11.8±0.07 11.1±0.21 
C-kit-2 23.5±0.11 20.4±0.23 18.7±0.17 17.8±0.24 15.8±0.17 16.4±0.32 
BCL-2 21.1±0.20 18.1±0.26 16.2±0.23 14.1±0.05 12.8±0.15 10.8±0.13 
Duplex DNA 0.0±0.05 0.0±0.1 0.0±0.07 0.0±0.05 0.0±0.05 0.0±0.11 
 
Here, 4.83 (which showed G-quadruplex sequence stabilisation of 10.6°C, 
11.8°C, 15.8°C and 12.8°C at 1 µM concentration against F21T, C-kit-1, C-kit-2 
and Bcl-2 G-quadruplex sequences, respectively) is nearly equivalent to 4.119 
(provided 13.0°C, 11.1°C, 16.4°C and 10.8°C stabilisation at 1 µM 
concentration against the same G-quadruplex sequences) with regards to their 
interactions towards the different G-quadruplex sequences. Thus there are 
opportunities to optimise this benzofused polyamide scaffold through both 
structural and functional group modifications. 
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An overall data comparison of these ligands suggests that benzofused 
polyamides made of three consecutive 5’-3’ substituted nitro indole carboxylic 
acids have a significantly higher ability to interact with and stabilise G-
quadruplex sequences than benzofused polyamides of two consecutive nitro 
indole carboxylic acids. On the other hand, benzofused polyamides made of 
three consecutive 5’-3’ substituted nitro indazole carboxylic acids have almost 
equivalent abilities to interact with G-quadruplex sequences types to 
benzofused polyamides of two consecutive nitro indazole carboxylic acids. 
 
2.17 Conclusions Based on the FRET Data Analysis of the 
Benzofused Polyamides of Libraries 1-5. 
 
Using a distamycin scaffold as a starting point, different types of benzofused 
building blocks were introduced in place of pyrroles with the help of a rational 
molecular modelling approach to improve the affinity of benzofused polyamides 
for G-quadruplexes while further reducing their affinity for duplex DNA in order 
to enhance their selectivity for quadruplex versus duplex DNA. 
A series of benzofused polyamides (18 molecules in total) (Library-1A and 
Library-1B) were initially synthesized through the 5′-2′ substitution of amide 
coupling reactions using different nitro-benzofused-carboxylic acids as building 
blocks and they were subsequently evaluated by FRET-based DNA thermal 
denaturation assays. However, these compounds failed to stabilize the G-
quadruplexes as much as expected. Though the molecules of library-1A and 
1B did not show significant interaction capacities toward G-quadruplex DNA 
types, the detailed FRET data analysis (i.e. ∆Tm values) of individual molecules 
provided some of the following preliminary ideas which in turn helped to design 
a new set of molecules. 
 Molecules including 4.15, 4.6 and 4.37 were found to show significant 
interaction at higher concentrations (5 µM) but they suddenly lost their 
stabilisation capacities at subsequent lower concentrations. These 
unexpected higher melting temperatures (for example, 4.37 provided 
18.1°C for F21T) were assumed to be contributed to by cooperative 
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binding of this molecule at high concentrations (5 µM). A dimer of 4.37 
may stack together over the terminal quartet of G-quadruplexes. As soon 
as molecular density decreases at the subsequent lower concentrations 
(i.e. 2 and 1 µM), the melting temperatures fall sharply (∆Tm=1.8 °C and 
1.1 °C, respectively). This means the molecular density of this molecule 
is not sufficient to make a dimer at low concentrations of 4.37 (Tables 
2.3, 2.4 and 2.7). 
 
 4.44 was slightly more interactive than any other molecules, as it 
provided stabilisation of 2.3°C, 1.5°C, 2.2°C and 2.9°C at 1 µM 
concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex 
sequences, respectively (Table 2.8). Thus it was assumed that the 
inclusion of nitrogen-containing building blocks (i.e. imidazole) may allow 
the possibility of hydrogen bond formation with guanine residues of the 
quadruplex and thereby enhance the ligand capacity to interact with the 
G-quadruplex structure to a certain extent. 
 
 Two structurally equivalent molecules (4.42 and 4.43) were synthesized 
to investigate whether an electron-withdrawing (Cl-) or donating group (-
CH3) on the 3
rd building block could have any impact on their interacting 
capacities towards G-quadruplexes. Though the melting temperatures of 
these two molecules were not impressive, the minor differences between 
the ∆Tm values of these two molecules suggested that an electron-
withdrawing functional group may have a enhancing impact on their G-
quadruplex-interacting capacities; 4.43 showed stabilisation of 1.0°C,  
0.7°C, 1.4°C and 1.4°C at 1 µM concentration against F21T, C-kit-1, C-
kit-2 and Bcl-2 G-quadruplex sequences, respectively, which was 
insignificantly better than that of 4.42 (provided ∆Tm values of 0.4°C, 
0.3°C, 0.9°C and 0.3°C at 1 µM concentration against F21T, C-kit-1, C-
kit-2 and Bcl-2 G-quadruplex sequences, respectively) (Table 2.8). 
The benzofused polyamides of library-1A and library-1B were assumed to 
have more π-π interactions with terminal G-quartets than previously reported 
biaryl polyamides117, 203 but this was not reflected in the FRET-based DNA 
melting assay. Therefore molecular modelling studies were done on library-1A 
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and 1B molecules to rationalise their poor FRET-based meting temperatures 
(∆Tm) with the aim of designing a chemical scaffold for a series of library-2 
benzofused polyamides. Molecular docking experiments were undertaken on 
the human telomeric quadruplex F21T (PDB ID 3CDM) (Section 2.5). 
Molecular modelling of the G-quadruplex-interactive biaryl benzofused 
polyamide helps assess the curvature of molecules (left panel of Figure 2.21), 
which assists in the stabilisation of DNA by covering the terminal quartet. 
Library-1 molecules (e.g., 4.5) do not possess the requisite curvature, and 
therefore cannot cover the central core of the G-quadruplex DNA to stabilise 
quadruplex DNA (Figure 2.21). They are linear in structure. For example, 
molecular models of 4.5 (containing benzothiophene and benzofuran building 
blocks) showed that the molecule does not stack effectively on the quadruplex 
interface, thereby producing few non-covalent interactions (Figure 2.21). These 
studies recommended that the 5’-2’ substituted central benzofused moiety be 
replaced with a 5′-3’ substituted benzofused moiety to introduce curvature within 
the benzofused polyamide molecules (Figure 2.22). Therefore a set of new 
molecules (library-2) was synthesized by including 5-nitro-benzofused-3-
carboxylic acid as a second building block instead of 5-nitro-benzofused-2-
carboxylic acid through 3′-5′ substitution. Commercially available 5-nitro-indole-
3-carboxylic acid was introduced in the middle of the polyamides. 
FRET data analysis of library-2 molecules clearly indicated that the introduction 
of curvature within benzofused polyamides dramatically improves their 
interacting capacity towards different G-quadruplex DNA used. Equivalent 
molecules from each of the libraries (i.e. 4.18 of library-1 can be compared 
directly with 4.52 of library-2) were taken and their FRET data subsequently 
analysed to evaluate the impact of the introduction of curvature on their 
stabilization capabilities. 4.18 provided 0.8°C, 1.6°C, 2.4°C and 0.6°C 
stabilisation; in contrast, the relatively curved 4.52 showed 2.4 °C, 7.8 °C, 8.1°C 
and 5.6°C stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and 
Bcl-2 G-quadruplex sequences respectively (Table 2.11 and 2.12). 
Molecular modelling of 4.18 (library-1 molecule) and 4.52 (library-2 molecule) 
bound to the telomeric F21T G-quadruplex illustrated the difference in the 
accommodation of library 1 molecules (4.18) and library 2 molecules (4.52). In 
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the case of 4.52, three benzofused molecules are capable of orienting directly 
over guanine bases, thereby enhancing stabilisation (Figure 2.27). 
Preliminary docking studies also suggested that the introduction of further 5’-3’-
substituted benzofused moieties to the polyamide core instead of 5’-2’-
benzofused moieties should enhance binding further (Fig. 2.28), and this was 
explored in library 3A. 
Here, a set of new molecules (library-3A) were synthesized by introducing 5-
nitro-indole-3-carboxylic acid in place of 5-nitro-benzofused-2-carboxylic acid 
either at the first or third building block positions of the library-2 molecules. 
Thus the final benzofused polyamides had more curvature compared to those of 
library-2. 
In general, the introduction of a second 5’-3’-benzofused moiety enhanced G-
quadruplex stabilisation. This is likely to have occured due to an enhanced 
shape-fit of the molecule within G-quadruplex DNA. FRET data analysis of the 
benzofused polyamides of library-2 and library-3A showed a clear difference 
in melting temperatures (∆Tm) between the two. The introduction of second 5’-
3’-benzofused moiety moderately improves the interacting capacity of 
polyamides. This can be explained through the comparison of ∆Tm values of 
two equivalent molecules - for example, 4.70 from library-3A and 4.52 from 
library-2. 4.70 showed comparatively more stabilising capacity than 4.52; the 
latter provided 2.4°C, 7.8°C, 8.1°C and 5.6°C stabilisation whilst the former 
provided 4.9°C, 9.2°C, 8.6°C and 7.4°C stabilisation at 1 µM concentration 
against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively 
(Tables 2.12, 2.17). This suggested that the introduction of additional curvature 
makes the ligand more potent. In addition, 4.52 and 4.70 both follow a nearly 
identical pattern of stabilisation towards the different G-quadruplex sequences 
used. However, molecular modelling of library-3A molecules suggested that 
the introduction of 5′-3′ substitution in the second of three consecutive building 
blocks (i.e. (5′-2′)-(5′-3′)-(5′-2′)) is more critical for the enhanced G-quadruplex 
stabilisation compared to the introduction of two 3′-5′ substitutions (i.e. (5′-3′)-
(5′-3′)-(5′-2′) or (5′-2′)-(5′-3′)-(5′-3′)) as seen in library-2 and library-3, 
respectively. Docking studies of the library-3A benzofused polyamides (such 
as 4.70) also suggested that the two 3′-5′ substituted benzofused moieties are 
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capable of interacting with the G-quadruplex, but appear to stack directly over 
the G tetrad (Section 2.9, Figure 2.35). The amidic tail of the molecule also 
appears to interact with DNA to some degree, thereby enhancing stabilisation. 
Therefore the curvature of library-3A molecules was taken as a molecular 
scaffold to investigate the electron-withdrawing nitro group at the 5′ position of 
the terminal building block, as it was observed from the previous library-1 
molecules (i.e. 4.42) that an electron-withdrawing functional group may have a 
positive impact on G-quadruplex interacting capacities. Therefore, a set of 
molecules (library-3B) were made through the modification of library-3A 
molecules by introducing a nitro group at the 5′ position of third building block. 
The synthesised molecules were capped with four different 5-nitro-3-carboxylic 
acid benzofused building blocks instead of benzofused building blocks 
containing a carboxylic acid in the 3’ position only (Figure 2.37). 
FRET data analysis suggested that the introduction of nitro group enhanced the 
interactive capacities of ligand molecules. This could be rationalised a number 
of ways, including by the formation of a hydrogen bond formation between nitro 
group of the ligand and amino, imine or carbonyl groups of the guanine residues 
of the G-quartet, by the potentially ability of the nitro group to recruit potassium 
ions which could help to stack the quartet together, or through possible 
electronic interactions provided by the addition of the nitro group. 
However, it is more convenient to evaluate the effect of nitro group inclusion by 
comparing between equivalent molecules of library-3A and library-3B. For 
example, 4.79 (a molecule of Library-3B) evidently showed better interacting 
capacity compared to the equivalent ligand 4.70 (a molecule of library-3A), 
since 4.70 provided 4.89°C, 9.2°C, 8.6°C, 7.4°C stabilisation and 4.79 provided 
6.0°C, 9.2°C, 11.2°C and 7.7°C stabilisation at 1 µM concentration against 
F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively. 
Similarly, the other equivalent molecules, including 4.78, 4.77 and 4.80 
(molecules of library-3B), showed nearly the same pattern of interaction 
compared to their equivalent molecules, 4.71, 4.72 and 4.73, respectively. 4.77 
showed a significant stabilising capacity for G-quadruplex DNA, providing 
stabilisation of 12.2 °C, 14.4 °C, 14.7 °C and 12.2 °C stabilisation at 1 µM 
concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, 
respectively. It is also notable that 4.77 is a more G-quadruplex interacting 
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benzofused polyamide than any other structurally equivalent molecules of 
library-3B. Even the molecule 4.80, which was capped with an additional 
nitrogen atom-containing benzimidazole, provided relatively low ∆Tm values of 
6.0°C, 9.2°C, 11.2°C and 7.7°C stabilisation at 1 µM concentration against 
F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively (Tables 
2.17, 2.24). Thus it is evident that indole is preferable as a third building block to 
enhance the stabilising capacity of ligands relative to the other benzofused 
building blocks tested. 
Therefore 4.77 was rationally considered to be a lead ligand for all of the G-
quadruplex sequences used and, accordingly, this specific polyamide was 
subjected to structural modifications via a structure-activity relationship to get a 
more potent ligand. Four additional molecules, including 4.23, 4.66, 4.60, 4.67 
and 4.93, were synthesized with all possible shape modifications of 4.77 
through changing the degree of curvature within their structures. It was 
observed that the linear molecule 4.23, made of three consecutive 5-nitro-
indole-2-caboxylic acids (through the three consecutive 5′-2′ substitutions 
(i.e.(5′-2′)-(5′-2′)-(5′-2′)), showed minimum G-quadruplex interactions (i.e. 0.3°C, 
0.4 °C, 0.03°C and 0.5°C stabilisation at 1 µM concentration against F21T, C-
kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively) compared to any 
other molecules which had been selected for SAR. The subsequent molecules 
with increasing degrees of curvature because of 5′-3′ substitutions were found 
to be increasingly more interactive towards G-quadruplex DNA. For example, 
relatively curved molecules 4.66 (i.e. (5′-3′)-(5′-2′)-(5′-2′)), 4.60 (i.e.(5′-2′)-(5′-3′)-
(5′-2′)) and 4.67 (i.e. (5′-2′)-(5′-2′)-(5′-3′)), with 5’-3’ substitutions of 5-nitro-
benzofused-3-carboxylic acid at different positions of nitro-benzofused 
polyamides, showed relatively more interacting capacities than the relatively 
linear 4.23 molecule (Table 2.30). However, it is notable that the molecule 4.60, 
with a 3′-5′ substitution at the middle, showed the most significant ∆Tm values 
(5.7°C, 11.5°C, 10.9°C and 6.6°C stabilisation at 1 µM concentration against 
F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively) among 
the molecules with a single 3′-5′ substitution as in 4.66 and 4.67 (i.e. at the first 
or third of three consecutive building blocks). This supported the previous 
observations (as seen in the comparative analysis of library-2 and library-3A 
molecules) that the introduction of 5′-3′ substitution in the second of three 
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consecutive building blocks (i.e. (5′-2′)-(5′-3′)-(5′-2′)) is more critical for 
enhanced G-quadruplex stabilisation. 
Accordingly, a molecule 4.77 (i.e. (5′-3′)-(5′-3′)-(5′-2′)) was found to be more 
interactive than the less curved 4.60 (i.e. (5′-2′)-(5′-3′)-(5′-2′)). Finally, molecule 
4.93 (i.e. (5′-3′)-(5′-3′)-(5′-3′)), with the highest degree of curvature because of 
three consecutive 5′-3′ substitution of 5-nitro-indole-3-carboxylic acids, was 
found to show a more significant interaction towards G-quadruplex DNA than 
that of 4.77; 4.93 provided 12.6°C, 17.6°C, 11.4°C and 13.5°C stabilisation at 1 
µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex 
sequences, respectively (Table 2.30). This is strong evidence for the idea that 
the greater the degree of curvature, the greater the interactions towards G-
quadruplex DNA, and this trend can be simplified as 4.93˃4.77˃4.60˃4.23 
(Figure 2.76). Finally, this structure-activity relationship (SAR) was then 
rationalised by the shape-based assessment of 4.93 analogues (Section 2.11) 
(i.e. the molecular modelling studies of benzofused polyamides 4.23 (Figure 
2.43), 4.60 (Figure 2.44), 4.77 (Figure 2.45) and 4.93 (Figure 2.46) (Table 
2.31)). 
 
Figure 2.86: Graph of the relationship between degree of curvature and ∆Tm 
values for different G-quadruplex DNA. 
A new library of molecules (library-4A) containing four different benzofused 
polyamides was synthesized to investigate the relevance of the electron-
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withdrawing NO2 group to the activity of the most active compound 4.93. The 
synthesised molecules were capped with a benzofused building block 
containing a carboxylic acid in the 3’ position only, instead of a 5-nitro-3-
carboxylic acid benzofused building block as found in 4.93, to further assess 
this factor. At the same time, the equivalent molecules from library-3A and 
library-4A were directly compared to investigate the effect of structural 
curvature within their structures on interactive capacity towards G-
quadruplexes. All of these molecules except 4.92 were found to be moderately 
interactive towards the different G-quadruplex sequence types; 4.92 provided 
9.3°C, 15.7°C, 13.4°C and 10.3°C stabilisation at 1 µM concentration against 
F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences respectively (Table 
2.34). The significant activity of 4.92 is due to the effect of the additional 
nitrogen atom of the terminal indazole building block, as discussed previously. 
The effect of the nitro group can be evaluated by the direct comparison of 
molecules 4.91 and 4.93 of library-4A and library-3B, respectively. The 
molecule 4.91, without a nitro group, provided 2.9°C, 8.2°C, 8.9°C and 7.5°C 
stabilisation, whereas the molecule 4.93 containing nitro group provided 12.6°C, 
17.6°C, 11.4°C and 13.5 °C stabilisation at 1 µM concentration against F21T, C-
kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively. Thus it is 
obvious that 4.93 is more interactive towards G-quadruplex sequences of all 
types used than 4.91. Therefore it is strongly evident that the nitro group play an 
important role in the improvement of ligand interacting capacities (Table 2.30 
and 2.34). 
Direct comparison between equivalent molecules 4.72 and 4.91 of library-3A 
and library-4A evaluate the effect of additional curvature due to the introduction 
of third benzofused (i.e. as 4.91) building block through the 5′-3′ substitution. 
4.91 provided 2.9°C, 8.2°C, 8.9°C and 7.5°C stabilisation while the equivalent 
4.72 provided 2.6°C, 6.8°C, 5.8°C and 4.2°C stabilisation at 1 µM concentration 
against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences respectively 
(Table 2.38). Thus molecule 4.91 (the more curved of the two) was found to be 
more G-quadruplex interactive than 4.72 (less curved). This observation 
suggests that the inclusion of a third 5’-3’-substituted benzofused moiety should 
enhance G-quadruplex stabilisation to a small degree compared to two 5’-3’-
substituted benzofused moieties (Figure 2.52). 
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Hence the most interactive compound 4.93 was then taken as a new lead for 
further structure-activity relationship studies. Accordingly, new sets of molecules 
were synthesized through the modification of the tertiary amine tails (i.e library-
4B) and functional groups (i.e library-4C) attached with the third benzofused 
building block of 4.93. A total of 4 molecules (i.e library-4B) were synthesized 
through the replacement of the N1, N1-dimethylpropane-1,3-diamine tertiary 
amine tail of 4.93. These molecules included 4.98, with a tail of 3-(piperidin-1-yl) 
propan-1-amine, 4.104, with a tail of 3-(pyrrolidin-1-yl)propan-1-amine, 4.109, 
with a tail of 3-morpholinopropan-1-amine, and 4.115, with a tail of 3-(4-
methylpiperazin-1-yl)propan-1-amine. 
FRET data analysis showed that these four molecules with different tails did not 
show the stabilising capacity like 4.93 showed. For example, 4.98 provided 
5.9°C, 15.5°C, 11.3°C and 9.6°C stabilisation, whereas 4.93 provided 12.6°C, 
17.6°C and 11.4°C stabilisation at 1 µM concentration. This suggested that the 
N1, N1-dimethylpropane-1, 3-diamine tail was better than any other tails used in 
improving the interacting capacities of benzofused polyamides.  
Library-4C molecules were synthesized (Figure 2.57) by the structural 
modification of 4.93 through the substitution of the nitro group with different 
functional groups for optimisation of the interacting capacity of lead ligand 4.93.  
Molecules, including 4.99 with a methyl group (-CH3), 4.110 with an amino 
group (-NH2), 4.116 with a methoxy group (-O-CH3), 4.117 with a chloride group 
(-Cl) and 4.87 with cyanide group (-CN), did show moderate interactions but not 
as significant as for 4.93. For example, 4.110 provided 2.1°C, 5.2°C, 6.1°C and 
5.8°C stabilisation, whereas 4.93 provided 12.6°C, 17.6°C and 11.4°C 
stabilisation at 1 µM concentration (Table 2.45). This suggests that the electron 
pulling nitro group is essential for improving the interacting capacity of 
benzofused polyamides. 
At the same time, the comparative FRET data analysis among the different 
benzofused polyamides in this group suggested that electron-withdrawing 
groups, like the chloride group (-Cl) for 4.117 and cyanide group (-CN) for 4.87,  
appeared to enhance interacting capacity whereas electron-donating groups 
like methyl groups (-CH3) for 4.99, methoxy groups (-O-CH3) for 4.116 and 
amino groups (-NH2) for 4.110, appeared to reduce the interacting capacity of 
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benzofused polyamides (Tables 2.45 and 2.46). Moreover, it is interesting that 
the comparatively more electron-withdrawing cyanide group-containing 4.87 
provided more stabilisation than the relatively less electron-withdrawing chloride 
group-containing 4.117 (Figure 2.58). Similarly, electron-donating group-
containing ligands, like 4.99 and 4.116, follow an equivalent degree of reduction 
in interacting capacity according to the strength of their electron-donating group 
(Figure 2.58). 
Since 4.92 of library-4A showed more significant interaction (i.e 9.3°C, 15.7°C, 
13.4°C and 10.3°C stabilisation at 1 µM concentration against F21T, C-kit-1, C-
kit-2 and Bcl-2 G-quadruplex sequences, respectively) (Table 2.34). compared 
to the other library members (i.e. molecules which have been capped with 
indole, such as 4.91, benzofuran, such as 4.90, and benzothiophine-3 
carboxylic acids, such as 4.89, respectively), it is necessary to verify the effect 
of indazole over indole in improving the interacting capacity of benzofused 
polyamides of three consecutive nitro-benzofused-acids. Therefore, a set of 5 
molecules (Library-4D) (Figure 2.61) were synthesized through the 
replacement of indole with indazole rings by following the structures of 4.77 and 
4.93 to verify the preference of either indole or indazole in providing interacting 
capacity of ligand towards G-quadruplex DNA. Benzofused polyamidse of three 
consecutive indazole units were supposed to provide a significant interaction 
but the FRET data analysis on the equivalent molecules 4.85 (i.e. molecule of 
three consecutive indazole units) and 4.93 (i.e. a molecule of three consecutive 
indole units) showed that 4.85 is less G-quadruplex interactive than 4.93. 4.85 
provided 1.4°C, 4.4°C, 8.2°C and 4.7°C stabilisation at 1 µM concentration 
against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively 
(Table 2.50). On the other hand, the molecule 4.86 (equivalent to 4.77) 
provided much better interaction (i.e. 8.0°C, 9.9°C, 13.1°C and 8.5°C of 
stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-
quadruplex sequences respectively) than 4.85 (Table 2.49). 
This difference in melting temparature is possibly due to the formation of 
intramolecular hydrogen bonds between proximal amine and imine groups of 
the indazole at the middle and terminal positions of 4.85. In contrast, in 4.86 the 
terminal building block is 5’-2’ substituted rather than 5’-3’ substitution as in 
4.85. This makes the amine and imine group of 4.86 too far away from each 
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other, so that these groups can only form hydrogen bonds with the guanine 
residues of G-quadruplex sequences rather making an intramolecular 
haydrogen bond as in 4.85. Thus three other molecules including 4.119 (i.e. 
equivalent to the shape of 4.93 and capped with nitro indole), 4.118 (i.e. 
equivalent to the shape of 4.93 but with a second building block of indole and 
capped with nitro indole) and 4.88 (i.e. equivalent to the shape of 4.77 and 
capped with nitro indole) were synthesized. 
The comparative FRET data analysis on 4.119, 4.118 and 4.93 showed that 
these molecules were significantly interactive towards G-quadruplex DNA types. 
As 4.119, 4.118 and 4.93 provided 13.0°C, 11.1°C 16.4°C and 10.8°C 
stabilisation, 10.2°C, 10.7°C, 13.9°C and 12.2°C stabilisation and 12.6°C, 
17.6°C, 11.4°C and 13.5 °C at 1 µM concentration against F21T, C-kit-1, C-kit-2 
and Bcl-2 G-quadruplex sequences respectively (Table 2.52, 2.55 and 2.59). 
This result suggests that replacement of the indazole unit with an indole unit in 
the middle and terminal positions of 4.118 and 4.119 makes the amine and 
imine groups far enough away from each other that these groups cannot 
participate in the formation of intramolecular hydrogen bonds. The overall data 
analysis of this library suggests that indole is a better building block for 
benzofused polyamides of three consecutive units than indazole. But it is also 
important to remember that indazole could be a better building block to make 
these compounds if these building blocks can be separated by an indole unit in 
such a way that they cannot form intramolecular hydrogen bonds. 
Lastly, two sets of molecules (9 compounds in total) (library-5) with varying 
degrees of structural curvature were synthesized using commercially available 
5-nitro-indole-3-carboxylic acid and 5-nitro-indazole-3-carboxylic acid building 
blocks by following the structural motif of lead molecule 4.93 (Figure 2.70). 
These molecules were synthesized with the aim of checking whether 
benzofused polyamides of three consecutive building blocks are better 
interactive ligands than benzofused polyamides of two consecutive building 
blocks. At the same time, the effect of electron-withdrawing and donating 
groups was also verified. FRET data analysis of 4.68 (molecule of two indole 
units with a nitro group at 5′ position of the second building block unit) and 
4.122 (molecule of two indole units without a nitro group at 5′ position of the 
second building block unit) clearly showed an extra effect of the nitro group, as 
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4.68 provided 3.9°C, 7.3°C, 9.1°C and 5.9°C stabilisation, compared to 0.4°C, 
1.6°C, 3.7°C and 1.3°C stabilisation from 4.122 (1 µM concentration against 
F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, respectively). This 
extra nitro group effect was further verified through observing exactly the same 
tendency in 4.83 (molecule of two indazole units with a nitro group at 5′ position 
of the second building block unit) versus 4.121 (molecule of two indazole units 
without a nitro group at 5′ position of the second building block unit) (Table 2.59 
and 2.62). 
The ∆Tm values of 4.21 (i.e. a molecule of (5′-2′)-(5′-2′) substitution), 4.64 (i.e. a 
molecule of (5′-3′)-(5′-2′) substitution) and 4.68 (i.e. a molecule of (5′-3′)-(5′-3′) 
substitution) showed that the linear-shaped 4.21 is less interactive than the 
relatively curved 4.64. Furthermore, the most curved molecule 4.68 was found 
to show the most significant interaction. This suggests that interacting activity 
increases with the degree of curvature in ligand molecules. The molecules of 
equivalent curvature 4.122 (i.e. a molecule of (5′-3′)-(5′-2′) substitution) and 4.83 
(i.e. a molecule of (5′-3′)-(5′-3′) substitution) also showed the same trend of 
interacting capacities as found for the benzofused polyamides of two 
consecutive indole units (Table 2.62). However, it is notable that 4.83 provided 
more significant stabilisation (i.e. 10.6°C, 11.8°C, 15.8°C and 12.8°C 
stabilisation at 1 µM concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-
quadruplex sequences, respectively) than 4.68. This means that a third indazole 
unit, as in 4.85, might be responsible for forming intramolecular hydrogen bonds 
and thereby reducing the stabilising capacity of ligand molecules. 
The reduction of electron-withdrawing nitro groups to the electron-donating 
amino groups sharply decreased the interacting capacity of ligand molecules 
(Tables 2.61 and 2.63). These molecules, including 4.69 (reduced form of 4.68) 
and 4.84 (reduced form of 4.83) showed far less significant ∆Tm values than 
their nitro group-containing parent molecules. Therefore, the data obtained from 
the library-5 molecules were found to be totally supportive to the observations 





 Conclusive remarks on overall FRET data analysis of all of the libraries- 
 Benzofused polyamides (i.e. library-1A and library-1B) of three 
consecutive 5-nitro-indole-2-caboxylic acids, synthesised through three 
consecutive 5′-2′ substitutions (i.e. (5′-2′)-(5′-2′)-(5′-2′)), showed minimum 
G-quadruplex interactions against F21T, C-kit-1, C-kit-2 and Bcl-2 G-
quadruplex sequences, respectively. These molecules (for example, 4.5) 
do not cover the central core of the quadruplex interface and therefore 
cannot stack effectively upon it. Thus they produce few non-covalent 
interactions. 
 
 It is evident from biophysical and molecular modelling studies that the 
introduction of a 5’-3’ substituted moiety (i.e. library-2 molecules of (5′-
2′)-(5′-3′)-(5′-2′) substitutions) instead of a 5’-2’-substituted moiety, as in 
library-2, had a significant effect on the binding of benzofused polyamide 
molecules to quadruplex DNA. This introduction of a 5’-3’ substituted 
benzofused molecule (for example, 4.52) in the middle of the benzofused 
polyamides dramatically improved their interacting capacity towards G-
quadruplex DNA. 
 
 The inclusion of either a first or third 5’-3’-substituted benzofused moiety 
enhanced G-quadruplex stabilisation to a small degree compared to 
inclusion of a second substituted benzofused molecule. 
 
 Introduction of 5-nitro-indole-3-carboxylic acid in place of 5-nitro-
benzofused-2-carboxylic acid either at the first or third building block of 
the library-2 molecules enhanced stabilisation of each quadruplex 
structure to a small degree. This likely occurs due to an enhanced 
shape-fit of the molecule within G-quadruplex DNA. However, the 
introduction of 5′-3′ substitution in the second of the three consecutive 
building blocks (i.e. (5′-2′)-(5′-3′)-(5′-2′)) is more critical to enhanced G-
quadruplex stabilisation compared to the introduction of two 3′-5′ 
substitutions (i.e. (5′-3′)-(5′-3′)-(5′-2′) or (5′-2′)-(5′-3′)-(5′-3′)) as seen in 




 The introduction of electron-withdrawing groups, especially nitro groups, 
at the 5’ position of the third benzofused building block significantly 
enhanced the interacting capacity of ligands. On the other hand, 
electron-donating groups, especially amino groups, significantly reduced 
the interacting capacity of ligands. 
 
 
 Benzofused polyamides (for example 4.93) with the highest degree of 
curvature (i.e. (5′-3′)-(5′-3′)-(5′-3′)) because of three consecutive 5′-3′ 
substitution of 5-nitro-indole-3-carboxylic acids (i.e. (5′-3′)-(5′-3′)-(5′-3′)) 
were found to show the most significant interaction towards G-
quadruplex DNA. 
 
 Benzofused polyamides of three consecutive building blocks (i.e. 4.93) 
(i.e. (5′-3′)-(5′-3′)-(5′-3′)) were found to be more significantly interactive 
ligands than the benzofused polyamides (i.e. 4.68) (i.e. (5′-3′)-(5′-3′)) of 
two consecutive building blocks. 
 
 Indole was found to be the preferable building block for relatively 
significant interactive capacity of benzofused polyamide of three 
benzofused carboxylic acids. 
 
 Indazole is a preferable building block for relatively significant interactive 
capacity of benzofused polyamides of two benzofused carboxylic acids. 
 
 Indazole might be the preferable building block for benzofused 
polyamides of three units when they are substituted as first and second 
building blocks. 
 
 The tertiary amine tail N1, N1-dimethylpropane-1,3-diamine was found to 





2.18 Cytotoxicity Test using the MTT Assay 
The MTT assay was used to evaluate the cell-killing ability of the synthesised 
molecules. The IC50 (the concentration of compound at which 50% of cells die) 
of selected molecules was calculated over 96 hour incubation. 
The newly synthesized compounds were evaluated in two human cancer cell 
lines, namely MDA-MB-231(triple negative breast cancer cell line) and HeLa 
(cervical cancer cell line). 
In total, seventy compounds were evaluated for their cytotoxic efficacy in the 
MDA-MB-231 cancer cell line through a preliminary MTT assay screen at a 
concentration of 25 µM. The nine molecules with the lowest IC50 were then 
selected for further cytotoxic studies in HeLa cell line. An upper limit of 50μM 
was set in the preliminary screen and compounds with IC50 values of 50 µM or 
more were considered to be poor leads for further analysis.  
 
2.18.1 MTT Assay Results with the MDA-MB-231 Cell Line (Breast Cancer 
Cell Line) and HeLa cell Line. 
 
According to the IC50 values described in Tables 2.66 and 2.67, the selected 
compounds (9 in total) from different libraries had the most significant 
cytotoxicity in the MDA-MB-231 cell line compared to the other molecules 
synthesized in different libraries. The compounds including 4.37, 4.41, 4.45, 
4.40, 4.11, 4.18 and 4.71 were found to show a significant cytotoxicity in 
significant cytotoxicity in the MDA-MB-231 cell line. On the other hand, four 
compounds including 4.45, 4.40, 4.11 and 4.18 were found to show a significant 
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Figure 2.87:  Dose Response Curves indicating the survival percentages of 
MDA-MB-231 cells at various concentrations of compounds 4.37, 4.41, 4.45, 
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 Figure 2.88:  Dose Response Curves indicating the survival percentages of 
Hela cells at various concentrations of compounds 4.45, 4.40, 4.11 and 4.18 
respectively. 
Table 2.66: Cytotoxic effect of compounds with their IC50 concentrations in the 
MDA-MB-231 cell line (the data presented here are means of three technical 
repeats)  
Library Compound code 





4.37 58 11.01514 
4.41 9.12 2.940204 
4.45 0.040 1.980034 
4.40 12.75 3.085585 
4.11 21.82 6.838431 
4.18 86.75 10.87524 
Library-3A 4.71 86.75 9.381942 
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Table 2.67: Cytotoxic effect of compounds with their IC50 concentrations in the 
HeLa cell line (the data presented here are means of three technical repeats)   
 
Library Compound code 




4.45 9.12 2.989671 
4.40 61.29 8.443619 
4.11 21.17 3.423395 
4.18 120 16.44182 
 
It is noteworthy that Library-2, 3 and 4 molecules, all showed interactivity with 
G-quadruplex through biophysical studies (i.e. FRET based DNA melting 
assay). However, the FRET results did not correlate with cytotoxicities. A 
number of the least interactive molecules with the G-quadruplex exhibited the 
most potent cytotoxicities. For example, compound 4.45 possesses a 
cytotoxicity of 40nM, but biophysical studies suggest insignificant binding to the 
G-quadruplex (i.e., ∆Tm values of 0.6°C, 1.3°C, 2.7°C and 1.5°C at 1 µM 
concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences, 
respectively). This suggests a potential alternative mechanism of action to G-
quadruplex stabilisation. 
Compound 4.71, on the other hand, was shown to be a potent quadruplex 
binding agent, with ∆Tm values of 7.2°C, 15.1°C, 8.3°C and 5.9°C at 1 µM 
concentration against F21T, C-kit-1, C-kit-2 and Bcl-2 G-quadruplex sequences 
observed in FRET binding studies. However, this molecule showed insignificant 
cytotoxicity towards MDA-MB 231 (i.e., IC50 values of 86.75 µM against MDA-
MB 321 cell line).  
In general, it is evident that increasing molecule curvature and enhancing G-
quadruplex stabilisation does not result in enhanced cytotoxicity in the case of 





2.19 Conclusion Based on the MTT Assay Results for the 
Benzofused Polyamides (Libraries 1-5). 
 
It is evident from the results of the cytotoxicity assay that there is a little 
correlation between the biophysical studies and the MTT assay results. 
The most cytotoxic molecules have a similar 3-dimensional shape (i.e., three 
5’/2’-substituted benzofused polyamide building blocks), suggesting that this 
particular shape may be associated with the cytotoxic effect. A similar cytotoxic 
effect is not observed for members of the other libraries which have different 3-
dimensional shapes.   For example, most of the cytotoxic molecules (i.e., 4.41, 
4.45 and 4.40), possess a 3-(pyrrolidin-1-yl) propan-1-amine fragment as an 
amidic tail, suggesting that this component may play a role in the cytotoxicity of 
these molecules. 
A degree of selectivity of the lead cytotoxic molecules between the MDA-MB-
231 and HeLa cell lines is evident. For example, the lead cytotoxic molecule 
4.45 has IC50 values of 0.040 µM and 9.12 µM for the MDA-MB-231 and HeLa 
cell lines, respectively. 
 
It should be noted that the dose response curves obtained for the HeLa cell line 
were not optimal, and so accurate IC50’s could not be obtained from these 
curves. Further cytotoxicity studies to improve the reliability of these results 
could not be carried out due to time constraints and technical issues relating to 
the cell culture facility in Britannnia House, so further studies will be undertaken 













2.20 Future Work 
Although a number of potent G-quadruplex stabilising agents have been 
generated during this study, a distinct lack of correlation between cytotoxicity 
and biophysical studies was observed. Therefore, in terms of a screening 
strategy, these results suggest that it is better to synthesize and test for 
cytotoxicity rather than undertake biophysical evaluation to aid selection of 
molecules for cytotoxicity testing. As such, in the case of the triaryl benzofused 
polyamides, a focused library should be generated around molecule 4.45 and a 
mechanism of action should be established. It is also necessary to modify the 
lead molecule structurally with the optimisation of amidic tail, functional group, 
benzofused building block types, solubility and other pharmacokinetic 
parameters.  Different techniques such as gene expression studies, bio-physical 
studies (including circular dichroism or RT-PCR) may be undertaken in the 
future to understand how the molecule induces cell-killing. Once the mechanism 
of action is established, a suitable lead candidate should be selected for 
progression to human tumour xenograft mouse model study in an appropriate 
human cancer type. 
It will also be necessary to study the mechanism of action of the cytotoxicity of 
4.45 and related molecules in the WI 38 cell line (a known cell line of normal 
human tissue). Once the mechanism of action is established, a suitable lead 
candidate should be selected for progression to human tumour xenograft 
mouse model study in an appropriate human cancer type, which will further 
progress for phase-1 clinical trials. 
Finally, a number of potent stabilisers of the G-quadruplex have been generated 
(e.g., compounds 4.93, 4.77), and it may be possible for these molecules to be 








Chapter 3: Materials  and Methods  
 
3.1 Chemical Sources 
All the chemicals and reagents used in this project were purchased from 
commercial companies including Sigma-Aldrich, Fluorochem, Maybridge, Acros, 
Alfa Aesar, Fluka and Fisher Scientific. 
 
3.2 Analytical Tools 
The Liquid Chromatography-Mass Spectroscopy (LC-MS) technique was widely 
employed to monitor the reaction progression and identification of newly 
synthesized molecules. LC-MS was performed on a Waters Alliance 2695 with 
water and acetonitrile as the mobile phases. Formic acid (0.1%) was used with 
acetonitrile to maintain acidic conditions during the course of chromatographic 
analysis. The gradient conditions were acetonitrile/water (95%) for 2 minutes 
which was increased to 50% acetonitrile over 3 minutes. The gradient was then 
held at 50% acetonitrile for 1 minute and then increased to 95% acetonitrile 
over 1.5 minutes. The quantity of acetonitrile was then returned to 5% over 1.5 
minutes and held for 0.5 minutes. The total duration of each run was 10 
minutes. The flow rate was 1.5 mL/minute; 200µL was split via a zero dead 
volume T-piece which passed into the mass spectrometer. The wavelength 
range of the UV detector was 220-400 nm. A diode array (535 scans) was 
functionalised with the system. A monolithic (C-18, 50X4.60 mm) column was 
used in the system. 
Proton NMR (1H) and carbon NMR (13C) experiments were carried out on a 
Bruker Avance 400 MHz spectrophotometer. Chemical shifts (δH) were cited in 
ppm (parts per million) and referenced to deuterated dimethyl sulfoxide (DMSO-
d6, residual signal 
1Hδ=2.54, 13Cδ=41.45) or deuterated methanol (MeOD, 
residual signal 1Hδ=3.31, 13Cδ=49.00). Multiplicities in 1H NMR spectra are 
quoted as s=singlet, d= doublet, t=triplet, m=multiplet, dd= doublet of doublets, 
ddd (doublet of doublet of doublets, dt=doublet of triplets, td=triplet of doublets, 
sp=septet and br=broad. The code (0) in 13C NMR spectra denotes the 
presence of quaternary carbon. 
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High Resolution Mass Spectrometry (HRMS) was carried out on a Thermo 
Navigator mass spectrometer coupled with liquid chromatography (LC) using 
electrospray ionisation (ES) and time-of-flight (TOF) mass spectrometry. Infra -
red spectra (IR) were recorded on a Perkin Elmer spectrum 1000 instrument. 
Every single reaction was checked by analytical thin layer chromatography 
(TLC) performed on E. Merck silica gel-60 F254 layered plates (0.25 mm). TLC 
plates were visualised under UV light (254 or 360 nm) and/or by staining the 
plates with vanillin spray or potassium permanganate solution followed by 
heating. 
3.3 General Synthetic Scheme of Benzofused Polyamides 
Initially, 5-amino benzofused-2-carboxylic acid was used to make a coupling 
reaction with a tertiary amine tail including 3-amino-N-methyl-N-
methylenepropan-1-aminium, 2-(piperidin-1-yl) ethan-1amine and 4-(pyrrolidin-
1-yl) butan-1-amine.  
 
Figure 3.1: General reaction scheme for the ligands synthesized. Here X = O, S 
or N.  
But this reaction did not work properly as the amino-benzofused carboxylic acid 
could couple with itself to make an aryl adduct. Thus in every reaction, 
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nitrobenzofused carboxylic acid was used in place of amino benzofused acid. 
Therefore, the synthesis involved the reduction of the nitro-group to an amino 
group through hydrogenation after each amide coupling reaction, so that 
subsequent coupling reactions had a free amino group to react with the next 
nitro benzofused carboxylic acid. A general reaction scheme using a N1,N1-
dimethylpropane-1,3-diamine tail is shown above (Figure 3.1).  
 




Figure 3.2: The mechanism for the HOBt-DIC-mediated amide coupling 
reaction.  
DIC (Diisopropylcarbodiimide) and HOBt (Hydroxybenzotriazole) are commonly 
used amide coupling reagents. These reagents act together to accelerate amide 
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coupling by activating the carboxylic acid into an ester to enhance its reactivity 
towards amines (Figure 3.2). 
However, amide formation using DIC may lead to partial racemization of the 
acid. In addition to ester formation, HOBt helps to minimize side reactions. 
Initially, the acid (1.2 eq.) was dissolved in DMF (5 mL for 100 mg of starting 
material) in a round bottom flask fitted with a magnetic stirrer. Then DIC (1.75 
eq.) and HOBt (2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for formation of the ester from the acid. The 
amine (1 eq.) was added to the mixture and the mixture allowed to stir until the 
reaction was complete, as indicated by TLC or LCMS. Finally, the reaction 
mixture was applied to a conditioned SCX-2 cartridge and the resultant product 
was purified by the ‘Catch and Release’ method. 
 
3.5 Purification by ‘Catch and Release’ Method 
 
All reaction intermediates and final products containing tertiary amine tails were 
purified by the ‘Catch and Release’ method using SCX-2 cartridges. These are 
packed with silica-based sulfonic acid cationic exchange resins. Due to the 
presence of tertiary nitrogens in the products, they are retained in the cartridge. 
The SCX-2 cartridges were activated by washing under vacuum with DCM (2x) 
and methanol (2x), and the reaction mixture allowed to pass through the column 
under gravity. The cartridges were subsequently washed with DCM (3x), DMF 
(3x) and MeOH (2x) under vacuum to remove impurities. Finally the product is 
released from the cartridge using 2M NH3 in MeOH. Excess MeOH was 
removed using a rotary evaporator. Structures of the synthesized compounds 
were confirmed by 1H NMR and LCMS. The purity of compounds was 
established using LCMS, and the target purity for each compound prior to 





Figure 3.3: “Catch and Release” purification procedure using SCX-2 cartridge 
(Image courtesy: Silicycle, ultra-pure silica gels) 243. 
 
3.6 Hydrogenation Reaction 
The nitrobenzofused intermediate was dissolved in 20 mL of ethanol and added 
to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on activated 
carbon) was added into the reaction vessel and mixed well. The reaction bottle 
was sealed and connected to a hydrogen reservoir. Air from the reaction bottle 
was removed by applying a vacuum, and was then flushed with hydrogen. 
Typically, a hydrogen pressure of approximately 40 psi was applied from the 
reservoir, and the bottle was then shaken vigorously to initiate the reaction. 
Progress of the reaction was monitored by TLC and LCMS, and on completion 
of the reaction the shaker was stopped, the bottle vented and the product 
recovered by means of filtration using Celite. Finally, the product is 






3.7 Biological Evaluation of Synthesized Molecules 
Preliminary assessment of G-quadruplex DNA stabilization was carried out with 
a FRET-based DNA melting assay using four different quadruplex sequences: 
human telomeric F21T, c-kit-1, c-kit-2 and Bcl-2 G-quadruplex sequences, and 
a hairpin duplex structure as a control. 
 
Implicit solvent molecular dynamics simulations were conducted over a 10ns 
time-frame using the human telomeric G-quadruplex sequence (PDB ID: 3CDM) 
and results were assessed visually and through free energy of binding 
calculations. Finally, G-quadruplex ligands were evaluated biologically through 
cytotoxicity testing via MTT assays. 
3.7.1 FRET-based DNA Melting Assay 
Fluorescence Resonance Energy Transfer (FRET) technology is widely 
employed for the evaluation of ligands and their capacities to interact with 
specific secondary DNA structures like G-quadruplexes. It is measured through 
an increase in nucleic acid melting temperature (ΔTm) 236. The difference 
between the Tm of the ligand-bound DNA and the Tm of the unbound DNA is 
defined as the ΔTm parameter 237. One strand of an oligonucleotide is labelled 
with FAM (fluorescein) as a fluorescent donor and a complementary strand (or 
other end of heparin) is labelled with TAMRA as an acceptor 238. The intensity of 
the FAM fluorescence upon excitation by heating is then measured as a 
function of temperature 239. 
3.7.2 Materials and Methods for FRET Melting Assay 
 
Quadruplex sequences used 
 
F21T: FAM-d (G3 [TTAG3]3-TAMRA)  
C-kit-1: FAM-d (G3AG3CGCTG3AG2AG3)-TAMRA. 
C-kit-2: FAM-d (G3CG3CGCGAG3AG4)-TAMRA. 
Bcl-2: FAM-d (G3CGC-G3-AG3AA-TTG3CG3-TAMRA) 




3.7.3 FRET Buffer Preparation 
 
Buffer solutions of 50 mM and 10 mM concentrations (500 mL each) were made 
with potassium hydroxide (1M) and potassium chloride (1M) and adjusted to pH 
7.4 by the drop-wise addition of cacodylic acid. These were stored at -20 oC in a 
freezer. 
 
3.7.4 DNA Annealing 
 
100µM of fluorescence-labelled F21T, STAT3 and control DNA duplexes 
(Eurogentec) were diluted with sterile DEPC water (DNA Grade, Fisher 
Scientific) to provide 20 µM solutions. 400nM solutions of each sequence were 
prepared by serial dilution using FRET buffer. They were annealed by heating 
to 85 oC for 5 minutes followed by cooling to room temperature over 2-4 hours 
using a Grant Bio PCH-2 Dry Block Heating/Cooling System. 
 
3.7.5 Ligand Solution 
 
5mM of stock solution was prepared for each ligand in dimethyl sulfoxide 
(99.9%, A.C.S. spectrophotometric grade, Sigma-Aldrich). Working solutions of 
100µM, 10µM, 4µM and 2µM were prepared by serially diluting with FRET 
buffer. 
3.7.6 Plate Preparation 
 
50µl of annealed sequence was added to each single well of a plate (Bio-Rad 
Laboratories), followed by 50µl of ligand solution. For each ligand of each 
concentration level, this process was repeated in triplicate. The same volume of 
pure FRET buffer was added to first line (A) of a 96 well plate to serve as a 
blank control. The plate was then processed in the DNA Engine Option 
(Continuous Fluorescence Detector, MJ Research) after 15 minutes of 
incubation at room temperature. The fluorescence measurement was made 
over a temperature range of 30 oC to 100 oC at intervals of 0.5 oC. The 
temperature was kept constant for 30 seconds before each measurement. The 
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incident radiation was set to 450-495 nm, and emitted radiation was measured 
at 515-545 nm. 
 
3.7.7 Data Processing 
 
The data was analysed using Scientific Graphing and Analysis Software 
(Version 7.0, Origin Lab Corp.). An increase in melting temperature (∆Tm) was 
determined by subtracting the value of the blank from the measured value for 
each sample. For each concentration of each ligand, an average ∆Tm value 
was calculated from the three corresponding wells and plotted against the 
concentration of ligand. 
 
3.8 Molecular Modelling and Molecular Dynamics (MD) Studies 
 
Molecular Modelling is a combinatory method of both theoretical and 
computational studies which is widely used to design, model or study a 
chemical scaffold targeting specific sequences of DNA and proteins. In fact, it 
covers the areas of Computational Chemistry, Drug Design, Computational 
Biology and Material Sciences. This technique mainly helps to explain the 
molecular and binding nature of a chemical compound at an atomistic level. 
These methods also contribute to determining x-ray crystallographic structures 
with the help of NMR experiments. 
Molecular Modelling and Molecular Dynamics (MD) Studies deal with the 
shape-fit of ligand molecules with their corresponding targets and thereby 
determines the binding affinity between the ligand and the receptor. Therefore, 
it is considered to be a competent method with which to study in detail the 
structure-activity relationships between libraries of novel ligand molecules 
synthesized in the field of drug discovery. Molecular docking calculations 
concern the use of static crystal structure, and are particularly useful in 
determining shape-fit in a receptor. On the other hand, the molecular dynamic 
simulation is based on the physical movement of individual atom in a molecule 
and of the molecule itself and the calculation involves the time-dependent 
behaviour of molecular scaffolds. Therefore, it provides valuable information on 
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the conformational changes of a molecular system (i.e. proteins or nucleic 
acids) as predicted over a certain time course.  
Thus molecular modelling and molecular dynamics simulations are gaining 
more significance and expanding their field through technological advancement. 
The speed of computers has doubled every two years (Moor’s Law 244) for the 
past number of years, and the use of specialised GPUs and super computers 
has allowed the docking of large libraries of molecules and simulation of large 
macro molecules. 
Molecular dynamic simulations provide the microscopic information including 
the positions of atoms and their velocities. Statistical mechanics convert the 
microscopic data to macroscopic variables such as pressure, energy and heat 
capacities. Statistical mechanics is able to calculate the changes of free energy 
for binding of a specific molecular system (i.e. ligand) and thereby determine 
the energetics and changes in the conformations. Thus the thermodynamic 
properties and the kinetics of a chemical scaffold can easily be determined 
using these techniques. In the field of drug discovery, the simulation of a 
chemical compound within its target receptor is supposed to provide the 
conformation of ligand-receptor complex with a lowest energy 245. 
 
3.8.1 Receptor Preparation 
 
The F21T quadruplex structure was downloaded from the Protein Data Bank 
(PDB ID: 3CDM). The quadruplex was then subjected to a number of steps of 
preparation in Chimera, including assignment of partial charges (AMBER 
ff98SB) and removal of hydrogens using the DockPrep module of AMBER, 
followed by writing to mol2 and pdb files. A molecular surface of the receptor 
was generated using write dms. 
3.8.2 Ligand Preparation 
 
All ligands were constructed and energy minimised using ChemBioOffice and 
exported in pdb format and converted into the Sybyl format mol2 using Chimera 
246. The DockPrep module in Chimera was then used to assign partial charges 
to each molecule (AM1-BCC charges in this instance), and atom types were 
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subsequently assigned via the AMBER GAFF force-field using 
ANTECHAMBER.    
3.8.3 Docking 
 
Docking experiments were undertaken using the DOCK6 software suite and the 
F21T quadruplex (PDB ID: 3CDM) was used in the study. In each case, the 
quadruplex interface was used as the receptor and the ligand used in the 
crystallography study was used as a guide for the docking site.  
The receptor was prepared (outlined above) and a number of steps were 
undertaken in DOCK6 to isolate the binding pocket of interest. Firstly, spheres 
were generated around the surface of the molecule using sphgen and 
Sphere_selector was then used to filter results. Spheres within 15Å of the ligand 
were selected for further analysis. This resulted in the assessment of the full 
quadruplex. 
Finally, every ligand was automatically positioned into the spheres with the 
maximum number of conformations set at a high level (500) to explore a large 
amount of conformational space, thus producing a docked ligand:DNA 
structure. 
3.8.4 Evaluation of Ligand Binding 
 
The ligand was evaluated based on the DOCK scoring function MMGBSA. 
During the docking process, a grid was created around the receptor. The grid 
was then used to allow rapid score evaluation in DOCK. Prior to scoring, 
orientations of the ligand which exhibited significant steric interactions with the 
receptor molecule were discarded using the bump filter.  
In evaluating ligand-DNA interactions, two factors were considered crucial; 
shape-fit of the molecule to the DNA receptor, and positioning of the molecule 
on the DNA-binding interface. The latter was considered particularly relevant as 
in order to stabilise the quadruplex structure, it is known that ligands must bind 





3.9 Cytotoxicity Test with the MTT Assay 
 
Cytotoxicity is the capacity of a drug or chemical compound to be toxic or 
growth inhibitory against a target cell line. Cytotoxicity studies are widely done 
to identify toxic compounds through the screening of a library of molecules. This 
tool is rationally designed to ensure that the newly synthesized molecules are 
toxic only to the desired cell line (for example, Breast Cancer Cell Line, MDA-
MB-231) but non-toxic or safe for the normal healthy cells at the same time. 
Thus, this method provides information with which to help avoid any kind of 
adverse effect on a normal cell line. 
A preliminary high-throughput screening was carried out to look for cytotoxic 
compounds which in turn aimed to develop more drug-like therapeutic agents 
through scrutinising and modifications. Therefore, this study defined the 
conditions to avoid any undesirable cytotoxic effect. 
MTT assay is based on the reduction of an MTT dye named 3-(4, 5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide by the NAD(P)H 
dependent enzyme oxidoreductase. MTT is reduced due to the NADH formed 
by the metabolically active cells present. Therefore, this colorimetric reaction 
under certain conditions is correlated with viable cell potential as this enzyme 
reduces the MMT dye to an insoluble purple coloured formazan crystal which 
can easily be visible under a spectrophotometer (usually between 500 and 600 
nm). This colour change directly reflects the number of viable cells present 





Figure 3.4: Schematic diagram showing the conversion of MTT to formazan in 
the presence of the electron acceptor 1-methoxy phenazine.  
 
As MTT dye is sensitive to light, the assay is usually carried out in dark 
conditions. NAD (P)H is mostly formed within the mitochondria of the cell, thus 
1-methoxy-phenazine methosulfate is used as an electron carrier to transfer the 
reduction equivalent from the mitochondrial matrix into the medium. However, 
the MTT assay can only detect the live cells because of its mechanism of 
action. 
The assays using tetrazolium dye are used to assess cytotoxicity (loss of viable 
cells) or the cytostatic efficacy (modification from proliferation to latency of living 
cells) of prospective drug-like molecules and toxic materials.  
 
3.9.1 Cell Lines Used for the MTT Assay 
 
HeLa (Cervical cancer), MDA-MB-231 (triple negative breast cancer) and NCI 
H1975 (non-small cell lung cancer) cell lines were used in this assay, which 






3.9.2 Methods and Materials for MTT assay 
 
The MTT assay is comprised of a number of crucial steps, from cell splitting to 
96-well plate reading in a spectrophotometer. The following steps were followed 




HeLa and MDA-MB-231 cell lines were cultivated in Dulbecco’s modified eagle 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% 
penicillin and streptomycin and 1% MEMNEAA (200x) non-essential amino 
acids. NCI H1975 cell lines were grown in RPMI-1640 supplemented with 10% 
fetal bovine serum (FBS) and 1% penicillin and streptomycin. These three cell 
lines were maintained in an incubator at 37°C with 5% CO2. 
 
3.9.4 Cell Passaging 
 
Cell passaging or splitting is a procedure that allows cells to be kept alive and 
growing under cultured conditions for a prolonged period of time. Cells should 
be passaged when they are 90-100% confluent. In this process a small number 
of confluent cells are transferred into a new vessel since a high density of 
rapidly dividing cells is related to cells entering senescence. Suspension 
cultures can be simply split with a small amount of culture comprising a few 
cells diluted into a larger volume of fresh media. However, in the case of 
adherent culture, cells first need to be detached with trypsin, then a small 
number of detached cells can be used to seed a new culture. 
70% ethanol was used to clean the fume hood, equipment, flasks, pipettes and 
other equipment before starting any process. DPBS (Dulbecco’s Phosphate 
Buffered Saline) and DMEM (Dulbecco’s Modified Eagle Medium) were taken 
out of the fridge ahead of time to become warm and ready to use. Cells 
contained in T-flasks were taken out from the incubator and checked under a 
microscope (dead cells floated and appeared round in shape whereas growing 
cells was attached to the bottom surface of the T-flask in a rod-shaped and 
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clustered fashion). Previous media was aspirated by using a vacuum pump (a 
sharp pointed pipette, 2 mL was used). 5 mL of DPBS was added to wash 
previous media fully and clean the T-flask, which was aspirated again to remove 
the floating dead cells. 1 mL of trypsin-EDTA was added to detach the growing 
cells and the flask was then incubated at 37°C in a 5% CO2 incubator for 2 
minutes. 10 mL of DMEM was added to inactivate the trypsin and the total cell 
suspension was then transferred into a falcon tube for centrifugation (2.5 
minutes, 21 °C, 1.5 rpm). The supernatant medium was aspirated out, leaving 
the cells at the bottom of the falcon tube. Finally, 5 mL of DMEM was added 
and mixed properly and an appropriate amount of cell suspension was 
transferred into a newly labelled T-flask according to the next passage time. 
Furthermore, an appropriate amount of DMEM was added into the same T-flask 
to make a total volume of 15 mL (in general, 15 mL is considered to be an 
optimum volume for survival of cells in T-flask). Lastly, the new T-flask was 
returned to the incubator (37°C, 5% CO2) for the next splitting schedule. Cells 
were passaged every 2 to 3 days. 
 
3.9.5 Cell Count and Plate Preparation (Seeding of Cells) 
 
Seeding is a process of spreading a defined amount (in volume or cell number) 
of a cell suspension onto a plate. 96-well polypropylene plates were used which 
are free of binding affinity for proteins or DNA, allowing complete sample 
recovery. This plate can withstand temperatures of -80 to +121°C. The following 
steps are used to seed the cells on to the plate: 
1. 1 mL of DMEM was added to suspend the cells. 
2. A haemocytometer was used to count cells, where a solution of cells was 
made with trypan blue stain (10 µL cells/ 90µL stain) to visualise the cells under 
an electron microscope. 
3. An appropriate amount of cell suspension was taken to make a dilution of 
cells with DMEM to confirm ~ 106 cells per well. 
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4. A multichannel pipette was used to seed the cells on to the plate, which was 
then returned for incubation at 37°C in 5% CO2 incubator (incubation time was 
varied from 24-72 hours). 
 
3.9.6 Addition of Tested Samples 
 
In this stage, the previous medium was aspirated out from every well by using 
sharp pipette tips and replaced with an equal amount (100 µL) of fresh medium 
and ligand of appropriate concentration, made from 5 mM stock solution by 
using DMSO, which were then added onto the cell seeded plate. Lastly, the 
plate was returned for further incubation at 37°C in a 5% CO2 incubator. The 
incubation time was varied from 24 to 72 hours. 
 
3.9.7 Plate Reading and Spectrometric Analysis 
 
The final step involves the reading of data obtained from processed plates. 
Firstly, the old medium was aspirated out from each well after the 
predetermined incubation period and subsequently each well was washed with 
100 µL of medium (high glucose content but without phenol red). Then all 
medium was aspirated out from each well and 100 µL of previously made 
MTT/medium phenol red-free solution was added into each well. A further 4 
hours of incubation was done at 37°C in a 5% CO2 incubator and the medium 
was then aspirated off from each well and 100µL of DMSO was added to 
dissolve the crystal formed. The plate was then incubated again for 5 minutes at 
37°C in 5% CO2 incubator and subsequently placed in shaker for 5 minutes 
(500 rpm) to remove all air bubbles. 
Absorbance was then taken by an Infinite 200 Pro-plate reader at a wavelength 
of 570 nm and the data was processed with the help of Tecan i-control 
application software. 
It is notable that the MTT solution was prepared in a 1:10 dilution with phenol 
red-free medium. The final solution was filtered through a 0.2 µm filter and 
stored in the dark at 4°C. 
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3.10 Standardisation of FRET Assay by using G-quadruplex 
Ligand TMPyP4 
Cationic porphyrins like TMPyP4 (Figure 2.10) are commonly chosen to use as 
G-quadruplex ligands 134. The ligand TMPyP4 was first reported to interact with 
DNA about 40 years ago; it has since been shown to be a G-quadruplex ligand 
135, 136. Since then the DNA-interacting capacity of this ligand has been widely 
assessed and it has been found to have a high level of affinity toward G-
quadruplex DNA with poor selectivity 137-139. However, sometimes it might be 
peculiar to show an extraordinary responses such as a unfolding of a 
quadruplexes in both d(CGG) repeats 140 or antithrombin aptamer141 and RNA 
sequences (r(CGG) repeats142. Interestingly this ligand showed interactions with 
a wide variety of G-quadruplexes. Thus it is still extensively studied and 





Figure 3.5: Structure of TMPyP4. 
The FRET assay has been standardised by evaluating commercially available 
G-quadruplex ligand TMPyP4 in the same conditions as used for benzofused-
polyamides. It is notable that TMPyP4 showed significantly higher interaction 
not only towards the G-quadruplex sequence types used but also with duplex 
DNA. None of the benzofused-polyamides show a minimum interaction with 





Table 3.1: G-quadruplex and duplex DNA stabilization by TMPyP4 in FRET 





5 µM 2 µM 1 µM 
TMPyP4 
F21T 35.3±0.43 35.3±0.11 35.3±0.26 
C-kit-1 40.0±0.22 41.0±0.34 40.5±0.13 
C-kit-2 33.4±0.31 31.7±0.20 32.1±0.15 
BCL-2 34.6±0.21 35.3±0.20 32.7±0.28 
Duplex DNA 38.0±0.42 38.0±0.14 29.0±0.07 
 
FRET result showed that TMPyP4 provided a very high level of interaction with 
the different types of quadruplex sequences and duplex DNA as well. It 
provided stabilisation capacities of 35.3 °C, 40.5 °C, 32.1 °C, 32.7 °C and 28.7 °C 
against F21T, c-kit-1, c-kit-2 and Bcl-2 G-quadruplex sequences respectively, 
and also provided 29.0 °C of stabilisation against duplex DNA at 1 µM 
concentration. This is indicative of the non-specificity it exhibits towards binding 
sites. 
 
3.10.1: Standardisation of FRET Assay by using DNA-Binding Ligand 
Distamycin A 
 
Duplex DNA used here was checked by doing a FRET assay using distamycin, 









Table 3.2: Duplex DNA stabilization by distamycin in FRET melting experiments 





5 µM 2 µM 1 µM 
Distamycin Duplex DNA 12.5±0.05 8.1±0.37 5.0±0.050 
 
Distamycin A showed ∆Tm values of 12.5 °C, 8.1 °C and 5.0 °C at 5 µM, 2 µM 
and 1 µM concentrations, respectively, against duplex DNA. This interacting 





















Chapter 4: Experimental (Chemistry) 
 
4.1 Synthesis of 5-amino-N-(3-(dimethylamino)propyl)benzofuran-2-
carboxamide ( 4.1) 
 
250 mg of 5-nitrobenzofuran-2-carboxylic acid (1.207 mmol, 1.2 eq.) was 
dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then 105 µl of DIC (2.589 mmol, 1.75 eq.) and 2.0 equivalents of HOBt (326 
mg, 2.405 mmol) were added to the acid (1.0 eq.). This mixture was stirred for 
at least 25 minutes at room temperature to ensure formation of the ester from 
the acid. Then 102.8 mg of N1, N1-dimethylpropane-1,3-diamine (1.0 mmol, 01 
eq.) was added to the mixture and it was then stirred further for 6 hours at which 
point TLC and LCMS analysis showed the completion of reaction. Finally the 
reaction mixture was applied to a conditioned IsoluteTM SCX-2 cartridge and the 
product was purified by ‘Catch and Release’ method (described in the section 
‘Method and Materials’ of chapter 3). A pale yellow solid was collected after 
drying under vacuum. Yield was 200mg, 60%. 







1H NMR (400 MHz, CD3OD) 
δH in ppm 
8.56(d,J=2.0,1H),8.48(s,1H),8.25(dd,J=9.2,2.4,1H),7.66(d,J=8.4,
1H),7.44(s,1H),3.453.40(m,2H),2.40(t,J=6.4, 2H), 2.239(s, 6H), 
1.74-1.70 (m, 2H). 
EIMS Found 292.00[M+H]+, Calculated for C14H17N3O4 291.12 [M]
+ 
 
4.2 Synthesis of 5-amino-N-(3-(dimethylamino) propyl) benzofuran-2-
carboxamide (4.2)        
 
 
200 mg of 4.1 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate was 
added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
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activated carbon) was also added into the same reaction vessel and it was 
mixed well. The reaction bottle was sealed and connected to a hydrogen 
reservoir. Air within the reaction bottle was removed by applying vacuum, and 
flushed with hydrogen. Typically, a hydrogen pressure of approximately 40 psi 
was applied from the reservoir and the bottle was then shaken vigorously to 
initiate hydrogenation. Progress and completion of reaction was monitored by 
TLC and LCMS. The hydrogenation was completed by 5 hours at which point 
TLC and LCMS analysis showed the completion of reaction. The shaker was 
stopped, the bottle was vented. After this the product was recovered by means 
of filtration using Celite and was concentrated by using a rotary evaporator. A 
pale yellow solid was collected after drying under vacuum. Yield was 162 mg, 
90%. 







1H NMR (400 MHz, CD3OD) 




EIMS Found 262.00[M+H] +, Calculated for C14H19N3O2 261.14 [M]
+ 
 
4.3 Synthesis of N-(3-(dimethylamino) propyl)-5-(5-nitrobenzofuran-2-
carboxamido) benzofuran-2-carboxamide (4.3) 
 
 
Initially, 144 mg of 5-nitrobenzofuran-2-carboxylic acid (0.697 mmol, 1.2 eq.) 
was dissolved in 10mL of DMF in a round bottom flask placed in a magnetic 
stirrer. Then DIC (188 µl, 1.21 mmol, 1.75 eq.) and HOBt (188.19 mg, 1.39 
mmol, 2.0 eq.) were added to the acid solution (1.0 eq.). This mixture was 
allowed to stir at room temperature for 30 minutes to ensure the ester formation 
from the acid. Then amine 4.2 (130 mg, 0.498 mmol, 1 eq.) was added to that 
mixture, and it was allowed to stir for 8 hours at which point TLC and LCMS 
analysis showed the completion of reaction. The product was purified from the 
reaction mixture by ‘Catch and Release’ method using a conditioned 
IsoluteTMSCX-2 cartridge (described in the section ‘Method and Materials’ of 
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chapter 3). Lastly this product was then dried under vacuum and a pale yellow 
coloured solid was obtained. Yield=147mg, 66%. 







δH in ppm  
10.85(s,1H),8.80(t,J=8.4,2H),8.32(d,J=6.4, 1H),8.27(s,1H), 
7.95(t,J=9.2,2H), 7.78(d,J=8.8,1H), 7.73(d,J=8.4,1H), 7.53 
(s,1H), 3.17-3.12(m,2H), 2.28(t,J=6.0,2H), 2.15(s,6H), 
1.67(t,J=6.8,2H). 
EIMS Found 451.0 [M+H] +, Calculated for C23H22N4O6, 450.15 [M]
+ 
 
4.4 Synthesis of 5-amino-N-(2-((3-(dimethyl amino) propyl) carbonyl) 
benzofuran5-yl) benzofuran-2-carboxamide (4.4). 
 
 
4.3 (147mg) was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate was 
added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) 20 was added into the reaction vessel, and mixed well. The 
reaction bottle was sealed and connected to a hydrogen reservoir. Air from the 
reaction bottle was removed by applying vacuum, and was then by flushed with 
hydrogen. Typically, a hydrogen pressure of approximately 40 psi was applied 
from the reservoir, and the bottle was then shaken vigorously to initiate the 
reaction. Progress of the reaction was monitored by TLC and LCMS. The 
reaction required about 4.5 hours at which point TLC and LCMS analysis 
showed the completion of reaction. The shaker was stopped, the bottle vented, 
and the product was recovered by means of filtration using Celite. Finally, the 
product is concentrated by using a rotary evaporator. A pale yellow solid was 
obtained after drying under vacuum. Yield=80 mg, 51%. 








δH in ppm   
10.61(s,1H),8.84(t,J=5.6,1H),8.28(d,J=2,1H),7.79(dd,J=8.8,2.0,
1H),7.64(d,J=9.2,1H),7.55(d,J=3.6,2H),7.38(d,J=8.4,1H),6.83(d,
J=2,1H),6.79(d,J=2.4,1H),2.51- 2.49 (m,2H), 2.25(t,J=6.8,2H), 
2.13(s,6H), 1.68-1.62(m,2H).  





4.5 Synthesis of 5-(benzo[b]thiophene-2-carboxamido)-N-(2-((3-(dimethyl 




48 mg of benzo[b]thiophene-2-carboxylic acid (0.266 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask. Then DIC (71.96 µl, 0.465 
mmol, 1.75 eq.) and HOBt (71.82 mg, 0.532 mmol, 2.0 eq.) were added to the 
acid (1.0 eq.) and this mixture was allowed to stir at room temperature for 25 
minutes to ensure the formation of ester from the acid. Then amine 4.4 (80 mg, 
0.19 mmol, 1 eq.) was added to the mixture, and that mixture was allowed to stir 
for 5 hours at which point TLC and LCMS analysis showed the completion of 
reaction. Finally the reaction mixture was applied to a conditioned IsoluteTM 
SCX-2 cartridge and the product was purified by ‘Catch and Release’ method 
(described in the section ‘Method and Materials’ of chapter 3). A cream solid 
was obtained after drying under vacuum. Yield=34mg, 31%. 









δH in ppm 
  10.69(d,J=7.8, 2H), 8.81(t,J=5.6,1H), 8.40(s,1H), 8.32(d,J=2,1H), 
8.30(d,J=2,1H),8.09(d,J=1.6,1H),8.058.02(m,1H),7.82(t,J=2.8,2H),
7.79(d,J=2.8,1H),7.76(d,J=8.8,1H), 7.67(d,J=8.8,1H), 7.55(s,1H), 
7.51-7.49 (m,2H), 2.51-2.49(m,2H), 2.27(t,J=6.8,2H), 2.15(s,6H), 




δC in ppm 
193.0, 191.0, 179.8, 158.2, 151.1, 140.1, 139.0, 137.9, 127.4, 
125.7, 124.2, 123.3, 121.4, 120.4, 116.0, 114.0, 111.5, 109.6, 
108.1, 106.6, 101.1, 94.9, 56.8, 45.1, 40.0, 39.8, 39.6, 39.4, 39.23, 
39.0, 38.8, 35.9.       




m/z (+EI) Calc. for C32H28N4O5S [M]




3363, 1658, 1637, 1583, 1540, 1469, 1433, 1346, 1321, 1292, 
1230, 1200, 1139, 1124, 1038, 941, 863, 838, 811, 786, 750, 736, 









Initially, 30 mg of 1H-benzo[d]imidazole-2-carboxylic acid hydrate (0.166 mmol, 
1.2 eq.) was dissolved in 5mL of DMF in a round bottom flask fitted with a 
magnetic stirrer. Then DIC (44.91 µl, 0.2905 mmol, 1.75 eq.) and HOBt (44.82 
mg, 0.332 mmol, 2.0 eq.) were added to the acid (1.0 eq.). This mixture was 
allowed to stir at room temperature for 30 minutes to ensure the formation of 
ester from the acid. Then amine 4.4 (50.0 mg, 0.119 mmol, 1 eq.) was added to 
the mixture, and was allowed to stir for 5 hours at which point TLC and LCMS 
analysis showed the completion of reaction. Finally the product was purified by 
‘Catch and Release’ method using conditioned IsoluteTM SCX-2 cartridge 
(described in the section ‘Method and Materials’ of chapter 3). A straw solid 
was obtained after drying in vacuum. Yield=12mg, 18 %. 







δH in ppm 
11.0(s,1H), 10.66(s,1H), 8.80(t,J=5.2,1H), 8.46(s,1H), 8.30(s,1H), 
8.00(d,J=8.8,1H), 7.82(s,2H), 7.75(d,J=8.8,2H), 7.66(d,J=8.8,2H), 
7.54(s,1H), 7.35(s, 2H), 3.31(t,J=6.8,2H), 2.28(t, J=6.8,2H), 
2.15(s,6H), 1.71-1.64(m ,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
157.9, 157.3, 156.6, 151.2, 150.9, 150.0, 149.4, 145.5, 134.4, 
134.2, 127.2, 127.1, 121.1, 120.6, 113.9, 111.9, 111.7, 
110,9,109.4, 56.8, 45.0, 40.0, 39.8, 39.6, 39.4, 39.2, 39.0, 38.8, 
37.2, 26.8. 









 3265, 2939, 2219, 1705, 1631, 1533, 1475, 1437, 1361, 1331, 









500 mg of 5-nitrobenzo[b]thiophene-2-carboxylic acid (2.24 mmol, 1.2 eq.) was 
dissolved in 15 mL of DMF in a round bottom flask. DIC (606 µl, 3.92 mmol, 
1.75 eq.) and HOBt (608.8 mg, 4.48 mmol, 2.0 eq.) were added to the acid (1.0 
eq.) and the mixture was allowed to stir at room temperature for 30 minutes to 
ensure the ester formation. 189.72 mg of N1, N1-dimethylpropane-1, 3-diamine 
(1.86 mmol, 1 eq.) was added into the same reaction mixture. Then this mixture 
was stirred for about 7 hours at which point TLC and LCMS analysis showed 
the completion of reaction. The reaction mixture was then applied to a 
conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 
chapter 3). The product was dried under vacuum and A pale yellow solid was 
collected. Yield=350.0 mg, 51%. 







δH in ppm 
8.53(d,J=3.6,1H), 8.06(dd,J=8.8,2.4,1H), 7.93(d,J=9.2,1H), 7.86(s, 
1H),3.41(t,J=6.8,2H),2.43(t,J=7.6,2H),2.73(s,6H),1.86(m,J=7.2,2H),  








350 mg 4.7 was dissolved in 20 mL of ethanol and1 mL of ethyl acetate in a 
hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on activated carbon) 
was added into the same bottle and mixed well. The bottle was sealed and 
connected to a hydrogen reservoir. Air within the reaction bottle was removed 
249 
 
under vacuum, and flushed with hydrogen. A hydrogen pressure of 
approximately 40 psi was applied from the reservoir, and the bottle was then 
shaken vigorously to initiate the reaction. Progress of the reaction was 
monitored by TLC and LCMS. The hydrogenation process took about 5 hours at 
which point TLC and LCMS analysis showed the completion of reaction. The 
bottle vented after stopping the shaker and the hydrogenated product has been 
recovered through filtration using Celite. Lastly the product was concentrated by 
the rotary evaporation. A cream solid was obtained after drying under vacuum. 
Yield was 310 mg, 98%. 








δH in ppm 
7.69(s,1H),7.58(d,J=8.8,1H),7.14(d,J=2,1H), 6.93(dd,J=8.8, 2.4,1H), 
3.44(t,J=6.8,2H),2.62(t,J=4.4,2H),2.43(s,6H),1.89-1.84(m,J=7.6,2H). 




4.9 Synthesis of N-(3-(dimethylamino)propyl)-5-(5-nitrobenzo[b]thiophene-
2-carboxamido) benzo[b]thiophene-2-carboxamide (4.9). 
 
 
At the beginning, 5-nitrobenzo[b]thiophene-2-carboxylic acid (304 mg, 1.30 
mmol, 1.2 eq.) was dissolved in 20 mL of DMF in a round bottom flask fitted 
with a magnetic stirrer. Then DIC (351 µl, 2.27 mmol, 1.75 eq.) and HOBt (351 
mg, 2.60 mmol, 2.0 eq.) were added to the acid (1.0 eq.) solution and this 
mixture was stirred at room temperature for about 30 minutes to ensure the 
esterification of acid. Then amine (304 mg, 1.09 mmol, 1 eq.) was added to that 
mixture and it was allowed to stir for 7 hours at which point TLC and LCMS 
analysis showed the completion of reaction. Finally the product was purified 
from the reaction mixture by the Catch and Release’ method using conditioned 
IsoluteTM SCX-2 cartridge (described in the section ‘Method and Materials’ of 
chapter 3). The product was concentrated and a pale yellow solid was obtained 
after drying in vacuum. Yield was 205mg, 39%. 
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δH in ppm 
10.95(s,1H), 8.42(s,1H), 8.88(d,J=2.4,1H), 8.83 (d, J=2.4,1H), 
8.55(s,1H),8.41(d,J=2,1H),8.30(d,J=8.8,1H),8.25(s,1H),7.97(t,J=8.8,
1H),7.77(dd,J=9.2,2.4,1H),7.24-7.12(m,1H),3.34(d,J=6,2H),2.61 
(t,J=7.6,2H), 2.39(s,6H), 1.793(t,J=7.2,2H).  
EIMS Found 483.0 [M+H]+, Calculated for  C23H22N4O4S2, 482.10 [M]
+ 
 
4.10 Synthesis of 5-amino-N-(2-((3-(dimethylamino) propyl) carbamoyl) 
benzo[b]thiophen-5-yl) benzo[b]thiophene-2-carboxamide (4.10). 
  
205 mg of 4.9 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate in a 
hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on activated carbon) 
was added into the reaction vessel and mixed well. The bottle was sealed and 
connected to a hydrogen reservoir. Air from the reaction bottle was removed by 
applying vacuum, and was then by flushed with hydrogen. Typically, 
approximately 40 psi of hydrogen pressure was applied from the reservoir, and 
the bottle was then shaken vigorously to initiate the reaction. Progress of the 
reaction was monitored by TLC and LCMS. A complete hydrogenation has 
taken 6 hours at which point TLC and LCMS analysis showed the completion of 
reaction. The shaker was stopped and the bottle was vented. The product was 
recovered by means of filtration using Celite. Finally, the product is 
concentrated by using a rotary evaporator. A yellow solid was obtained after 
drying in vacuum. Yield was 175 mg, 91%. 

















4.11 Synthesis of N-(2-((2-((3-(dimethylamino) propyl) carbamoyl) 




26 mg of benzofuran-2-carboxylic acid (0.158 mmol, 1.2 eq.) was dissolved in 5 
mL of DMF in a round bottom flask fitted with a magnetic stirrer. Then DIC (43 
µl, 0.276 mmol, 1.75 eq.) and HOBt (43 mg, 0.316 mmol, 2.0 eq.) were added 
to the acid (1.0 eq.) and this mixture was allowed to stir at room temperature for 
30 minutes to ensure the formation of ester from the acid. Then amine 4.10 (60 
mg, 0.132 mmol, 1 eq.) was added to the mixture and this mixture was allowed 
to stir for 5 at which point TLC and LCMS analysis showed the completion of 
reaction. Finally the reaction mixture was applied to a conditioned IsoluteTM 
SCX-2 cartridge and the product was purified by ‘Catch and Release’ method 
(described in the section ‘Method and Materials’ of chapter 3). An orange solid 
was obtained after drying in vacuum. Yield=28mg, 36%. 







δH in ppm 
10.77(s,1H), 10.71(s,1H), 8.82(t,J=5.2,1H), 8.56(d,J=1.6,1H), 
8.44(s,2H),8.06(d,J=7.6,2H),8.01(d,J=8.8,1H),7.92(dd,J=8.8,1.6,1
H), 7.85(d,J=5.2,2H), 7.82(dd,J=8.8,2.0,1H), 7.75(d,J=8.4,1H), 
7.55-7.51(m,1H), 7.39 (t,J=7.6, 1H), 3.34-3.29(m,2H), 2.40 
(t,J=7.2,2H), 2.24(s,6H), 1.76-1.69(m,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
161.3, 160.3, 156.8, 154.4, 148.6,141.1, 140.8, 139.5, 139.4, 
136.1, 135.9, 138.8, 135.6, 127.2, 127.1, 125.9, 124.5, 123.8, 
123.0, 122.9, 120.6, 120.0, 116.1, 115.6, 111.95, 110.8, 56.4, 
44.68, 40.0, 39.8, 39.2,26.6. 
EIMS Found 597.3 [M+H]+, Calculated for C32H28N4O4S2, 596.15 [M]
+ 





3282, 2931, 2217, 1632, 1518, 1473, 1443, 1383, 1335, 1302, 





4.12 Synthesis of 5-(benzo[b]thiophene-2-carboxamido)-N-(2-((3-(dimethyl 




Initially, 28 mg of benzo[b]thiophene-2-carboxylic acid (0.158 mmol, 1.2 eq.) 
was dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then DIC (43 µl, 0.276 mmol, 1.75 eq.) and HOBt (43 mg, 0.316 mmol, 
2.0 eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then amine 4.10 (60 mg, 0.132 mmol, 1 eq.) was added to the same mixture 
and it was allowed to stir for 6 hours at which point TLC and LCMS analysis 
showed the completion of reaction. Finally the product was purified by ‘Catch 
and Release’ method using conditioned IsoluteTM SCX-2 cartridge (described in 
the section ‘Method and Materials’ of chapter 3). A pale yellow solid was 
collected after drying in vacuum. Yield=25 mg, 31%. 








δH in ppm 
10.79(s,1H), 10.73(s,1H), 8.81(t,J=5.2,1H), 8.53( d,J=1.6,1H), 
8.47(s,1H), 8.44(s,2H), 8.08-8.04(m,3H), 8.01 (d,J=8.8,2H), 
7.87(dd,J=8.8,2.0,1H), 7.82(dd,J=8.8,2.0,1H),7.53-7.47 (m, 2H), 
3.34-3.27(m,2H), 2.34(t,J=7.2,2H), 2.19(s,6H), 1.74-1.67(m,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
161.3, 160.5, 160.3, 141.2, 140.9, 140.4, 139.8, 139.5, 139.4, 139.1, 
136.1, 135.98, 335.92, 135.6, 126.5, 125.9, 125.4, 125.0, 124.4, 
123.0, 122.9, 122.8, 120.4, 120.0, 115.8, 115.7,56.5, 44.8,39.6, 39.2, 
38.8,26.7. 









3302, 1634, 1575, 1526, 1445, 1339, 1300, 1271, 1231, 1154, 966, 






4.13 Synthesis of N-(2-((3-(dimethylamino) propyl) carbamoyl) 
benzo[b]thiophen-5-yl)-5-nitro benzofuran-2-carboxamide (4.13). 
 
 
Initially, 5-nitrobenzofuran-2-carboxylic acid (143.48 mg, 0.693 mmol, 1.2 eq.) 
was dissolved in 20 mL of DMF in a round bottom flask which was placed on a 
magnetic stirrer. Then DIC (187.49 µl, 1.21 mmol, 1.75 eq.) and HOBt (187.11 
mg, 1.386 mmol, 2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for 30 minutes for the esterification of acid. 
Then amine 4.8 (160 mg, 0.577 mmol, 1 eq.) was added to the mixture, and it 
was allowed to stir for 8 hours at which point TLC and LCMS analysis showed 
the completion of reaction. Finally the reaction mixture was applied to a 
conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 
chapter 3). An orange solid was obtained after drying in vacuum. Yield=170mg, 
65%.  







δH in ppm  
10.85(s,1H),8.79(d,J=2.0,2H),8.43(s,1H),8.05(s,1H),7.99(s,1H),7.9
5(t,J=8.0,2H),7.82(d,J=6.8,1H),3.30(t,J=6.0,2H),2.39(S,2H),2.23(s,
6H), 1.72(t,J=6.8,2H).  
EIMS Found 567.10 [M+H]+, Calculated for C23H22N4O5S, 466.13 [M]
+ 
 
4.14 Synthesis of 5-amino-N-(2-((3-(dimethylamino) propyl) carbamoyl) 





170 mg of 4.13 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate 
was added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) 20 was added into the same, and mixed well. The reaction 
bottle was sealed and connected to a hydrogen reservoir. Air from the reaction 
bottle was removed by means of vacuum, and was then by flushed with 
hydrogen. Approximately 40 psi of hydrogen pressure was applied from the 
reservoir, and the bottle was then shaken vigorously to initiate the reaction. 
Progress of the reaction was monitored by TLC and LCMS, and on completion 
of the reaction after 7 hours at which point TLC and LCMS analysis showed the 
completion of reaction.The shaker was stopped, the bottle vented. The product 
was recovered by means of filtration using Celite. Finally, the product is 
concentrated by using a rotary evaporator. A brown solid was obtained after 
drying in vacuum. Yield=145mg, 91%. 







δH in ppm 
10.61(s,1H), 8.82(s,1H), 8.45(s,1H), 8.06(s,1H), 7.97(d,J=8.8,1H), 
7.85(dd,J=8.8,2.0,1H),7.57(s,1H),7.39(d,J=8.8,1H),6.85-
6.80(m,2H), 3.32-3.27(m,2H), 2.51-2.49(m,2H), 2.27(t,J=6.8,2H), 
2.14(s,6H), 1.71-1.64(m,2H).  




4.15 Synthesis 5-(benzo[b]thiophene-2-carboxamido)-N-(2-((3-(dimethyl 




Initially, benzo[b]thiophene-2-carboxylic acid (40 mg, 0.224 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (60 µl, 0.392 mmol, 1.75 eq.) and HOBt (60.48 mg, 0.448 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then amine 4.14 (70 mg, 0.16 mmol, 1 eq.) was added to the same mixture and 
the mixture was allowed to stir for 5 hours at which point TLC and LCMS 
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analysis showed the completion of reaction. Finally the reaction mixture was 
applied to a conditioned IsoluteTM SCX-2 cartridge and the product was purified 
by ‘Catch and Release’ method (described in the section ‘Method and 
Materials’ of chapter 3). A pale yellow solid was obtained after drying in 
vacuum. Yield=28mg, 41%. 
 
 
Figure 4.1: 1H and 13C NMR spectroscopic data of compound 4.15 as a 












δH in ppm   
10.71(d,J=3.2,2H), 8.79(t,J=5.6,1H), 8.47(s,1H), 8.41(s,1H), 
8.34(s,1H), 8.04(t,J=8.8,2H), 8.01(d,J=9.2,1H), 7.87(d,J=2,1H), 
7.84(s,2H), 7.81(d,J=2.4,1H), 7.76(d,J=8.8,1H), 7.52-7.48 (m, 




(100MHz,(CD3)2SO); δC in ppm  
161.3, 160.3, 156.7, 151.2, 149.3, 141.1, 140.4, 139.9,139.4, 
139.1,135.7, 135.6,134.6, 127.2, 126.5, 125.7, 125.4, 
125.0,124.4,122.9, 122.8, 121.0, 120.1, 115.9, 113.9, 112.0, 
111.0, 56.5, 44.8, 39.3, 37.6,26.7. 
EIMS Found 597.10 [M+H]+, Calculated for C32H28N4O4S2 596.15 [M]
+ 





3285, 2936, 2762, 1741, 1660, 1634, 1585, 1539, 1470, 1447, 
1427, 1343, 1297, 1273, 1232, 1207, 1142, 1126, 1040, 945, 893, 
876, 847, 819, 809, 777, 755, 740, 720, 690. 
 
 
4.16 Synthesis of N-(3-(dimethyl amino) propyl)-5-(5-nitro benzo 
[b]thiophene-2-carboxamido) benzofuran-2-carboxamide (4.16). 
 
 
Initially, 118 mg of 5-nitrobenzo[b]thiophene-2-carboxylic acid (0.54 mmol, 1.2 
eq.) was dissolved in 10mL of DMF in a round bottom flask fitted with a 
magnetic stirrer. Then DIC (146 µl, 0.945 mmol, 1.75 eq.) and HOBt (145.8 mg, 
1.08 mmol, 2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for 30 minutes for the esterification of the 
acid. Then amine 4.2 (100.0 mg, 0.383 mmol, 1 eq.) was added to the mixture 
and the mixture was allowed to stir for 8 hours at which point TLC and LCMS 
analysis showed the completion of reaction. Finally the reaction mixture was 
applied to a conditioned IsoluteTM SCX-2 cartridge and the product was purified 
by ‘Catch and Release’ method (described in the section ‘Method and 
Materials’ of chapter 3). A deep brown solid was obtained after drying in 












δH in ppm  
10.87(s,1H), 8.87(d,J=5.2,2H), 8.38(s,1H), 8.27(dd,J=8.8,4.0,2H), 
7.83(t,J=5.6,1H),7.66(dd,J=8.8,2.8,2H),7.45(s,1H),3.35(d,J=5.2,2
H), 2.51 (s,6H), 2.45(s,2H), 1.86(s,2H).  




4.17 Synthesis of 5-(5-aminobenzo[b]thiophene-2-carboxamido)-N-(3 
(dimethylamino) propyl) benzofuran-2-carboxamide (4.17).  
 
 
52 mg of 4.16 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate was 
added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) 20 was added into the reaction vessel, and mixed well. The 
reaction bottle was sealed and connected to a hydrogen reservoir. Air within the 
reaction bottle was removed by the application of vacuum, and was then by 
flushed with hydrogen. A hydrogen pressure of approximately 40 psi was 
applied from the reservoir, and the bottle was then shaken vigorously to initiate 
the reaction. Progress of the reaction was monitored by TLC and LCMS, and on 
completion of the reaction after 5 hours at which point TLC and LCMS analysis 
showed the completion of reaction. The shaker was stopped, the bottle vented, 
and the product was recovered by means of filtration using Celite. Finally, the 
product is concentrated by using a rotary evaporator. A light yellow solid was 
















δH in ppm                                                                                                                                           
10.59(s,1H),8.83(t,J=5.6,1H),8.24(d,J=2,1H),8.14(s,1H),7.807.75(m
,1H),7.65(d,J=8.8,2H),7.54(s,1H),7.06(d,J=1.6,1H),6.86(dd,J=8.8,2.
4,1H), 3.33-3.28(m,2H), 2.51(t,J=1.6,2H), 2.28-2.42 (m,2H), 2.14 
(s,6H), 1.69-1.64(m,2H). 
EIMS Found 536.10[M+H]+, Calculated for C23H24N4O3S, 435.15 [M]
+ 
4.18 Synthesis of 5-(5-(benzofuran-2-carboxamido) benzo[b]thiophene-2-




At the beginning, 46 mg of benzofuran-2-carboxylic acid (0.288 mmol, 1.2 eq.) 
was dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then DIC (77 µl, 0.504 mmol, 1.75 eq.) and HOBt (77 mg, 0.576 mmol, 
2.0 eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the ester formation. Then 90 mg of 
amine 4.17 (0.206 mmol, 1 eq.) was added to the mixture as, and the mixture 
was allowed to stir for 5 hours at which point TLC and LCMS analysis showed 
the completion of reaction. Lastly the reaction mixture was applied to a 
conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 















δH in ppm   
10.77(s,1H),10.63(s,1H),8.83(s,1H),8.57(s,1H),8.39(s,1H), 
8.27(s,1H),8.07(d,J=8.8,1H),7.94(d,J=7.2,1H),7.85(t,J=8,2H), 
7.77(t,J=7.2,2H), 7.68 (d,J=8.8,1H), 7.53(t,J=7.6,2H), 7.39 (t,J=7.2, 
1H), 3.32(t,J=6.8,2H), 2.27(t,J=6.4,2H), 2.21 (s,6H), 1.68(t,J=6.8,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
160.2, 158.0, 156.8, 154.4, 150.9, 149.9, 148.5, 140.9, 139.3, 
136.1,135.7, 134.3, 127.2, 127.0, 125.7, 123.9, 123.0, 122.9, 120.6, 
116.1,113.9, 111.9, 111.8, 110.8, 109.4, 56.8, 45.0, 39.8, 39.2, 39.0, 
37.3, 35.7. 
EIMS Found 580.17 [M+H] +, Calculated for C32H28N4O5S, 579.20 [M]
+  
HRMS M/z (+EI) found 581.1851[M+H]




3245, 2936, 1637, 1543, 1523, 1470, 1446, 1380, 1327, 1297, 1233, 




4.19 Synthesis of N-(3-(dimethylamino) propyl)-5-nitro-1H-indole-2-
carboxamide (4.19).        
 
 
Initially, 400 mg of 5-nitro-1H-indole-2-carboxylic acid (1.94 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (524 µl, 3.39 mmol, 1.75 eq.) and HOBt (523 mg, 3.88 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
temperature for 30 minutes to ensure the formation of ester from the acid. Then 
N1, N1-dimethylpropane-1, 3-diamine (160 µl, 1.56 mmol, 1 eq.) was added to 
the mixture and it was allowed to stir for about 7 hours at which point TLC and 
LCMS analysis showed the completion of reaction. At last the reaction mixture 
was applied to a conditioned IsoluteTM SCX-2 cartridge and the product was 
purified by ‘Catch and Release’ method (described in the section ‘Method and 
Materials’ of chapter 3). A yellow solid was obtained after drying in vacuum. 











δH in ppm  
12.42(s,1H), 8.83(s,1H), 8.70(d,J=2,1H), 8.06(dd,J=8.8,2.0,1H), 
7.56(d,J=9.2,1H), 7.37(s,1H), 3.34-3.30(m,2H), 2.27 (t,J=7.2,2H), 
2.13 (s,4H), 1.67(t,2H). 




4.20 Synthesis 5-amino-N-(3-(dimethylamino) propyl)-1H-indole-2-
carboxamide (4.20).        
 
 
200mg of 4.19 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate was 
added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) 20 was added into the same, and mixed well. The reaction 
bottle was sealed and connected to a hydrogen reservoir. Air from the reaction 
bottle was removed under vacuum, and the reaction mixture was then flushed 
with hydrogen. Typically, a hydrogen pressure of approximately 40 psi was 
applied from the reservoir, and the bottle was then shaken vigorously to initiate 
the reaction. Progress of the reaction was monitored by TLC and LCMS, and 
the shaker was stopped on completion of the reaction after about 6 hours at 
which point TLC and LCMS analysis showed the completion of reaction. The 
product was recovered by means of filtration using Celite. Finally, the product is 
concentrated by using a rotary evaporator. An orange solid was obtained after 
drying in vacuum. Yield=250mg, 93%. 







δH in ppm  
7.27(s,1H),7.25(s,1H),6.96(d,J=2,1H),6.87(s,1H),6.83(d,J=3.6,1H)
, 6.80(d,J=2.0,1H), 3.40(t,J=6.8,2H), 3.33-3.32(m,2H), 2.44-2.41 
(m,2H), 1.80 (t,J=7.2,4H), 1.11(d,J=6.8,2H). 





4.21 Synthesis of N-(3-(dimethylamino) propyl)-5-(5-nitro-1H-indole-2-
carboxamido)-1H-indole-2-carboxamide (4.21). 
 
47 mg of 5-nitro-1H-indole-2-carboxylic acid (0.230 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask and stirred. Then DIC (62 µl, 
0.402 mmol, 1.75 eq.) and HOBt (62 mg, 0.460 mmol, 2.0 eq.) were added to 
the acid (1.0 eq.) and this mixture was allowed to stir at room temperature for 
30 minutes to ensure the formation of ester from the acid.  
 
 
Figure 4.2: 1H and 13C NMR spectroscopic data of compound 4.21 as a 
representative of library-5 compounds 
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Then amine 4.20 (50 mg, 0.192 mmol, 1 eq.) was added to the mixture and the 
mixture was allowed to stir for 8 hours at which point TLC and LCMS analysis 
showed the completion of reaction. Lastly the reaction mixture was applied to a 
conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 
chapter 3). An orange solid was obtained after drying in vacuum. Yield=16mg, 
19%.  












(t,J=7.2,2H), 2.17 (s,6H), 1.69(t,J=6.8,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
162.2, 160.8, 158.5, 141.2, 139.4, 135.4, 133.5, 132.6, 131.0, 
126.8, 126.3, 119.2, 118.5, 118.3, 112.9, 112.8, 112.2, 105.5, 
102.2, 56.7, 45.0, 38.8, 35.7.  
EIMS Found 449.0 [M+H] +, Calculated for C23H24N6O4, 448.18 [M]
+ 
HRMS M/z (+EI) Calc. for C23H24N6O4 [M]




3270, 2970, 2301, 1738, 1611, 1536, 1536, 1468, 1439, 1365, 
1342, 1312, 1236, 1209, 1169, 1128, 1094, 1039, 866, 802, 743, 
683. 
4.22 Synthesis of 5-amino-N-(2-((3-(dimethylamino) propyl) carbamoyl)-1H-
indol-5-yl)-1H-indole-2-carboxamide (4.22). 
 
242 mg of 4.21 was dissolved in 20 mL of ethanol and 1mL of ethyl acetate was 
added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) 20 was added into the reaction vessel, and mixed well. The 
sealed reaction bottle was connected to a hydrogen reservoir. Air from the 
reaction bottle was removed by applying vacuum, and it was then by flushed 
with hydrogen. Typically, a hydrogen pressure of approximately 40 psi was 
applied from the reservoir, and the bottle was then shaken vigorously to initiate 
the reaction. Progress of the reaction was monitored by TLC and LCMS, and on 
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completion of the reaction after about 6 hours at which point TLC and LCMS 
analysis showed the completion of reaction.The shaker was stopped, the 
bottle vented, and the product was recovered by means of filtration using Celite. 
Finally, the product is concentrated by using a rotary evaporator. A yellow solid 
was obtained after drying in vacuum. Yield=210 mg, 93%. 







δH in ppm  
11.55(s,1H), 11.24(s,1H), 9.95(s,1H), 8.50(t,J=5.6,1H), 8.07(s,1H), 
7.47(dd,J=8.8,1.6,1H), 7.37 (d,J=8.8,1H), 7.15(d,J=8.8,1H), 
7.07(d,J=8.8,2H), 6.71(s,1H), 6.62(dd,J=8.8,2.0,1H), 3.31-
3.26(m,2H), 2.25 (t,J=6.8,2H), 2.13(s,4H), 2.12 (s,2H), 1.67-
1.61(m,2H). 
EIMS Found 419.0 [M+H] +, Calculated for C23H26N6O2, 418.21 [M]
+ 
4.23 Synthesis of 5-amino-N-(2-((3-(dimethylamino) propyl) carbamoyl)-1H-
indol-5-yl)-1H-indole-2-carboxamide (4.23). 
 
Initially, 50 mg of 5-nitro-1H-indole-2-carboxylic acid (0.186 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (51 µl, 0.325 mmol, 1.75 eq.) and HOBt (50.8 mg, 0.372 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then amine 4.22 (65 mg, 0.155 mmol, 1 eq.) was added and the mixture was 
allowed to stir for 5 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Finally the reaction mixture was added to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). A pale 















δH in ppm   
12.48(s,1H), 11.75(s,1H), 11.58(s,1H), 10.45(s,1H), 10.14(s,1H), 
8.78(s,1H), 8.53(s,1H), 8.17(s,1H), 8.11(s,2H), 7.71(s,1H), 
7.63(d,J=9.2,1H), 7.57(d,J=8.4,1H), 7.50 (t,J=9.6,2H), 7.43(s,2H), 




(100MHz,(CD3)2SO); δC in ppm  
162.2, 160.9, 159.3, 158.6, 141.2, 139.4, 135.4, 133.9, 133.4, 
132.6, 132.5, 131.3, 131.1, 126.9, 126.3, 119.2, 118.7, 118.5, 
118.3, 1130, 112.8, 112.6, 112.3, 112.1, 105.6, 103.3, 102.2, 56.6, 
44.9, 39.2, 35.7, 30.7.  
EIMS Found 607.10 [M+H]+, Calculated for C32H30N8O5, 606.23 [M]
+ 





3242, 2938, 1660, 1634, 1585, 1545, 1519, 1471, 1445, 1417, 
1382, 1328, 1295, 1250, 1230, 1126, 1096, 1067, 982, 870, 810, 
740, 679, 661. 




Initially, 21.87 mg of 1-methyl-1H-indole-2-carboxylic acid (0.125 mmol, 1.2 eq.) 
was dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then DIC (34 µl, 0.218 mmol, 1.75 eq.) and HOBt (34 mg, 0.250 mmol, 
2.0 eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes for the formation of ester from the acid. Then 
amine 4.22 (50 mg, 0.104 mmol, 1 eq.) was added and the mixture was stirred 
for 6 hours at which point TLC and LCMS analysis showed the completion of 
reaction. At last the reaction mixture was applied to a conditioned IsoluteTM 
SCX-2 cartridge and the product was purified by ‘Catch and Release’ method 
(described in the section ‘Method and Materials’ of chapter 3). A yellow 













δH in ppm   
11.76(s,1H),11.60(s,1H),10.27(s,1H),10.20(s,1H), 8.54(d,J=5.6,1H), 
8.17(s,1H), 8.10(t,J=6.4,1H), 7.70(d,J=8.0,1H), 7.58(d,J=8.4,1H), 
7.56-7.54(m,2H),7.44(t,J=8.8,2H),7.40(d,J=2.8,1H), 
7.32(t,J=6.4,2H), 7.16(t,J=7.6,1H), 7.14(s,1H), 4.05(s,3H). 3.66-
3.61(m, 2H), 3.08 (s, 2H), 2.73 (s, 4H), 2.15(s, 2H).  
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
162.3, 161.2, 160.9, 160.2, 159.3, 156.8, 139.2, 138.5, 133.7, 
133.4, 132.5, 132.4, 131.6, 131.3, 126.8, 125.5, 123.7, 121.6, 
120.2, 118.4, 112.6, 112.2, 112.1, 110.5, 105.0, 56.8, 45.1, 39.4, 
35.7, 31.4, 30.7, 28.9, 27.2.  




m/z (+EI) Calc. for C33H33N7O3 (M)




3268, 2968, 2343, 2300, 1738, 1616, 1536, 1467, 1438, 1368, 









     
29 mg of 1-methyl-1H-indole-2-carboxylic acid (0.156 mmol, 1.2 eq.) was 
dissolved in 5 mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (45 µl, 0.228 mmol, 1.75 eq.) and HOBt (45 mg, 0.330 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
temperature for 30 minutes to confirm esterification. Then amine 4.14 (60 mg, 
0.137 mmol, 1 eq.) was added and the mixture was allowed to stir for 12 hours 
at which point TLC and LCMS analysis showed the completion of reaction. 
Finally the reaction mixture was applied to a conditioned IsoluteTM SCX-2 
cartridge and the product was purified by ‘Catch and Release’ method 
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(described in the section ‘Method and Materials’ of chapter 3). A pale yellow 
solid was obtained after drying in vacuum. Yield=18mg, 23%.               








δH in ppm   
10.70(s,1H), 10.48(s,1H), 8.77(s,1H), 8.47(s,1H), 8.38(s,1H), 
8.06(s,1H), 8.00(d,J=8.8,1H), 7.86(d,J=8.8,1H), 7.82(d,J=8.4,2H), 
7.73(t,J=8.4,2H), 7.57(d,J=8.4,1H), 7.36(s,1H), 7.34(t,J=7.6,1H), 
7.15(t,J=7.6, 1H), 4.05(s,3H), 3.32(t,J=6.8,2H), 2.28(t,J=6.8,2H), 
2.15(s,6H), 1.69(t,J=7.2,2H). 
13C NMR (100MHz,(CD3)2SO); δC in ppm  
161.3, 160.5, 156.7, 151.0, 149.3, 141.1, 139.4, 138.6, 135.7, 
135.6, 135.1, 131.9, 127.2, 125.4, 124.4, 123.9, 122.9, 121.7, 
120.9, 120.3, 115.9, 113.5, 111.9, 111.0, 110.5, 105.5, 56.7, 45.0, 
41.4, 39.6, 38.8,37.7, 31.4. 
EIMS Found 594.2 [M+H] +, Calculated for C33H31N5O4S, 593.2097 [M]
+ 





3266, 2938, 2219, 1705, 1632, 1532, 1475, 1438, 1360, 1331, 
1308, 1221, 1159, 1097, 1039, 945, 885, 807, 770, 741, 715, 619. 
4.26 Synthesis of 5-nitro-N-(2-(piperidin-1-yl) ethyl) benzofuran-2-
carboxamide (4.26) 
 
   
Initially, 200 mg of 5-nitrobenzofuran-2-carboxylic acid (0.966 mmol, 1.2 eq.) 
was dissolved in 10mL of DMF in a round bottom flask and it is stirred to mix 
well. Then DIC (260 µl, 1.69 mmol, 1.75 eq.) and HOBt (260 mg, 1.93 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was stirred at room 
temperature for at least 30 minutes to ensure the formation of ester from the 
acid. Then 2-(piperidin-1-yl) ethan-1-amine (104 mg, 0.805 mmol, 1 eq.) was 
added and the mixture was allowed to stir for 14 hours at which point TLC and 
LCMS analysis showed the completion of reaction. Finally the product was 
purified by ‘Catch and Release’ method using the conditioned IsoluteTM SCX-2 
cartridge (described in the section ‘Method and Materials’ of chapter 3). A pale 












δH in ppm  
8.50(d,J=2.4,1H), 8.21(dd,J=6.8,2.4,1H), 7.60 (d,J=9.2,1H), 
7.43(s,1H), 3.60(t,J=6.8,2H), 2.85-2.64(m,2H), 2.48(s,4H), 1.68-
1.63(m,4H), 1.30(d,2H). 








155 mg of 4.26 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate 
was added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) 20 was added into the same and mixed it well. The sealed 
reaction bottle was connected to a hydrogen reservoir and air from the reaction 
bottle was removed by applying vacuum. The mixture was then flushed with 
hydrogen. A hydrogen pressure of approximately 40 psi was applied from the 
reservoir, and the bottle was then shaken vigorously to initiate the 
reaction. Progress of the reaction was observed by TLC and LCMS. The shaker 
was stopped after about 6 hours at which point TLC and LCMS analysis 
showed the completion of reaction. The bottle was vented and the product was 
recovered by means of filtration using Celite. Finally, the product was 
concentrated by using a rotary evaporator. A pale yellow solid was obtained 
after drying in vacuum. Yield=136 mg, 96 %. 







δH in ppm  
7.26(t,J=6.0,2H),6.95(d,J=2.0,1H),6.90(dd,J=8.8,2.4,1H),3.56(t,
J=6.8,2H),2.64(t,J=6.8,2H), 2.55(s,4H), 1.64-1.58(m,4H), 
1.45(d, 6.0,2H). 





4.28 Synthesis of 5-nitro-N-(2-((2-(piperidin-1-yl) ethyl) carbamoyl) 
benzofuran-5-yl) benzofuran-2-carboxamide (4.28) 
 
 
Initially, 60 mg of 5-nitrobenzofuran-2-carboxylic acid (0.208 mmol, 1.2 eq.) has 
been dissolved in 10mL of DMF in a round bottom flask placed into a magnetic 
stirrer. Then DIC (78.69 µl, 0.509 mmol, 1.75 eq.) and HOBt (78.57 mg, 0.582 
mmol, 2.0 eq.) were added to the acid (1.0 eq.) and this mixture was allowed to 
stir at room temperature for 30 minutes to ensure the ester formation from the 
acid. The mixture was allowed to stir for 14 hours after addition of an amine 
4.27 (60 mg, 0.208 mmol, 1 eq.), at which point TLC and LCMS analysis 
showed the completion of reaction. At last the reaction mixture was applied to a 
conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 
chapter 3). A pale yellow colured solid was obtained after drying in vacuum. 
Yield=65mg, 65%. 








δH in ppm 
10.80(s,1H),8.81(d,J=2.40,1H),8.34(dd,J=9.2,2.4,1H),8.27(d,J=
2,1H),7.97-7.94(m,2H),7.78(dd,J=8.8,2.0,1H), 7.66(d,J=8.8,1H), 
2.8(s, 2H), 2.43(t, J=6.8, 2H), 2.36(s, 4H), 1.51-1.45(m,4H), 
1.37(dJ=4.8,2H). 




4.29 Synthesis of 5-amino-N-(2-((2-(piperidin-1-yl) ethyl) carbamoyl) 






65 mg of 4.28 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate was 
added into a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) 20 was added into the same and mixed it well. The reaction 
bottle was sealed and connected to a hydrogen reservoir. Air of the bottle was 
removed by applying vacuum, and it was then flushed with hydrogen. 
Approximately 40 psi hydrogen pressure was applied from the reservoir, and 
the bottle was then shaken vigorously to initiate the reaction. Progress of the 
reaction was monitored by TLC and LCMS, and the shaker was stopped on 
completion of the reaction after 6 hours at which point TLC and LCMS analysis 
showed the completion of reaction. The bottle was vented and the product was 
recovered by means of filtration using Celite. Finally, the product was 
concentrated by using a rotary evaporator. A brown solid was obtained after 
drying in vacuum. Yield=52 mg, 85%. 












2H),2.50-2.48(m,2H), 2.43(m,2H), 2.36(s,4H), 1.49-1.45(m,4H). 




4.30 Synthesis of 5-(benzofuran-2-carboxamido)-N-(2-((2-(piperidin-1-yl) 
ethyl) carbonyl) benzofuran-5-yl) benzofuran-2-carboxamide (4.30) 
 
 
Initially, 23 mg of benzofuran-2-carboxylic acid (0.139 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (38 µl, 0.243 mmol, 1.75 eq.) and HOBt (38 mg, 0.278 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was stirred at room 
temperature for at least 30 minutes to ensure the ester formation from the acid. 
Then amine 4.29 (52 mg, 0.116 mmol, 1 eq.) was and the mixture was allowed 
to stir for 7 hours at which point TLC and LCMS analysis showed the 
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completion of reaction. Finally the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). A pale 
yellow coloured solid was obtained after drying under vacuum. Total yield 
was12mg, 18%. 
 















13C NMR (100MHz,(CD3)2SO); δC in ppm  
195.9, 194.7, 193.9, 184.0, 181.3, 162.6, 161.2, 155.8, 154.6, 
150.5, 149.4, 138.9, 137.0, 130.8, 127.5, 123.5, 121.1, 
116.1,112.2,110.7, 109.3,106.9, 98.7, 95.3, 75.9,66.7,59.3, 
40.0, 39.87, 39.6, 39.2,39.0,38.8, 37.9. 
EIMS Found 591.3 [M+H]+, Calculated for C34H30N4O6, 590.21 [M]
+ 





3351, 2925, 1658, 1583, 1538, 1473, 1358, 1297,1198, 1128, 
1045, 942, 870, 802, 743, 609. 
 
 
4.31 Synthesis of 5-(benzo[b]thiophene-2-carboxamido)-N-(2-((2-




 22 mg of benzo[b]thiophene-2-carboxylic acid (0.125 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask placed at magnetic stirrer. 
Then DIC (33 µl, 0.218 mmol, 1.75 eq.) and HOBt (33mg, 0.25 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
temperature for 30 minutes to ensure the formation of ester from the acid. Then 
amine 4.29 (40 mg, 0.089 mmol, 1 eq.) was added and the mixture was allowed 
271 
 
to stir for 6 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Lastly the product was purified by ‘Catch and Release’ 
method using a conditioned IsoluteTM SCX-2 cartridge (described in the section 
‘Method and Materials’ of chapter 3). A white solid was obtained after drying in 
vacuum. Yield=8 mg, 15%. 









δH in ppm  
10.70(d,J=4,2H), 8.78(s,1H), 8.40(s,1H),8.32-8.30(m,2H), 
8.07(d,J=7.6,1H), 8.04-8.02(m,1H), 7.95(s,1H), 7.83(d,J=4,1H) 
,7.80(d,J=2,1H), 7.76(d,J=8.8,1H), 7.67(d,J=9.2,1H), 7.60(s,1H), 
7.52-7.48(m,2H), 2.88(s,2H), 2.72(s,2H),  
2.08(s,2H), 1.59(d,J=6.0,4H), 1.44(s,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
179.7, 179.3, 176.3, 176.0, 174.4,174.2, 172.7, 166.7, 166.5, 
166.1, 158.9, 158.6, 149.3, 139.8, 136.18, 134.7, 132.8, 131.2, 
130.5, 125.8, 118.7, 116.0, 112.1, 108.0, 107.5, 106.2, 104.8, 
47.2, 41.9, 40.0, 39.8, 39.6, 39.4, 39.2. 
EIMS Found 607.0 [M+H] +, Calculated for C34H30N4O5S 606.1937 [M]
+ 
HRMS m/z (+EI) Calc. for C34H30N4O5S, 606.1937 [M]




3281, 2956, 1638, 1574, 1531, 1468, 1393, 1339, 1290, 1233, 
1154, 1086, 1039, 952, 878, 809, 738, 716. 
 
 




Initially, 500 mg of 5-nitrobenzofuran-2-carboxylic acid (2.41 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (650.77 µl, 4.21 mmol, 1.75 eq.) and HOBt (650.7 mg, 4.82 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the ester formation from the acid. 
Then 4-(pyrrolidin-1-yl) butan-1-amine (284 µl, 2.0 mmol, 1 eq.) was added and 
the mixture was stirred for 8 hours at which point TLC and LCMS analysis 
showed the completion of reaction. Finally the reaction mixture was applied to a 
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conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 
chapter 3). A brown solid was obtained after drying in vacuum. Yield=545 mg, 
82%. 








δH in ppm   
8.51(d,J=2.4,1H),8.22(dd,J=9.2,2.4,1H),7.60(d,J=12.8,,1H), 
7.44(s,1H), 3.37-3.32(m,2H), 2.51(s,2H), 2.48(s,2H), 
2.45(s,2H), 1.72-1.69(m,4H), 1.67-1.61(m,4H). 




4.33 Synthesis of 5-amino-N-(4-(pyrrolidin-1-yl) butyl) benzofuran-2-
carboxamide (4.33) 
  
545 mg of 4.32 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate 
was added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) 20 was added into the reaction mixture and mixed it well. The 
sealed bottle has been connected to a hydrogen reservoir. Air from the reaction 
bottle was removed by applying vacuum, and it was then flushed with hydrogen. 
Typically, a hydrogen pressure of approximately 40 psi was applied from the 
reservoir and the bottle was then shaken vigorously to initiate the reaction. 
Progress of the reaction was monitored by TLC and LCMS. The reaction 
required about 6 hours at which point TLC and LCMS analysis showed the 
completion of reaction. The shaker was stopped, the bottle was vented, and the 
product was recovered by filtration using Celite. Finally, the product was 
concentrated by using a rotary evaporator. An orange solid was obtained after 





















4.34 Synthesis of 5-nitro-N-(2-((4-(pyrrolidin-1-yl) butyl) carbamoyl) 
benzofuran-5-yl) benzofuran-2-carboxamide (4.34) 
 
 
At first, 481 mg of 5-nitrobenzofuran-2-carboxylic acid (2.32 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (627.68 µl, 4.06 mmol, 1.75 eq.) and HOBt (626.4 mg, 4.64 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes for esterification. Then amine (500 mg, 1.65 
mmol, 1 eq.) was added and the mixture was allowed to stir for 13 hours at 
which point TLC and LCMS analysis showed the completion of reaction. Finally 
the reaction mixture separated by conditioned IsoluteTM SCX-2 cartridge and the 
product was purified by ‘Catch and Release’ method (described in the section 
‘Method and Materials’ of chapter 3). A pale yellow solid was obtained after 
drying in vacuum. Yield=360 mg, 44%. 









 δH in ppm  
8.72(s,1H), 8.39(d,J=6.4,1H), 8.17(s,1H), 7.84(d,J=9.2,1H), 7.76 
(t,J=1.2,1H), 7.68(t,J=1.2,1H), 7.59(d,J=4.8,1H), 7.46(s,1H), 
7.27(d,J=4, 1H), 3.36( s,2H), 2.59(t, J=8.0,2H), 1.83(s,4H), 
1.67(s,2H), 1.29-1.24(m,4H), 1.11(d ,J=6.4,2H). 






4.35 Synthesis of 5-amino-N-(2-((4-(pyrrolidin-1-yl) butyl) carbamoyl) 
benzofuran-5-yl) benzofuran-2-carboxamide (4.35) 
 
 
200mg of 4.34 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate was 
added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) 20 was added into the reaction mixture and mixed it well. The 
reaction bottle was sealed and connected to a hydrogen reservoir. Air from the 
reaction bottle was removed by applying vacuum, and it was flushed with 
hydrogen. A hydrogen pressure of approximately 40 psi was applied from the 
reservoir, and the bottle was then shaken vigorously to initiate the reaction. 
Progress of the reaction was monitored by TLC and LCMS and the shaker was 
stopped on completion of the reaction after 4 hour at which point TLC and 
LCMS analysis showed the completion of reaction. The bottle was vented, and 
the product was recovered by means of filtration using Celite. Lastly, the 
product is concentrated by using a rotary evaporator. A brown solid was 
obtained after drying in vacuum. Yield=160mg, 86%. 







δH in ppm  
8.14(d,J=6.0,1H), 7.68(dd,J=5.2,1.6,1H), 7.52(d,J=14.4,1H), 
7.41(s,2H), 7.41(s,1H), 6.99(d, J=4.8, 1H), 6.94(dd,J=8.8,2.0, 
1H), 3.42(s,2H), 2.71(s,4H), 2.63(s,2H), 1.67(s,2H), 1.66(s,4H), 
1.19(s,2H). 
EIMS Found 460.21  [M+H] +, Calculated for C26H28N4O4, 459.0 [M]
+  
 4.36 Synthesis of 5-(benzofuran-2-carboxamido)-N-(2-((4-(pyrrolidin-1-yl) 
butyl) carbamoyl) benzofuran-5-yl) benzofuran-2-carboxamide (4.36) 
 
 
Initially, 29.58 mg of benzofuran-2-carboxylic acid (0.182 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask placed at a magnetic stirrer. 
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Then DIC (50 µl, 0.3185 mmol, 1.75 eq.) and HOBt (50 mg, 0.364 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to form ester. Then amine 4.35 (60 mg, 0.130 
mmol, 1 eq.) was added and the mixture was allowed to stir for 6 hours at which 
point TLC and LCMS analysis showed the completion of reaction. Finally the 
reaction mixture was applied to a conditioned IsoluteTM SCX-2 cartridge and the 
product was purified by ‘Catch and Release’ method (described in the section 
‘Method and Materials’ of chapter 3). A deep yellow solid was obtained after 
drying in vacuum. Yield=14mg, 18%. 









δH in ppm  




1.50(d,J=7.2,4H), 1.14-1.09(m,2H).  
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
171.4, 163.7, 157.7, 156.3, 153.1, 151.1,145.3, 139.9, 127.1, 
123.0,120.9,114.2,111.9,111.0,109.3,99.1,92.2,90.8,69.7,55.3,53.
5,46.7,41.9,40.0, 39.8, 39.6, 39.4, 38.8,38.6, 31.8, 31.7, 
30.6,30.1, 25.9, 23.0. 
EIMS Found 605.1 [M+H]+, Calculated for C35H32N4O6, 604.23  [M]
+ 





3405, 2919, 1657, 1585, 1541, 1474, 1376, 1298, 1233, 941, 852, 
801, 741. 
 
4.37 Synthesis of 5-(benzo[b]thiophene-2-carboxamido)-N-(2-((4-




At first, 33 mg of benzo[b]thiophene-2-carboxylic acid (0.182 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (49 µl, 0.318 mmol, 1.75 eq.) and HOBt (49 mg, 0.364 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
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temperature for 30 minutes to ensure the formation of ester. Then amine 
4.35(60 mg, 0.130 mmol, 1 eq.) was added and this mixture was allowed to stir 
for 6 hours at which point TLC and LCMS analysis showed the completion of 
reaction. The product was purified by ‘Catch and Release’ method using 
conditioned IsoluteTM SCX-2 cartridge (described in the section ‘Method and 
Materials’ of chapter 3). A deep yellow solid was obtained after drying in 
vacuum. Yield was 14mg, 18%. 















13C NMR (100MHz,(CD3)2SO); δC in ppm  
162.2,160.3,157.9, 156.6, 151.2, 150.9, 150.0, 149.4, 
140.4,139.9, 139.1, 134.6, 134.2, 127.2, 126.5, 125.7, 
125.3, 125.0, 122.8, 120.9, 120.6, 113.9, 113.8, 112.0, 
111.7, 110.9, 109.4, 55.1, 53.4, 40.0, 39.2, 30.7, 25.6, 23.9, 
23.0. 
EIMS Found 621.20 [M+H]+, Calculated for C35H32N4O5S, 620.20 
[M]+ 





3312, 1656, 1585, 1535, 1471, 1434, 1231, 1198, 941, 870, 
802, 752, 739, 620, 568. 
 
4.38 Synthesis of 5-(5-nitrobenzo[b]thiophene-2-carboxamido)-N-(4-
(pyrrolidin1-yl) butyl) benzofuran-2-carboxamide (4.38). 
 
 
Initially, 153 mg of 5-nitrobenzo[b]thiophene-2-carboxylic acid (0.685 mmol, 1.2 
eq.) was dissolved in 10mL of DMF in a round bottom flask fitted with a 
magnetic stirrer. Then DIC (184 µl, 1.19 mmol, 1.75 eq.) and HOBt (184 mg, 
1.37 mmol, 2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
277 
 
allowed to stir at room temperature for 30 minutes to form ester from the acid. 
Then amine 4.33(172 mg, 0.571 mmol, 1 eq.) was added and the mixture was 
allowed to stir for 7 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Finally the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). A 
yellow coloured solid was obtained after drying in vacuum. Yield=145mg, 50%. 







δH in ppm   
10.85(s,1H),8.95(s,1H),8.75(t,J=5.6,1H),8.55(s,1H),8.35(d,J=8.8,1
H), 8.28(dd,J=8.8,2.4, 1H), 7.76(dd,J=8.8, 2.0,1H), 8.23 
(d,J=2,1H), 7.66(d,J=8,1H), 7.55(s, 1H), 3.31-3.26(m, 4H), 
2.73(s,2H), 2.51-2.49(m,2H), 1.69-1.66(m,4H), 1.61-1.54(m,2H), 
1.53-1.46(m,2H). 
EIMS Found 507.10 [M+H]+, Calculated for C26H26N4O5S,506.58 [M]
+ 
 
4.39 Synthesis of 5-(5-aminobenzo[b]thiophene-2-carboxamido)-N-(4-
(pyrrolidin-1-yl) butyl) benzofuran-2-carboxamide (4.39) 
 
 
145 mg of 4.38 was dissolved in 20 mL of ethanol and1 mL of ethyl acetate was 
added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) 20 was added into the reaction vessel, and mixed that well. 
The reaction bottle was sealed and connected to a hydrogen reservoir. Air of 
the reaction bottle was removed by applying vacuum and it was flushed with 
hydrogen. Typically, approximately 40 psi of a hydrogen pressure was applied 
from the reservoir and the bottle was then shaken vigorously to initiate the 
reaction. Progress of the reaction was monitored by TLC and LCMS and the 
shaker was stopped after 5 hours at which point TLC and LCMS analysis 
showed the completion of reaction. The bottle was vented and the product was 
recovered by process of filtration using Celite. Finally the product was 
concentrated by using a rotary evaporator. A yellow solid was obtained after 
drying in vacuum. Yield was 96mg, 71%. 
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δH in ppm  
10.67(s,1H),8.80(t,J=5.6,1H),8.24(d,J=2,1H),8.16(s,1H),7.78(dd,J
=8.8,2.0,1H), 7.65-7.626(m,2H), 7.54(s,1H), 7.06(d,J=2,1H), 
6.86(dd,J=8.8, 2.0,1H), 3.31-3.26(m, 4H), 2.73(s,2H), 2.51(s,2H), 
1.61-1.54(m,2H), 1.22-1.13(m,4H), 1.05-0.99(m,2H).                                                                                                                                                                                                       
EIMS Found 476.30 [M+H]+, Calculated for C26H28N4O3S, 476.18 [M]
+ 
 





30 mg of benzo[b]thiophene-2-carboxylic acid (0.151 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (41 µl, 0.264 mmol, 1.75 eq.) and HOBt (41 mg, 0.302 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was stirred at room 
temperature for 30 minutes to ensure the formation of ester from the acid. Then 
amine 4.39 (60 mg, 0.126 mmol, 1 eq.) was added and the mixture had been 
stirred for 6 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Finally the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). A pale 





Figure 4.3: 1H and 13C NMR spectroscopic data of compound 4.40 as a 
















δH in ppm   
10.72(s,1H), 10.62(s,1H), 8.77(s,1H), 8.50 (d,J=1.6,1H), 
8.42(s,1H), 8.24(d,J=2,1H), 7.37 ( s,1H), 8.08-8.05(m,2H), 
7.95(s,1H), 7.84(dd,J=8.8,2.0,1H), 7.75(dd,J=8.8,2.0,1H), 7.66 
(d,J=8.8,1H), 7.56(s,1H), 7.52-7.48 (m, 2H), 3.34-3.28(m,4H), 
2.89(s,2H), 2.55(s,2H), 2.50 (s,2H), 1.71(s,4H), 1.58-1.53(m,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
160.4, 160.2, 157.9, 150.9, 150.0, 140.9, 140.4, 139.8, 139.4, 
139.1, 136.1, 135.9, 134.4, 127.3, 125.9, 125.7, 125.4, 125.0, 
123.0, 122.8, 120.5, 115.8, 113.8, 111.7, 109.4, 54.9, 53.4, 48.5, 
40.0, 39.6, 39.0, 35.7, 26.9, 25.2, 22.9. 









3299, 2939, 1635, 1590, 1574, 1528, 1469, 1446, 1432, 1343, 
1298, 1275, 1236, 1198, 1153, 1035, 878, 845, 805, 753, 738, 
715. 
 
4.41 Synthesis of 1-methyl-N-(2-((2-((4-(pyrrolidin-1-yl) butyl) carbamoyl) 
benzofuran-5-yl) carbamoyl) benzofuran-5-yl)-1H-indole-2-carboxamide 
(4.41) 
 
26.52 mg of 1-methyl-1H-indole-2-carboxylic acid (1.2 eq.) was dissolved in 10 
mL of DMF in a round bottom flask fitted with a magnetic stirrer. Then DIC (40 
µl, 0.262 mmol, 1.75 eq.) and HOBt (40 mg, 0.30 mmol, 2.0 eq.) were added to 
the acid (1.0 eq.) and this mixture was stirred at room temperature for 30 
minutes to ensure the formation of ester. Then amine 4.35 (50 mg, 0.108 mmol, 
1 eq.) was added and that mixture was allowed to stir for 8 hours at which point 
TLC and LCMS analysis showed the completion of reaction. Finally the reaction 
mixture was applied to a conditioned IsoluteTM SCX-2 cartridge and the product 
was purified by ‘Catch and Release’ method (described in the section ‘Method 
and Materials’ of chapter 3). A deep yellow solid was obtained after drying in 















δH in ppm  
10.69(s,1H), 10.50(s,1H), 8.81(t,J=5.6,1H), 8.38(s,1H), 8.30(s,1H), 
7.81(d,J=9.2,3H),7.75(t,2H),7.67(d,J=8.8,1H),7.60(t,2H),7.36(d,J=6
,1H), 7.33(d,J=7.6,1H), 7.17(t,1H), 4.05 (s,2H), 3.29(d,J=6,2H), 
2.50(s,4H), 2.48(s,2H), 1.68(s,4H), 1.52(d,J=6.8,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
179.4, 162.3, 160.5, 157.9, 156.6, 151.0, 150.9, 150.0, 149.3, 
138.6, 135.1, 134.2, 132.0, 127.2, 127.2, 125.4, 123.9, 121.7, 
120.9, 120.7, 120.2, 114.0, 113.5, 111.9, 111.7, 110.9, 110.5, 
109.4, 105.5, 55.1, 53.4, 40.0, 39.2, 31.4, 30.6, 29.4.  
EIMS Found 617.60 [M+H] +, Calculated for C36H35N5O5, 617.26 [M]
+ 





2937, 2785, 1709, 1644, 1584, 1530, 1469, 1437, 1390, 1349, 
1316, 1286, 1233, 1198, 1145, 1125, 1025, 1006, 944, 916, 878, 
862, 803, 782, 748, 732, 637. 
 
 
4.42 Synthesis of 3-methyl-N-(2-((2-((4-(pyrrolidin-1-yl) butyl) carbamoyl) 
benzofuran-5-yl) carbamoyl) benzofuran-5-yl) benzofuran-2-carboxamide 
(4.42) 
 
Initially, 24 mg of 3-methylbenzofuran-2-carboxylic acid (0.130 mmol, 1.2 eq.) 
was dissolved in 5 mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then DIC (35 µl, 0.2275 mmol, 1.75 eq.) and HOBt (35 mg, 0.260 mmol, 
2.0 eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 


















δH in ppm   
10.69(s,1H), 10.59(s,1H), 7.95(s,1H), 7.88(t, 2H), 7.82(s,2H), 
7.80(s,1H), 7.72(t, J=9.2,2H), 7.68(t,J=9.2,2H), 7.54(t,J=7.6, 
2H), 7.41(t,J=7.8,1H), 2.89(s,2H), 2.73(s,2H), 1.73(s,4H), 
1.56(s,4H), 1.24(s,2H), 1.19(s,2H). 
13C NMR (100MHz,(CD3)2SO); δC in ppm  
162.2, 158.0, 157.9, 156.6, 152.7, 151.2, 150.9, 150.0, 149.3, 
142.7, 134.4, 134.2, 130.6, 129.2, 127.4, 127.2, 127.1, 122.3, 
121.2, 121.1, 120.6, 115.1, 114.1, 113.9, 111.8, 111.7, 110.9, 
109.4, 54.8, 53.3, 40.0, 39.2, 35.7, 30.7, 26.8, 22.9. 
EIMS Found 619.20 [M+H]+, Calculated for C36H34N4O6, 618.24 [M]
+ 





3305, 2948, 1639, 1582, 1533, 1470, 1433, 1345, 1296, 1233, 
1198, 1129, 1085, 1041, 942, 874, 801, 738, 717. 
 
Then amine 4.35(50 mg, 0.108 mmol, 1 eq.) was added and the mixture was 
allowed to stir for 9 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Finally the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). A deep 
yellow solid was obtained after drying in vacuum. Yield=12 mg, 18%. 
 
4.43 Synthesis of 5-chloro-N-(2-((2-((4-(pyrrolidin-1yl) butyl) carbamoyl) 




At first, the 5-chlorobenzofuran-2-carboxylic acid (36 mg, 0.1826 mmol, 1.2 eq.) 
was dissolved in 5 mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then DIC (49.4 µl, 0.319 mmol, 1.75 eq.) and HOBt (49.30 mg, 0.3652 
mmol, 2.0 eq.) were added to the acid (1.0 eq.) and this mixture was allowed to 
stir at room temperature for 30 minutes to ensure the formation of ester from the 
acid. Then amine 4.35(60 mg, 0.13043 mmol, 1 eq.) was added and the mixture 
was allowed to stir for 12 hours at which point TLC and LCMS analysis showed 
the completion of reaction.  
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13C NMR (100MHz,(CD3)2SO); δC in ppm  
157.9, 156.6, 156.3, 152.9, 151.3, 150.9, 150.1, 150.0, 149.4, 
134.28, 134.20, 128.7, 128.1, 127.2, 127.1, 122.2, 121.1, 
120.6, 118.9, 114.1, 113.9, 113.6, 112.0, 111.7, 110.9, 110.1, 
109.4, 55.2, 53.5, 40.0, 39.4, 38.8, 27.1, 25.8, 23.0.  
EIMS Found 638.20 [M+H] +, Calculated for C35H31ClN4O6, 638.19 
[M]+ 





3336, 1656, 1582, 1542, 1476, 1435, 1357, 1296, 1231, 
1197, 1170, 1144, 1087, 1064, 941, 890, 871, 801, 750, 739, 
695, 629, 598. 
 
Finally the reaction mixture was applied to a conditioned IsoluteTM SCX-2 
cartridge and the product was purified by ‘Catch and Release’ method 
(described in the section ‘Method and Materials’ of chapter 3). A deep yellow 
solid was obtained after drying in vacuum. Yield=26 mg, 31%. 





Initially, 29.58 mg of 1H-benzo[d]imidazole-5-carboxylic acid (0.182 mmol, 1.2 
eq.) was dissolved in 10mL of DMF in a round bottom flask fitted with a 
magnetic stirrer. Then DIC (49.24 µl, 0.3185 mmol, 1.75 eq.) and HOBt (49.14 
mg, 0.364 mmol, 2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for 30 minutes to ensure the ester formation. 
Then amine 4.35 (60 mg, 0.13043 mmol, 1 eq.) was added and the mixture was 
allowed to stir for 7 hours at which point TLC and LCMS analysis showed the 
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completion of reaction. Finally the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). A deep 
yellow solid was obtained after drying in vacuum. Yield=27mg, 34%. 








δH in ppm  
10.43(s,1H),8.81(S,1H),8.38(s,2H),8.35(s,1H),8.31(s,1H),7.95(s,1H),
7.90(d,J=12,1H),7.81(s,2H),7.77(s,1H),7.72(t,J=5.6,2H),7.66(d,J=8.8
,1H), 7.56(s,1H), 7.05(d,J=8,1H), 6.79(d,J=7.8,1H), 3.29(s,2H), 
2.88(s,2H), 2.39(s,4H), 2.38(s,2H), 1.61(s,4H), 1.55(s,2H).  
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
166.0, 157.9, 156.6, 150.9, 150.0, 149.3, 144.2, 135.6, 134.2, 129.1, 
128.3, 127.2, 127.1, 121.7, 121.1, 120.6, 113.9, 113.6, 113.5, 111.7, 
110.9, 109.3, 55.3, 53.5, 41.6, 39.0, 38.6, 38.0, 36.8, 35.7, 27.1, 
25.9, 23.3, 23.0.  
EIMS Found 605.20 [M+H]+, Calculated for C34H32N6O5, 604.24 [M]
+ 





3305, 1638, 1586, 1523, 1473, 1433, 1338, 1292, 1238, 1199, 1144, 
940, 871, 802, 738. 
 





Initially, 23 mg of 1-methyl-1H-indole-2-carboxylic acid (0.126 mmol, 1.2 eq.) 
was dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then DIC (34 µl, 0.2205 mmol, 1.75 eq.) and HOBt (34 mg, 0.252 mmol, 
2.0 eq.) were added to the acid (1.0 eq.) and this mixture was stirred at room 
temperature for at least 30 minutes to ensure the formation of ester from the 
acid. Then amine 4.39 (50 mg, 0.105 mmol,1 eq.) was added and the mixture 
was allowed to stir for 5 hours at which point TLC and LCMS analysis showed 
the completion of reaction. Finally the reaction mixture was applied to a 
conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 
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chapter 3). A pale yellow solid was obtained after drying in vacuum. Yield=8 
mg, 12%. 







δH in ppm   
10.64(s,1H), 10.53(s,1H), 8.78(t,J=5.6,1H) 8.52(d,J=1.6,1H), 8.38 
(s,1H),8.25(d,J=1.6,1H), 8.04(d,J=8.8,1H), 7.87(dd,J=8.8,2.0,1H), 
7.78(dd,J=9.2,2.4,1H),7.72(d,J=7.6,1H),7.67(d,J=8.8,1H),7.58(t,J
=8.4,2H),7.38(s,1H),7.32(t,J=7.2,1H),7.16(t,J=7.2,1H),3.31(t,J=5.




(100MHz,(CD3)2SO); δC in ppm  
162.5, 160.6, 160.3, 159.8, 153.8, 151.7, 151.0, 150.0, 141.2, 
139.4, 138.7, 136.9,136.4, 135.9,134.8, 131.8, 127.3, 124.2, 
122.8, 120.7, 115.6, 113.8, 110.9, 109.5, 107.2, 106.0, 53.3, 40.0, 
39.8,39.4, 39.2, 39.0, 31.4, 30.7, 26.7, 22.8. 









3287, 2947, 1638, 1591, 1574, 1530, 1468, 1447, 1432, 1392, 
1340, 1292, 1233, 1201, 1154, 1038, 878, 810, 739, 716. 




248 mg of 5-nitro-1H-indole-3-carboxylic acid (1.2096 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (325 µl, 2.114 mmol, 1.75 eq.) and HOBt (325 mg, 2.4192 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then amine 4.8 of 280 mg (1.008 mmol, 1 eq.) was added to the mixture and 
the mixture was allowed to stir for 14 hours at which point TLC and LCMS 
analysis showed the completion of reaction. Finally the reaction mixture was 
separated by conditioned IsoluteTM SCX-2 cartridge and the product was 
purified by ‘Catch and Release’ method (described in the section ‘Method and 















J=6.8,2H), 2.18(s,6H), 1.70(t,J=7.2,2H).  
EIMS Found 465.90 [M+H]+, Calculated for C23H23N5O4S, 465.14 [M]
+ 
 




245 mg of 4.46 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate 
was added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) 20 was added into the reaction vessel, and mixed it well. The 
reaction bottle was sealed and connected to a hydrogen reservoir. Air from the 
reaction bottle was removed by applying vacuum, and was then by flushed with 
hydrogen. Typically, a hydrogen pressure of approximately 40 psi was applied 
from the reservoir, and the bottle was then shaken vigorously to initiate the 
reaction. Progress of the reaction was monitored by TLC and LCMS. The 
reaction required about 6 hours at which point TLC and LCMS analysis showed 
the completion of reaction. The shaker was stopped, the bottle was vented, and 
the product was recovered by the process of filtration using Celite. Finally, the 
product is concentrated by using a rotary evaporator. A deep brown solid was 
obtained after drying in vacuum. Yield was 196 mg, 86%. 








δH in ppm 
11.43(s,1H), 9.78(s,1H), 8.84(t,J=5.2,1H), 8.52 (s,1H), 8.22(s,1H), 
8.07(s,1H),7.96(s,1H),7.83(d,J=8.8,1H), 7.53(s, 1H), 7.21(d,J=8.4, 
1H),6.64(d,J=8.8,1H),3.38-3.33(m,2H),2.29(t,J=7.2,2H), 
2.14(s,6H), 1.75-1.64(m,J=2H). 





4.48 Synthesis of 5-(benzofuran-2-carboxamido)-N-(2-((3-(dimethylamino) 




43 mg of benzofuran-2-carboxylic acid (0.262 mmol, 1.2 eq.) was dissolved in 
10 mL of DMF in a round bottom flask placed at a magnetic stirrer. Then DIC 
(71 µl, 0.4585 mmol, 1.75 eq.) and HOBt (71 mg, 0.534 mmol, 2.0 eq.) were 
added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
temperature for 30 minutes to ensure the formation of ester from the acid. Then 
amine 4.47 (95 mg, 0.218 mmol, 1 eq.) was added to the mixture and the 
mixture was allowed to stir for 6 hours at which point TLC and LCMS analysis 
showed the completion of reaction. At last the reaction mixture was applied to a 
conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 
chapter 3). A cream solid was obtained after drying in vacuum. Yield=36.5 mg, 
29 %. 







δH in ppm  
11.85(d,J=2.4,1H), 10.51(s,1H), 9.93(s,1H), 8.87(t,J=5.2,1H), 
8.66(d,J=2,1H), 8.49(d,J=1.6,1H), 8.36(d,J=2.8,1H), 8.31 (s,1H), 
8.04(s,1H),8.97(s,1H),7.85-7.78(m,2H),7.74(d,J=8.4,1H),7.67(dd, 
J=8.8,2.0,1H),7.53-7.48(m,2H),7.37(t,J=7.2,1H),3.35-3.30(m,2H), 
2.59(t,J=7.2,2H), 2.38(s,6H), 1.78(t,J=7.2,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
164.5, 163.3, 162.2, 161.5, 156.4, 154.3, 149.2, 140.6, 139.5, 
137.2, 134.3, 133.4, 131.8, 129.4, 127.2, 126.8, 126.3, 123.7, 
122.7, 122.6, 119.8, 117.1, 113.5, 111.8, 111.7, 110.4, 109.9, 
55.7, 43.8, 39.4, 35.7, 30.7. 









3259, 2937, 2219, 1705, 1631, 1532, 1474, 1436, 1386, 1361, 
1330, 1308, 1247, 1221, 1160, 1097, 1038, 945, 885, 865, 807, 
769,740, 715, 659, 618. 
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4.49 Synthesis 5-(benzo[b]thiophene-2-carboxamido)-N-(2-((3-(dimethyl 




Initially, 44 mg of benzo[b]thiophene-2-carboxylic acid (0.248 mmol, 1.2 eq.) 
was dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then DIC (67 µl, 0.434 mmol, 1.75 eq.) and HOBt (67 mg, 0.496 mmol, 
2.0 eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then amine 4.47 (90 mg, 0.206 mmol, 1 eq.) was added to the mixture and the 
mixture was allowed to stir for 7 hours at which point TLC and LCMS analysis 
showed the completion of reaction. Finally the reaction mixture was applied to a 
conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 
chapter 3). A cream solid was obtained after drying in vacuum. Yield=38mg, 
31%. 







δH in ppm   
11.82(s,1H),10.56(s,1H),9.92(s,1H),8.80(t,J=5.2,1H),8.62(d,J=1.6,
1H), 8.48(d,J=1.6,1H), 8.43 (s,1H), 8.37(s,1H), 8.07(t,J=6.4,1H), 
8.02-7.98(m,2H),7.95(t,J=2.8,2H),7.81(dd,J=8.8,2.0,1H), 
7.69(dd,J=8.8, 2.0,1H), 7.51-7.46(m,2H), 3.33-3.28(m,2H), 
2.29(t,J=6.8,2H), 2.15(s,6H), 1.72-1.65(m,2H).  
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
163.2, 162.2, 161.3, 159.9, 140.8, 140.6, 140.3, 139.5, 139.2, 
137.2, 134.3, 133.3, 132.1, 126.4, 126.2, 125.2, 124.9, 124.4, 
122.7, 122.6, 119.8, 116.9, 114.7, 113.3, 111.7, 110.4, 56.8,45.1, 
40.0, 39.2, 30.7, 27.0. 









3258, 2938, 2218, 1634, 1576, 1523, 1475, 1443, 1385, 1361, 
1341, 1307, 1273, 1246, 1223, 1192, 1159, 1096, 1038, 951, 889, 




4.50 Synthesis of N-(2-((3-(dimethylamino) propyl) carbamoyl) 
benzofuran-5-yl)-5-nitro-1H-indole-3-carboxamide (4.50).        
 
 
At the beginning 189.42 mg of 5-nitro-1H-indole-3-carboxylic acid (0.919 mmol, 
1.2 eq.) was dissolved in 10mL of DMF in a round bottom flask fitted with a 
magnetic stirrer. Then DIC (248 µl, 1.60 mmol, 1.75 eq.) and HOBt (248 mg, 
1.838 mmol, 2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for 30 minutes to ensure the formation of 
ester from the acid. Then amine 4.2 (200 mg, 0.766 mmol, 1 eq.) was added to 
the mixture and that mixture was allowed to stir for 11 at which point TLC and 
LCMS analysis showed the completion of reaction. Finally the reaction mixture 
was applied to a conditioned IsoluteTM SCX-2 cartridge and the product was 
purified by ‘Catch and Release’ method (described in the section ‘Method and 
Materials’ of chapter 3). A brown solid was obtained after drying in vacuum. 
Yield=162mg, 47%. 







δH in ppm  
12.35(s,1H),10.11(s,1H),9.17(d,J=2,1H),8.82(t,J=5.6,1H),8.58(s,1
H), 8.32(d,J=2,1H), 8.11(dd,J=8.8,2.4,1H), 7.74(dd,J=8.8,2.0,1H), 
7.70 (d,J=5.2,1H), 7.65(d,J=8.8,1H), 7.55(s,1H), 3.34-3.29(m,2H), 
2.28 (t,J=7.2,2H), 2.14 (s,6H), 1.70-1.65(m,2H). 






4.51 Synthesis of 5-amino-N-(2-((3-(dimethylamino) propyl) carbamoyl) 
benzofuran-5-yl)-1H-indole-3-carboxamide (4.51).        
 
 
160 mg of 4.50 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate 
was added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) 20 was added into the reaction vessel, and mixed it well. The 
reaction bottle was sealed and connected to a hydrogen reservoir. Air from the 
reaction bottle was removed by applying vacuum, and was then by flushed with 
hydrogen. Typically, a hydrogen pressure of approximately 40 psi was applied 
from the reservoir, and the bottle was then shaken vigorously to initiate the 
reaction. Progress of the reaction was monitored by TLC and LCMS. Reaction 
required about 5 at which point TLC and LCMS analysis showed the completion 
of reaction. The shaker was stopped, the bottle was vented, and the product 
was recovered by means of filtration using Celite. Finally, the product is 
concentrated by using a rotary evaporator. A pale yellow solid was obtained 
after drying in vacuum. Yield=142 mg, 95%. 







δH in ppm   
11.39(s,1H), 9.72(s,1H), 8.85(t,J=5.6,1H), 8.27(d,J=2,1H), 
8.13(s,1H), 7.75(d,J=3.6,1H), 7.73(d,J=2,1H), 7.53(s,1H), 7.45 
(d,J=2,1H), 7.19(d,J=4.4,1H), 6.62-6.60 (m, 1H), 3.65(s,1H), 3.35-
3.30(m,2H), 2.28 (t,J=6.8,2H), 2.14 (s,6H), 1.69(t,J=6.8,2H). 




4.52 Synthesis 5-(benzofuran-2-carboxamido)-N-(2-((3-(dimethylamino) 
propyl) carbamoyl) benzofuran-5-yl)-1H-indole-3-carboxamide (4.52).        
 
Initially, 43.30 mg of benzofuran-2-carboxylic acid (0.267 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (72 µl, 0.467 mmol, 1.75 eq.) and HOBt (72.09 mg, 0.534 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was stirred at room 
temperature for at least 25 minutes to ensure the esterification. Then amine 
4.51(80 mg, 0.190 mmol, 1 eq.) was added and the mixture was allowed to stir 
for 6 hours at which point TLC and LCMS analysis showed the completion of 
reaction. Finally the reaction mixture was applied to a conditioned IsoluteTM 
SCX-2 cartridge and the product was purified by ‘Catch and Release’ method 
(described in the section ‘Method and Materials’ of chapter 3). A cream solid 
was obtained after drying in vacuum. Yield=37 mg, 35%. 
 







δH in ppm  
11.93(s,1H),10.52(s,1H),9.94(d,J=8.8,1H),8.85(s,1H),8.68(dd,J=
6.0,1.6,1H), 8.36(s,1H), 8.32(d,J=2,1H), 7.83(t,J=8,2H), 7.78-
7.74(m,1H), 7.72(s,1H), 7.66-7.61(m,2H), 7.53 (d,J=9.6,1H), 
7.52-7.47(m,2H), 7.37 (t, J=7.6,1H), 3.87-3.80(m,2H), 3.39-3.32 
(m,2H), 2.52 (s,6H), 1.76(t,J=7.2,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
164.7, 163.3,158.5, 157.0, 156.6, 154.3, 150.4, 149.2, 149.0, 
135.7, 133.4, 131.5, 127.1, 126.9, 126.3, 123.7, 122.7, 120.4, 
113.0, 111.9, 111.5, 110.4, 110.0, 63.5, 52.2, 42.5, 39.5, 39.1, 
38.9, 35.8, 23.1, 22,7.  
EIMS Found 563.21 [M+H]+, Calculated for C32H29N5O5, 562.30 [M]
+ 
HRMS m/z(+EI) Calc.for C32H29N5O5, 563.2169 [M]




3284, 2972, 1738, 1616, 1547, 1469, 1442, 1417, 1381, 1325, 









29 mg of 1-methyl-1H-indole-2-carboxylic acid (0.165 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (45 µl, 0.2887 mmol, 1.75 eq.) and HOBt (45 mg, 0.330 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then amine 4.47 (60 mg, 0.1379 mmol, 1 eq.) was added and the mixture was 
allowed to stir for 6 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Finally the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). An 
orange solid was obtained after drying in vacuum. Yield=35mg, 43%. 







δH in ppm  
11.84(s,1H), 10.30(s,1H), 9.92(s,1H), 8.81(s,1H), 8.67(s,1H), 8.46 
(s,1H), 8.36(d,J=16,1H), 8.00(s,1H), 7.93(s,1H), 7.78(d,J=7.6,1H), 
7.68(d,J=8,1H), 7.61-7.55(m,2H), 7.45(d,J=8.8,1H), 7.34 (s,1H), 
7.30(t,J=7.6,1H), 7.12 (t,J=7.6,1H), 4.04(s,3H), 3.29(d,J=6.0,2H), 
2.31 (t,J=6.8,2H), 2.17 (s,6H), 1.68(t,J=6.82H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
163.3, 162.2, 161.5, 160.2, 156.7, 140.7, 139.6, 138.5, 137.2, 
134.3, 133.1, 132.4, 126.4, 125.5, 124.4, 123.6, 122.8, 121.6, 
120.1, 119.6, 117.1, 114.7, 113.1, 111.7, 110.5, 110.3, 105.0, 
56.6, 44.9, 38.8, 35.7, 31.4, 30.7. 




m/z (+EI) Calc. for C33H32N6O3S 592.2257 [M]




3257, 2932, 1647, 1575, 1548, 1521, 1476, 1435, 1386, 1359, 
1338, 1308, 1246, 1224, 1169, 1149, 1096, 1037, 945, 915, 874, 
806, 747, 717, 660. 
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4.54 Synthesis N-(3-((2-((3-(dimethylamino) propyl) carbamoyl) 
benzo[b]thiophen-5-yl) carbamoyl)-1H-indol-5-yl)-1H-benzo[d]imidazole-2-
carboxamide (4.54). 
Initially, 30 mg of 1H-benzo[d]imidazole-2-carboxylic acid hydrate (0.165 mmol, 
1.2 eq.) was dissolved in 10mL of DMF in a round bottom flask fitted with a 
magnetic stirrer.  
 
 
Figure 4.4: 1H and 13C NMR spectroscopic data of compound 4.54 as a 
representative of library-2 compounds 
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Then DIC (45 µl, 0.228 mmol, 1.75 eq.) and HOBt (45 mg, 0.330 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
temperature for 30 minutes to ensure the esterification of the acid. Then amine 
4.47 (60 mg, 0.137 mmol, 1 eq.) was added and the mixture was allowed to stir 
for 6 hours at which point TLC and LCMS analysis showed the completion of 
reaction. Finally the reaction mixture was applied to a conditioned IsoluteTM 
SCX-2 cartridge and the product was purified by ‘Catch and Release’ method 
(described in the section ‘Method and Materials’ of chapter 3). A deep brown 
solid was obtained after drying in vacuum. Yield was 30 mg, 38%. 








δH in ppm   
13.37(s,1H), 11.82(d,J=2.4,1H), 10.77(s,1H), 9.92(s,1H), 8.83-
8.80(m,2H), 8.48(d,J=2,1H), 8.35(d,J=7.2,1H), 8.03(s,1H), 
7.97(s,1H),7.79(dd,J=8.8,2.0,2H),7.65(dd,J=8.8,2.0,2H),7.49(d,J=
8.8,1H), 7.35-7.33(m,2H), 3.34-3.29(m,2H), 2.34 (t,J=7.2,2H), 
2.20 (s,4H), 1.71(t,J=7.2,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
163.2, 162.2, 161.3, 156.9, 146.0, 140.8, 139.5, 137.2, 134.3, 
133.4, 131.6, 129.4,126.2, 124.4, 122.6, 119.8, 117.2, 114.7, 
113.5, 111.8, 110.5, 56.6, 44.9, 40.0, 39.6, 39.4, 38.8, 37.7, 35.7, 
30.7, 26.8.  









3231, 2929, 1738, 1648, 1555, 1522, 1468, 1431, 1385, 1366, 




4.55 Synthesis of 5-(benzo[b]thiophene-2-carboxamido)-N-(2-((3-
(dimethylamino) propyl) carbamoyl) benzofuran-5-yl)-1H-indole-3-
carboxamide (4.55). 
 
Initially, 27 mg of benzo[b]thiophene-2-carboxylic acid (0.148 mmol, 1.2 eq.) 
was dissolved in 5 mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then DIC (40 µl, 0.259 mmol, 1.75 eq.) and HOBt (40 mg, 0.296 mmol, 
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2.0 eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then amine 4.51(52 mg, 0.124 mmol, 1 eq.) was added and the mixture was 
allowed to stir for 5 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Finally the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). A light 
yellow solid was obtained after drying in vacuum. Yield=14 mg, 20%. 








δH in ppm   
11.76(s,1H), 10.53(s,1H), 9.86(s,1H), 8.79(s,1H), 8.59(s,1H), 
8.40(s,1H),8.30(d,J=9.6,2H),8.04(dd,J=6.8,2.0,1H),7.98(t,J=6.8,1
H),7.72(d,J=2.0,1H),7.63-7.60(m,2H),7.51(s,1H),7.47(t,J=3.6,3H), 
3.37(s,2H). 2.25 (t,J=6.8,2H), 2.13 (s,6H), 1.65(t,J=6.8,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
163.1, 157.9, 150.3, 149.7, 140.6, 140.3, 139.2, 135.8, 133.3, 
132.1, 127.2, 126.4, 126.2, 125.2, 124.9, 122.8, 120.0, 113.2, 
112.7, 111.5, 110.4, 109.4, 56.8, 45.1, 40.0, 39.8, 39.6, 39.4, 
39.0, 38.8, 37.3, 26.9.  









3275, 2971, 2344, 2298, 1738, 1649, 1628, 1604, 1534, 1468, 
1437, 1366, 1343, 1310, 1270, 1237, 1207, 1178, 1148, 1081, 
1041, 938, 879, 792, 743, 722, 682, 662. 
 
 
4.56 Synthesis of N-(3-((2-((3-(dimethylamino) propyl) carbamoyl) 
benzofuran-5-yl) carbamoyl)-1H-indol-5-yl)-1H-benzo[d]imidazole-2-
carboxamide (4.56)       
 
Initially, 30 mg of 1H-benzo[d]imidazole-2-carboxylic acid hydrate (0.186 mmol, 
1.2 eq.) was dissolved in 10mL of DMF in a round bottom flask fitted with a 
magnetic stirrer. Then DIC (50 µl, 0.3255 mmol, 1.75 eq.) and HOBt (50 mg, 
0.372 mmol, 2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
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allowed to stir at room temperature for 30 minutes to ensure the formation of 
ester from the acid. Then amine 4.51(65 mg, 0.155 mmol, 1 eq.) was added and 
the mixture was allowed to stir for 5 hours at which point TLC and LCMS 
analysis showed the completion of reaction. At last the reaction mixture was 
taken to a conditioned IsoluteTM SCX-2 cartridge for purification and the product 
was purified by ‘Catch and Release’ method (described in the section ‘Method 
and Materials’ of chapter 3). A yellow solid was obtained after drying in 
vacuum. Yield=51 mg, 58%. 







δH in ppm  
13.45(s,1H), 11.82(s,1H), 10.74(s,1H), 9.87(s,1H), 8.82(s,2H), 
8.33(s,2H), 7.73(t,J=9.3,2H), 7.63-7.58(m,2H), 7.54(d,J=4.0,1H), 
7.48(dd,J=8.4,3.6,1H),7.33(s,2H),7.19-7.14(m,1H), 
3.30(d,J=5.6,2H), 2.33(d,J=6.4,2H), 2.19(s,6H), 1.69(t,J=6.4,2H).  
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
163.2, 162.3, 158.0, 157.0, 150.3, 149.7, 146.0, 141.9, 135.8, 
133.4, 131.6, 129.3, 127.2, 126.3, 123.4, 120.1, 119.6, 117.1, 
113.5, 112.8, 111.8, 111.5, 110.6, 109.4, 56.7, 44.9, 40.1, 39.4, 
38.8, 37.2, 26.7.  




m/z (+EI) Calc. for C31H29N7O4, 563.2281 [M]




3215, 2971, 1738, 1624, 1592, 1531, 1470, 1434, 1330, 1210, 
1159, 1079, 945, 867, 766, 736. 
 




40 mg of 1-methyl-1H-indole-2-carboxylic acid (0.229 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (62 µl, 0.400 mmol, 1.75 eq.) and HOBt (62 mg, 0.458 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
temperature for 30 minutes to ensure the formation of ester from the acid. Then 
amine 4.51 (80 mg, 0.190 mmol, 1 eq.) was added and the mixture was allowed 
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to stir for 7 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Finally the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). An 
orange solid was obtained after drying in vacuum. Yield=82 mg, 75%. 







δH in ppm   
11.80(s,1H),10.31(s,1H),9.88(s,1H),8.81(d,J=3.2,1H),8.72(d,J=2.0
,1H),8.34(s,2H),7.77-7.74(m,1H),7.69(dd,J=8.0,2.8,1H), 
7.62(d,J=8.8,2H), 7.55(t,J=6.0,2H), 7.48(dd,J=8.4,3.2,1H), 7.37 
(d,J=2.8,1H), 7.31-7.29(m,1H), 7.17-7.11(m,1H), 3.50(s,3H), 
3.30(t,J=6.0,2H), 2.28-2.24 (m,2H), 2.14(s,6H), 1.69-1.65(m,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
163.2, 162.3, 160.2, 158.0, 150.3, 149.8, 138.5, 135.8, 133.2, 
132.5, 129.1, 127.3, 126.4, 125.6, 123.6, 121.6, 120.1, 120.0, 
117.0, 113.2, 112.7, 111.6, 111.5, 110.5, 109.4, 105.1, 56.9, 45.1, 
40.0, 39.2, 37.3, 35.7, 31.4. 




m/z (+EI) Calc. for C33H32N6O4, 576.2485 [M]




3197, 1705, 1626, 1535, 1469, 1435, 1359, 1333, 1215, 1181, 
1148, 1077, 1048, 1024, 1005, 871, 809, 789, 769, 747, 622. 
 
 
4.58 Synthesis of N-(3-(dimethylamino) propyl)-5-(5-nitro-1H-indole-3-
carboxamido)-1H-indole-2-carboxamide (4.58).        
 
 
Initially, 171 mg of 5-nitro-1H-indole-3-carboxylic acid (0.830 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (224 µl, 1.45 mmol, 1.75 eq.) and HOBt (224 mg, 1.66 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
temperature for 30 minutes to ensure the formation of ester from the acid. Then 
amine 4.20 (180 mg, 0.692 mmol, 1 eq.) was added and the mixture was 
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allowed to stir for about 7 hours at which point TLC and LCMS analysis showed 
the completion of reaction. Finally the reaction mixture was applied to a 
conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 
chapter 3). A yellow solid was obtained after drying in vacuum. Yield=122mg, 
40 %. 







δH in ppm  
11.55(s,1H), 9.89(s,1H), 9.18(d,J=2.4,1H), 8.55(d,J=7.8,2H), 
8.15(t,J=4.0,1H),8.09(dd,J=9.2,2.4,1H),7.95(s,1H),7.68(d,J=8.8,1
H), 7.48-7.40 (m,1H), 7.41(d,J=8.8,1H), 7.07(s,1H), 3.34-
3.30(m,2H), 2.29 (t,J=7.2,2H), 2.16(s,6H), 1.69(t,J=6.8,2H).  




4.59 Synthesis of 5-(5-amino-1H-indole-3-carboxamido)-N-(3-(dimethyl 
amino) propyl)-1H-indole-2-carboxamide (4.59)        
 
 
120 mg of 4.58 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate 
was added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) 20 was added into the reaction vessel, and mixed it well. The 
reaction bottle was sealed and connected to a hydrogen reservoir. Air from the 
reaction bottle was removed by applying vacuum, and was then by flushed with 
hydrogen. Typically, a hydrogen pressure of approximately 40 psi was applied 
from the reservoir, and the bottle was then shaken vigorously to initiate the 
reaction. Progress of the reaction was monitored by TLC and LCMS. The 
complete hydrogenation took about 6 hours at which point TLC and LCMS 
analysis showed the completion of reaction. The shaker was stopped, the bottle 
was vented, and the product was recovered by means of filtration using Celite. 
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Finally, the product is concentrated by using a rotary evaporator. A yellow solid 
was obtained after drying in vacuum. Yield=85mg, 77%. 







δH in ppm   
11.53(s,1H),11.32(s,1H), 9.46(s,1H), 8.55(t,J=5.2,1H), 8.11(s,2H), 
7.48(t,J=8.4,2H), 7.39(d,J=8.8,1H), 7.16 (d,J=8.4,1H), 7.07(s,1H), 
6.59-6.57(m,1H), 3.35-3.30(m,2H), 2.28 (t,J=7.2,2H), 2.15(s,6H), 
1.72-1.65(m ,2H). 








Initially, 41.23 mg of 5-nitro-1H-indole-2-carboxylic acid (0.20 mmol, 1.2 eq.) 
was dissolved in 5 mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then DIC (54 µl, 0.35 mmol, 1.75 eq.) and HOBt (54 mg, 0.40 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was stirred at room 
temperature for 30 minutes to ensure the formation of ester from the acid. Then 
amine 4.59(60 mg, 0.143 mmol, 1 eq.) was added and the mixture was allowed 
to stir for 7 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Lastly the reaction mixture was purified by conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). A 














δH in ppm   
12.46(s,1H), 11.72(s,1H), 11.49(s,1H), 10.49(s,1H), 9.65(s,1H), 
8.77 (d,J=1.6,1H), 8.60(s,1H), 8.51(s,1H), 8.31(d,J=2.0,1H), 
8.10(t,J=8.8,2H), 7.75(s,1H), 7.69(t,J=7.2,1H), 7.64(d,J=9.2,1H), 
7.47 (t,J=8.8,2H), 7.38(d,J=8.8,1H), 7.06(s,1H), 3.33(m,2H), 2.30 
(t,J=6.8,2H), 2.15(s,6H), 1.70(t,J=6.8,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
163.0, 162.2, 160.9, 158.5, 141.2, 139.4, 135.5, 133.3, 133.0, 
132.2, 131.9, 126.9, 126.47, 126.42,119.2, 118.2, 113.4, 112.8, 
111.9, 111.6, 110.8, 105.6, 102.0, 56.8, 45.1, 39.6, 39.2, 38.7, 
37.2, 35.7, 30.7, 27.2. 




m/z (+EI) Calc. for C32H30N8O5, 606.2339 [M]




3236, 1631, 1544, 1469, 1418, 1384, 1317, 1259, 1099, 1067, 
806, 768, 743, 663. 
 
4.61 Synthesis of 5-(5-(benzofuran-2-carboxamido)-1H-indole-3-
carboxamido)-N-(3-(dimethylamino) propyl)-1H-indole-2-carboxamide 
(4.61).        
 
Initially, 33 mg of benzofuran-2-carboxylic acid (0.20 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (54 µl, 0.35 mmol, 1.75 eq.) and HOBt (54 mg, 0.40 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
temperature for 30 minutes to ensure the formation of ester from the acid. Then 
amine 4.59(85 mg, 0.143 mmol, 1 eq.) was added and the mixture was allowed 
to stir for 4 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Finally the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). An 











δH in ppm   
11.53(s,1H),10.52(s,1H),9.67(s,1H),8.68(d,J=2.0,1H),8.55(t,J=5.6,
1H),8.34(s,1H),8.16(s,1H),7.96(s,1H),7.83(t,J=8.0,2H),7.74(d,J=8.
4,1H), 7.66(dd,J=8.8,2.0,1H), 7.50 (t,J=7.2,3H), 7.42-7.35(m,2H), 




(100MHz,(CD3)2SO); δC in ppm  
163.0, 162.2, 160.9, 156.8, 156.4, 154.3, 149.2, 133.4, 133.0, 
132.3, 131.6, 128.8, 127.2, 126.9, 126.8, 126.4, 123.7, 122.7, 
118.2, 116.9, 113.6, 111.9, 111.8, 111.6, 110.8, 109.8, 102.1, 
56.8, 45.1, 39.2, 35.7, 27.2. 









3261, 2973, 2255, 1635, 1590, 1540, 1470, 1447, 1355, 1309, 
1258, 1231, 1176, 1047, 1023, 999, 866, 814, 744, 677, 614. 
 
4.62 Synthesis of N-(3-(dimethylamino) propyl)-5-nitro-1H-indole-3-
carboxamide (4.62).        
 
Initially, 300 mg of 5-nitro-1H-indole-3-carboxylic acid (1.45 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (278 µl, 1.80 mmol, 1.75 eq.) and HOBt (278 mg, 2.06 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
temperature for 30 minutes to ensure the formation of ester from the acid. Then 
N1, N1-dimethylpropane-1, 3-diamine (106 mg, 1.04 mmol, 1 eq.) was added 
and the mixture was continued to stir for 9 hours at which point TLC and LCMS 
analysis showed the completion of reaction. Finally the reaction mixture was 
purified through conditioned IsoluteTM SCX-2 cartridge and the product was 
purified by ‘Catch and Release’ method (described in the section ‘Method and 
Materials’ of chapter 3). A pale yellow solid was obtained after drying in 












 δH in ppm   
12.54(s,1H),9.11(d,J=2.4,1H),8.278.25(m,2H),8.06(dd,J=9.2,2.4,1
H), 7.64 (d, J=9.2,1H), 3.34-3.29(m,2H), 2.33 (t,J=7.2,2H), 2.19 
(s,6H), 1.70(t,J=6.8,2H). 
EIMS Found 290.10 [M+H] +, Calculated for C14H18N4O3, 290.13 [M]
+ 
4.63 Synthesis of 5-amino-N-(3-(dimethyl amino) propyl)-1H-indole-3-
carboxamide (4.63).        
 
 
205 mg of 4.62 was dissolved in 20 mL of ethanol and added to a 
hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on activated carbon) 
was added into the reaction vessel, and mixed well. The reaction bottle was 
sealed and connected to a hydrogen reservoir. Air within the bottle was 
removed by applying vacuum, and it ws flushed with hydrogen. A hydrogen 
pressure of approximately 40 psi was applied from the reservoir and the bottle 
was then shaken vigorously to initiate the reaction. Progress of the reaction was 
monitored by TLC and LCMS. The shaker was stopped upon the completion of 
the reaction after 5 hours at which point TLC and LCMS analysis showed the 
completion of reaction. The bottle was vented and the product was recovered 
by means of filtration using Celite. Finally, the product is concentrated by using 
a rotary evaporator. A deep brown solid was obtained after drying in vacuum. 
Yield=180 mg, 97%. 








 δH in ppm  
11.24(d,J=2,1H),7.83-7.79(m,2H),7.38(d,J=2,1H), 
7.11(d,J=8.8,1H), 6.56-6.54 (m,1H), 4.56(s,2H), 3.29-
3.24(m,2H), 2.31 (t,J=7.2,2H), 2.17 (s,6H), 1.66(t,J=7.2,2H).  





4.64 Synthesis of 5-amino-N-(3-(dimethylamino) propyl)-1H-indole-3-
carboxamide (4.64).        
 
Initially, 95 mg of 5-nitro-1H-indole-2-carboxylic acid (0.461 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (124 µl, 0.806 mmol, 1.75 eq.) and HOBt (124 mg, 0.922 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then amine 4.63(100 mg, 0.38 mmol, 1 eq.) was added and the mixture was 
allowed to stir for 7 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Finally the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). A 
yellow solid was obtained after drying in vacuum. Yield=61mg, 36%. 







δH in ppm  
12.38(s,1H),11.50(s,1H),10.42(s,1H),8.74(d,J=2.0,1H),8.47(d,J=1.
6,1H), 8.10(dd,J=9.2,2.4,1H), 7.98(d,J=2.4,1H), 7.89(t,J=7.2,1H), 
7.71 (s,1H), 7.66-7.62(m,2H), 7.42(d,J=8.4,1H), 2.49(t,J=2.0,2H), 
2.29(t,J=7.2,2H), 2.14(s,6H), 1.69-1.63(m,2H).  
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
164.4, 158.5, 141.2, 139.4, 135.5, 133.3, 131.6, 126.4, 126.1, 
118.4, 111.4, 110.8, 57.0, 45.1, 39.9, 39.7, 39.5, 39.3, 39.0, 38.8, 
36.9, 35.7, 27.5.  




m/z (+EI) Calc. for C23H25N6O4, 448.1859 [M]




3250, 2933, 1541, 1513, 1540, 1470, 1442, 1416, 1386, 1325, 
1281, 1236, 1210, 1164, 1097, 1066, 1039, 990, 890, 867, 830, 





4.65 Synthesis of 5-amino-N-(3-((3-(dimethylamino) propyl) carbamoyl)-
1H-indol-5-yl)-1H-indole-2-carboxamide (4.65).        
 
 
120 mg of 4.64 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate 
was added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) was added into the reaction vessel, and mixed this well. The 
reaction bottle was sealed and connected to a hydrogen reservoir. Air from the 
reaction bottle was removed by applying vacuum, and was then by flushed with 
hydrogen. Typically, a hydrogen pressure of approximately 40 psi was applied 
from the reservoir, and the bottle was then shaken vigorously to initiate the 
reaction. Progress of the reaction was monitored by TLC and LCMS analysis. 
The completion of the reaction required about 6 hours at which point TLC and 
LCMS analysis showed the completion of reaction. The shaker was stopped, 
the bottle was vented, and the product was recovered by the process of filtration 
using Celite. Finally, the product is concentrated by using a rotary evaporator. A 
yellow solid was obtained after drying in vacuum. Yield=82 mg, 74 %. 







δH in ppm   
11.47(s,1H),11.09(s,1H),9.93(s,1H),8.32(d,J=1.2,,1H),7.83(d,J=7.
6,2H), 7.71(s,1H), 7.42(dd,J=8.4,1.2,1H), 7.34(d,J=8.8,1H), 7.05 
(d,J=8.4,1H), 6.98(s,1H), 6.49(dd,J=8.8,1H), 3.13-3.09(m,2H), 
2.50(s,2H), 2.16(t,J=7.2,2H), 1.98(s,6H),1.53-1.46(m,2H). 
EIMS Found 418.30 [M+H] +, Calculated for C23H26N6O2, 418.21 [M]
+ 
 
4.66 Synthesis of N-(3-((3-(dimethylamino) propyl) carbamoyl)-1H-indol-5-
yl)-5-(5-nitro-1H-indole-2-carboxamido)-1H-indole-2-carboxamide (4.66).        
 
 
Initially, 57 mg of 5-nitro-1H-indole-2-carboxylic acid (0.278 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
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Then DIC (75 µl, 0.488 mmol, 1.75 eq.) and HOBt (75 mg, 0.549 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
temperature for 30 minutes to ensure the formation of ester from the acid. Then 
amine 4.65(82 mg, 0.196 mmol, 1 eq.) was added and the mixture was allowed 
to stir for 6 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Finally the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). A 
yellow solid was obtained after drying in vacuum. Yield=64 mg, 54%. 











7.68(dd,J=8.8,1.6,1H), 7.64(d,J=9.2,1H), 7.58 (dd,J=8.8,1.6,1H), 
7.51(s,1H), 6.78 (d,J=6.8,1H), 6.59 (d,J=6.8,1H), 3.32-
3.27(m,2H), 2.28(t,J=7.2,2H), 2.15(s,6H), 1.67(t,J=6.8,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
164.5, 159.2, 158.6, 141.2, 139.5, 135.4, 133.9, 133.1, 132.7, 
131.9, 131.1, 127.9, 126.9, 126.4, 126.1, 119.2, 118.7, 118.5, 
116.8, 113.2, 113.0, 112.8, 112.3, 111.4, 110.8, 105.6, 103.4, 
57.0, 45.1, 39.0, 36.9, 27.5.  




m/z (+EI) Calc. for C32H30N8O5, 606.2339 [M]




3252, 2921, 1646, 1616, 1587, 1554, 1519, 1471, 1417, 1372, 
1324, 1286, 1248, 1216, 1166, 1135, 1099, 1069, 963, 943, 862, 
802, 766, 743, 730, 681, 627. 




Initially, 53 mg of 5-nitro-1H-indole-3-carboxylic acid (0.258 mmol, 1.2 eq.) was 
dissolved in 5 mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (70 µl, 0.451 mmol, 1.75 eq.) and HOBt (70 mg, 0.516 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
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temperature for 30 minutes to ensure the formation of ester from the acid. Then 
amine 4.22 (90 mg, 0.215 mmol, 1 eq.) was added and that mixture was 
allowed to stir for 4 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Lastly the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). A deep 
brown solid was obtained after drying in vacuum. Yield=38 mg, 29%. 








 δH in ppm   
12.45(s,1H), 11.68(s,1H), 11.57(s,1H), 10.15(s,1H), 9.93(s,1H), 
9.18(d,J=1.8,1H), 8.57(s,1H), 8.52(s,1H), 8.19(s,1H), 8.11(s,1H), 
8.09(d,J=2.4,1H), 7.69(d,J=9.2,1H), 7.54-7.50(m,2H), 7.47(s,1H), 
7.44(d,J=5.6,1H), 7.41(d,J=3.2,1H), 7.10(d,J=1.2,1H), 3.34-
3.29(m,2H), 2.30(t,J=7.2,2H), 2.16(s,6H), 1.69(t,J=6.8,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
162.2, 162.1, 160.9, 159.4, 141.8, 139.3, 133.5, 133.4, 132.5, 
132.4, 131.9, 131.6, 131.3, 127.0, 126.9, 125.9, 118.6, 118.4, 
117.9, 117.4, 112.7, 112.4, 112.1, 103.2, 102.2, 56.8, 45.0, 38.8, 
37.2, 35.7, 30.7, 27.1.  




m/z (+EI) Calc. for C32H30N8O5, 606.2339 [M]




3242, 2934, 1638, 1543, 1522, 1471, 1419, 1380, 1323, 1298, 
1251, 1228, 1201, 1130, 1094, 1072, 1040, 962, 869, 809, 790, 
778, 744, 715, 691, 660. 
 
 
4.68 Synthesis of N-(3-(dimethylamino) propyl)-5-(5-nitro-1H-indole-3-
carboxamido)-1H-indole-3-carboxamide (4.68).        
 
 
 Initially, 200 mg of 5-nitro-1H-indole-3-carboxylic acid (0.968 mmol, 1.2 eq.) 
was dissolved in 5 mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then DIC (261 µl, 1.69 mmol, 1.75 eq.) and HOBt (260 mg, 1.93 mmol, 
2.0 eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes for esterification of acid. Then amine 4.63 
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(180 mg, 0.692 mmol, 1 eq.) was added to the mixture and the mixture was 
allowed to stir for 15 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Finally the reaction mixture purified by the help of 
conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 
chapter 3). A deep brown solid was obtained after drying in vacuum. Yield=170 
mg, 58%. 











, 2.15 (s,6H), 1.67 (t,J=6.8,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
164.5, 162.0, 141.8, 139.2, 132.9, 132.3, 131.6, 127.7, 126.1, 
125.9, 118.0, 117.3, 116.7, 112.8, 112.7, 112.6, 111.2, 110.7, 
57.0, 45.1, 38.8, 36.8, 27.5.  
EIMS Found 449.10 [M+H]+, Calculated forC23H24N6O4, 448.18  [M]
+ 





3265, 2971, 2344, 2297, 1738, 1604, 1533, 1468, 1437, 1367, 
1342, 1311, 1270, 1208, 1178, 1148, 1072, 1038, 938, 882, 792, 
744, 683, 662. 
 
 
4.69 Synthesis of 5-amino-N-(3-((3-(dimethylamino) propyl) carbamoyl)-1H-
indol-5-yl)-1H-indole-3-carboxamide (4.69).        
 
 
 170 mg of 4.68 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate 
was added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) 20 was added into the reaction vessel, and mixed it well. The 
sealed reaction bottle was connected to a hydrogen reservoir. Air from the 
reaction bottle was removed by applying vacuum and it was flushed with 
hydrogen. Typically, a hydrogen pressure of approximately 40 psi was applied 
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from the reservoir, and the bottle was then shaken vigorously to initiate the 
reaction. Progress of the reaction was monitored by TLC and LCMS. The 
shaker was stopped after 4.5 hours at which point TLC and LCMS analysis 
showed the completion of reaction. The bottle was vented and the product was 
recovered by means of filtration using Celite. Finally, the product is 
concentrated by using a rotary evaporator. A deep brown solid was obtained 
after drying in vacuum. Yield=140 mg, 89%. 








 δH in ppm   
11.46(s,1H), 11.26(d,J=2.0,1H), 9.49(s,1H), 8.43(d,J=2.0,1H), 
8.13(d,J=2.8,1H), 7.95(s,1H), 7.89(t,J=5.2,1H), 7.62(dd, 
J=8.8,2.0,1H), 7.47(d,J=2.0,1H), 7.35(d, J=8.4,1H), 7.14(d,J=8.4, 
1H), 6.56(dd, J=8.4, 2.0,1H), 3.31-3.26(m,2H), 2.73( s,2H), 2.28(t, 
J=7.2, 2H), 2.15(s,6H), 1.69 (m,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
164.6, 163.4, 162.2, 142.6, 133.1, 132.6, 129.6, 127.7, 127.6, 
127.5, 126.1, 116.7, 112.5, 112.3, 111.7, 111.0, 110.6, 109.4, 
104.4, 57.0, 45.2, 36.9, 35.7.  









3240, 2941, 2827, 1652, 1614, 1534, 1469, 1433, 1386, 1360, 
1315, 1278, 1248, 1212, 1160, 1100, 1028, 933, 802, 768, 660, 
612. 
 
4.70 Synthesis of 5-(benzofuran-2-carboxamido)-N-(3-((3-(dimethylamino) 
propyl) carbamoyl)-1H-indol-5-yl)-1H-indole-3-carboxamide (4.70).        
 
Initially, 33 mg of benzofuran-2-carboxylic acid (0.2002 mmol, 1.2 eq.) was 
dissolved in 5 mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (54 µl, 0.35 mmol, 1.75 eq.) and HOBt (54 mg, 0.40 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
temperature for 30 minutes to ensure the formation of ester from the acid. Then 
amine 4.69(60 mg, 0.143 mmol, 1 eq.) was added and the mixture was allowed 
to stir for 5 hours at which point TLC and LCMS analysis showed the 
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completion of reaction. Finally the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). A 
cream solid was obtained after drying in vacuum. Yield=12.5 mg, 16%. 







 δH in ppm  
8.45(s,1H),8.34(d,J=1.6,1H),8.14(d,J=1.6,1H),8.02(s,1H),7.76(s,1H),
7.64(d,J=7.6,1H),7.56(d,J=8,2H),7.51(s,2H),7.42(dd,J=8.8,2.0,1H), 
7.37(s,1H), 7.36 (d,J=4,1H), 7.33(d,J=7.6,2H), 7.23 (t,J=7.2,2H), 
3.33(t,J=6.8,2H), 2.38 (t,J=7.6,2H), 2.18 (s,6H), 1.76-1.70(m,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm 
170.3, 168.4, 166.8, 159.5, 156.5, 150.3, 135.9, 135.4, 133.4,132.3, 
130.3, 129.8, 128.9, 128.2, 127.7, 126.9, 124.9, 123.7, 119.5, 119.3, 
115.7, 114.9, 112.9, 112.8, 112.4, 112.1, 111.8, 58.3, 49.6, 49.0, 
45.4, 38.7.  









3214, 2970, 1740, 1623, 1592, 1538, 1474, 1437, 1359, 1313, 1258, 
1216, 1177, 1156, 1092, 1047, 1023, 1001, 944, 805, 747, 627. 
 
4.71 Synthesis of 5-(benzo[b]thiophene-2-carboxamido)-N-(3-((3-
(dimethylamino) propyl) carbamoyl)-1H-indol-5-yl)-1H-indole-3-
carboxamide (4.71).        
 
 
42 mg of benzo[b]thiophene-2-carboxylic acid (0.234 mmol, 1.2 eq.) was 
dissolved in 5 mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (63.57 µl, 0.411 mmol, 1.75 eq.) and HOBt (63.45 mg, 0.46 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for at least 30 minutes for the esterification of acid. Then 
amine 4.67 (70 mg, 0.167 mmol, 1 eq.) was added and the mixture was allowed 
to stir for 4 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Lastly the reaction mixture was applied to a conditioned 
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IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). A 
yellow solid was obtained after drying in vacuum. Yield=44 mg, 45%. 







 δH in ppm   
11.70(s,1H),11.45(s,1H),10.53(s,1H),9.71(s,1H),8.61(d,J=1.6,1H), 
8.47(d,J=1.6,1H),8.43(s,1H),8.35(d,J=6.4,1H),8.06(dd,J=6.8,2.4,1
H), 8.00(dd,J=6.4,2.4,1H), 7.96(s,1H), 7.90(t,J=5.6,1H), 7.72-
7.66(m,2H), 7.49-7.46(m,3H), 7.39(d,J=8.8,1H), 3.31-3.26(m,2H), 
2.28(t,J=7.2,2H), 2.14(s,6H), 1.67(t,J=6.8,2H).  
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
164.5, 162.9, 162.2, 159.9, 140.7, 140.3, 139.3, 133.3, 132.9, 
132.6, 131.9, 128.8, 127.6, 126.6, 126.25, 126.20, 125.2, 124.9, 
122.7, 116.6, 113.4, 112.6, 111.5, 111.1, 110.8, 110.6, 57.0, 45.2, 
38.8, 36.9, 35.74, 30.7. 









3252, 2937, 1633, 1529, 1471, 1434, 1382, 1334, 1242, 1204, 
1153, 1095, 1071, 868, 801, 765, 737, 715. 
4.72 Synthesis of N-(3-((3-((3-(dimethylamino)propyl)carbamoyl)-1H-indol-
5-yl)carbamoyl)-1H-indol-5-yl)-1-methyl-1H-indole-2-carboxamide (4.72).        
 
 
Initially, 38 mg of 1-methyl-1H-indole-2-carboxylic acid (0.217 mmol, 1.2 eq.) 
was dissolved in 5 mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then DIC (58.59 µl, 0.379 mmol, 1.75 eq.) and HOBt (59 mg, 0.434 
mmol, 2.0 eq.) were added to the acid (1.0 eq.) and this mixture was allowed to 
stir at room temperature for 30 minutes to ensure the formation of ester from the 
acid. Then 65 mg of amine 4.69 (0.155 mmol, 1 eq.) was added to the mixture 
and this mixture was stirred for 8 hours at which point TLC and LCMS analysis 
showed the completion of reaction. Finally the product of the reaction mixture 
was separated by using a conditioned IsoluteTM SCX-2 cartridge and the 
product was purified by ‘Catch and Release’ method (described in the section 
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‘Method and Materials’ of chapter 3). An orange solid was obtained after 
drying in vacuum. Yield=27 mg, 30 %. 







 δH in ppm   
11.70(s,1H),11.49(s,1H),10.29(s,1H),9.70(s,1H),8.69(d,J=1.6,1H
),8.49(d,J=1.6,1H),8.348.29(m,2H),7.97(d,J=2.4,2H),7.69(d,J=8.
0,1H), 7.65-7.62(m,2H), 7.44(d,J=8.8,1H), 7.37 (d,J=4.4,2H), 
7.29 (t,J=7.2,1H), 7.13 (t,J=7.6,1H), 4.05-4.00(m,3H), 3.32-
3.27(m,2H), 2.54 (t,J=7.2,2H), 2.34 (s,6H), 1.78-1.71(m, 2H).  
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
164.7, 162.9, 162.2, 160.1, 138.5, 133.1, 132.9, 132.6, 132.5, 
132.2, 127.7, 126.5, 126.1, 125.5, 123.6, 121.6, 120.1, 116.6, 
113.3, 112.5, 111.4, 111.1, 110.8, 110.5, 110.4, 105.0, 56.1, 
44.0, 40.0, 39.2, 36.4, 35.7, 31.4.  
EIMS Found 575.40 [M+H]+, Calculated for C33H33N7O3, 575.26 [M]
+ 
HRMS m/z (+EI) Calc. for C33H33N7O3, 575.2645 [M]




3257, 2972, 2342, 1739, 1649, 1601, 1537, 1471, 1435, 1363, 
1309, 1251, 1214, 1152, 1085, 1044, 878, 803, 745, 682, 660. 
 
4.73 Synthesis of N-(3-((3-((3-(dimethylamino) propyl) carbamoyl)-1H-
indol-5-yl) carbamoyl)-1H-indol-5-yl)-1H-benzo[d]imidazole-2-carboxamide 
(4.73).        
 
 
Initially, 34 mg of 1H-benzo[d]imidazole-2-carboxylic acid hydrate (0.186 mmol, 
1.2 eq.) was dissolved in 10 mL of DMF in a round bottom flask fitted with a 
magnetic stirrer. Then DIC (51 µl, 0.3255 mmol, 1.75 eq.) and HOBt (51 mg, 
0.372 mmol, 2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for 30 minutes to ensure the formation of 
ester from the acid. Then 65 mg of amine 4.69 (0.155 mmol, 1 eq.) was added 
and the mixture was allowed to stir for 6 hours at which point TLC and LCMS 
analysis showed the completion of reaction. Finally the reaction mixture was 
applied to a conditioned IsoluteTM SCX-2 cartridge and the product was purified 
by ‘Catch and Release’ method (described in the section ‘Method and 
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Materials’ of chapter 3). A light yellow solid was obtained after drying in 
vacuum. Yield=18 mg, 21%. 








 δH in ppm  
11.72(d,J=2.4,1H), 11.49(d,J=2.4,1H), 10.73(s,1H), 9.71(s,1H), 
8.81(d,J=2.0,1H), 8.50(d,J=1.6,1H), 8.32(d,J=2.8,1H), 8.02-
7.95(m,2H), 7.64(d,J=2.0,1H), 7.62(t,J=2.4,1H), 7.60(d,J=2.0,1H), 
7.46 (d,J=8.8,1H), 7.36(d,J=9.2,1H), 7.35-7.32(m,2H), 3.32-
3.27(m,2H), 2.50-2.47 (m,2H), 2.30(s,6H), 1.77-1.70(m,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
164.6, 162.9, 156.9, 146.0, 133.4, 132.9, 132.7, 131.3, 128.8, 
127.7, 126.4, 126.1, 117.0, 116.8, 113.7, 112.6, 111.6, 111.2, 
110.9, 110.5, 56.4, 44.4, 40.0, 39.8, 39.6, 39.4, 39.2, 39.0, 38.7, 
36.5, 26.9.  




m/z (+EI) Calc. for C31H30N8O3, 562.2441 [M]




3023, 2970, 1740, 1620, 1538, 1473, 1434, 1363, 1313, 1277, 
1219, 1144, 1023, 1001, 894, 805, 769, 746, 622. 
 
4.74 Synthesis of 5-(benzofuran-3-carboxamido)-N-(2-((3-(dimethylamino) 
propyl) carbamoyl) benzofuran-5-yl)-1H-indole-3-carboxamide (4.74).       
Initially, 37.91 mg of benzofuran-3-carboxylic acid (0.233 mmol, 1.2 eq.) was 
dissolved in 10 mL of DMF in a round bottom flask. Then DIC (63.03 µl, 0.407 
mmol, 1.75 eq.) and HOBt (62.91 mg, 0.466 mmol, 2.0 eq.) were added to the 
acid (1.0 eq.) and this mixture was allowed to stir at room temperature for 30 
minutes to ensure the formation of ester from the acid. Then amine 4.51(70 mg, 
0.166 mmol, 1 eq.) was added and the mixture was allowed to stir for 6 hours at 
which point TLC and LCMS analysis showed the completion of reaction. Finally 
the reaction mixture was applied to a conditioned IsoluteTM SCX-2 cartridge and 
the product was purified by ‘Catch and Release’ method (described in the 











 δH in ppm  
8.52(d,J=6.8,2H), 8.44(d,J=1.6,1H), 8.13(s,1H), 8.08(t,J=2.8,1H), 
7.97(s,1H), 7.70(dd,J=9.2,2.4,1H), 7.58(s,1H), 7.58-7.53(m,2H), 
7.47(s,1H), 7.45(s,1H), 7.41 (dd,J=7.2,1.6,1H), 
7.37(dd,J=4.0,1.6,1H), 7.34 (dd,J=7.2,1.2,1H), 3.50(t,J=6.4,2H), 
3.19-3.15 (m,2H), 2.99 (s,6H), 2.06-1.98(m,2H).  
13C 
NMR 
(100MHz,(CD3)2SO);  δC in ppm 
166.6, 163.9, 161.1, 156.8, 153.1, 150.7, 148.5, 136.4, 135.6, 
133.1, 130.3, 128.9, 127.7, 126.6, 126.3, 124.9, 123.1, 122.8, 
119.3, 118.9, 115.6, 115.3, 112.9, 112.7, 112.4, 112.1, 111.2, 58.2, 
49.6, 49.0, 45.4, 38.7. 









3230, 2977, 2325, 1737, 1637, 1592, 1536, 1471, 1439, 1366, 





4.75 Synthesis of 5-(benzo[b]thiophene-3-carboxamido)-N-(2-((3-(dimethyl 
amino) propyl) carbamoyl) benzofuran-5-yl)-1H-indole-3-carboxamide (4.75).        
 
 
Initially, 41.28 mg of benzo[b]thiophene-3-carboxylic acid (0.266 mmol, 1.2 eq.) 
was dissolved in 10mL of DMF in a round bottom flask. DIC (71.88 µl, 0.465 
mmol, 1.75 eq.) and HOBt (71.82 mg, 0.532 mmol, 2.0 eq.) were added to the 
acid (1.0 eq.) and this mixture was allowed to stir at room temperature for 30 
minutes to ensure the formation of ester from the acid. Then amine 4.51 (80 
mg, 0.190 mmol, 1 eq.) was added and the mixture was allowed to stir for 5 
hours at which point TLC and LCMS analysis showed the completion of 
reaction. Finally the reaction mixture was applied to a conditioned IsoluteTM 
SCX-2 cartridge and the product was purified by ‘Catch and Release’ method 






Figure 4.5: 1H and 13C NMR spectroscopic data of compound 4.75 as a 





















(m,2H), 2.15(s,6H), 1.68-1.63(m,2H). 
13C NMR (100MHz,(CD3)2SO); δC in ppm 
163.2, 161.5, 158.0, 150.3, 149.7, 139.4, 137.3, 133.1, 132.6, 
131.4, 131.1, 127.2, 126.4, 124.9, 124.4, 122.8, 120.0, 112.7, 
111.5, 110.4, 109.4, 56.8, 45.1, 40.1, 39.9, 39.7, 39.4, 39.2, 
39.0, 38.8, 37.3, 26.9.  
EIMS Found 580.10 [M+H]+, Calculated for C32H29N5O4S, 579.19 [M]
+ 





3300, 2255, 1637, 1577, 1525, 1479, 1439, 1338, 1313, 1225, 
1173, 1048, 1023, 999, 888, 859, 821, 759, 632. 
 
 
4.76 Synthesis of N-(3-((2-((3-(dimethylamino) propyl) carbamoyl) 
benzofuran-5-yl) carbamoyl)-1H-indol-5-yl)-1H-indazole-3-carboxamide 
(4.76).        
 
 
Initially, 47 mg of 1H-indazole-3-carboxylic acid (0.290 mmol, 1.2 eq.) was 
dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (78 µl, 0.507 mmol, 1.75 eq.) and HOBt (78.3 mg, 0.58 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
temperature for 30 minutes to ensure the formation of ester from the acid. Then 
87 mg of amine 4.51 (0.207 mmol, 1 eq.) was added and the mixture was 
allowed to stir for 6 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Finally the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). A 
brown solid was obtained after drying in vacuum. Yield=13 mg, 13 %. 
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3.58(m,2H), 2.25 (t,J=5.6,2H), 2.15(s,6H), 1.66(t,J=6.0,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
163.2, 160.7, 158.0, 156.8, 150.3, 149.7, 141.8, 138.4, 135.7, 
133.0, 132.3, 127.2, 126.3, 126.2, 123.1, 121.9, 121.8, 118.1, 
112.8, 111.6, 111.5, 111.0, 110.4, 109.3, 56.8, 45.1, 40.65, 38.7, 
37.3, 26.9, 24.8. 




m/z (+EI) Calc. for C31H29N7O4, 563.2281 [M]




3301, 2950, 1636, 1590, 1529, 1470, 1433, 1343, 1299, 1276, 
1236, 1202, 1153, 1037, 879, 806, 753, 738, 716, 623. 
 
4.77 Synthesis of N-(3-((3-((3-(dimethylamino) propyl) carbamoyl)-1H-
indol-5-yl) carbamoyl)-1H-indol-5-yl)-5-nitro-1H-indole-2-carboxamide 
(4.77).        
 
Initially, 43mg of 5-nitro-1H-indole-2-carboxylic acid (0.206 mmol, 1.2 eq.) was 
dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (56 µl, 0.3605 mmol, 1.75 eq.) and HOBt (56 mg, 0.412 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then 72 mg of amine 4.69 (0.172 mmol, 1 eq.) was added and the mixture was 
allowed to stir for 7 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Finally the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). A 
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Figure 4.6: 1H and 13C NMR spectroscopic data of compound 4.77 as a 













 δH in ppm  
12.52(s,1H), 11.74(d,J=2.4,1H), 11.48(d,J=2.4,1H), 10.52(s,1H), 
9.72(s,1H),8.77(d,J=2.4,1H), 8.64 (d,J=1.6,1H), 8.49(d,J=2.0,1H), 
8.36(d,J=2.8,1H),8.11(dd,J=8.8,2.0,1H),7.97(d,J=2.8,1H),7.92(t,J
=6,1H), 7.76(s,1H), 7.73(dd,J=8.8,2.0,1H), 7.66-7.63 (m,2H), 
7.48(d,J=8.8,1H), 7.38(d,J=8.8,1H), 3.31-3.26(m,2H), 2.29 
(t,J=7.2,2H), 2.15(s,6H), 1.67(t,J=7.2,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
164.6, 163.0, 158.5, 141.2, 139.4, 135.5, 133.3, 132.8, 132.7, 
131.8, 128.8, 127.7, 126.5, 126.4, 126.1, 119.2, 118.5, 116.7, 
113.5, 112.8, 112.7, 111.6, 111.2, 110.8, 110.8, 105.6, 56.9, 45.0, 
39.3, 36.9, 27.4, 23.2. 




m/z (+EI) Calc. for C32H30N8O5, 606.2339 [M]




3266, 2941, 2219, 1705, 1630, 1534, 1475, 1440, 1361, 1331, 
1308, 1221, 1160, 1098, 1039, 945, 886, 807, 770, 741, 715, 619. 
 
4.78 Synthesis of N-(3-(dimethylamino) propyl)-5-(5-(5-
nitrobenzo[b]thiophene-2-carboxamido)-1H-indole-3-carboxamido)-1H-
indole-3-carboxamide (4.78).      
   
Initially, 67 mg of 5-nitrobenzo[b]thiophene-2-carboxylic acid (0.301 mmol, 1.4 
eq.) was dissolved in 10mL of DMF in a round bottom flask fitted with a 
magnetic stirrer. Then DIC (81 µl, 0.526 mmol, 1.75 eq.) and HOBt (81 mg, 
0.602 mmol, 2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for 30 minutes to ensure the formation of 
ester from the acid. Then amine 4.69(90 mg, 0.215 mmol, 1 eq.) was added and 
the mixture was allowed to stir for 6 hours at which point TLC and LCMS 
analysis showed the completion of reaction. Finally the reaction mixture was 
applied to a conditioned IsoluteTM SCX-2 cartridge and the product was purified 
by ‘Catch and Release’ method (described in the section ‘Method and 
Materials’ of chapter 3). A deep yellow solid was obtained after drying in 













 δH in ppm   
11.72(d,J=2.4,1H), 11.45(d,J=2.4,1H), 10.75(s,1H), 9.71(s,1H), 
8.94(t,J=2.0,1H), 8.64-8.60(m,2H), 8.47(d,J=1.6,1H), 8.37-
8.33(m,2H), 8.29-8.27(m,1H), 7.96(s,1H), 7.90(t,J=5.6,1H), 7.70-
7.64 (m,2H), 7.48(d,J=8.8,1H), 7.37(d,J=8.4,1H), 3.31-
3.26(m,2H), 2.33 (t,J=6.8,2H), 2.18(s,6H), 1.72-1.65(m,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
164.6, 162.9, 162.3, 159.2, 146.1, 145.3, 144.5, 139.1, 133.4, 
132.9, 132.7, 131.6, 126.6, 126.1, 125.8, 124.1, 120.9, 119.9, 
116.6, 113.6, 112.6, 110.8, 110.6, 56.9, 45.0, 40.0, 39.4, 39.2, 
39.0, 38.8, 27.4, 23.2. 









3219, 1706, 1625, 1532, 1509, 1472, 1435, 1340, 1312, 1269, 
1212, 1151, 1023, 1003, 945, 863, 803, 769, 736. 
 
4.79 Synthesis of N-(3-(dimethylamino) propyl)-5-(5-(5-nitrobenzofuran-2-
carboxamido)-1H-indole-3-carboxamido)-1H-indole-3-carboxamide (4.79).      
 
    
Initially, 52 mg of 5-nitrobenzofuran-2-carboxylic acid (0.251 mmol, 1.4 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (68 µl, 0.439 mmol, 1.75 eq.) and HOBt (68 mg, 0.502 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
temperature for 30 minutes to ensure the formation of ester from the acid. Then 
75 mg of amine 4.69 (0.179 mmol, 1 eq.) was added to the mixture and that 
mixture was allowed to stir for 5 hours at which point TLC and LCMS analysis 
showed the completion of reaction. Lastly, the reaction mixture was applied to a 
conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 













 δH in ppm   
11.73(s,1H),11.48(s,1H),10.67(s,1H),9.71(s,1H),8.84(d,J=2.4,1
H), 8.65(d,J=1.2,1H), 8.48(s,1H), 8.36(dd,J=8.8,2.0,2H), 
8.02(s,1H), 
7.97(d,J=9.2,3H),7.697.63(m,2H),7.47(d,J=8.8,1H),7.38(d,J=8.4




(100MHz,(CD3)2SO); δC in ppm 
 164.7, 162.9, 157.0, 155.6, 152.0, 144.1, 133.4, 132.9, 132.7, 
131.3, 127.8, 126.5, 126.1, 122.1, 119.5, 116.8, 112.9, 111.6, 
111.1, 110.9, 110.5, 56.4, 44.4, 40.6, 39.8, 39.4, 39.2, 39.0, 
38.4, 36.5, 26.8, 23.2.  









3276, 2972, 1739, 1649, 1606, 1530, 1464, 1435, 1367, 1311, 
1211, 1148, 1067, 953, 884, 865, 792, 771, 744, 682. 
4.80 Synthesis of N-(3-((3-((3-(dimethylamino) propyl) carbamoyl)-1H-
indol-5-yl) carbamoyl)-1H-indol-5-yl)-5-nitro-1H-benzo[d]imidazole-2-
carboxamide (4.80).        
 
 
Initially, 59 mg of 5-nitro-1H-benzo[d]imidazole-2-carboxylic acid (0.284 mmol, 
1.4 eq.) was dissolved in 10mL of DMF in a round bottom flask fitted with a 
magnetic stirrer. Then DIC (77 µl, 0.497 mmol, 1.75 eq.) and HOBt (77 mg, 
0.568 mmol, 2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
stirred at room temperature for 30 minutes for complete esterification. Then 
amine 4.69 (85 mg, 0.203 mmol, 1 eq.) was added to the mixture and this 
mixture was allowed to stir for 4 hours at which point TLC and LCMS analysis 
showed the completion of reaction. Finally the reaction mixture was separated 
by using a conditioned IsoluteTM SCX-2 cartridge and the product was purified 
by ‘Catch and Release’ method (described in the section of chapter 3). An 











 δH in ppm  
11.68(d,J=2.4,1H), 11.43(d,J=2.4,1H), 10.89(s,1H), 9.67(s,1H), 
8.79(d,J=1.6,1H),8.56(d,J=2.0,1H),8.43(d,J=2.0,1H),8.32(d,J=2.8,
1H), 8.20(dd,J=8.8,2.4,1H), 7.94(s,2H), 7.89(t,J=6.4,1H), 7.85-
7.81(m,1H),7.64-7.59 (m,2H), 7.45(d,J=8.4,1H), 7.36(d,J=8.8,1H), 
3.30-3.25(m,2H),2.36(t,J=7.2,2H), 2.20(s,6H), 1.72-1.65(m,2H).  
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm 
164.8, 162.9, 162.3, 156.9, 151.1, 146.2, 145.2, 143.2, 136.1, 
133.8, 132.7, 132.5, 131.2, 126.4, 126.0, 123.8, 117.3, 117.1, 
116.0, 113.7, 111.9, 111.2, 110.9, 110.6, 48.5, 44.7, 38.9, 38.7, 
35.7, 30.7, 27.0.  









2970, 1740, 1638, 1537, 1479, 1366, 1228, 1217, 1154, 1024, 
1004, 944, 887, 802, 778, 733. 
 
 
4.81 Synthesis N-(3-(dimethylamino) propyl)-5-nitro-1H-indazole-3-
carboxamide (4.81).   
 
Initially, 250 mg of 5-nitro-1H-indazole-3-carboxylic acid (1.207 mmol, 1.2 eq.) 
was dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then DIC (326 µl, 2.11 mmol, 1.75 eq.) and HOBt (326 mg, 2.414 mmol, 
2.0 eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then 3-amino-N-methyl-N-methylenepropan-1-aminium (85 µl, 0.828 mmol, 1 
eq.) was added and the mixture was allowed to stir for 7 hours at which point 
TLC and LCMS analysis showed the completion of reaction. Finally the reaction 
mixture was applied to a conditioned IsoluteTM SCX-2 cartridge and the product 
was purified by ‘Catch and Release’ method (described in the section ‘Method 
and Materials’ of chapter 3). A yellow solid was obtained after drying in 

















EIMS Found 291.13  [M+H]+, C13H17N5O3, 290.20 [M]
+ 
4.82 Synthesis 5-amino-N-(3-(dimethylamino) propyl)-1H-indazole-3-
carboxamide (4.82).   
 
 
180 mg of 4.81 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate 
was added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) was added into the reaction vessel and it was mixed well. The 
reaction bottle was sealed and connected to a hydrogen reservoir. Air from the 
reaction bottle was removed by applying vacuum and it was then flushed with 
hydrogen. Typically, a hydrogen pressure of approximately 40 psi was applied 
from the reservoir and the bottle was then shaken vigorously to initiate the 
reaction. Progress of the reaction was monitored by TLC and LCMS. The 
shaker was stopped and the bottle was vented after 6 hours at which point TLC 
and LCMS analysis showed the completion of reaction. The product was 
recovered by means of filtration using Celite. Finally, the product is 
concentrated by using a rotary evaporator. A pale yellow solid was obtained 
after drying in vacuum. Yield=145 mg, 90 %. 

















4.83 Synthesis of N-(3-(dimethylamino) propyl)-5-(5-nitro-1H-indazole-3-
carboxamido)-1H-indazole-3-carboxamide (4.83).   
 
  
Initially, 155 mg of 5-nitro-1H-indazole-3-carboxylic acid (0.75 mmol, 1.4 eq.) 
was dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then 202 µl of DIC (1.313 mmol, 1.75 eq.) and HOBt (202 mg, 1.50 
mmol, 2.0 eq.) were added to the acid (1.0 eq.) and this mixture was allowed to 
stir at room temperature for 30 minutes to ensure the formation of ester from the 
acid. Then 140 mg of 4.82 (0.536 mmol, 1 eq.) was added to the mixture and 
the mixture was allowed to stir for 7 hours at which point TLC and LCMS 
analysis showed the completion of reaction. Finally the reaction mixture was 
applied to a conditioned IsoluteTM SCX-2 cartridge and the product was purified 
by ‘Catch and Release’ method (described in the section ‘Method and 
Materials’ of chapter 3). A light yellow solid was obtained after drying in 
vacuum. Yield=109 mg, 45%. 








 δH in ppm  
13.56(s,1H), 10.66(s,1H), 9.12(d,J=2.0,1H), 8.81(dJ=1.6,1H), 
8.43(t,J=5.6,1H), 8.26(dd,J=9.2,2.4,1H), 7.88-7.82(m,2H), 




(100MHz,(CD3)2SO); δC in ppm 
162.1, 160.1, 143.7, 142.6, 140.9, 138.5, 138.2, 132.9, 121.9, 
121.5, 121.0, 118.9, 112.4, 110.5, 57.0, 45.0, 39.2, 39.0, 38.8, 
36.9, 27.1.  
EIMS Found 451.0 [M+H] +, Calculated for C21H22N8O4, 450.17 [M]
+ 
HRMS M/z (+EI) Calc. for C21H22N8O4, 450.1764 [M]




3376, 3201, 2923, 2818, 1655, 1638, 1597, 1531, 1481, 1335, 






4.84 Synthesis of 5-amino-N-(3-((3-(dimethylamino) propyl) carbamoyl)-1H-
indazol-5-yl)-1H-indazole-3-carboxamide (4.84).   
 
 
200 mg of 4.83 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate 
was added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) was added into the reaction vessel and it was mixed well. The 
reaction bottle was sealed and connected to a hydrogen reservoir. Air from the 
reaction bottle was removed by applying vacuum and it was flushed with 
hydrogen. Typically, a hydrogen pressure of approximately 40 psi was applied 
from the reservoir, and the bottle was then shaken vigorously to initiate the 
reaction. Progress of the reaction was monitored by TLC and LCMS. The 
shaker was stopped and the bottle was vented after 5 hours at which point TLC 
and LCMS analysis showed the completion of reaction. The product was 
recovered by means of filtration using Celite. Finally, the product was 
concentrated by using a rotary evaporator. A deep brown solid was obtained 
after drying in vacuum. Yield=140 mg, 75 %. 








 δH in ppm   
13.67(s,2H), 10.15(s,1H), 8.77(d,J=1.2,1H), 8.39(t,J=6.0,1H), 
7.78(dd,J=9.2,2.0,1H), 7.56(d,J=9.2,1H), 7.36(d,J=8.8,1H), 
7.32(d,J=2.0,1H), 6.86(dd,J=8.8,2.0,1H), 3.35-3.30(m, 2H), 
2.49(t,J=7.2,2H), 2.14(s,6H), 2.08(d,J=1.2,2H), 1.68(t,J=7.2,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm 
162.2, 161.4, 152.5, 144.2, 138.3, 138.1, 136.9, 136.2, 135.9, 
133.4, 123.4, 121.9, 121.2, 111.7, 110.9, 102.9, 57.1, 45.2, 38.5, 
27.8, 22.5.  




m/z (+EI) Calc. for C21H24N8O2, 420.2022 [M]




3200, 2927, 1638, 1596, 1535, 1482, 1335, 1317, 1224, 1152, 





4.85 Synthesis N-(3-(dimethylamino) propyl)-5-(5-(5-nitro-1H-indazole-3-
carboxamido)-1H-indazole-3-carboxamido)-1H-indazole-3-carboxamide 
(4.85).   
 
Initially, 49.5 mg of 5-nitro-1H-indazole-3-carboxylic acid (0.239 mmol, 1.4 eq.) 
was dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then DIC (65 µl, 0.418 mmol, 1.75 eq.) and HOBt (65 mg, 0.478 mmol, 
2.0 eq.) were added to the acid (1.0 eq.) and this mixture was stirred at room 
temperature for at least 30 minutes to ensure the formation of ester from the 
acid. Then 72 mg of amine 4.84 (0.171 mmol, 1 eq.) was added to the mixture 
and the mixture was allowed to stir for 5 hours at which point TLC and LCMS 
analysis showed the completion of reaction. Finally the reaction mixture was 
applied to a conditioned IsoluteTM SCX-2 cartridge and the product was purified 
by ‘Catch and Release’ method (described in the section ‘Method and 
Materials’ of chapter 3). A deep grey solid was obtained after drying in vacuum. 
Yield=14.4 mg, 15%. 








 δH in ppm   
13.76(s,1H), 13.52(s,2H), 10.73(s,1H), 10.41(s,1H), 
9.16(d,J=2.0,1H), 8.93(d,J=1.2,1H), 8.83(d,J=1.6,1H), 8.44(s,1H), 
8.29(dd,J=9.2,2.4,1H), 7.91-7.87(m,2H), 7.85(dd,J=8.8,2.0,1H), 
7.66(d,J=9.2,1H), 7.58(d,J=8.8,1H), 3.38-3.33(m,2H), 
2.40(t,J=7.2,2H), 2.24(s,6H), 1.73(t,J=7.2, 2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm 
171.5, 162.2, 160.9, 160.0, 143.3, 142.8, 142.8, 140.9, 138.4, 
138.3, 138.1, 136.9, 133.3, 131.4, 130.6, 127.5, 122.1, 121.9, 
121.5, 121.0, 119.0, 112.2, 110.9, 56.7, 44.7, 39.2, 38.8, 36.7, 
26.9.  
EIMS Found 610.10 [M+H]+, calculated for C29H27N11O5, 609.21 [M]
+ 
HRMS m/z (+EI) Calc. for C29H27N11O5, 609.2197 [M]




3200, 3013, 2970, 2945, 1740, 1651, 1594, 1540, 1478, 1366, 
1343, 1317, 1228, 1217, 1150, 1090, 1023, 1000, 942, 897, 853, 




4.86 Synthesis of N-(3-(dimethylamino) propyl)-5-(5-(5-nitro-1H-
benzo[d]imidazole-2-carboxamido)-1H-indazole-3-carboxamido)-1H-
indazole-3-carboxamide (4.86).   
 
Initially, 52 mg of 5-nitro-1H-benzo[d]imidazole-2-carboxylic acid (0.253 mmol, 
1.2 eq.) was dissolved in 10 mL of DMF in a round bottom flask fitted with a 
magnetic stirrer. Then 68 µl of DIC (0.442 mmol, 1.75 eq.) and HOBt (68 mg, 
0.506 mmol, 2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for 30 minutes to ensure the esterification of 
acid. Then 76 mg of amine 4.85(0.180 mmol, 1 eq.) was added to the mixture 
and the mixture was allowed to stir for 7 hours at which point TLC and LCMS 
analysis showed the completion of reaction. At last the reaction mixture was 
applied to a conditioned IsoluteTM SCX-2 cartridge and the product was purified 
by ‘Catch and Release’ method (described in the section ‘Method and 
Materials’ of chapter 3). A brown solid was obtained after drying in vacuum. 
Yield=14 mg, 13%. 







 δH in ppm   
13.82(s,1H),13.51(s,1H), 11.13(s,1H), 10.42(s,1H), 
8.94(d,J=1.6,1H), 8.79(d,J=1.2,1H), 8.57(d,J=2.0,1H), 
8.43(t,J=5.6,1H), 8.19(dd,J=8.8,2.0,1H), 7.95(s,1H), 
7.90(dd,J=8.8,2.0,1H), 7.84(dd,J=8.8,2.4,2H), 7.69(d,J=8.8,1H), 





(100MHz,(CD3)2SO); δC in ppm  
162.29, 162.23, 160.8, 157.3, 154.9, 149.6, 143.0, 142.7, 138.6, 
138.4, 138.28, 138.20, 133.2, 132.9, 128.0, 121.9, 121.8, 121.5, 
118.3, 113.8, 112.5, 112.2, 56.9, 44.9, 39.0, 36.8, 35.7, 30.7, 
27.0.  









3280, 2944, 1638, 1591, 1574, 1531, 1468, 1392,1 290, 1232, 
1154, 1034, 953, 879, 809, 737, 716, 618. 
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4.87 Synthesis of 5-cyano-N-(3-((3-((3-(dimethylamino) propyl) carbamoyl)-
1H-indol-5-yl) carbamoyl)-1H-indol-5-yl)-1H-indole-2-carboxamide (4.87). 
 
Initially 56 mg of 5-cyano-1H-indole-2-carboxylic acid (0.298 mmol, 1.2 eq.) was 
dissolved in 10 mL of DMF in a round bottom flask placed into a stirrer. 
 
 
Figure 4.7: 1H and 13C NMR spectroscopic data of compound 4.87 as a 
representative of library-4C compounds 
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Then 80 µl of DIC (0.5215 mmol, 1.75 eq.) and HOBt (80 mg, 0.596 mmol, 2. 
0eq.) were added to the acid (1.0 eq.) and mix it well and the mixture was 
allowed to stir at room temperature for 30 minutes to ensure the formation of 
ester from the acid. Then 104 mg of amine 4.69(0.2488 mmol, 1 eq.) was added 
and the mixture was allowed to stir for 5 hours at which point TLC and LCMS 
analysis showed the completion of reaction. The reaction mixture was applied to 
a conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 
chapter 3). An orange solid was obtained after drying in vacuum. Yield=75 mg, 
51%. 




















EIMS Found 587.10 [M+H]+, calculated for C33H30N8O3, 586.2441 [M] 
HRM
S 
m/z (+EI) Calc. for C33H30N8O3, 586.2441 [M]




3238, 2933, 2218, 1651, 1616, 1539, 1473, 1434, 1386, 1362, 
1330, 1310, 1248, 1213, 1159, 1098, 1023, 1003, 944, 885, 805, 
768, 737, 660, 618. 
 
 






Initially, 36 mg of 5-nitro-1H-indole-2-carboxylic acid (0.171 mmol, 1.2 eq.) was 
dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
 
 
Figure 4.8: 1H and 13C NMR spectroscopic data of compound 4.88 as a 
representative of library-4D compounds 
Then 46 µl of DIC (0.299 mmol, 1.75 eq.) and HOBt (46 mg, 0.342 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
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room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then 60 mg of amine 4.84(0.142 mmol, 1 eq.) was added and the mixture was 
allowed to stir for 4 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Finally the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). An 
orange solid was obtained after drying in vacuum. Yield=10 mg, 12%. 




























3198, 2928, 1646, 1591, 1539, 1487, 1377, 1337, 1315, 1288, 
1228, 1134, 1023, 998, 955, 883, 800, 779, 759, 732. 
 
 
4.89 Synthesis of 5-(benzo[b]thiophene-3-carboxamido)-N-(3-((3-
(dimethylamino) propyl) carbamoyl)-1H-indol-5-yl)-1H-indole-3-
carboxamide (4.89).        
 
Initially, 30 mg of benzo[b]thiophene-3-carboxylic acid (0.167 mmol, 1.2 eq.) 
was dissolved in 5 mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then 45 µl of DIC (0.29 mmol, 1.75 eq.) and HOBt (45 mg, 0.334 mmol, 
2.0 eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then 50 mg of amine 4.69 (0.119 mmol, 1 eq.) was added and the mixture was 
allowed to stir for 10 hours at which point TLC and LCMS analysis showed the 
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completion of reaction. Finally the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). A pale 
yellow solid was obtained after drying in vacuum. Yield=12 mg, 18 %. 








 δH in ppm 
11.72(dd,J=10.0,2.4,1H),11.48 (d,J=2.4,1H),) 10.30(s,1H), 
9.71(s,1H), 8.64(d,J=8.8,1.6,1H), 8.60(d,J=2,1H), 
8.49(dd,J=5.2,1.6,1H), 8.34(t,J=3.2,2H), 8.08(dd,J=5.6,1.2,1H), 
7.98-7.93(m,2H), 7.67-7.63(m,1H), 7.58-7.54 (m,1H), 7.49-
7.43(m,2H), 7.40-7.33 (m,2H), 3.34-3.26(m,2H), 2.41-2.21 
(m,2H), 2.22 (s,6H),  1.70(t,J=7.2,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
164.7, 164.6, 162.9, 161.5, 156.8, 139.9, 137.3, 133.1, 132.9, 
132.6, 132.3, 131.3, 131.0, 128.6, 126.1, 124.8, 124.4, 122.7, 
116.7, 116.6, 111.1, 110.8, 110.6, 56.6, 52.1, 44.6, 39.6, 39.0, 
38.7, 36.6, 27.0, 23.2.  





m/z (+EI) Calc. for C32H30N6O3S, 578.2100 [M]




3226, 2970, 1740, 1640, 1588, 1535, 1467, 1437, 1362, 1309, 
1230, 1208, 1151, 1048, 1023, 1004, 946, 810, 766, 736, 626. 
 
 
4.90 Synthesis of 5-(benzofuran-3-carboxamido)-N-(3-((3-(dimethylamino) 
propyl) carbamoyl)-1H-indol-5-yl)-1H-indole-3-carboxamide (4.90).     
    
Initially, 33 mg of benzofuran-3-carboxylic acid (0.20 mmol, 1.2 eq.) was 
dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then 55 µl of DIC (0.35 mmol, 1.75 eq.) and HOBt (55 mg, 0.40 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
temperature for 30 minutes to ensure the formation of ester from the acid. Then 
60 mg of amine 4.69 (0.143 mmol, 1 eq.) was added and the mixture was 
allowed to stir for 7 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Finally the reaction mixture was applied to a conditioned 
332 
 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). An 
orange solid was obtained after drying in vacuum. Yield=25 mg, 32%. 







 δH in ppm  
11.88(s,1H), 11.70(s,1H), 10.23(s,1H), 9.74(s,1H), 8.86 (s,1H), 
8.64(s,1H), 8.59(s,1H), 8.50(d,J=8.0,1H), 8.36(s,1H), 8.19-
8.16(m,2H), 8.01(s,1H), 7.69(d,J=7.2,1H), 7.62 (dd,J=8.8,2.0,2H), 
7.43(d,J=10.0,1H), 7.38-7.36 (m,2H), 3.69-3.59(m,2H), 3.37-3.31 
(m,2H), 2.51 (s,6H), 1.97(s,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
168.3, 156.8, 156.1, 148.5, 135.7, 135.4, 133.4, 133.0, 130.2, 
129.8, 127.7, 127.0, 126.7, 126.3, 124.9, 123.1, 119.6, 115.4, 
115.0, 112.8, 112.4, 112.3, 112.1, 58.4, 53.9, 49.6, 49.4, 48.8, 
42.7, 38.7, 28.5, 23.9. 




m/z (+EI) Calc. for C32H30N6O4, 562.2329 [M]




3245, 2969, 1617, 1542, 1473, 1377, 1328, 1221, 1170, 1127, 
1077, 1040, 866, 805, 768, 741, 659. 
 
4.91 Synthesis of N-(3-(dimethylamino) propyl)-5-(5-(1-methyl-1H-indole-3-
carboxamido)-1H-indole-3-carboxamido)-1H-indole-3-carboxamide (4.91).   
 
Initially, 31 mg of 1-methyl-1H-indole-3-carboxylic acid (0.177 mmol, 1.2 eq.) 
was dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then 48 µl of DIC (0.311 mmol, 1.75 eq.) and HOBt (48 mg, 0.355 mmol, 
2.0 eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then 62 mg of amine 4.69 (0.148 mmol, 1 eq.) was added to the mixture and 
the mixture was allowed to stir for 6 hours at which point TLC and LCMS 
analysis showed the completion of reaction. At last the reaction mixture was 
applied to a conditioned IsoluteTM SCX-2 cartridge and the product was purified 
by ‘Catch and Release’ method (described in the section ‘Method and 
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Materials’ of chapter 3). An orange solid was obtained after drying in vacuum. 
Yield=18 mg, 21%. 







 δH in ppm   
11.60(s,J=2.4,1H), 11.44(s,1H), 9.72(s,1H), 9.67(s,1H), 
8.55(d,J=1.6,1H), 8.47(d,J=1.6,1H), 8.40(dd,J=15.6,1.6,1H), 
8.31(t,J=6.8,2H), 8.29-8.25(m,1H), 7.91(t,J=5.6,1H), 7.72 
(dd,J=8.8,2.0,1H), 7.65(dd,J=8.8,2.0,1H), 7.53(d,J=8.0,1H), 
7.41(d,J=8.8,1H), 7.36(dd,J=8.8,3.2,1H), 7.25(t,J=7.2,1H), 
7.18(t,J=7.2,1H), 3.88(s,2H), 3.30-3.26(m,2H), 2.31 (t,J=7.2,2H), 
2.16 (s,6H), 1.69-1.64(m, 2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
173.6, 164.5, 163.0, 162.6, 162.2, 143.1, 138.2, 133.2, 132.7, 
132.6, 132.4, 132.1, 127.6, 126.9, 126.6, 126.4, 126.1, 120.9, 
120.7, 116.6, 111.1, 110.6, 110.2,109.8, 56.9,  
45.0, 40.0, 39.2, 36.8, 35.7, 33.0, 30.7, 27.4. 
EIMS Found [M+H]+ 576.40, Calculated for C33H33N7O3, 575.26 [M]
+ 
HRMS m/z (+EI) Calc. for C33H33N7O3, 




3294, 1631, 1526, 1446, 1339, 1300, 1235, 1155, 873, 838, 802, 
750, 714. 
  
      
4.92 Synthesis of N-(3-((3-((3-(dimethylamino) propyl) carbamoyl)-1H-
indol-5-yl) carbamoyl)-1H-indol-5-yl)-1H-indazole-3-carboxamide (4.92).        
 
Initially, 48.80 mg of 1H-indazole-3-carboxylic acid (0.301 mmol, 1.4 eq.) was 
dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then 58 µl of DIC (0.376 mmol, 1.75 eq.) and HOBt (58 mg, 0.43 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
temperature for 30 minutes to ensure the formation of ester from the acid. Then 
90 mg of amine 4.69 (0.215 mmol, 1 eq.) was added and the mixture was 
allowed to stir for 7 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Lastly the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
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method (described in the section ‘Method and Materials’ of chapter 3). A light 
yellow solid was obtained after drying in vacuum. Yield=32 mg, 27%. 
 
 
Figure 4.9: 1H and 13C NMR spectroscopic data of compound 4.92 as a 














 δH in ppm  
13.89(s,1H), 11.82(s,1H), 11.49(s,1H), 10.18(s,1H), 9.69(s,1H), 
8.80 (d,J=1.6,1H), 8.46(d,J=1.6,1H), 8.33(s,1H), 
8.29(d,J=8.0,1H), 7.96(d,J=6.8,1H), 7.91(t,J=5.2,1H), 7.69-
7.66(m,2H), 7.62(dd,J=8.8,2.0,1H), 7.45 (t,J=8.4,2H), 
7.38(d,J=8.8,1H), 7.29(t,J=7.6,1H), 3.32-3.27(m,2H), 2.29 
(t,J=6.8,2H), 2.14(s,6H), 1.69-166(m ,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm   
164.5, 162.9, 160.6, 141.2, 138.6, 133.1, 132.9, 132.7, 132.0, 
128.6, 127.6, 126.57, 126.52, 126.1, 122.1 121.7, 121.6, 116.9, 
116.7, 113.3, 112.6, 111.4, 111.1, 110.8, 110.7, 110.6, 57.0, 45.1, 
39.4, 27.5, 23.2. 
EIMS Found 563.20 [M+H]+,calculated for C31H30N8O3, 562.2441 [M] 
HRM
S 
m/z (+EI) Calc. for C31H30N8O3, 562.2441 [M]




3216, 2970, 2815, 1656, 1622, 1551, 1536, 1470, 1448, 1436, 
1343, 1305, 1253, 1234, 1209, 1159, 1122, 1111, 1049, 1023, 
1000, 907, 880, 818. 
 
4.93 Synthesis of N-(3-(dimethylamino)propyl)-5-(5-(5-nitro-1H-indole-3-
carboxamido)-1H-indole-3-carboxamido)-1H-indole-3-carboxamide (4.93).        
 
 
Initially, 30 mg of 5-nitro-1H-indole-3-carboxylic acid (0.143 mmol, 1.2 eq.) was 
dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then 39 µl of DIC (0.250 mmol, 1.75 eq.) and HOBt (39 mg, 0.286 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then 50 mg of amine 4.69 (0.119 mmol, 1 eq.) was added to the mixture and 
this mixture was allowed to stir for 6 hours at which point TLC and LCMS 
analysis showed the completion of reaction. Finally the reaction mixture was 
applied to a conditioned IsoluteTM SCX-2 cartridge and the product was purified 
by ‘Catch and Release’ method (described in the section ‘Method and 












 δH in ppm   
12.47(s,1H), 11.66(s,1H), 11.48(s,1H), 9.98(s,1H), 9.69(s,1H), 
9.20 (s,1H), 8.59(d,J=14.4,2H), 8.50(s,1H), 8.33(t,J=3.6,2H), 
8.09(dd,J=8.8,2.0,1H), 7.96(d,J=5.6,1H), 7.74(dd,J=8.8,1.6,1H), 
7.69-7.63(m,2H), 7.44(d,J=8.8,1H), 7.37 (d,J=8.8,1H), 




(100MHz,(CD3)2SO); δC in ppm  
164.8, 163.0, 162.3, 162.0, 158.4, 141.8, 140.4, 139.2, 138.8, 
132.9, 132.6, 131.6, 127.8, 126.6, 126.1, 125.9, 120.0, 118.0, 
116.7, 112.7, 112.65, 112.60, 110.7, 110.5, 561, 43.9, 39.1, 38.9, 
38.7, 35.7, 30.7, 26.4. 




m/z (+EI) Calc. for C32H30N8O5, 606.2339 [M]




3266, 2939, 2219, 1705, 1631, 1533, 1475, 1437, 1361, 1331, 
1308, 1220, 1159, 1097, 1039, 945, 886, 807, 770, 741, 715, 619. 
 
 
4.94 Synthesis of 5-nitro-N-(3-(piperidin-1-yl) propyl)-1H-indole-3-
carboxamide (4.94).        
 
Initially, 200 mg of 5-nitro-1H-indole-3-carboxylic acid (0.970 mmol, 1.2 eq.) was 
dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then 262.43 µl of DIC (1.69 mmol, 1.75 eq.) and HOBt (262 mg, 1.94 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then 115.55 mg of 3-(piperidin-1-yl)propan-1-amine (0.809 mmol, 1 eq.) was 
added and the mixture was allowed to stir for 16 hours at which point TLC and 
LCMS analysis showed the completion of reaction. Finally the reaction mixture 
was applied to a conditioned IsoluteTM SCX-2 cartridge and the product was 
purified by ‘Catch and Release’ method. A yellow solid was obtained after 












 δH in ppm   




EIMS Found 331.10 [M+H]+, calculated for C17H22N4O3, 330.16 [M]
+ 
4.95 Synthesis of 5-amino-N-(3-(piperidin-1-yl) propyl)-1H-indole-3-
carboxamide (4.95).        
 
 
164 mg of 4.94 was dissolved in 20 mL of ethanol and added to a 
hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on activated carbon) 
was added into the reaction vessel and it was mixed well. The reaction bottle 
was sealed and connected to a hydrogen reservoir. Air from the reaction bottle 
was removed by applying vacuum and it was then flushed with hydrogen. 
Typically, a hydrogen pressure of approximately 40 psi was applied from the 
reservoir, and the bottle was then shaken vigorously to initiate the 
reaction. Progress of the reaction was monitored by TLC and LCMS. The 
shaker was stopped and the bottle was vented after 5 hours at which point TLC 
and LCMS analysis showed the completion of reaction. The product was 
recovered by means of filtration using Celite. Lastly the product is concentrated 
by using a rotary evaporator. A yellow solid was obtained after drying in 
vacuum. Yield=145 mg, 97%. 







 δH in ppm  
7.96(s,1H), 7.77(s,1H), 7.50(t,J=1.6,1H), 7.22(dd,J=5.6,0.8,1H), 
6.75(dd,J=6.4,2.0,1H), 3.41-3.32(m,2H), 2.95(s,2H), 2.42-
2.38(m,4H), 1.83-1.80 (m,2H), 1.611.55 (m,4H), 1.44(d,J=4.4, 
2H). 





4.96 Synthesis of N-(3-(dimethylamino) propyl)-5-(5-nitro-1H-indole-3-
carboxamido)-1H-indole-3-carboxamide (4.96).        
 
 
Initially, 117 mg of 5-nitro-1H-indole-3-carboxylic acid (0.568 mmol, 1.2 eq.) was 
dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then 153 µl of DIC (0.994 mmol, 1.75 eq.) and HOBt (153 mg, 1.136 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was stirred at room 
temperature for 30 minutes to ensure the formation of ester from the acid. Then 
142 mg of amine 4.95 (0.473 mmol, 1 eq.) was added and the mixture was 
allowed to stir for 8 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Finally the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). A 
cream solid was obtained after drying in vacuum. Yield=136 mg, 59%. 







 δH in ppm  
12.35(s,1H), 11.48(s,1H), 9.95(s,1H), 9.18(d,J=3.6,1H), 8.58 
(s,1H), 8.13-8.10(m,1H), 8.08(t,J=4.8,1H), 7.91-7.90(m,1H), 7.78-
7.64 (m,2H), 7.24(d,J=8.4,1H), 3.37(s,2H), 3.30-3.25(m,2H), 2.51-
2.49(m,4H), 1.72-1.65 (m,2H), 1.511.46 (m,4H), 1.37(d,J=4.8, 
2H). 
EIMS Found 301.20 [M+H]+, C17H24N4O, 300.19 [M]
+ 
 
4.97 Synthesis of 5-amino-N-(3-((3-(dimethylamino) propyl) carbamoyl)-1H-
indol-5-yl)-1H-indole-3-carboxamide (4.97).        
 
145 mg of 4.96 was dissolved in 20 mL of ethanol and1 mL of ethyl acetate was 
added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) was added into the reaction vessel, and mixed well. The 
reaction bottle was sealed and connected to a hydrogen reservoir. Air from the 
339 
 
reaction bottle was removed by applying vacuum, and was then by flushed with 
hydrogen. Typically, a hydrogen pressure of approximately 40 psi was applied 
from the reservoir, and the bottle was then shaken vigorously to initiate the 
reaction. Progress of the reaction was monitored by TLC and LCMS. The 
shaker was stopped and the bottle was vented after 5 hours at which point TLC 
and LCMS analysis showed the completion of reaction. The product was 
recovered by means of filtration using Celite. Finally, the product is 
concentrated by using a rotary evaporator. A deep brown solid was obtained 
after drying in vacuum. Yield=125 mg, 92%. 








 δH in ppm  
8.59(s,1H), 8.27(d,J=1.6,1H), 8.01(s,1H), 7.97 (s,2H), 7.88(s,1H), 
7.62(d,J=1.6,1H), 7.49(dd,J=7.2,2.0,1H), 7.42 (d,J=8.4,1H), 
7.25(d,J=8.8,1H), 6.78(dd,J=8.4,2.0,1H), 3.67-3.41(m,2H), 3.33-
3.32(m,2H), 2.57-2.53(m,4H), 1.87(t,J=7.6,2H), 1.63-1.58 (m,4H), 
1.44-1.39 (m,2H), 1.30(t, J=4.8,2H). 
 EIMS Found 459.20 [M+H]+, calculated for C26H30N6O2, 458.24 [M]
+ 
 
4.98 Synthesis of 5-nitro-N-(3-((3-((3-(piperidin-1-yl) propyl) carbamoyl)-
1H-indol-5-yl) carbamoyl)-1H-indol-5-yl)-1H-indole-3-carboxamide (4.98). 
 
       
Initially, 36 mg of 5-nitro-1H-indole-3-carboxylic acid (0.175 mmol, 1.2 eq.) was 
dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then 48 µl of DIC (0.307 mmol, 1.75 eq.) and HOBt (48 mg, 0.351 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then 67 mg of amine 4.97(0.146 mmol, 1 eq.) was added and the mixture was 
allowed to stir for 6 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Finally the reaction mixture was separated by using a 
conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 











 δH in ppm   
12.42(s,1H),11.65(d,J=2.4,1H),11.47(d,J=2.0,1H),9.97(s,1H),9.69




H), 1.55 (t,J=5.2,4H), 1.39(s, 2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
164.7, 164.2, 162.9, 162.2, 162.0, 145.7, 141.8, 139.9, 139.3, 
134.1,133.0, 132.9, 132.7, 132.6, 132.1, 131.6, 128.9, 126.8, 
126.6, 126.1, 125.9, 125.8, 118.0, 117.3, 112.7, 111.1, 110.7, 
110.5, 107.2, 55.7, 53.4, 39.2, 35.7,30.7, 24.6.  
EIMS Found 647.40 [M+H]+, calculated for C35H34N8O5, 646.26 [M]
+ 





3200, 2976, 1739, 1595, 1530, 1470, 1434, 1379, 1330, 1210, 
1157, 1078, 945, 867, 790, 796, 733. 
4.99 Synthesis of 1-methyl-N-(3-((3-((3-(piperidin-1-yl) propyl) carbamoyl)-
1H-indol-5-yl) carbamoyl)-1H-indol-5-yl)-1H-indole-3-carboxamide (4.99).        
 
 
Initially, 29 mg of 1-methyl-1H-indole-3-carboxylic acid (0.135 mmol, 1.2 eq.) 
was dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then 44 µl of DIC (0.2835 mmol, 1.75 eq.) and HOBt (44 mg, 0.324 
mmol, 2.0 eq.) were added to the acid (1.0 eq.) and this mixture was allowed to 
stir at room temperature for 30 minutes to ensure the formation of ester from the 
acid. Then 62 mg of amine 4.97 (0.135 mmol, 1 eq.) was added and the mixture 
was allowed to stir for 6 hours at which point TLC and LCMS analysis showed 
the completion of reaction. Finally the reaction mixture was applied to a 
conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 
chapter 3). A deep brown solid was obtained after drying in vacuum. Yield=15 













 δH in ppm  
11.61(s,1H),11.46(s,1H),9.72(s,1H),9.67(s,1H),8.56(d,J=1.6,1H), 




3.26(m,2H),2.42(t,J=6.8,2H), 2.42(s,4H), 1.75-1.68 (m,2H), 1.53-
1.38 (m,4H), 1.38(s, 2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
164.8, 164.6, 163.0, 162.6, 162.2, 147.2, 142.2, 136.7, 133.2, 
133.0, 132.7, 132.6, 132.1, 126.9, 126.6, 126.1, 122.0, 121.3, 
120.7, 116.5, 112.5, 110.66, 110.62, 109.8, 56.1, 53.7, 40.0, 39.4, 
39.0, 38.8, 35.7, 33.0, 30.7, 26.4, 25.1, 23.7. 
EIMS Found 616.40 [M+H]+, Calc. for C36H37N7O3, 615.29 [M]
+ 





3244, 2971, 1738, 1618, 1534, 1466, 1433, 1368, 1306, 1265, 
1234, 1200, 1128, 1102, 1037, 946, 869, 800, 770, 746, 719, 660. 
 
 
4.100 Synthesis of 5-nitro-N-(3-(pyrrolidin-1-yl) propyl)-1H-indole-3-
carboxamide (4.100).      
   
 
Initially, 150 mg of 5-nitro-1H-indole-3-carboxylic acid (0.728 mmol, 1.2 eq.) was 
dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then 196 µl of DIC (1.27 mmol, 1.75 eq.) and HOBt (196 mg, 1.4 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
temperature for 30 minutes to ensure the formation of ester from the acid. Then 
3-(pyrrolidin-1-yl) propan-1-amine (77 mg, 0.604 mmol, 1 eq.) was added and 
the mixture was allowed to stir for 8 hours at which point TLC and LCMS 
analysis showed the completion of reaction. Finally the reaction mixture was 
applied to a conditioned IsoluteTM SCX-2 cartridge and the product was purified 
by ‘Catch and Release’ method (described in the section ‘Method and 











 δH in ppm  
12.24(s,1H),9.09(d,J=3.6,1H), 8.23 (t,J=5.6,2H), 
8.05(dd,J=9.2,2.4,1H), 7.63(d,J=8.8,1H), 3.34-3.29(m,2H), 
2.56(s,2H), 2.45 (s,4H), 1.73 (t,J=7.2,2H), 1.65(s, 4H). 
EIMS Found 317.10 [M+H]+, Calc. for C16H20N4O3, 316.15 [M]
+  
 
4.101 Synthesis of 5-amino-N-(3-(pyrrolidin-1-yl) propyl)-1H-indole-3-
carboxamide (4.101).        
 
 
148 mg of 4.100 was dissolved in 20 mL of ethanol and added to a 
hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on activated carbon) 
was added into the reaction vessel and it was mixed well. The reaction bottle 
was sealed and connected to a hydrogen reservoir. Air within the reaction bottle 
was removed under high vacuum and it was then flushed with hydrogen. 
Typically, a hydrogen pressure of approximately 40 psi was applied from the 
reservoir and the bottle was then shaken vigorously to initiate the reaction. 
Progress of the reaction was monitored by TLC and LCMS. The shaker was 
stopped and the bottle was vented on completion of the reaction after 4 hours at 
which point TLC and LCMS analysis showed the completion of reaction. Finally 
the product was recovered by means of filtration using Celite. Finally, the 
product is concentrated by using a rotary evaporator. A yellow solid was 
obtained after drying in vacuum. Yield=127 mg, 95%. 







 δH in ppm   
11.30(s,1H), 7.87-7.82(m,2H), 7.37 (s,1H), 7.12(d,J=3.6,1H), 
6.60(t,J=6.4,1H), 3.31-3.27(m,2H), 2.87(s,2H),2.73(s,2H), 2.57-
2.52(m,4H), 1.76-1.71 (m,4H).  






4.102 Synthesis N-(3-(dimethylamino) propyl)-5-(5-nitro-1H-indole-3-
carboxamido)-1H-indole-3-carboxamide (4.102).        
 
 
Initially, 109 mg of 5-nitro-1H-indole-3-carboxylic acid (0.528 mmol, 1.2 eq.) was 
dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then 142 µl of DIC (0.24 mmol, 1.75 eq.) and HOBt (142 mg, 1.05 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then 126 mg of amine 4.101(0.440 mmol, 1 eq.) was added and the mixture 
was allowed to stir for 9 hours at which point TLC and LCMS analysis showed 
the completion of reaction. Finally the reaction mixture was separated by using 
a conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 
chapter 3). A yellow solid was obtained after drying in vacuum. Yield=165 mg, 
79%.  







 δH in ppm   
11.56(s,1H), 9.98(s,1H), 9.21(s,1H), 8.62(s,1H), 8.50(s,1H), 
8.17(s,1H), 8.00(d,J=3.6,1H), 7.96 (s,2H), 7.69(d,J=9.2,2H), 
7.43(s,1H), 3.31(m,2H), 2.53-2.51(m,2H), 2.51 (s,4H), 1.71 
(m,2H), 1.69(s, 4H).  
EIMS Found 475.20 [M+H]+, Calc. for C25H26N6O4, 474.20 [M]
+ 
 
4.103 Synthesis of 5-amino-N-(3-((3-(dimethylamino) propyl) carbamoyl)-
1H-indol-5-yl)-1H-indole-3-carboxamide (4.103).        
 
 
131 mg of 4.102 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate 
was added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
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activated carbon) was added into the reaction vessel and it was mixed well. The 
reaction bottle was sealed and connected to a hydrogen reservoir. Air from the 
reaction bottle was removed by applying vacuum and it was then flushed with 
hydrogen. Typically, a hydrogen pressure of approximately 40 psi was applied 
from the reservoir and the bottle was then shaken vigorously to initiate the 
reaction. Progress of the reaction was monitored by TLC and LCMS. The 
shaker was stopped and the bottle vented upon completion of the reaction after 
6 hours at which point TLC and LCMS analysis showed the completion of 
reaction. The hydrogenated product was recovered by means of filtration using 
Celite. Finally, this product is concentrated by using a rotary evaporator. A deep 
brown solid was obtained after drying in vacuum. Yield=117mg, 95%. 








 δH in ppm   
11.60(s,1H), 11.37(d,J=2.4,1H), 9.55(s,1H), 8.48(d,J=2.0,1H), 
8.21-8.18(m,2H),8.07(d,J=2.8,1H),7.59(dd,J=8.8,2.0,1H), 
7.48(d,J=2,1H),7.36(d,J=8.8,1H),7.16d,J=8.4,1H),6.59(d,J=2.4,1H)
, 3.65(s,2H), 3.16(t,J=7.2,2H), 2.88(s, ,4H), 2.73 (s,4H), 2.51 
(t,J=1.6,2H), 1.01(d, J=6.4,2H). 




4.104 Synthesis of 5-nitro-N-(3-((3-((3-(pyrrolidin-1-yl) propyl) carbamoyl)-
1H-indol-5-yl) carbamoyl)-1H-indol-5-yl)-1H-indole-3-carboxamide (4.104).    
 
     
Initially, 34 mg of 5-nitro-1H-indole-3-carboxylic acid (0.162 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then 44 µl of DIC (0.283 mmol, 1.75 eq.) and HOBt (44 mg, 0.324 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was stirred at room 
temperature for at least 30 minutes to ensure the formation of ester from the 
acid. Then 60 mg of amine 4.103 (0.136 mmol, 1 eq.) was added to the mixture 
and this mixture was allowed to stir for 8 hours at which point TLC and LCMS 
analysis showed the completion of reaction. Finally the reaction mixture was 
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separated by using a conditioned IsoluteTM SCX-2 cartridge and the product 
was purified by ‘Catch and Release’ method (described in the section ‘Method 
and Materials’ of chapter 3). A deep grey solid was obtained after drying in 
vacuum. Yield=18 mg, 21%. 








 δH in ppm  
11.95(s,1H),11.67(s,1H),11.48(s,1H), 9.98(s,1H), 9.70(s,1H), 
9.20(s,1H), 8.61(s,1H), 8.58(d,J=1.6,1H), 8.50(d,J=3.6,1H), 
8.33(d,J=3.6,1H),8.09(dd,J=9.2,2.4,1H),7.95(s,3H),7.74(dd,J=8.8,
2.0,1H), 7.69-7.66(m,2H), 7.44(d,J=8.4,1H), 7.37(d,J=8.8,1H), 




(100MHz,(CD3)2SO);δC in ppm  
164.7, 163.0, 162.3, 162.05, 162.0, 161.6, 156.1, 147.1, 141.8, 
136.9, 132.98, 132.94, 132.68, 132.65, 128.5, 127.7, 126.6, 
126.1, 125.9, 118.0, 117.3, 112.7, 111.2, 110.7, 110.6, 72.2, 53.3, 
53.2, 39.2, 38.7, 35.7, 30.7, 28.1, 22.9. 




m/z (+EI) Calc. for C34H32N8O5, 632.2496 [M]




3259, 2972, 2317, 1738, 1605, 1537, 1471, 1438, 1340, 1213, 
1065, 865, 792, 771, 744, 682. 
 
4.105 Synthesis of N-(3-morpholinopropyl)-5-nitro-1H-indole-3-
carboxamide (4.105).        
 
Initially, 150 mg of 5-nitro-1H-indole-3-carboxylic acid (0.728 mmol, 1.2 eq.) was 
dissolved in 10 mL of DMF in a round bottom flask placed in a magnetic stirrer. 
Then 196 µl of DIC (1.27 mmol, 1.75 eq.) and HOBt (196 mg, 1.4 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
temperature for 30 minutes to ensure the formation of ester from the acid. Then 
87.36 mg of 3-morpholinopropan-1-amine (0.606 mmol, 1 eq.) was added and 
the mixture was allowed to stir for 7 hours at which point TLC and LCMS 
analysis showed the completion of reaction. Finally the reaction mixture was 
applied to a conditioned IsoluteTM SCX-2 cartridge and the product was purified 
by ‘Catch and Release’ method (described in the section ‘Method and 
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Materials’ of chapter 3). A yellow solid was obtained after drying in vacuum. 
Yield=169 mg, 70%. 







 δH in ppm   
12.26(s,1H), 9.09(d,J=2.0,1H), 8.25(s,1H), 8.20 (t,J=5.6,1H), 
8.05(dd,J=8.8,2.0,1H), 7.63(d,J=8.8,1H), 3.57(t,J=4.4,4H), 3.33-
3.26(m,2H), 2.52-2.50(m,2H), 2.35 (t,J=6.8,4H), 1.73-1.66(m, 2H). 




4.106 Synthesis of 5-amino-N-(3-morpholinopropyl)-1H-indole-3-
carboxamide (4.106).        
 
 
128 mg of 4.105 was dissolved in 20 mL of ethanol and added to a 
hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on activated carbon) 
was added into the reaction vessel and it was mixed well. The reaction bottle 
was sealed and connected to a hydrogen reservoir. Air from the reaction bottle 
was removed by applying vacuum and it was then flushed with hydrogen. 
Typically, a hydrogen pressure of approximately 40 psi was applied from the 
reservoir and the bottle was then shaken vigorously to initiate the reaction. 
Progress of the reaction was monitored by TLC and LCMS. The shaker was 
stopped and vented on completion of the reaction after 7 hours at which point 
TLC and LCMS analysis showed the completion of reaction. The product was 
recovered by means of filtration using Celite. Finally, the product is 
concentrated by using a rotary evaporator. An orange solid was obtained after 
drying in vacuum. Yield=110 mg, 96%. 







 δH in ppm   
11.17(s,1H), 7.81(s,1H), 7.74(s,1H), 7.35 (s,1H), 
7.10(d,J=8.4,1H), 6.55-6.53(m,1H), 3.79-3.70(m,2H), 3.56(s,4H), 
3.293.19(m,2H), 2.50 (s,4H), 2.31 (t,J=6.8,2H), 1.70-1.63(m, 2H). 





4.107 Synthesis of N-(3-(dimethylamino) propyl)-5-(5-nitro-1H-indole-3-
carboxamido)-1H-indole-3-carboxamide (4.107).        
 
 
Initially, 82 mg of 5-nitro-1H-indole-3-carboxylic acid (0.397 mmol, 1.2 eq.) was 
dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then 107 µl of DIC (0.694 mmol, 1.75 eq.) and HOBt (107 mg, 0.794 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then 100 mg of amine 4.106(0.331 mmol, 1 eq.) was added and the mixture 
was allowed to stir for 7 hours at which point TLC and LCMS analysis showed 
the completion of reaction. Finally the reaction mixture was applied to a 
conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 
chapter 3). A yellow solid was obtained after drying in vacuum. Yield=94 mg, 
58%. 







δH in ppm  
12.45(s,1H), 11.52(s,1H), 9.98(s,1H), 9.20(s,1H), 8.61(s,1H), 
8.49(s,1H), 8.11(dd,J=9.2,2.4,1H), 8.01(s,1H), 7.96 (s,1H), 7.70-
7.68(m,2H), 7.37(d,J=1.6,1H), 3.57(s,4H), 3.32(d,J=6.0,2H), 3.31 
(d,J=6.0,2H), 2.38 (s,4H), 1.73(t, J=6.8,2H). 




4.108 Synthesis of 5-amino-N-(3-((3-(dimethylamino) propyl) carbamoyl)-





92 mg of 4.107 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate 
was added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) was added into the reaction vessel and mixed it well. The 
reaction bottle was sealed and connected to a hydrogen reservoir. Air from the 
reaction bottle was removed by applying vacuum and it was then flushed with 
hydrogen. Typically, a hydrogen pressure of approximately 40 psi was applied 
from the reservoir, and the bottle was then shaken vigorously to initiate the 
reaction. Progress of the reaction was monitored by TLC and LCMS. The 
shaker was stopped after 4.5 hours at which point TLC and LCMS analysis 
showed the completion of reaction.The bottle was vented and the product was 
recovered by means of filtration using Celite. Finally, the product is 
concentrated by using a rotary evaporator. A deep brown solid was obtained 
after drying in vacuum. Yield=81 mg, 94%. 








 δH in ppm, 
11.47(s,1H), 11.27(s,1H), 8.44(s,1H), 8.13(d,J=2.8,1H), 8.00-
7.95(m,2H),7.88(t,J=5.2,1H),7.60(dd,J=8.4,2.0,1H),7.46(d,J=2,1H
), 7.33(d,J=8.4,1H), 7.12(d,J=8.4,1H), 6.55(dd,J=8.8,2.0,1H), 
3.73(s,2H), 3.27(d,J=5.6,2H), 2.69(s,4H), 2.32(s ,2H), 1.69-1.64 
(m,4H), 1.15-1.11 (m,2H).  





carboxamido)-1H-indole-3-carboxamido)-1H-indole-3-carboxamide (4.109).  
 
Initially, 31 mg of 5-nitro-1H-indole-3-carboxylic acid (0.148 mmol, 1.2 eq.) was 
dissolved in 10mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then 40 µl of DIC (0.259 mmol, 1.75 eq.) and HOBt (40 mg, 0.297 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then 57 mg of amine 4.108(0.123 mmol, 1 eq.) was added to the same mixture 
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and it was stirred for 6 hours at which point TLC and LCMS analysis showed 
the completion of reaction. Finally the reaction mixture was separated by using 
a conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 
chapter 3). An orange coloured solid was obtained after drying in vacuum. 
Yield=14 mg, 18%. 
 
Figure 4.10: 1H and 13C NMR spectroscopic data of compound 4.109 as a 
representative of library-4B compounds 
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δH in ppm   
12.48(s,1H), 11.66(d,J=1.6,1H), 11.46(d,J=1.6,1H), 9.97(s,1H), 
9.69(s,1H), 9.20(d,J=2.0,1H), 8.61(s,1H), 8.57(d,J=1.6,1H), 
8.49(d,J=1.6,1H), 8.33(d,J=3.6,1H), 8.11(dd,J=8.8,2.4,1H), 
7.96(s,1H), 7.88(d,J=6.0,1H), 7.76(dd,J=8.8,2.0,1H), 7.69-
7.65(m,2H), 7.49(d,J=8.4,1H), 7.35(d,J=8.4,1H), 3.29(t,J=6.0,2H), 




100MHz,(CD3)2SO); δC in ppm  
164.6, 162.9, 162.2, 162.0, 141.8, 139.3, 133.0, 132.9, 132.7, 
132.6, 131.6, 127.6, 126.6, 126.1, 125.9, 118.0, 117.3, 112.8, 
112.7, 112.6, 112.5, 111.1, 110.7, 110.6, 66.1, 56.1, 53.3, 40.6, 
39.4, 36.8, 35.7, 30.7, 26.4, 23.3.  




m/z (+EI) Calc. for C34H32N8O6, 648.2445 [M]




3338, 2966, 1615, 1534, 1465, 1330, 1248, 1211, 1169, 1111, 
1079, 1034, 863, 769, 747, 623, 585, 568, 557. 
 
 
4.110 Synthesis of 5-amino-N-(3-((3-((3-(dimethylamino) propyl) 
carbamoyl)-1H-indol-5-yl) carbamoyl)-1H-indol-5-yl)-1H-indole-3-
carboxamide (4.110).        
 
25 mg of 4.93 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate was 
added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) 20 was added into the reaction vessel. It was mixed well. The 
reaction bottle was sealed and connected to a hydrogen reservoir. Air from the 
reaction bottle was removed by applying vacuum, and was then by flushed with 
hydrogen. Typically, a hydrogen pressure of approximately 40 psi was applied 
from the reservoir. The bottle was then shaken vigorously to initiate the 
reaction. Progress of the reaction was monitored by TLC and LCMS. The 
shaker was stopped after 5.5 hours at which point TLC and LCMS analysis 
showed the completion of reaction. The bottle was then vented and the 
hydrogenated product was recovered by means of filtration using Celite. Finally, 
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the product is concentrated by using a rotary evaporator. A deep brown solid 
was obtained after drying in vacuum. Yield=14 mg, 61%. 








 δH in ppm   
11.60(s,1H), 11.46(s,1H), 11.31(d,J=9.2,1H), 9.63(d,J=3.6,1H), 
9.48(d,J=8.0,1H), 8.54(d,J=3.6,1H), 8.45(dd,J=6.41.6,,1H), 
8.27(s,1H), 8.13(dd,J=7.2,2.4,1H), 7.92(s,1H), 7.87(t,J=5.2,1H), 
7.67-7.63(m,2H), 7.45 (dd,J=2,1H), 7.35(t,J=8.8,2H), 7.15-
7.09(m,1H), 6.57-6.50(m,1H), 3.63-3.52(m, ,2H), 2.25 
(t,J=7.2,2H), 2.12 (s,4H), 1.64(t, J=6.8,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
164.4, 162.9, 159.7, 156.8, 156.3, 155.9, 154.7, 145.7, 144.6, 
133.4, 132.9, 130.7, 129.6, 126.5, 126.1, 124.5, 119.6, 118.6, 
115.2, 111.5, 111.1, 110.6, 107.8, 94.6, 66.2, 56.9, 45.1, 39.3, 
39.1, 38.9, 38.7, 23.2,  









3240, 2926, 1612, 1538, 1470, 1438, 1364, 1312, 1280, 1213, 
1178, 1065, 1038, 991, 889, 792, 762, 745, 724, 677. 
 
 
4.111 Synthesis of N-(3-(4-methylpiperazin-1-yl) propyl)-5-nitro-1H-indole-
3-carboxamide (4.111).        
 
 
Initially, 250 mg of 5-nitro-1H-indole-3-carboxylic acid (1.207 mmol, 1.2 eq.) was 
dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then DIC (324 µl, 2.10 mmol, 1.75 eq.) and HOBt (324 mg, 2.40 mmol, 2.0 eq.) 
were added to the acid (1.0 eq.) and this mixture was allowed to stir at room 
temperature for at least 20 minutes to ensure the formation of ester from the 
acid. Then 130 mg of 3-(4-methylpiperazin-1-yl) propan-1-amine (0.833 mmol, 1 
eq.) was added and the mixture was allowed to stir for 8 hours at which point 
TLC and LCMS analysis showed the completion of reaction. Lastly the reaction 
mixture was separated by a conditioned IsoluteTM SCX-2 cartridge and the 
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product was purified by ‘Catch and Release’ method (described in the section 
‘Method and Materials’ of chapter 3). A yellow solid was obtained after drying 
in vacuum. Yield=201 mg, 38%. 







 δH in ppm  
12.26(s,1H), 9.07(d,J=2.4,1H), 8.23(s,1H), 8.17 (t,J=5.2,1H), 
8.06-8.03(m,1H), 7.62(d,J=8.8,1H), 3.37(s,1H), 3.31-3.26(m,3H), 
2.55 (s,2H), 2.33(t,J=6.8,8H), 1.71-1.64(m ,2H). 




4.112 Synthesis of 5-amino-N-(3-(4-methylpiperazin-1-yl) propyl)-1H-




201 mg of 4.111 was dissolved in 20 mL of ethanol and added to a 
hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on activated carbon) 
was added into the reaction vessel and it was mixed well. The sealed reaction 
bottle was connected to a hydrogen reservoir. Air within the reaction bottle was 
removed under vacuum and it was flushed with hydrogen. Approximately 40 psi 
of hydrogen pressure was applied from the reservoir and the bottle was then 
shaken vigorously to initiate the reaction. Progress of the reaction was 
monitored by TLC and LCMS and the shaker was stopped on completion of the 
reaction after 4 hours at which point TLC and LCMS analysis showed the 
completion of reaction. The bottle was vented and the product was recovered 
by using filtration using Celite. Finally the product is concentrated by using a 
rotary evaporator. An orange solid was obtained after drying in vacuum. 












 δH in ppm   
11.22(s,1H), 7.58(s,1H), 7.38 (s,1H), 7.11 (d,J=8.4,1H), 
6.54(d,J=8.8,1H), 3.94(s,2H), 3.26(d,J=6.0,2H), 2.50(s,1H), 2.13 
(s,8H), 1.87(s,3H), 1.66(t,J=6.8,2H).  




4.113 Synthesis of N-(3-(dimethylamino) propyl)-5-(5-nitro-1H-indole-3-
carboxamido)-1H-indole-3-carboxamide (4.113).        
 
 
Initially, 144.9 mg of 5-nitro-1H-indole-3-carboxylic acid (0.70 mmol, 1.4 eq.) 
was dissolved in 15 mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then 188.6 µl of DIC (1.22 mmol, 1.75 eq.) and HOBt (189 mg, 1.40 
mmol, 2.0 eq.) were added to the acid (1.0 eq.). This mixture was allowed to stir 
at room temperature for 30 minutes to ensure the ester formation. Then 160 mg 
of amine 4.112 (0.50 mmol, 1 eq.) was added to the mixture and the mixture 
was allowed to stir for 6 hours at which point TLC and LCMS analysis showed 
the completion of reaction. Finally the reaction mixture was applied to a 
conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 
chapter 3). A deep brown solid was obtained after drying in vacuum. Yield=135 
mg, 58%. 








 δH in ppm  
11.52(s,1H),9.97(s,1H),9.19(d,J=6.0,1H), 8.59(s,1H), 
8.46(d,J=2.0,1H), 8.09(dd,J=9.2,2.4,1H), 7.98(s,1H), 7.94(s,1H), 
9.92 (s,1H), 7.68-7.65(m,2H), 7.40(d,J=8.8,1H), 3.28(t,J=6.0,2H), 
2.50(s,1H), 2.35-2.29 (m,8H), 2.11(s,3H), 1.68(t,J=7.2,2H). 





4.114 Synthesis of 5-amino-N-(3-((3-(dimethylamino) propyl) carbamoyl)-
1H-indol-5-yl)-1H-indole-3-carboxamide (4.114).        
 
 
135 mg of 4.113 was dissolved in 20 mL of ethanol and 1 mL of ethyl acetate 
was added to a hydrogenation reaction bottle. 20 mg of 10% Pd (palladium on 
activated carbon) was added into the reaction vessel. This mixture was mixed 
well. The reaction bottle was sealed and connected to a hydrogen reservoir. Air 
from the reaction bottle was removed by applying vacuum and flushed with 
hydrogen. A hydrogen pressure of approximately 40 psi was applied from the 
reservoir and the bottle was then shaken vigorously to initiate the reaction. 
Progress of the reaction was monitored by TLC and LCMS analysis. The shaker 
was stopped after 6 hours at which point TLC and LCMS analysis showed the 
completion of reaction.The product was recovered by means of filtration using 
Celite. Finally, the product is concentrated by using a rotary evaporator. A deep 
brown solid was obtained after drying. Yield=107 mg, 84%. 








 δH in ppm  
11.59(s,1H), 11.37(s,1H), 9.54(s,1H), 8.47(s,1H), 8.16(s,1H), 
7.98(s,1H),7.93(t,J=5.6,1H),7.62(dd,J=8.8,1.6,1H),7.50(d,J=1.6,1H)
, 7.37(d,J=8.8,1H), 7.16(d,J=8.8,1H), 6.60(dd,J=8.4,2.0,1H), 
3.80(s,1H), 3.70-3.63(m,2H), 3.32-3.28(m,2H), 2.34 (t,J=6.8,8H), 
2.12(s,3H), 1.72-1.65(m,2H). 
EIMS Found 474.20 [M+H] +, Calculated for C26H31N7O2, 473.25 [M]
+ 
4.115 Synthesis of N-(3-(4-methylpiperazin-1-yl)propyl)-5-(5-(5-nitro-1H-
indole-3-carboxamido)-1H-indole-3-carboxamido)-1H-indole-3-
carboxamide (4.115).        
 
Initially, 45.5 mg of 5-nitro-1H-indole-3-carboxylic acid (0.221 mmol, 1.2 eq.) 
was dissolved in 10 mL of DMF in a round bottom flask placed at a magnetic 
stirrer. Then DIC (60 µl, 0.386 mmol, 1.75 eq.) and HOBt (60 mg, 0.442 mmol, 
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2.0 eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the formation of ester from the acid. 
Then amine 4.114 (75 mg, 0.158m mol, 1 eq.) was added to the mixture and it 
was allowed to stir for 4 hours at which point TLC and LCMS analysis showed 
the completion of reaction. Lastly the reaction mixture was separated by using 
the conditioned IsoluteTM SCX-2 cartridge and the product was purified by 
‘Catch and Release’ method (described in the section ‘Method and Materials’ 
of chapter 3). A yellow solid was obtained after drying in vacuum. Yield=12mg, 
12%.  







 δH in ppm   
12.36(s,1H),11.63(s,1H), 11.43(s,1H), 9.95(s,1H), 9.67(s,1H), 
9.18(d,J=2.0,1H), 8.57(d,J=9.8,2H), 8.47(s,1H), 8.32(s,1H), 
8.09(dd,J=8.8,2.0,1H), 7.94(s,1H), 
7.85(t,J=5.2,1H),7.75(d,J=8.8,1H),7.68-7.64(m,2H), 
7.42(d,J=8.8,1H), 7.35(d,J=8.8,1H), 3.35(s,1H), 3.28(t,J=6.4,2H), 
2.33 (t,J=6.4,8H), 2.11(s,3H), 1.69-1.64(m,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm 
 164.3, 163.0, 162.3, 162.0, 141.8, 139.2, 132.9, 132.6, 128.5, 
127.5, 126.6, 126.1, 125.9, 118.0, 117.4, 116.7, 116.6, 113.3, 
112.8, 112.7, 112.6, 112.4, 111.1, 110.7, 105.1, 55.7, 54.7, 52.6, 
45.6, 39.3, 38.7, 35.7, 30.7, 26.7, 23.2.  









3160, 1621, 1583, 1538, 1470, 1434, 1361, 1331, 1310, 1269, 
1241, 1213, 1180, 1147, 1120, 1076, 1047, 1022, 997, 943, 899, 
870, 789, 767, 745, 692, 621. 
4.116 Synthesis of N-(3-(dimethylamino) propyl)-5-(5-(5-methoxy-1H-
indole-3-carboxamido)-1H-indole-3-carboxamido)-1H-indole-3-
carboxamide (4.116).        
 
 
Initially, 40 mg of 5-methoxy-1H-indole-3-carboxylic acid (0.207 mmol, 1.2 eq.) 
was dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then 56 µl of DIC (0.362 mmol, 1.75 eq.) and HOBt (56 mg, 0.415 mmol, 
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2.0 eq.) were added to the acid (1.0 eq.) and this mixture was stirred at room 
temperature for 30 minutes to ensure the ester formation. Then 62 mg of amine 
4.69 (0.148 mmol, 1 eq.) was added and the mixture was allowed to stir for 5 
hours at which point TLC and LCMS analysis showed the completion of 
reaction. Finally the reaction mixture was applied to a conditioned IsoluteTM 
SCX-2 cartridge and the product was purified by ‘Catch and Release’ method 
(described in the section ‘Method and Materials’ of chapter 3). A yellow solid 
was obtained after drying under vacuum. Yield=11mg, 13%. 







 δH in ppm  
11.56(dd,J=11.6,2.8,1H), 11.42(d,J=2.4,1H), 9.65(d,J=4.0,2H), 
8.58(d,J=2.0,1H),8.46(d,J=2.0,1H),8.31(t,J=3.2,2H),7.95(d,J=2.8,
1H), 7.89(t,J=5.6,1H), 7.79(d,J=2.4,1H), 7.70 (m,2H), 7.51(s,1H), 
7.41-7.34(m,3H), 6.81(dd,J=8.8,2.4,1H), 3.27(t,J=6.8,2H), 2.51-
2.49(m,3H), 2.30(t,J=6.8,2H), 2.16(s,6H), 1.69-1.64(m,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
264.5, 163.1, 163.0, 154.3, 133.2, 133.0, 132.6, 131.0, 128.4, 
127.6, 127.2, 126.6, 126.2, 126.1, 116.6, 112.5, 112.2, 111.1, 
110.8, 110.6, 110.4, 102.5, 57.0, 55.1, 45.1, 39.8, 39.6, 39.4, 
39.2, 39.0, 38.8, 36.8, 27.5. 









3199, 2932, 1640, 1590, 1538, 1485, 1315, 1288, 1223, 1135, 
1023, 1000, 956, 883, 801, 779, 759, 734. 
4.117 Synthesis of 5-chloro-N-(3-((3-((3-(dimethylamino) propyl) 
carbamoyl)-1H-indol-5-yl) carbamoyl)-1H-indol-5-yl)-1H-indole-3-
carboxamide (4.117).        
 
Initially, 58 mg of 5-chloro-1H-indole-3-carboxylic acid (0.298 mmol, 1.2 eq.) 
was dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then 81 µl of DIC (0.521 mmol, 1.75 eq.) and HOBt (81 mg, 0.597 mmol, 
2.0 eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for 30 minutes to ensure the esterification. Then 104 mg of 
amine 4.69(0.248 mmol, 1 eq.) was added to the mixture and the mixture was 
allowed to stir for 4 hours at which point TLC and LCMS analysis showed the 
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completion of reaction. At last the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). An 
orange solid was obtained after drying in vacuum. Yield=22mg, 15%. 







 δH in ppm  
 11.94(s,1H), 11.63(s,1H), 11.45(s,1H), 9.77(s,1H), 9.66(s,1H), 




7.36(d,J=8.8,1H), 7.19(dd,J=8.4,2.0,1H), 3.30-3.25(m,2H), 
2.27(t,J=7.2,2H), 2.14(s,6H), 1.70-1.63(m,2H). 
13C 
NMR 
(100MHz,(CD3)2SO);δC in ppm  
164.6, 162.7, 162.1, 155.7, 147.5, 134.8, 133.1, 132.8, 132.7, 
129.6, 127.7, 127.4, 126.5, 125.2, 123.2, 121.9, 120.4, 119.7, 
116.7, 111.1, 110.8, 110.4, 106.0, 45.2, 39.8, 39.6, 39.4, 39.2, 
38.8, 35.7, 30.7, 27.5.  




m/z (+EI) Calc. for C32H30ClN7O3, 595.2092 [M]




3284, 2972, 2302, 1737, 1639, 1594, 1570, 1527, 1469, 1333, 
1233, 1208, 1161, 1088, 1046, 866, 794, 761, 731. 
 
4.118 Synthesis of N-(3-((3-((3-(dimethylamino) propyl) carbamoyl)-1H-
indol-5-yl) carbamoyl)-1H-indol-5-yl)-5-nitro-1H-indazole-3-carboxamide 
(4.118).    
 
 
Initially, 118 mg of 5-nitro-1H-indazole-3-carboxylic acid (0.568 mmol, 1.2 eq.) 
was dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic 
stirrer. Then 153 µl of DIC (0.994 mmol, 1.75 eq.) and HOBt (153 mg, 1.136 
mmol, 2.0 eq.) were added to the acid (1.0 eq.). This mixture was allowed to stir 
at room temperature for 30 minutes to ensure the formation of ester from the 
acid. Then 170 mg of amine 4.69(0.406 mmol, 1 eq.) was added to the mixture 
and it was then allowed to stir for 6 hours at which point TLC and LCMS 
analysis showed the completion of reaction. Finally the reaction mixture was 
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applied to a conditioned IsoluteTM SCX-2 cartridge and the product was purified 
by ‘Catch and Release’ method (described in the section ‘Method and 
Materials’ of chapter 3). An orange solid was obtained after drying in vacuum. 
Yield=76mg, 31%. 







 δH in ppm  
11.69(d,J=2.0,1H), 11.45(d,J=2.0,1H), 10.45(s,1H), 9.7(s,1H), 
9.16(d,J=3.6,1H), 8.81(d,J=1.6,1H), 8.48(d,J=1.6,1H), 
8.35(d,J=2.8,1H), 8.27(dd,J=9.2,2.4,1H), 7.97(d,J=2.8,2H), 
7.92(t,J=5.6,1H), 7.86(d,J=9.2,1H), 7.70-7.67(m,2H), 
7.46(d,J=8.4,1H), 7.39(d,J=8.8,1H), 3.32-3.27 (m,2H), 
2.36(t,J=7.2, 2H), 2.22(s,6H), 1.71-1.66(m,2H). 
13C 
NMR 
(100MHz,(CD3)2SO); δC in ppm  
164.6, 162.9, 162.2, 159.7, 143.4, 142.7, 141.2, 133.2, 132.9, 
132.7, 131.7, 128.7, 127.7, 126.5, 126.1, 121.2, 121.0, 119.1, 
117.0, 116.7, 113.7, 112.6, 112.1, 111.5, 111.1, 110.9, 110.6, 
56.8, 44.9, 39.0, 36.8.  
EIMS Found 608.20 [M+H] +, Calculated for C31H29N9O5, 607.22 [M]
++. 
HRMS m/z (+EI) Calc. for C31H29N9O5, 607.2292 [M]




3376, 3181, 2961, 2289, 1737, 1666, 1639, 1596, 1570, 1526, 
1473, 1435, 1365, 1328, 1306, 1207, 1160, 1138, 1087, 938, 
889, 855, 791, 763, 729. 
 4.119 Synthesis of N-(3-(dimethylamino) propyl)-5-(5-(5-nitro-1H-indole-3-
carboxamido)-1H-indazole-3-carboxamido)-1H-indazole-3-carboxamide 
(4.119).     
 
Initially, 36 mg of 5-nitro-1H-indole-3-carboxylic acid (0.171 mmol, 1.2 eq.) was 
dissolved in 10 mL of DMF in a round bottom flask fitted with a magnetic stirrer. 
Then 46 µl of DIC (0.299 mmol, 1.75 eq.) and HOBt (46 mg, 0.342 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was stirred at room 
temperature for at least 30 minutes to ensure the ester formation. Then amine 
4.84(60 mg, 0.142 mmol, 1 eq.) was added and the mixture was allowed to stir 
for 4 hours at which point TLC and LCMS analysis showed the completion of 
reaction. Finally the reaction mixture was separated by using conditioned 
IsoluteTM SCX-2 cartridge and the final product was purified by ‘Catch and 
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Release’ method (described in the section ‘Method and Materials’ of chapter 
3). An orange solid was obtained after drying in vacuum. Yield=16 mg, 19%. 























m/z (+EI) Calc. for C30H28N10O5,




3266, 2940, 2219, 1705, 1630, 1533, 1475, 1439, 1360, 1331, 
1308, 1220, 1159, 1098, 1039, 945, 886, 807, 770, 741, 714, 619. 
4.120 Synthesis of N-(3-(dimethylamino) propyl)-5-(1H-indole-3-




46 mg of 1H-indole-3-carboxylic acid (0.286 mmol, 1.2 eq.) was dissolved in 10 
mL of DMF in a round bottom flask fitted with a magnetic stirrer. Then 77 µl of 
DIC (0.498 mmol, 1.75 eq.) and HOBt (77 mg, 0.572 mmol, 2.0 eq.) were added 
to the acid (1.0 eq.) and this mixture was allowed to stir at room temperature for 
30 minutes to ensure the formation of ester from the acid. Then 62 mg of amine 
4.63 (0.238 mmol, 1 eq.) was added to the mixture and the mixture was allowed 
to stir for 6 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Finally the reaction mixture was applied to a conditioned 
IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch and Release’ 
method (described in the section ‘Method and Materials’ of chapter 3). An 
orange solid was obtained after drying in vacuum. Yield=20 mg, 21%. 
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 δH in ppm   
11.64(s,1H), 11.43(s,1H), 9.68(s,1H), 8.44(d,J=2.0,1H), 8.33(s,1H), 
8.25(dd,J=6.8,1.2,1H), 7.96(s,1H), 7.89(d,J=5.6,1H), 7.64 
(d,J=2.0,1H), 7.47(d,J=6.4,1H), 7.37(d,J=8.4,1H), 7.18-7.14(m,2H), 
3.31-3.26(m,2H), 2.28(t,J=6.8,2H), 2.14(s,6H), 1.67(t,J=7.2,2H).  
13C 
NMR 
(100MHz,(CD3)2SO);δC in ppm   
164.5, 163.0, 136.1, 132.8, 132.7, 128.1, 127.6, 126.5, 126.1, 121.9, 
121.1, 120.4, 116.8, 112.7, 111.8, 111.1, 110.8, 110.7, 57.0, 45.2, 
38.8, 36.9, 27.5. 




m/z (+EI) Calc. for C23H25N5O2, 403.2008 [M]




2970, 2251, 2125, 1740, 1631, 1537, 1474, 1439, 1365, 1319, 1213, 
1050, 1023, 1004, 819, 755, 619. 
 
 




Initially, 49 mg of 1H-indazole-3-carboxylic acid (0.2988 mmol, 1.2 eq.) was 
dissolved in 10 mL of DMF in a round bottom flask placed in a magnetic stirrer. 
Then 81 µl of DIC (0.5229 mmol, 1.75 eq.) and HOBt (81 mg, 0.5976 mmol, 2.0 
eq.) were added to the acid (1.0 eq.) and this mixture was allowed to stir at 
room temperature for at least 25 minutes for the esterification of the acid. Then 
amine 4.82 (65 mg, 0.249 mmol, 1 eq.) was added and the mixture was allowed 
to stir for 7 hours at which point TLC and LCMS analysis showed the 
completion of reaction. Finally the reaction mixture was separated by 
conditioned IsoluteTM SCX-2 cartridge and the product was purified by ‘Catch 
and Release’ method (described in the section ‘Method and Materials’ of 



















(100MHz,(CD3)2SO); δC in ppm  
162.2,160.9,141.2,138.4,138.3,138.2,133.2,126.6,122.2,121.9,12
1.7,121.5,112.1,110.8,110.4,57.1,45.1,40.0,38.8,37.0,27.2. 




m/z (+EI) Calc. for C21H23N7O2, 405.1913 [M]




3263, 2972, 2302, 1739, 1635, 1606, 1532, 1470, 1437, 1368, 
1345, 1313, 1211, 1150, 1118, 1073, 1039, 963, 868, 810, 798, 
770, 749, 734. 
 
 





Initially, 50 mg of 5-nitro-1H-benzo[d]imidazole-2-carboxylic acid (0.24 mmol, 
1.2 eq.) was dissolved in 10 mL of DMF in a round bottom flask fitted with a 
magnetic stirrer. Then 65 µl of DIC (0.42 mmol, 1.75 eq.) and HOBt (65 mg, 
0.48 mmol, 2.0 eq.) were added to the acid (1.0 eq.) and this mixture was 
allowed to stir at room temperature for 30 minutes to ensure the formation of 
ester from the acid. Then 52 mg of amine 4.82 (0.20 mmol, 1 eq.) was added to 
the mixture and the mixture was allowed to stir for 4 hours at which point TLC 
and LCMS analysis showed the completion of reaction. Finally the reaction 
mixture was applied to a conditioned IsoluteTM SCX-2 cartridge and the product 
was purified by ‘Catch and Release’ method (described in the section ‘Method 
and Materials’ of chapter 3). An orange solid was obtained after drying under 


















(100MHz,(CD3)2SO); δC in ppm   
163.2,162.1,156.8,150.8,143.2,138.4,138.3,132.4,121.9,121.4,1
18.6,116.0,112.7,110.7,105.4,56.8,44.8,40.0,38.8,36.8,26.9. 
EIMS Found 450.0[M+H]+, Calculated for C21H22N8O4, 450.1764 [M]
+ 





3376, 3199, 2923, 1656, 1637, 1597, 1530, 1480, 1334, 1317, 
1294, 1250, 1223, 1152, 1099, 1087, 1042, 993, 923, 891, 856, 
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